BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

- LOCATION: CROWNE PLAZA SFO 1177 AIRPORT BOULEVARD BURLINGAME, CALIFORNIA
- DATE: THURSDAY, MAY 24, 2012 9 A.M.
- REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152
- BRS FILE NO.: 91095

INDEX

ITEM DESCRIPTION	PAGE NO.
AGENDA	
1. CALL TO ORDER.	4
2. PLEDGE OF ALLEGIANCE.	4
3. ROLL CALL	4
REPORTS & DISCUSSION ITEMS	
4. CHAIRMAN'S REPORT.	6
5. PRESIDENT'S REPORT. FINANCIAL REPORT	17 34
ACTION ITEMS	
6. CONSIDERATION OF PERFORMANCE REVIEW BY MOSS-ADAMS.	41
 CONSIDERATION OF APPLICATIONS FOR EARLY TRANSLATION III RESEARCH AWARDS (RFA 11-02). 	74
CLOSED SESSION	
8. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO CIRM EARLY TRANSLATION III AWARD (HEALTH & SAF 125290.30(F)(3)(B) AND (C)).	
ACTION ITEMS	
9 CONSIDERATION OF APPOINTMENT OF NEW SCIENTIFIC MEMBERS OF THE GRANTS WORKING GROUP.	185
2	

I N D E X (CONT'D.)PAGE NO. 10. CONSIDERATION OF RECOMMENDATIONS FROM 187 THE IP AND INDUSTRY SUBCOMMITTEE, 207 11. CONSIDERATION OF RECOMMENDATIONS FROM FINANCE SUBCOMMITTEE. 12. CONSIDERATION OF STRATEGIC PLAN. 219 13. CONSIDERATION OF RENEWAL OF CONTRACT 245 WITH REMCHO JOHANSEN & PURCELL, LLP. 258 14. CONSIDERATION OF RECOMMENDATIONS FROM THE GOVERNANCE SUBCOMMITTEE. 15. CONSIDERATION OF RECOMMENDATIONS 248 FROM STANDARDS WORKING GROUP REGARDING REVIEW AND OVERSIGHT OF CIRM-FUNDED RESEARCH. 16. CONSIDERATION OF RESOLUTION HONORING WITHDRAWN TED LOVE. 17. CONSIDERATION OF MINUTES FROM THE 265 MARCH ICOC BOARD MEETING. DISCUSSION ITEMS 18. SPOTLIGHT ON DISEASE PRESENTATION. NOT REPORTED 19. PUBLIC COMMENT. NONE 3

	BARRISTERS' REPORTING SERVICE
1	BURLINGAME, CALIFORNIA; THURSDAY, MAY 24, 2012
2	9 A.M.
3	
4	CHAIRMAN THOMAS: GOOD MORNING. I WOULD
5	LIKE TO CALL THIS MEETING OF THE INDEPENDENT
6	CITIZENS OVERSIGHT COMMITTEE TO ORDER ON THIS
7	BEAUTIFUL MAY MORNING IN SAN FRANCISCO. WE WELCOME
8	EVERYBODY WHO IS HERE AND EVERYBODY ON THE PHONE
9	LISTENING TO WHAT WILL BE A MOST INTERESTING AND
10	CHALK FULL AGENDA TODAY.
11	LET'S BEGIN BY TURNING THIS OVER TO MARIA
12	WHO WILL DO THE PLEDGE OF ALLEGIANCE FOLLOWED BY THE
13	ROLL CALL. MARIA.
14	MS. BONNEVILLE: PLEASE STAND IF YOU ARE
15	ABLE.
16	(THE PLEDGE OF ALLEGIANCE.)
17	MS. BONNEVILLE: ROBERT BIRGENEAU. DAVID
18	BRENNER. SUE BRYANT.
19	DR. BRYANT: HERE.
20	MS. BONNEVILLE: KEN BURTIS.
21	DR. BURTIS: HERE.
22	MS. BONNEVILLE: MARCY FEIT. MICHAEL
23	FRIEDMAN.
24	DR. FRIEDMAN: HERE.
25	MS. BONNEVILLE: LEEZA GIBBONS.
	4

	BARRISTERS' REPORTING SERVICE
1	MS. GIBBONS: HERE.
2	MS. BONNEVILLE: MICHAEL GOLDBERG.
3	MR. GOLDBERG: HERE.
4	MS. BONNEVILLE: SAM HAWGOOD.
5	DR. HAWGOOD: HERE.
6	MS. BONNEVILLE: STEPHEN JUELSGAARD.
7	DR. JUELSGAARD: HERE.
8	MS. BONNEVILLE: SHERRY LANSING. BERT
9	LUBIN.
10	DR. LUBIN: HERE.
11	MS. BONNEVILLE: MICHAEL MARLETTA.
12	DR. MARLETTA: HERE.
13	MS. BONNEVILLE: SHLOMO MELMED. PHIL
14	PIZZO. FRANCISCO PRIETO. ELIZABETH FINI.
15	DR. FINI: HERE.
16	MS. BONNEVILLE: ROBERT QUINT.
17	DR. QUINT: HERE.
18	MS. BONNEVILLE: DUANE ROTH. JOAN
19	SAMUELSON.
20	MS. SAMUELSON: HERE.
21	MS. BONNEVILLE: DAVID SERRANO-SEWELL.
22	JEFF SHEEHY. JON SHESTACK. OSWALD STEWARD.
23	DR. STEWARD: HERE.
24	MS. BONNEVILLE: JONATHAN THOMAS.
25	CHAIRMAN THOMAS: HERE.
	5

	BARRISTERS' REPORTING SERVICE
1	MS. BONNEVILLE: ART TORRES.
2	MR. TORRES: HERE.
3	MS. BONNEVILLE: KRISTINA VUORI.
4	DR. VUORI: HERE.
5	MS. BONNEVILLE: EUGENE WASHINGTON.
6	CHAIRMAN THOMAS: THANK YOU, MARIA. I'D
7	LIKE TO START, AS ALWAYS, WITH OUR CHAIRMAN'S
8	REPORT. FIRST AND FOREMOST WOULD LIKE TO INTRODUCE
9	A NEW MEMBER OF OUR BOARD WHO SORT OF SLIPPED IN THE
10	ROLL CALL THERE UNNOTICED. HE IS DR. MICHAEL
11	MARLETTA SITTING OVER HERE BETWEEN DRS. LUBIN AND
12	STEWARD. MICHAEL IS THE PRESIDENT AND CEO OF THE
13	SCRIPPS RESEARCH INSTITUTE, ALSO THE CECIL H. AND
14	IDA M. GREEN PROFESSOR OF CHEMISTRY AT SCRIPPS.
15	HE'S A MEMBER OF THE NATIONAL ACADEMY OF SCIENCES,
16	THE AMERICAN ACADEMY OF ARTS AND SCIENCES, AND THE
17	INSTITUTE OF MEDICINE, AND IS A FORMER RECIPIENT OF
18	THE PRESTIGIOUS MACARTHUR FELLOWSHIP.
19	MICHAEL, WE ARE DELIGHTED TO HAVE YOU. HE
20	WAS AN APPOINTEE OF TREASURER BILL LOCKYEAR TO
21	REPLACE DR. FLOYD BLOOM ON OUR BOARD. WELCOME, AND
22	I THINK YOU WILL FIND THIS TO BE A MOST INTERESTING
23	UNDERTAKING AS WE PROCEED THROUGH OUR MANY THINGS
24	THAT WE DO OVER THE YEAR. SO THANK YOU AND
25	DELIGHTED TO HAVE YOU HERE.

6

1	(APPLAUSE.)
2	CHAIRMAN THOMAS: CONTINUING NOW WITH THE
3	CHAIR'S REPORT, I HAD THE PRIVILEGE OF BEING ABLE TO
4	ATTEND AND SPEAK AT THE OPENING OF OUR ELEVENTH, I
5	BELIEVE, ELEVENTH AND TWELFTH FUNDED FACILITIES, ONE
6	AT THE BUCK INSTITUTE AND ONE AT UC SANTA CRUZ SINCE
7	OUR LAST BOARD MEETING. THE LEVEL OF ENTHUSIASM AND
8	INTEREST FOR THESE TWO FACILITIES AND THE WORK THAT
9	IS GOING TO BE DONE IN THEM WAS PALPABLE AT EACH OF
10	THESE MEETINGS. THEY WERE VERY HIGHLY ATTENDED,
11	MOST ENTHUSIASTICALLY ATTENDED, AND WE WERE
12	DELIGHTED TO BE ABLE TO SAY THAT WE PLAYED A PART IN
13	MAKING THESE BUILDINGS A REALITY AND TO HELP
14	FACILITATE THE EXTRAORDINARY RESEARCH THAT BOTH
15	INSTITUTIONS HAVE GOING NOW AND WILL HAVE IN THE
16	FUTURE.
17	NEXT WOULD LIKE TO TALK ABOUT OUR FUNDING.
18	THIS IS SOMETHING OF GREAT INTEREST TO US. AS YOU
19	KNOW, HISTORICALLY CIRM HAS BEEN FUNDED ON A
20	SEMIANNUAL BASIS THROUGH BOND PROCEEDS THAT COME
21	FROM STATE GENERAL OBLIGATION BOND ISSUES UNDERTAKEN
22	BY THE STATE TREASURER. THE TREASURER'S OFFICE
23	ACTUALLY HAS TWO WAYS IN WHICH IT CAN FUND
24	PARTICIPATING AGENCIES. ONE IS THROUGH THE BOND
25	MEASURES OR BOND ISSUES, RATHER. THE OTHER IS
	7

1	THROUGH DRAWING DOWN ON COMMERCIAL PAPER FACILITIES
2	THAT THEY HAVE AVAILABLE TO THEM. AND IN THE CASE
3	OF THE LATTER, THEY WOULD DRAW DOWN FOR THE
4	PARTICIPATING AGENCIES. AND ONCE THE AMOUNT OF
5	OUTSTANDING COMMERCIAL PAPER REACHES A CERTAIN
6	LEVEL, THEY WOULD AGGREGATE THAT TOGETHER AND
7	REFINANCE ALL OF THAT THROUGH A SUBSEQUENT BOND
8	ISSUE.
9	AS YOU KNOW, THE SPRING IS ONE OF THE
10	TIMES OF OUR SEMIANNUAL FUNDING, AND THAT FUNDING IS
11	DESIGNED TO MEET THE AGENCY'S NEEDS THROUGH THE END,

12 IN THIS CASE, THE END OF CALENDAR 2012. WE ARE, AS 13 YOU MAY RECALL, MOSTLY A TAXABLE ENTITY. THAT IS, 14 WE ARE COVERED THROUGH TAXABLE BOND MEASURES, BOND 15 ISSUES WITH SOME EXCEPTION. THIS PARTICULAR SPRING 16 THE TREASURER'S OFFICE HAS DECIDED THAT RATHER THAN 17 INCLUDE US IN THEIR BOND ISSUE, WE'LL BE INCLUDED IN THE COMMERCIAL PAPER OPTION, WHICH WE ARE DELIGHTED 18 19 THAT THEY HAVE CHOSEN TO DO THIS.

20 WE'RE BASICALLY -- WE DON'T REALLY CARE 21 WHETHER WE'RE FUNDED THROUGH BONDS OR CP. IT'S THE 22 SAME TO US. WE HAVE AS ALWAYS SUBMITTED A LIST OF 23 THE NEEDS THAT WE HAVE AND THE AMOUNT THAT WE NEED 24 TO HAVE FUNDED THROUGH THE END OF THE YEAR IN THIS 25 CASE, AND WE ARE MOST PLEASED THROUGH THE

8

1	EXCEPTIONAL HELP OF THE DEPARTMENT OF FINANCE AND
2	THE STATE TREASURER'S OFFICE TO INFORM YOU THAT WE
3	WILL BE RECEIVING ONCE AGAIN THE FULL AMOUNT THAT WE
4	HAVE REQUESTED TO PROCEED FORTH FOR THE REST OF THE
5	CALENDAR YEAR.
6	SO THERE ARE LOTS OF SORT OF
7	TECHNICALITIES AND ISSUES ATTENDANT ON WHEN WE GET
8	IT AND TIMING AND SUBMISSION, ALL THAT STUFF; BUT
9	FOR PURPOSES OF TODAY'S MEETING, JUST KNOW THAT WE
10	ARE FULLY FUNDED AND ARE FULL STEAM AHEAD WITH
11	RESPECT TO BOTH THE DEPARTMENT OF FINANCE AND THE
12	STATE TREASURER'S OFFICE, BOTH OF WHICH REMAIN
13	EXTREMELY SUPPORTIVE OF ALL THAT WE ARE DOING.
14	ANOTHER MATTER, WE ARE GOING TO HEAR
15	TODAY, ONE OF THE AGENDA ITEMS IS THE BUDGET. AND
16	WITH RESPECT TO THAT, OBVIOUSLY WE ARE MINDFUL OF
17	ALL OF THE DISCUSSIONS AT THE STATE LEVEL CONCERNING
18	THE STATE BUDGET, AND WE ARE, I THINK YOU WILL SEE,
19	PROPOSING A VERY PRUDENT BUDGET GOING FORWARD. AND
20	WE WILL CONTINUE TO MONITOR THE SITUATION AT THE
21	STATE AS IT MAY DEVELOP OVER THE NEXT FEW MONTHS AS
22	THEY PROCEED TO NAIL DOWN THE BUDGET THAT THEY ARE
23	CURRENTLY CONSIDERING.
24	ONE OF THE THINGS I WANTED TO BRING TO THE
25	BOARD'S ATTENTION, WE HAVE, AS YOU KNOW, AN RFA OUT
	9

1	FOR OUR NEW STRATEGIC PARTNERSHIP PROGRAM. IT'S
2	SOMETHING WE'RE VERY EXCITED ABOUT AS YET ANOTHER
3	WAY TO GET BEST-IN-CLASS PROPOSALS IN FOR PROJECTS
4	FROM VARIOUS ENTITIES THROUGHOUT THE STATE OF
5	CALIFORNIA. WE'RE IN THE PROCESS RIGHT NOW, WE HAVE
6	RECEIVED LETTERS OF INTENT FROM A NUMBER OF PARTIES
7	WHO ARE INTERESTED IN APPLYING FOR THIS. THOSE
8	LETTERS OF INTENT CAME IN IN NUMBERS EXCEEDING WHAT,
9	I THINK, WE WERE EXPECTING AND HAVE SOME REAL
10	QUALITY IN THE MIX.
11	PREVIOUSLY THE BOARD HAD AUTHORIZED UP TO
12	\$30 MILLION TO GO TOWARDS THE STRATEGIC PARTNERSHIP
13	PROGRAM. WE WILL BE, THROUGH OUR NORMAL GRANTS
14	WORKING GROUP PROCESS, EVALUATING THE PROPOSALS THAT
15	HAVE COME IN. AND IF IT DEVELOPS THAT THERE ARE
16	MORE THAN WE HAD ORIGINALLY ANTICIPATED THAT WE FEEL
17	AND THE GRANTS WORKING GROUP FEELS ARE WORTHY OF
18	FUNDING, AT THAT TIME WE MAY COME BACK TO THE BOARD
19	TO DISCUSS THE POTENTIAL OF INCREASING THE AMOUNT
20	THAT WE HAD ORIGINALLY ALLOCATED FOR THAT PURPOSE.
21	SO THAT'S SORT OF A STAY TUNED ITEM.
22	EVERYBODY SHOULD HAVE ON THEIR DESKS HERE
23	IN THE ROOM OUR NEW ANNUAL REPORT, WHICH YOU WOULD
24	SEE, I THINK. HOPEFULLY EVERYBODY HAS ONE THERE.
25	WE ARE DELIGHTED TO HAVE THIS. IT IS, AS YOU WILL
	10
	TO

1	SEE, A BIT OF A DIFFERENT FORMAT THAN WHAT WE'VE HAD
2	IN THE PAST. AND IT IS THE PRODUCT OF A GREAT DEAL
3	OF WORK BY OUR STAFF WHO HAS, NOT JUST IN TERMS OF
4	COMING UP WITH THIS DIFFERENT FORMAT, BUT IN PUTTING
5	TOGETHER CONTENT THAT IN A MERE EIGHT PAGES WE THINK
6	CONVEYS THE STORY OF CIRM, THE STATUS OF OUR
7	FUNDING, WHERE WE ARE IN THE PROCESS IN TERMS OF
8	BASIC RESEARCH THROUGH CLINICAL TRIAL FUNDING, THE
9	SUBJECT MATTER OF ALL OF THE DIFFERENT AWARDS, THE
10	MAJOR AWARDS WE HAVE, WHICH AS OF TODAY, AS YOU
11	KNOW, STANDS AT 43.
12	BY THE END OF THE DAY, WHEN WE HAVE VOTED
13	ON THE EARLY TRANSLATION AWARDS, THAT NUMBER WILL
14	INCREASE. BUT WITH RESPECT TO THE ANNUAL REPORT,
15	YOU WILL SEE, AS OF THE SNAPSHOT WHEN THAT WAS
16	FINALIZED A FEW WEEKS AGO, IT CONVEYS VERY NICELY
17	AND UNDERSTANDABLY AND IN PLAIN ENGLISH THE STORY OF
18	CIRM AND THE PROGRESS THAT WE ARE MAKING, WHICH IS
19	CONSIDERABLE ACROSS MANY FRONTS. SO KUDOS TO OUR
20	WHOLE COMMUNICATIONS TEAM ON THAT.
21	IN ADDITION TO THAT, YOU WILL SEE THAT WE
22	HAVE NEW BUSINESS CARDS HERE, BUSINESS CARD-LOOKING
23	CARDS, THAT ARE MEANT TO BE HANDED OUT TO FOLKS TO
24	GIVE THEM A NUMBER OF DIFFERENT WAYS TO CONTACT US,
25	TO GET INFORMATION ABOUT CIRM, AND TO SORT OF GET
	11

1	THE FULL PICTURE. SO WE ENCOURAGE YOU TO HAND THOSE
2	OUT. AND I THINK YOU'LL FIND THAT THEY ARE VERY
3	WELL RECEIVED AS A NEW SOURCE OF INFORMATION.
4	A WORD ABOUT SORT OF AN INTERESTING
5	DEVELOPMENT THAT HAPPENED AT OUR LAST GRANTS WORKING
6	GROUP, WHICH WAS THE DISEASE TEAM II GRANTS WORKING
7	GROUP. THE ACTUAL RECOMMENDATIONS FROM THAT MEETING
8	WILL BE FORTHCOMING IN OUR JULY BOARD MEETING. BUT
9	AT THE END OF THAT MEETING, WE DID SOMETHING THAT
10	WAS NEW, WHICH WAS WE ASKED THE GRANTS WORKING GROUP
11	WHO HAVE NOW BEEN THROUGH MANY ITERATIONS ACROSS
12	MANY DIFFERENT RFA'S, THIS PARTICULAR GROUP, WE SAID
13	HOW MIGHT WE IMPROVE OUR PROCESS HERE? WHAT ARE
14	SOME IDEAS THAT WE MIGHT USE TO EITHER UNDERTAKE NEW
15	INITIATIVES OR THINGS THAT WOULD BETTER THE WHOLE
16	SEQUENCE THAT WE HAVE IN THESE MEETINGS?
17	AND THAT LED TO A MOST INTERESTING
18	HOUR-AND-A-HALF-LONG DISCUSSION, NOTABLE BOTH FOR
19	THE REAL ENGAGEMENT AS WE HAD SEEN THROUGHOUT THE
20	ENTIRE THREE DAYS OF THE GRANTS WORKING GROUPS BY
21	THE MEMBERS AND A REAL INTEREST IN HELPING US TO
22	DEVELOP NEW IDEAS. AND THIS CAME ON A LATE FRIDAY
23	AFTERNOON WHEN YOU WOULDN'T EXPECT PEOPLE TO BE
24	FULLY ENGAGED, BUT THEY WERE REALLY ENGAGED AND SOME
25	GREAT STUFF CAME OF IT.

12

1	WE'VE HAD SOME INTERNAL DISCUSSIONS SINCE
2	THEN, AND WE'RE GOING TO BE BRINGING SOME NEW IDEAS
3	TO THE BOARD AS WE CONTINUE TO REFINE THE
4	SUGGESTIONS THAT CAME OUT OF THAT MEETING SHORTLY.
5	THEN, LET'S SEE HERE, ONE OTHER THING I
6	WANT TO FLAG FOR YOU IS WE HAVE NOT TO DATE, AS FAR
7	AS I KNOW, EVER HAD A BOARD RETREAT. AND WE THINK
8	THAT THIS IS SOMETHING THAT AFTER THE FIRST OF THE
9	YEAR WILL BE SOMETHING THAT WE WOULD BENEFIT FROM
10	GREATLY. TO BEGIN WITH, AS YOU KNOW, AT THE END OF
11	THIS YEAR, A NUMBER OF THE BOARD SEATS ARE UP, AND
12	WE ARE LIKELY TO HAVE SOME ADDITIONAL NEW MEMBERS AT
13	THAT POINT. AND A RETREAT THAT WOULD HELP, AMONG
14	OTHER THINGS, EDUCATE THE NEW BOARD MEMBERS, I
15	THINK, WOULD BE SOMETHING THAT WOULD BE A WELCOME
16	THING.
17	NO. 2, AS YOU KNOW, WE ARE DUE TO HAVE THE
18	FINAL REPORT BY THE IOM AT THE END OF THIS CALENDAR
19	YEAR. THAT REPORT IS SOMETHING THAT WILL BE MUCH
20	ANTICIPATED AND UNDOUBTEDLY VERY INTERESTING AND
21	VERY HELPFUL IN ITS INSIGHTS AND RECOMMENDATIONS.
22	AND THIS WOULD BE SOMETHING WE WOULD ALSO
23	CONTEMPLATE BEING ON THE AGENDA OF THIS RETREAT.
24	AND THEN THE THIRD ITEM WOULD BE
25	CONSIDERATION OF A NUMBER OF THESE IDEAS I JUST
	13

1	REFERENCED THAT CAME OUT OF THIS DISCUSSION
2	FOLLOWING THE GRANTS WORKING GROUP DISCUSSION. SO
3	ALL OF THIS, I THINK, WOULD BE BENEFICIAL TO HAVE A
4	RETREAT. WE'LL PROBABLY TIME IT TO BE, MARIA,
5	IMMEDIATELY ADJACENT TO THE JANUARY BOARD MEETING.
6	SO IT'S NOT A MATTER OF MAKING EXTRA TIME, AND IT
7	WILL BE A PUBLIC SESSION AS IT WOULD HAVE TO BE. SO
8	MEMBERS OF THE PUBLIC ARE WELCOME. SO JUST STAY
9	TUNED FOR MORE ON THAT, BUT I DID WANT TO FLAG THAT
10	FOR YOU.
11	SO THAT CONCLUDES THE CHAIR'S REPORT. WE
12	HAVE A VERY FULL AGENDA TODAY, SO WE WANT TO MAKE
13	SURE WE MOVE THINGS ALONG. AND I'D LIKE TO NOW TURN
14	THIS OVER TO ALAN FOR THE PRESIDENT'S REPORT.
15	MS. GIBBONS: QUICK QUESTION.
16	CHAIRMAN THOMAS: YES, LEEZA. SORRY.
17	MS. GIBBONS: EXCUSE ME, ALAN. JUST A
18	VERY QUICK QUESTION. FIRST OF ALL, KUDOS AGAIN TO
19	THESE FORGIVE ME. JUST A VERY QUICK QUESTION.
20	FIRST OF ALL, IF ANYBODY IS THINKING OF LEAVING THE
21	BOARD, THE ENTICEMENTS OF THAT RETREAT MIGHT MAKE
22	PEOPLE WANT TO STAY, PAJAMA PARTY, GAMES,
23	EVERYTHING. INCREDIBLE.
24	THESE ARE GREAT. I DON'T KNOW WHO ALL WAS
25	INVOLVED IN THIS. THESE ARE ABSOLUTELY FANTASTIC.
	14

1	MY QUESTION IS CAN WE GET EXTRA COPIES OF THIS
2	PIECE?
3	CHAIRMAN THOMAS: ABSOLUTELY. YES. I
4	WILL SAY THE IDEA OF HAVING THE ANNUAL REPORT IN
5	THAT FORM WAS ORIGINALLY PROPOSED BY AMY ADAMS,
6	WHO'S BEEN ADVOCATING FOR THIS AS SOMETHING THAT WE
7	THOUGHT MIGHT BE A LITTLE BIT EASIER HANDOUT TO GIVE
8	TO FOLKS. THE WHOLE COMMUNICATIONS TEAM LED BY
9	KEVIN MCCORMACK, DON GIBBONS, AND AMY AND TODD,
10	EVERYBODY WORKED EXTENSIVELY ON THAT. AND THERE
11	WERE MANY ITERATIONS. AND IT LOOKS SIMPLE; BUT AS
12	YOU KNOW, SOMETHING LIKE THAT TOOK A LOT OF WORK.
13	SO WOULD LIKE TO THANK THEM FOR THAT.
14	SO, YES, MR. SENATOR.
15	MR. TORRES: YES. I JUST WANT TO ALSO
16	THANK MARIA BONNEVILLE FOR WORKING ON THAT BROCHURE
17	BECAUSE IT HAS RECEIVED GREAT KUDOS FROM MANY
18	FOUNDATIONS THAT I SERVE ON WANTING TO REPLICATE
19	THAT BECAUSE WE SAVE SO MUCH MONEY BY DOING IT IN
20	THIS FORMAT. AND IT'S EASILY ACCESSIBLE, EASILY
21	TRANSFERABLE AT EVENTS OR RALLIES OR WHATEVER,
22	ESPECIALLY FOR PATIENT ADVOCATES. AND I THINK
23	THAT'S WHERE MOST OF THE THING LIES.
24	SECONDLY, I WOULD JUST CAUTION BY USING
25	THE WORD "RETREAT." IF WE CAN NAME IT SOMETHING
	15
	±J

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	ELSE LIKE WORKSHOP, ORIENTATION, OR WHATEVER BECAUSE
2	THE GENERAL PUBLIC OUT THERE THINKS WE'RE GOING TO
3	BE IN A RESORT SOMEWHERE. AND OBVIOUSLY WE'VE NEVER
4	BEEN IN THAT SITUATION. SO I JUST LET'S FIND A
5	DIFFERENT WORD OTHER THAN RETREAT.
6	CHAIRMAN THOMAS: SO NOTED. ANY OTHER
7	COMMENTS? YES, MARIA.
8	MS. BONNEVILLE: OH, NO. I WAS JUST GOING
9	ТО
10	CHAIRMAN THOMAS: OKAY. ALL RIGHT. THANK
11	YOU. AND I'D ALSO LIKE, BEFORE I TURN IT OVER TO
12	ALAN, JUST TO NOTE, THANK A COUPLE OTHER MEMBERS OF
13	OUR VERY HARDWORKING STAFF WITH RESPECT TO ALL OF
14	THE WORK ON THE FINANCING THROUGH THE STATE OF
15	CALIFORNIA. LYNN HARWELL AS OUR LEAD ON THAT AND
16	HAS DONE A YEOMAN'S WORK IN HELPING US TO POSITION
17	TO CONTINUE GETTING FULL FUNDING AND ALL THE MANY
18	DIFFERENT ASPECTS ATTENDANT ON THAT EFFORT. SO
19	THANK YOU, LYNN.
20	WITH RESPECT TO OUR BUDGET, MATT PLUNKETT,
21	OUR CFO, AS YOU'VE HEARD FROM PRELIMINARY
22	PRESENTATIONS ON THIS IN PAST BOARD MEETINGS, SPENT
23	AN ENORMOUS AMOUNT OF TIME, HAS RECONFIGURED OUR
24	BUDGET INTO SOMETHING I THINK THAT'S MUCH MORE
25	UNDERSTANDABLE AND LINEAR AND COMPREHENSIVE AND HAS
	16
	10

	BARRISTERS' REPORTING SERVICE
1	BEEN VERY WELL RECEIVED BY ALL FOLKS WHO HAVE HEARD
2	IT. SO, MATT, THANK YOU FOR THAT.
3	SO TURN IT OVER TO ALAN.
4	MS. BONNEVILLE: I JUST WANTED TO NOTE FOR
5	THE RECORD THAT FRANCISCO PRIETO, MARCY FEIT, AND
6	JEFF SHEEHY ARE NOW PRESENT. AND I WANTED TO CHECK
7	TO SEE IF DUANE ROTH IS ON THE LINE.
8	MR. ROTH: I AM.
9	MS. BONNEVILLE: AND DR. MELMED. THANK
10	YOU.
11	DR. TROUNSON: SO THANK YOU, CHAIR AND
12	BOARD. AGAIN, STARTING WITH THE SCIENCE SIDE, JUST
13	BEFORE I ACTUALLY START, THERE ARE SOME IN THE
14	POCKET OF YOUR FOLDER IS THREE PAPERS THAT WERE
15	PUBLISHED JUST RECENTLY. AND SO I THOUGHT TO
16	INCLUDE THESE BECAUSE SOME OF THESE ARE
17	COMMENTARIES. ONE IS ON CIRM AND DELIVERING CELL
18	THERAPEUTICS IN NATURE CELL BIOLOGY. I WAS INVITED
19	TO MAKE THEIR COMMENTARY. THERE'S ONE BY ELLEN
20	FEIGAL AND ELONA BAUM, KEVIN WHITTLESEY, AND JOYCE
21	FREY-VASCONCELLS IN THE JOURNAL THAT WE SUPPORT, THE
22	STEM CELLS AND TRANSLATIONAL MEDICINE, REALLY
23	TALKING ABOUT REALLY TAKING ON FOLLOWING ON THE WORK
24	THAT WAS DONE WITH FDA AROUND THE USE OF ANIMAL
25	MODELS IN TRANSLATION. SO IF PEOPLE ARE INTERESTED
	17

17

	BARRISTERS' REPORTING SERVICE
1	IN THAT, I THINK YOU'D FIND THAT INFORMATIVE.
2	THEY'RE IN THE BINDER.
3	AND LASTLY, THERE'S ONE, A COMMENTARY ON
4	STEM CELLS WHICH IS REALLY FOCUSED ON WHAT I WANT TO
5	TELL YOU RIGHT AT THE MOMENT, WHICH IS THE
6	CONVERSION OF CELLS IN THE BODY FROM ONE CELL TYPE
7	TO ANOTHER. SO I WANTED TO TELL YOU A LITTLE BIT
8	ABOUT HEART DISEASE HERE BECAUSE IT'S ALL OF A
9	SUDDEN THERE'S A CASCADE OF WHAT I THINK ARE VERY,
10	VERY IMPORTANT STUDIES.
11	THIS ONE IS THE ONE WE COMMENT ON IN THE
12	JOURNAL EMBO, WHICH IS A VERY PRESTIGIOUS JOURNAL,
13	AND WE WERE ASKED TO MAKE A COMMENT ON THE PAPER.
14	AND IT'S OUT OF DEEPAK SRIVASTAVA'S LABORATORY AT
15	GLADSTONE INSTITUTE. AND IF YOU LOOK AT THIS
16	FIGURE, WHICH IS FROM THAT ARTICLE, READ IT BECAUSE
17	IT'S ONLY A COUPLE OF PAGES ANYWAY, WHAT YOU CAN DO
18	WITH FIBROBLASTS OR SKIN CELLS, IF YOU LIKE, THE
19	CELLS WHICH YOU OFTEN GET FROM SKIN AND OTHER
20	TISSUE, VERY COMMON CELL WHICH IS THROUGHOUT THE
21	BODY, YOU CAN ACTUALLY TRANSFECT THEM WITH
22	TRANSCRIPTION FACTORS AND ALTER THEIR FATE INTO IPS
23	CELLS. EVERYBODY KNOWS THAT PRETTY WELL NOW.
24	AND YOU CAN ALSO DO THAT FROM EMBRYONIC
25	STEM CELLS. YOU CAN ALTER THEIR FATE TO
	18

1	CARDIOMYOCYTES. SO IF YOU HAVE CARDIOMYOCYTES, THE
2	POTENTIAL IS THAT YOU COULD DELIVER THEM TO THE
3	HEART AND TRANSPLANTATION. SO THERE'S SOME VERY
4	INTERESTING WORK GOING IN DERIVING THESE CELLS AND
5	USING THEM FOR TRANSPLANTATION.
6	WHAT'S REALLY MORE INTERESTING, I THINK,
7	WE WILL NOW, AND I THINK IT'S ACTUALLY GOING TO BE A
8	REALLY NEW PLATFORM FOR WORK REALLY ACROSS THE WHOLE
9	STEM CELL SPACE, IS THAT YOU CAN USE A DIFFERENT SET
10	OF TRANSCRIPTION FACTORS, AND YOU CAN ACTUALLY
11	CONVERT THEM DIRECTLY TO CARDIOMYOCYTES WITHOUT
12	HAVING GONE BACK TO THE VERY PRIMITIVE CELLS. THE
13	VERY PRIMITIVE CELLS, OF COURSE, WILL FORM TERATOMAS
14	IF THEY'RE ACTUALLY TRANSPLANTED IN AN
15	UNDIFFERENTIATED STATE. SO HERE YOU BYPASS THAT
16	PARTICULAR ISSUE BY CONVERTING THEM DIRECTLY TO
17	CARDIOMYOCYTES. SO THAT'S EFFECTIVE TECHNOLOGY
18	WHICH REALLY CAME FROM DEEPAK SRIVASTAVA'S
19	LABORATORY.
20	WHAT HE'S JUST RECENTLY SHOWN IS THAT YOU
21	CAN USE A RETROVIRAL VECTOR AND YOU CAN ACTUALLY
22	INJECT THAT INTO THE HEART. YOU CAN CONVERT THE
23	STROMAL OR FIBROBLAST COMPONENTS IN THE HEART IN
24	SITU INTO CARDIOMYOCYTES AND, THEREFORE, REDUCE THE
25	SCAR AND EFFECTIVELY IMPROVE THE OUTPUT OF THE
	19

1	HEART. SO THIS IS A DIRECT CONVERSION OF THOSE
2	CELLS WHICH ARE STROMAL, WHICH ARE COMPANION CELLS
3	TO CARDIOMYOCYTES, THE HEART MUSCLE CELLS, WHICH ARE
4	THERE IN RELATIVELY LARGE NUMBERS. YOU CAN CONVERT
5	THEM TO HEART MUSCLE CELLS IN SITU.
6	NOW, THIS IS, I THINK, A VERY IMPORTANT
7	OBSERVATION AND ONE WHICH HAS DRAWN A LOT OF
8	INTEREST.
9	NOW, THERE IS SECONDLY ANOTHER PAPER. A
10	PAPER CAME OUT FROM ERIC OLSON'S LAB IN THE
11	UNIVERSITY OF TEXAS ON USING A DIFFERENT SYSTEM.
12	THEY SHOWED THAT FOUR TRANSCRIPTION FACTORS
13	COOPERATE TO REPROGRAM CARDIOMYOCYTES INTO HEART
14	MUSCLE CELLS IN THE LABORATORY. SO THIS STUDY WAS
15	REALLY CONFIRMING THE SRIVASTAVA STUDY, THAT
16	RETROVIRAL FORCED EXPRESSION OF THESE TRANSCRIPTION
17	FACTORS, THESE PARTICULAR FOUR, SO THEY USED FOUR
18	INSTEAD OF THREE, SO THEY ADDED AN EXTRA
19	TRANSCRIPTION FACTOR HERE, BUT THAT'S, I THINK,
20	REALLY BY THE BY WHETHER YOU USE THREE OR FOUR. AND
21	THEY PRODUCED CARDIOMYOCYTES IN THE DIVIDING CELL
22	FRACTION WHICH CARDIOMYOCYTES DON'T DIVIDE. SO IT
23	HAS TO BE IN THE CELLS, THE COMPANION CELLS, THESE
24	STROMAL CELLS IN THE HEART.
25	SO THEY SHOWED THAT IT'S THOSE CELLS WHICH
	20

WERE ACTUALLY TURNED INTO CARDIOMYOCYTES. AND THESE
 CELLS PRODUCE FUNCTIONAL MYOCYTES, IMPROVING CARDIAC
 FUNCTION AN ADVERSE VENTRICULAR REMODELING, WHICH
 MEANS THAT THE PROBLEM AFTER THE HEART ATTACK
 GENERALLY INCREASES AND INCREASES. WELL, THEY WERE
 ABLE TO STOP THE CONTINUATION OF THAT VENTRICULAR
 REMODELING WHICH CAUSES THE BIG SCAR TO OCCUR.

8 SO INDEPENDENT CONFIRMATION, WHICH IS 9 REALLY, REALLY IMPORTANT WHEN YOU GET INTO THIS 10 SCIENTIFIC FIELD. OFTEN, UNFORTUNATELY, THERE'S ONE OBSERVATION AND IT'S NOT REPEATED BY AN INDEPENDENT 11 12 LABORATORY. SO I'LL JUST SHOW YOU THIS FIGURE 13 BECAUSE ON THE RIGHT-HAND SIDE AS YOU LOOK AT IT, 14 THE INJURED CELLS ARE THE ONES ARE THEY'RE GETTING 15 THE VIRUS WITH THESE TRANSCRIPTION FACTORS ON THE 16 FAR RIGHT-HAND SIDE. AND IT SHOWS THOSE CELLS BEING 17 CONVERTED TO CARDIOMYOCYTES, AND THE GREEN CELL DOWN THERE IS THE ONE WHICH IS ACTUALLY WORKING IN TERMS 18 19 OF CONTRACTION. SO THEY'RE FUNCTIONAL, THEY'RE 20 EFFECTIVE, THEY'RE THERE IN REASONABLE NUMBERS, AND 21 IT LOOKS LIKE FROM THESE TWO STUDIES ARE A VERY 22 WORTHWHILE AREA TO PURSUE. NOT READY FOR PRIME TIME 23 YET, BUT READY TO PURSUE. 24 NOW, IN ADDITION TO ALL OF THAT, ANOTHER 25 PAPER APPEARED IN APRIL THIS YEAR. AND THIS WAS USE

21

NOT OF TRANSCRIPTION FACTORS, BUT MICRO-RNA. AND
 THESE MICRO-RNA'S ARE ABLE TO DO THE SAME JOB AS THE
 TRANSCRIPTION FACTORS. THEY HAVE TO BE INTRODUCED
 ALSO INTO THE CELL. YOU HAVE TO INTRODUCE THEM IN
 THE SAME WAY YOU WOULD INTRODUCE A TRANSCRIPTION
 FACTOR. SO THERE'S A VIRAL APPROACH TO INTRODUCING
 THIS.

8 THIS PAPER WAS PUBLISHED IN CIRCULATION 9 RESEARCH FROM THE DUKE CARDIAC RESEARCH CENTER 10 GROUP. AND THEY USED A COMBINATION OF FOUR OF THESE MICRO-RNA'S, NUMBERS 133, 208, AND 499. AND THEY'RE 11 12 CAPABLE OF INDUCING DIRECT CELLULAR PROGRAM OF THE 13 FIBROBLAST TO CARDIOMYOCYTE-LIKE CELLS IN THE 14 LABORATORY, AND ALSO THEY'RE ABLE TO DEMONSTRATE THAT IN MICE THAT THEY'RE ABLE TO EFFECT THAT CHANGE 15 16 ALSO WHEN INJECTED INTO MICE IN A LENTIVIRAL VECTOR. 17 OTHER STUDIES HAVE BEEN USING A DIFFERENT APPROACH, BUT LENTIVIRAL APPROACH SEEMS TO BE ONE WHICH IS 18 19 MUCH MORE ACCEPTABLE TO THE REGULATORY AUTHORITIES. 20 SO HERE WE HAVE NOW TWO DIFFERENT APPROACHES TO CONVERSION OF HEART CELLS FROM THE 21 22 COMPANION CELLS TO THE WORKING CELLS. NOW, THIS IS 23 A VERY IMPORTANT CHANGE, I THINK, AND A VERY 24 IMPORTANT STEP IN THE WHOLE OF STEM CELL MEDICINE 25 AND SOMETHING THAT WE WANT TO BE THOUGHTFUL ABOUT.

22

1 THE PICTURES THERE SHOW THAT THE CONVERSION OF THE 2 CELLS IN THE MOUSE HEART WERE FROM ONE TYPE TO THE 3 WORKING CARDIOMYOCYTES. 4 SO IN ADDITION TO THAT, THERE WAS ANOTHER 5 PAPER THAT JUST CAME OUT ON MAY 22D, WHICH IS NOT 6 VERY LONG AGO, CHAIR, ALSO IN THIS WHOLE AREA. THE 7 PARTICULAR AREA IS INCREDIBLY ALIVE, AND IT'S NOT EXACTLY SYNONYMOUS WITH THOSE OTHER STUDIES. THEY 8 9 SHOWED THAT IPS CELLS COULD BE REPROGRAMMED FROM 10 SKIN SAMPLES OF PATIENTS WITH ADVANCED HEART FAILURE, DIFFERENTIATED, AND A FUNCTIONAL 11 12 CARDIOMYOCYTE. SO YOU CAN TAKE PATIENTS WHO ARE 13 VERY ILL WITH ADVANCED HEART FAILURE AND REPROGRAM 14 THEM INTO IPS CELLS. AND THEN THEY COULD SHOW THAT 15 THE CARDIOMYOCYTES THAT THEY'RE ABLE TO DEVELOP IN 16 CULTURE SHOWED SYNCHRONIZED ELECTRICAL ACTIVITY 17 BETWEEN THE HUMAN AND THE NEONATAL RAT MYOCYTES IN 18 CO-CULTURE. AND WHEN THEY WERE TRANSPLANTED IN 19 HEARTS, THEY ENGRAFTED, SURVIVED, AND STRUCTURALLY 20 INTEGRATED INTO RAT CARDIOMYOCYTES. 21 SO YOU CAN ACTUALLY TAKE CELLS FROM THESE 22 PATIENTS AND CONVERT THEM. AND SO WHETHER YOU

24 TRANSPLANT OR YOU CONVERT THEM IN SITU, WHICH IS

CONVERT THEM TO THE IPS CELL AND USE THEM AS A

23

25 VERY ATTRACTIVE, I THINK, AND AVOID SOME OF THE

23

1	ISSUES OF CULTURING CELLS AND WHAT YOU MIGHT GET AS
2	A CONSEQUENCE OF HANDLING, MANIPULATING THOSE CELLS.
3	IF WE CAN BUILD A ROBUST TECHNOLOGY IN
4	THIS AREA, I THINK WE'VE GOT SOMETHING VERY SPECIAL
5	IN HEART DISEASE. AND YOU COULD THINK THIS MIGHT
6	APPLY TO A RANGE OF OTHER CONDITIONS. SO I THINK
7	IT'S A VERY INTERESTING SET OF PAPERS AND ONE WHICH
8	I THINK IS GOING TO SET THE FIELD IN THAT DIRECTION
9	FOR SOME TIME. SO I WANTED YOU TO BE AWARE OF THAT.
10	THE OTHER PAPER, THE LAST PAPER I WANT TO
11	DRAW YOUR ATTENTION TO I THINK IS A VERY IMPORTANT
12	PAPER, AND IT'S REALLY ONE THAT I IDENTIFIED OUT OF
13	SCIENCE TRANSLATIONAL MEDICINE. AND IT COMES FROM A
14	LARGE GROUP OF PEOPLE WHO ARE WORKING AT THE
15	UNIVERSITY OF PENN, CELL GENE, UCSF, UCLA, WALTER
16	REED NATIONAL MILITARY MEDICAL CENTER.
17	AND THEY'VE LOOKED AT THE DECADE LONG
18	SAFETY AND FUNCTION OF RETROVIRAL MODIFIED CHIMERIC
19	ANTIGEN RECEPTOR T-CELLS. IMPORTANT PART ABOUT THIS
20	IS THEY'RE STUDYING THE PATIENTS WHO HAVE HAD THESE
21	GENETICALLY MODIFIED CELLS TRANSPLANTED AND WHETHER
22	IN A DECADE LONG EXPERIENCE WHAT IS THE OUTCOME?
23	WHAT ARE THE DANGERS? WHAT ARE THE ISSUES
24	ASSOCIATED WITH USING THESE GENETICALLY MODIFIED
25	CELLS? THERE WAS A LOT OF CONCERN THAT PARTICULARLY
	24

1	IF YOU USE THE KIND OF RETROVIRAL VECTORS THAT THEY
2	USE IN ORDER TO GET THESE TRANSFORMATIONS, THAT YOU
3	MIGHT END UP WITH ISSUES, PARTICULARLY IF THE
4	INSERTIONS ARE ANYWHERE NEAR GROWTH FACTOR GENES OR
5	GENES RELATED TO GROWTH FACTORS THAT MIGHT INDUCE
6	CLONAL CONVERSION TO CELLS THAT WOULD MULTIPLY IN AN
7	UNREGULATED WAY.

SO THESE WERE CONCERNS THAT THE FIELD HAD. 8 9 THEY STUDIED THREE LARGE CLINICAL TRIALS TO EVALUATE 10 GAMMA RETROVIRAL VECTOR ENGINEERED T-CELLS FOR HIV. 11 AND IN THOSE PATIENTS THEY FOUND THE T-CELLS IN JUST 12 ABOUT EVERY ONE OF THE PATIENTS SAMPLED EVEN AFTER 13 11 YEARS. SO THESE ARE DONOR CELLS WITH THESE RETROVIRAL INSERTIONS. THEY'RE THERE AFTER 11 YEARS 14 15 AT FREQUENCIES WELL ABOVE T LEVELS FOR MOST VACCINE 16 APPROACHES. SO THAT WAS INTERESTING, THAT THESE 17 CELLS WOULD HANG ON AND WORK FOR THAT LENGTH OF TIME BECAUSE WE'RE ALSO TOLD THAT THESE T-CELLS WILL 18 19 PROBABLY DECAY VERY QUICKLY.

THE TRANSGENE RETAINED EXPRESSION AND
FUNCTION IN SITU, AND THERE WAS NO EVIDENCE OF
VECTOR INDUCED IMMORTALIZATION; THAT IS, CONVERSION
TO THIS UNCONTROLLED GROWTH, WHICH WOULD BE A REAL
CONCERN IN PATIENTS IF THAT HAPPENED. SO THESE
DONOR T-CELLS HAD STABLE LEVELS OF ENGRAFTMENT, AND

25

1	THE DECAY HALF-LIFE WAS GREATER THAN 16 YEARS, WHICH
2	IS TERRIFIC. I THINK THAT'S REALLY PERHAPS A
3	LITTLE UNEXPECTED. IF YOU TALK TO MOST T-CELL
4	RESEARCHERS, THEY WOULD HAVE THOUGHT THAT THE DECAY
5	LEVEL WOULD HAVE BEEN MUCH, MUCH QUICKER THAN THAT.
6	SO I'LL SHOW YOU THESE RESULTS WILL
7	HAVE, I THINK, A BIG IMPACT IN HUMAN STUDIES BECAUSE
8	IT WILL CREATE A VERY STRONG INTEREST IN UTILIZING
9	THIS APPROACH. AND I'M JUST SHOWING YOU THIS FIGURE
10	BECAUSE THESE ARE THE THREE STUDIES, AND THEY'RE
11	FOLLOWING THE PATIENTS OVER THE 11 YEARS, WHICH IS
12	THE X AXIS THERE. AND YOU CAN SEE THERE'S SOME
13	VARIATION IN THE PATIENTS, BUT THEY'RE MAINTAINING
14	THOSE T-CELL LEVELS PRETTY CONSISTENTLY ACROSS THAT
15	11-YEAR TIME FRAME.
16	SO I THINK THIS IS A VERY NICE PAPER. I
17	THINK IT'S ONE WHICH WILL BE REALLY STRONGLY
18	WELCOMED. AND I HAVEN'T SPOKEN TO PEOPLE LIKE JEFF
19	SHEEHY ABOUT IT, BUT I ACTUALLY THINK THE HIV FIELD
20	WILL FEEL THAT THIS IS A VERY STRONG, POSITIVE
21	PAPER. BUT I THINK IT'S ALSO STRONGLY POSITIVE FOR
22	THE USE OF THIS APPROACH IN A NUMBER OF OTHER
23	CONDITIONS, PARTICULARLY GENETIC DISEASE AND OTHER
24	CONDITIONS WHICH ARE REALLY ON THE VERGE OF ALSO
25	MOVING INTO CLINICAL TRIALS.

26

	BARRISTERS' REPORTING SERVICE
1	SO BACK TO BUSINESS. WE HAVE A NEW HIRE.
2	BILL GIMBEL, OUR I.T. DIRECTOR, HAS COME ON BOARD.
3	BILL HAS BEEN WITH US FOR SOME YEARS, AND BILL IS
4	HERE. SO WELCOME, BILL. THANK YOU VERY MUCH FOR
5	JOINING US.
6	(APPLAUSE.)
7	DR. TROUNSON: SO BILL WAS A CONTRACTOR
8	FOR US, I THINK, NOW FOR TWO YEARS. YES. IT SEEMED
9	LIKE HE'S THERE FOREVER. HE'S ALWAYS ONE OF THE
10	LAST PEOPLE TO LEAVE THE PLACE. HE'S A FANTASTIC
11	PERSON, AND I'M VERY PLEASED HE WAS ABLE TO CONVERT
12	TO BE A FULL-TIME STAFF MEMBER.
13	THE UPCOMING RFA'S, JUST TO REMIND YOU,
14	EARLY TRANSLATIONAL III IS BEING DECIDED HERE AT
15	THIS MEETING. BASIC BIOLOGY IV, THE GRANTS WORKING
16	GROUP REVIEW IS IN JUNE. THE IPS CELL INITIATIVE,
17	WE'RE GOING TO POST PROBABLY LATE JUNE. I HAVE A
18	LITTLE CONCERN, AND I'VE TALKED TO ART AND OTHER
19	MEMBERS OF OUR TEAM ABOUT THIS. THERE'S A BILL
20	THAT'S BEING DISCUSSED IN COMMITTEE AT THIS STAGE,
21	AND IT'S ONE I THINK THAT A LOT OF THE ACADEMIC
22	INSTITUTIONS ARE VERY CONCERNED ABOUT AND SHOULD BE
23	BECAUSE IT RELATES TO WHAT YOU WOULD HAVE TO DO WITH
24	SAMPLES OBTAINED FROM PATIENTS, AND IT MAKES IT
25	ALMOST IMPOSSIBLE TO REALLY DO THE KIND OF STUDIES

27

1	THAT WE'RE TALKING ABOUT IN SOME OF OUR RESEARCH
2	PROGRAMS, PARTICULARLY THIS IPS CELL INITIATIVE.
3	SO I'VE TALKED TO ART ABOUT THAT. HE'S
4	ENGAGED ON THIS. WE'RE LOOKING AT IT. WE'RE
5	KEEPING A MONITOR ON IT, BUT THE UNIVERSITIES,
6	MEDICAL CENTERS ARE PRETTY ENGAGED ON IT. IF YOU
7	AREN'T ENGAGED, I THINK MAYBE HAVE A TALK TO ART. I
8	THINK IT'S A VERY IMPORTANT ISSUE FOR MEDICAL
9	RESEARCH. AND I THINK UNFORTUNATELY THE REAL KEY
10	PARTS OF IT HAVE BEEN MISSED BY WHOEVER WAS DRAFTING
11	THE BILL. SO LET'S HOPE THAT WE GET A LITTLE BETTER
12	SENSE HERE FOR THE SAKE OF MEDICAL RESEARCH.
13	SO WE MAY BE PUTTING THIS DOWN A LITTLE
14	BIT, HOPING THAT BECAUSE IF THE BILL CAME
15	THROUGH, IT WOULD MAKE LIFE VERY, VERY DIFFICULT FOR
16	US TO DELIVER ON THIS.
17	OUR GENOMICS INITIATIVE, WE EXPECT TO POST
18	THE RFA IN JULY. DISEASE TEAM THERAPY DEVELOPMENT,
19	THERE'S GOING TO BE A FUNDING DECISION IN JULY. SO
20	THAT'S REALLY IMPORTANT, OF COURSE, THAT PROGRAM.
21	NEW FACULTY PHYSICIAN SCIENTIST TRANSLATIONAL
22	RESEARCH AWARD, HECK OF A MOUTHFUL. THAT'S GOING TO
23	BE THE GRANTS WORKING GROUP WILL REVIEW THAT IN
24	OCTOBER. AND THE STRATEGIC PARTNERSHIP AWARDS,
25	THOSE APPLICATIONS, THE TENTATIVE REVIEW IN
	28

SEPTEMBER.

1

2 OUR COLLABORATIVE FUNDING PROGRAMS, WE NOW 3 HAVE 21 COLLABORATIVE FUNDING PARTNERS, WHICH I THINK IS TERRIFIC. WE'VE GONE OVER 20. AND THAT 4 5 NOW INCLUDES THE MUSCULAR DYSTROPHY ASSOCIATION THAT'S SIGNED AN MOU WITH US. AND THANKS TO MATT 6 7 FOR HELPING IN THAT PROCESS. MATT AND PARTICULARLY 8 NANCY KOCH, WHO HELPS ME RUN THAT PROGRAM, VERY, 9 VERY EFFICIENT, VERY EFFECTIVE IN THIS COLLABORATIVE 10 PARTNER ARRANGEMENT. THEY'RE THE THIRD FOUNDATION TO JOIN US 11 12 AFTER THE NEW YORK STEM CELL FOUNDATION AND JDRF. 13 WE HAVE ADDITIONAL FOUNDATION OUTREACH CURRENTLY 14 UNDER WAY. SO WE'RE TRYING TO BRING THOSE 15 FOUNDATIONS INTO THE PROGRAMS SO THEY WOULD FUND 16 OUT-OF-CALIFORNIA COMPONENTS; BUT ALSO, IF THEY 17 CARED TO, THEY COULD FUND IN-CALIFORNIA COMPONENTS TOGETHER WITH US. THAT IS MORE LEVERAGE MONEY FOR 18 19 WHAT WE DO. 20 BASIC BIOLOGY IV RFA INCLUDES INDIA, 21 FRANCE, CHINA, AND GERMANY PARTICIPATING AS 22 CO-FUNDERS. AND IT'S THE FIRST INVOLVEMENT FOR INDIA AND FRANCE IN THOSE PROGRAMS. AND THE FOURTH 23 24 ANNUAL FUNDERS MEETING IS GOING TO BE HELD AT THE

25 ISSCR MEETING IN JAPAN. WE HAVE A SCIENTIFIC

29

-	
1	RESOURCE WEB PORTAL, AND I THINK IT WOULD BE
2	INTERESTING TO MANY OF THE BOARD MEMBERS. THIS WILL
3	FACILITATE ACCESS AND INFORMATION EXCHANGE AMONGST
4	SCIENTISTS IN CALIFORNIA AND THOSE RESEARCHERS WHO
5	ARE IN THE COLLABORATIVE FUNDING PARTNER
6	JURISDICTIONS. IT ENHANCES OUR ABILITY TO LOCATE
7	RESOURCES WORLDWIDE.
8	SO THIS ENABLES US TO ACTUALLY BE MORE
9	EFFECTIVE AT WHAT WE DO, AND WE'RE DOING IT THROUGH
10	A PARTNER CALLED SCIENCE EXCHANGE. THEY HAVE THE
11	CAPACITY TO DO THIS. WE'RE ADDING THE PORTAL TO THE
12	EXISTING SCIENCE EXCHANGE PLATFORM. CIRM AND THE
13	COLLABORATIVE FUNDING PARTNERS WILL POPULATE THE
14	SITE WITH RELEVANT, NONCONFIDENTIAL INFORMATION FOR
15	ZERO COST.
16	THE TIMING WILL BE THE PROJECT UNDER WAY.
17	THE FIRST WE'RE TRYING TO DO WITH GERMANY AND THAT'S
18	CURRENTLY UNDER WAY. AND WE HOPE TO BE FULLY
19	OPERATIONAL BY THE END OF THE YEAR. SO IN
20	CALIFORNIA, CALIFORNIAN RESEARCHERS WILL BE ABLE TO
21	LOCATE QUALIFIED PARTNER RESEARCHERS ELIGIBLE FOR
22	COLLABORATIVE FUNDING PARTNERING ON SPECIFIC RFA'S
23	AND VICE VERSA. THE COLLABORATIVE FUNDING
24	RESEARCHERS CAN IDENTIFY CALIFORNIAN RESEARCHERS
25	WITH THE DESIRED SKILLS AND EXPERTISE.
	30

1	WE'VE HAD OUR PERFORMANCE AUDIT, WHICH IS
2	COMPLETE. I THINK YOU WILL HEAR THE RESULTS OF THAT
3	TODAY. YOU'VE GOT SOME INFORMATION IN YOUR FOLDERS.
4	WE WERE FOUND TO BE IN FULL AND ABSOLUTE COMPLIANCE.
5	THERE WERE RECOMMENDATIONS FOR IMPROVED PERFORMANCE,
6	AND STAFF PLAN TO FOLLOW UP, ANALYZE EACH OF THESE
7	RECOMMENDATIONS, TAKE APPROPRIATE ACTION, TRACK THE
8	OUTCOMES, AND PRESENT THE FULL PLAN AT THE NEXT ICOC
9	MEETING. SO IT'S UNDER WAY. MANY OF THE ACTIONS
10	ARE ACTUALLY UNDER WAY, AND THE TEAM IS FULLY
11	ENGAGED IN GETTING THESE RECOMMENDATIONS ACTIVATED
12	UPON.
13	THERE'S A WORKSHOP WITH CHINA. MOST IS
14	THE MINISTRY OF SCIENCE AND TECHNOLOGY IN CHINA
15	FOCUSED ON NETWORKING AND COLLABORATIVE
16	OPPORTUNITIES BETWEEN SCIENTISTS IN CHINA AND
17	CALIFORNIA TO BE HELD JUNE 10TH THROUGH THE 12TH IN
18	SHANGHAI. IT WILL BE ATTENDED BY 10 TO 12
19	CALIFORNIAN SCIENTISTS AND 15 TO 20 CHINESE
20	SCIENTISTS, INCLUDING THE LEADING STEM CELL
21	RESEARCHERS THERE. AND THE FOCUS WILL BE ON
22	NEURODEGENERATIVE DISEASES, SPINAL CORD INJURY, AND
23	BASIC STEM CELL BIOLOGY.
24	WE ALSO HAVE OUR FIRST WORKSHOP WITH OUR
25	SOUTH AMERICAN COLLEAGUES IN SAO PAOLO IN OCTOBER.
	31

1	WE'VE CONFIRMED 11 SCIENTISTS FROM CALIFORNIA, WHICH
2	INCLUDE THE CITY OF HOPE, KECK GRADUATE INSTITUTE,
3	SALK, STANFORD, UC SAN DIEGO, UC IRVINE, SANTA
4	BARBARA, SAN DIEGO IS THERE, UCSF. THERE ARE PEOPLE
5	COMING FROM ALL OF THESE PLACES. THERE ARE FOUR
6	SCIENTISTS FROM ARGENTINA AND 19 FROM BRAZIL. THE
7	ARGENTINEANS HAVE GOT A CONFERENCE ACTUALLY AT THAT
8	SAME TIME, BUT I WANTED TO TRY AND DRAW SOME OF THE
9	ARGENTINEAN SCIENTISTS INTO THIS MEETING.
10	SO OUR APPROACHES WILL BE AGAIN FOCUSED ON
11	NEURODEGENERATION, CARDIOVASCULAR, EYE, AND LIVER
12	DISEASES.
13	IN TERMS OF INDUSTRY ENGAGEMENT, WE HAVE
14	BIO COMING UP. I THINK ELONA BAUM WILL BE AT BIO.
15	I'M THINKING ELLEN MIGHT BE AT BIO AS WELL. I WON'T
16	BE. THE FOCUS WILL BE ON REGENERATIVE THERAPIES IN
17	THE CLINIC. SO CIRM WILL BE CO-HOSTING WITH THE
18	ALLIANCE FOR REGENERATIVE MEDICINE A WORKSHOP DURING
19	THE BIO CONFERENCE. SO THAT'S THE ONE THAT'S
20	FOCUSED ON REGENERATIVE THERAPIES.
21	THERE'S A STEM CELL MEETING ON THE MESA
22	WHICH HAPPENS EVERY YEAR OCTOBER 30TH TO 31ST. AND
23	THE PLANNING IS UNDER WAY FOR A SECOND INDUSTRY
24	PARTNERING CONFERENCE AS PART OF THE STEM CELL
25	MEETING ON THE MESA. THAT'S STRONGLY SUPPORTED BY
	32

	BARRISTERS' REPORTING SERVICE
1	OUR COLLEAGUES DOWN THERE. BUT IT WENT VERY, VERY
2	WELL LAST YEAR.
3	WE HAVE A STRATEGIC PARTNER RFA POSTED
4	WEBINAR. DEADLINE FOR LETTERS OF INTENT ON THE MAY
5	16TH. CIRM WILL BE LED BY ELLEN FEIGAL HELD A
6	WEBINAR REGARDING THAT RFA, IN ADDITION TO OUTLINING
7	THE REQUIREMENTS, PROVIDED GUIDANCE ON HOW TO
8	PREPARE A STRONG RFA. SO WE RESPONDED TO INDUSTRY'S
9	NEEDS, TRYING TO GIVE THEM MORE INFORMATION ABOUT
10	HOW TO MORE EFFECTIVELY PREPARE THEIR APPLICATION.
11	AND SO THIS REALLY CAME OUT OF SOME RECOMMENDATIONS
12	FROM THE GRANTS WORKING GROUP. WE LISTENED TO WHAT
13	THE DEFICIENCIES WERE IN SOME OF THE INDUSTRY
14	APPLICATIONS, AND WE'RE TRYING TO GIVE THEM SOME
15	HEADS UP ABOUT THE DOS AND DON'TS OF ACTUALLY
16	APPLYING FOR CIRM FUNDING. AND I THINK IT WENT VERY
17	WELL.
18	ELLEN IS ALSO GOING TO PREPARE A WHITE
19	PAPER FOR US SO THAT IT'S RESIDENT THERE ON OUR
20	WEBSITE AND PEOPLE WILL BE ABLE TO LOOK AT IT, GET
21	THE DOS AND DON'TS, HELP THEM TO PREPARE BETTER
22	APPLICATIONS. AND WE'RE FULLY IN OUTREACH TO BOTH
23	VC'S AND PHARMA AT THE PRESENT TIME. MAYBE A LITTLE
24	TOO EFFECTIVELY PERHAPS. AS THE CHAIRMAN SAID,
25	WE'VE BEEN KIND OF OVERWHELMED WITH RESPONSE FROM
	33

1	INDUSTRY AT THE MOMENT. I THINK IT WOULD BE A FAIR
2	THING TO SAY THAT WE GOT A LOT MORE INTEREST FROM
3	INDUSTRY THAN WE EXPECTED FOR OUR STRATEGIC
4	PARTNERING RFA.
5	SO I'LL HAND OVER TO MATT NOW TO DO THE
6	FINANCE REPORT. BUT JUST THANKS TO EVERYBODY AGAIN.
7	THE TEAM HERE AT CIRM HAS BEEN WORKING OVERTIME.
8	IT'S BEEN GREAT WORKING WITH THEM ALL, AND IT'S BEEN
9	VERY EFFECTIVE COLLABORATION WITH MARIA AND HER
10	COLLEAGUES AS WELL. THANK YOU.
11	DR. PLUNKETT: THANK YOU, ALAN. SO I WILL
12	RUN THROUGH THE CIRM FINANCES. AS OF APRIL 30TH OF
13	THIS YEAR THROUGH THE END OF LAST MONTH, THE
14	OPERATING EXPENSES TOTALED \$11.0 MILLION. THE PRIOR
15	YEAR PERIOD WAS \$10.1 MILLION. GRANTS DISBURSEMENT,
16	194 MILLION VERSUS THE PRIOR YEAR PERIOD OF 172
17	MILLION. AND THE AVAILABLE BOND CASH AS OF THE END
18	OF LAST MONTH WAS 93 MILLION. THIS IS A DECREASE OF
19	\$65 MILLION FROM THE JANUARY 31ST NUMBERS WHICH I
20	SHARED WITH YOU AT THE MARCH BOARD MEETING IN
21	SACRAMENTO.
22	TO PROVIDE SOME FURTHER DETAIL ON THE
23	OPERATING EXPENSES AS COMPARED TO THE PRIOR YEAR
24	TEN-MONTH PERIOD, THE LARGEST INCREASE WAS DUE TO
25	EMPLOYEE EXPENSES, AN INCREASE OF 14 PERCENT OVER
	34

1	THE PRIOR YEAR PERIOD. SOME OTHER LARGER VARIANCES
2	THAT I WILL HIGHLIGHT FOR THE ICOC INCLUDE LOWER
3	THAN EXPECTED EXPENSE OR LOWER THAN THE PRIOR
4	YEAR PERIOD ON GRANTS REVIEWS, LOWER BY 31 PERCENT;
5	LOWER SPENDING ON INFORMATION TECHNOLOGY BY 33
6	PERCENT; AND AN INCREASE OF \$138,000 IN SCIENTIFIC
7	MEETINGS.

THE DRIVER FOR THE INCREASE IN EMPLOYEE 8 9 EXPENSES WAS THE INCREASE FROM 46 TO 54 FTE'S. THE 10 CONTRACTING INCREASE IN EXPENSE PRIMARILY REFLECTS 11 THE EXPENSES ON THE IOM REVIEW. THE SCIENTIFIC 12 MEETINGS REFLECTS THE WORLD STEM CELL SUMMIT, WHICH 13 WAS \$111,000, AND THEN THE ADDITIONAL FIGURE FOR 14 MEETINGS WAS THE GRANTEE MEETING WAS \$175,000. THIS OCCURS EVERY 18 MONTHS. AND THE COST OF THE GRANTS 15 16 WORKING GROUP MEETING WHICH WAS HELD IN APRIL IS NOT 17 YET REFLECTED IN ACTUAL EXPENDITURES.

IN ADDITION, THIS IS A FORECAST TO FISCAL
YEAR-END AS OF JUNE 30TH. AND WHAT I'VE DONE HERE
IS HIGHLIGHTED FOR EACH OF THE BUDGET CATEGORIES THE
FISCAL YEAR 11-12 BUDGET, A FORECAST TO YEAR-END,
AND THEN THE VARIANCE IN BOTH DOLLARS AND PERCENTAGE
TERMS.
THE OVERALL FIGURES ON OUR FISCAL YEAR

25 11-12 BUDGET IS \$18.5 MILLION. WE'RE FORECASTING A

35

1	FIGURE OF 16.5 TO YEAR-END, AND THAT'S \$2 MILLION
2	UNDER BUDGET. THE LARGEST DRIVER IN THIS IS \$1.1
3	MILLION IN UNDERSPENDING IN EMPLOYEE EXPENSES. THIS
4	IS DUE TO THE FACT THAT A NUMBER OF OUR POSITIONS
5	HAVE BEEN EXTREMELY HARD TO FILL, AND WE'VE HAD
6	SEVERAL POSITIONS THAT HAVE BEEN OPEN FOR MUCH OR
7	ALL OF THE YEAR TO DATE.
8	SO AS YOU'RE LOOKING AT THESE FIGURES, IF
9	YOU WANT TO THINK ABOUT WHAT AN ACTUAL RUN RATE
10	EXPENSE WOULD BE, I WOULD SUGGEST ADDING BACK IN
11	THAT VARIANCE. SO IT'S REALLY MORE LIKE A 17.6
12	MILLION PER YEAR SPENDING ON A RUN RATE BASIS.
13	IN ADDITION, SOME OF THE ADDITIONAL
14	SAVINGS THAT HAVE RESULTED IN UNDERSPENDING ON OUR
15	BUDGET, SOME OF THE LARGER ITEMS ARE LOWER THAN
16	EXPECTED SPENDING ON CONTRACTING, LOWER THAN
17	EXPECTED SPENDING ON GRANTS REVIEWS, AND LOWER THAN
18	EXPECTED SPENDING ON SCIENTIFIC MEETINGS.
19	THAT CONCLUDES THE BUDGET REPORT, AND I'D
20	BE HAPPY TO FIELD QUESTIONS FROM ANY MEMBERS OF THE
21	BOARD.
22	CHAIRMAN THOMAS: DR. TROUNSON.
23	DR. TROUNSON: JUST A QUICK UPDATE. I
24	THINK THAT BILL THAT I WAS SPEAKING ABOUT AS FILED
25	IN COMMITTEE AT THIS STAGE, IT MAY NOT HAVE
	36
	UC UC

	BARRISTERS' REPORTING SERVICE
1	COMPLETELY GONE AWAY, BUT I THINK THERE IS SOME VERY
2	SOLID OPPOSITION TO IT. SO I THINK PEOPLE OUGHT TO
3	KEEP A WATCHFUL EYE ON IT, BUT IT DIED IN COMMITTEE
4	TODAY, THIS MORNING. SO JUST AN UPDATE FOR YOU.
5	CHAIRMAN THOMAS: THANK YOU. ANY
6	QUESTIONS FOR MATT?
7	MR. TORRES: MR. CHAIRMAN.
8	CHAIRMAN THOMAS: YES, MR. SENATOR.
9	MR. TORRES: WE ARE IN VERY DIFFICULT
10	TIMES, AND I THINK HAVING THE CHANCELLOR HERE, WHO I
11	RESPECT TREMENDOUSLY, UNDERSTANDS THAT MORE THAN
12	ANYBODY GIVEN THE TREMENDOUS IMPACT THAT THIS BUDGET
13	HAS HAD AND THE REVENUE STREAM HAS HAD ON THE
14	UNIVERSITY OF CALIFORNIA.
15	WE SHOULD ALSO BE AWARE THAT AT THE END OF
16	2010, THEN ATTORNEY GENERAL JERRY BROWN REDUCED THE
17	SALARIES OF ALL OF OUR CONSTITUTIONAL OFFICERS AND
18	STATE LEGISLATORS BY 18 PERCENT. THE CONSTITUTIONAL
19	PAY COMMISSION IS NOW CONSIDERING AN ADDITIONAL 5
20	PERCENT REDUCTION IN THEIR SALARIES AS WELL. SO
21	THAT WOULD BE A TOTAL OF 23 PERCENT REDUCTION IN
22	STATE CONSTITUTIONAL OFFICERS FROM THE GOVERNOR ON
23	DOWN TO MEMBERS OF THE LEGISLATURE.
24	SO THE FACT THAT WE ARE TRYING TO SAVE
25	MONEY IS TREMENDOUS AS A STATE AGENCY, NO. 1. NO.
	37

1	2, AS THE LEGISLATURE AND THE GOVERNOR GRAPPLES WITH
2	THE STATE BUDGET, WHICH THEY HAVE TOLD ME THEY WILL
3	HOPEFULLY PASS BY THE JUNE 15TH DEADLINE, A BALANCED
4	BUDGET REQUIRED BY THE CONSTITUTION, IS GOING TO BE
5	A TREMENDOUS CHALLENGE. AND SO I JUST WANT TO
6	INDICATE THAT THE WORK OF DR. TROUNSON, DR. THOMAS,
7	AND OUR STAFF, INCLUDING OUR CFO, MATT, IS VERY,
8	VERY IMPORTANT THAT IT BECOME AS TRANSPARENT AS
9	POSSIBLE, THAT THE EFFORTS THAT WE ARE UNDERTAKING,
10	ESPECIALLY THE ROLE OF COMMERCIAL PAPER, WHICH WILL
11	BE LESS EXPENSIVE THAN THE DEBT SERVICE ON BONDS, IS
12	ALSO AN EFFORT FOR US TO TRY AND SAVE MONEY AS MUCH
13	AS WE CAN.
14	SO I'M NOT TROUBLED BY PEOPLE NOT
15	ACCEPTING POSITIONS WITHIN THE AGENCY BECAUSE THAT
16	HELPS US SAVE MONEY AS WELL, BUT THE TAXPAYERS NEED
17	TO KNOW THAT THEIR MONEY IS BEING WELL SPENT HERE,
18	THAT WE ARE FISCALLY PRUDENT, THAT WE ARE FISCAL AND
19	CONSERVATIVE OVERSEERS OF THE REVENUES THAT THEY
20	HAVE ENTRUSTED US WITH SINCE 2004 WHEN THIS
21	INITIATIVE PASSED, AND THAT WE WILL CONTINUE AS AN
22	AGENCY TO OVERSEE THE DEVELOPMENTS IN SACRAMENTO
23	BETWEEN NOW AND JUNE 15TH, AND WE WILL RESPOND
24	ACCORDINGLY AS BEST WE CAN IN TERMS OF OUR OWN
25	INITIATIVES, I THINK, WITH THE LEADERSHIP HERE OF
	38

	BARRISTERS' REPORTING SERVICE
1	THE INSTITUTE AND THIS BOARD.
2	AND, AGAIN, MY THANKS AGAIN TO MICHAEL
3	GOLDBERG WHO SERVES AS OUR FINANCE CHAIR
4	SUBCOMMITTEE CHAIR WHO HAS BEEN VERY SENSITIVE TO
5	THESE ISSUES. AND I JUST APPLAUD YOUR LEADERSHIP,
6	MICHAEL, IN TERMS OF THE ISSUES THAT YOU'VE BEEN
7	ABLE TO SUSTAIN. THANK YOU.
8	CHAIRMAN THOMAS: THANK YOU FOR THOSE
9	COMMENTS.
10	YES, MR. SERRANO-SEWELL.
11	MR. SERRANO-SEWELL: MY RECOLLECTION IS AT
12	OUR LAST MEETING, FULL COMMISSION MEETING, THERE
13	WERE SOME QUESTIONS AROUND, AND IF MICHAEL AND/OR
14	MARCY CAN SHARE WITH US HOW THAT GOT RESOLVED,
15	ISSUES AROUND OUTSIDE COUNSEL, SPECIFICALLY JAMES
16	HARRISON, TRAVEL, I SEE THERE AN INCREASE, AND THOSE
17	SORTS OF ISSUES, HOW THEY GOT RESOLVED AND THE
18	INTERNAL DISCUSSIONS BETWEEN THE COMMITTEE CHAIRS
19	AND STAFF.
20	CHAIRMAN THOMAS: DAVID, THERE HAS BEEN
21	DISCUSSION ON THAT. THE BUDGET ITSELF IS ON THE
22	AGENDA LATER TODAY, SO WE WILL ADDRESS THAT WHEN WE
23	GET TO THERE. THANK YOU.
24	YES, JOAN.
25	MS. SAMUELSON: I'D JUST LIKE TO ADD A
	39

1	LITTLE TAG LINE TO THE SENATOR'S STATEMENT WHICH I
2	COMPLETELY AGREE WITH AND I THINK IS EXTREMELY
3	IMPORTANT. I THINK IT'S IMPORTANT THAT THE PUBLIC
4	BE REMINDED THAT WHAT WE HAVE BEEN ASKED TO DO AS
5	OUR MISSION IS SPEND MONEY TO CONDUCT RESEARCH BY
6	ISSUING THE BONDS AND SO ON. AS YOU WERE DESCRIBING
7	EARLIER, WE DON'T PAVE HIGHWAYS, WE DON'T ISSUE
8	DRIVER'S LICENSES, WE DON'T EDUCATE PEOPLE, WHICH
9	THERE MAY BE MANY EFFICIENCIES, BUT IN OUR CASE THE
10	LESS MONEY WE SPEND, POTENTIALLY THE LESS RESEARCH
11	IS DONE. AND SO THERE'S ENORMOUS PRESSURE ON US, I
12	THINK, THAT MIGHT BE REDUCED A BIT IF THE PUBLIC IS
13	CLEAR ABOUT THAT. SO I'M JUST TRYING TO CLEAR THE
14	AIR A LITTLE BIT.
15	MR. TORRES: I THINK THAT'S AN IMPORTANT
16	POINT, BUT MY REFERENCE WAS TO THE 6-PERCENT CAP
17	THAT THIS AGENCY OPERATES UNDER, WHICH NO OTHER
18	STATE AGENCY OPERATES UNDER. AND THE FACT THAT WE
19	WILL BRING IN BETWEEN NOW AND 2012 201 MILLION IN
20	NEW REVENUE TO THE STATE AS A RESULT OF THIS BOARD'S
21	EFFORTS AND THIS AGENCY'S EFFORTS. SO 94 PERCENT
22	GOES DIRECTLY TO RESEARCH. AND OUR INTENT IS NEVER
23	TO DIMINISH THAT APPROPRIATELY, BUT TO CONTINUE THE
24	WORK THAT WE'VE BEEN DOING BECAUSE THAT'S THE
25	MANDATE THAT THE VOTERS GAVE US. BUT MY REFERENCE
	40

	BARRISTERS' REPORTING SERVICE
1	WAS TO THE FACT THAT AS A STATE AGENCY, WE ARE
2	OPERATING VERY FISCALLY RESPONSIBLY.
3	MS. SAMUELSON: RIGHT. EXACTLY. THANK
4	YOU.
5	CHAIRMAN THOMAS: OKAY. THANK YOU. ALAN,
6	DO YOU WANT TO COMMENT ON THE LAST SLIDE? WHO'S
7	THAT HANDSOME GUY IN THE MIDDLE THERE?
8	DR. TROUNSON: I ASSURE YOU, CHAIRMAN, I
9	DID NOT DO THIS SLIDE. YOU WILL ALL BE AWARE THAT I
10	NEVER APPEARED IN IT IN THE PAST. SO SOMEBODY'S
11	TAKEN SOME LICENSE TO THIS SLIDE. THEY WILL BE
12	REWARDED.
13	CHAIRMAN THOMAS: PHOTOSHOP IS AN
14	INTERESTING TOOL. OKAY. WE'LL NOW MOVE TO THE NEXT
15	ITEM ON OUR AGENDA. AS YOU KNOW, SB 1064 IN 2010
16	MANDATED THAT WE UNDERTAKE A PERFORMANCE AUDIT EVERY
17	THREE YEARS. THE FIRST OF THOSE IS NOW CONCLUDED
18	AND READY FOR YOUR REVIEW HERE AT THIS MEETING. IT
19	WAS CONDUCTED BY THE FIRM OF MOSS-ADAMS, AND WE HAVE
20	HERE MARK STERANKA AND MARY CASE, WHO ARE GOING TO
21	GIVE A PRESENTATION ON THAT PERFORMANCE AUDIT. SO
22	MARY OR MARK, I TURN IT OVER TO YOU. THANK YOU.
23	MS. CASE: GOOD MORNING, MEMBERS OF THE
24	BOARD. I'M MARY CASE, AUDIT PARTNER FROM
25	MOSS-ADAMS. AND WITH ME TODAY IS MY COLLEAGUE MARK
	41

1	STERANKA, SENIOR MANAGER. WE WANT TO THANK YOU VERY
2	MUCH FOR HAVING US WITH YOU TODAY TO PROVIDE A BRIEF
3	SYNOPSIS OF OUR PERFORMANCE AUDIT REPORT FOR CIRM.
4	AND WE'RE GOING TO LEAVE TIME AT THE END FOR
5	QUESTIONS, BUT WE WOULD WELCOME YOUR QUESTIONS ALONG
6	THE WAY IF YOU LIKE.
7	FIRST OF ALL, WHAT WE'RE GOING TO DO IS GO
8	THROUGH THE SCOPE OF THE WORK THAT WE DID FOR CIRM
9	AND THE AUDITING STANDARDS THAT WE FOLLOWED FOR OUR
10	WORK, THE SELECTION PROCESS THAT WAS MADE FOR OUR
11	ENGAGEMENT, AND OUR INDEPENDENCE OF CIRM. WE'RE
12	ALSO GOING TO REVIEW THE PROCESS UNDERTAKEN TO
13	PERFORM THE WORK FOR YOU AND TO DRAW OUR CONCLUSIONS
14	AND FORMULATE OUR RECOMMENDATIONS ALONG THE WAY.
15	WE'RE GOING TO SHARE A SUMMARY OF OUR
16	OBSERVATIONS, AND WE'RE GOING TO GO THROUGH OUR
17	FINDINGS FAIRLY BRIEFLY WITH SOME EXAMPLES, AND
18	WE'RE GOING TO DISCUSS OUR RECOMMENDATIONS IN A
19	TIERED FORMAT, IN A TIERED FRAMEWORK BASED ON
20	PRIORITIZATION.
21	SO LAST SUMMER CIRM ENGAGED A FIRM WITH
22	SIGNIFICANT PERFORMANCE AUDIT KNOWLEDGE TO ASSIST
23	THEM WITH THE PROCESS OF SELECTING A FIRM TO PERFORM
24	CIRM'S PERFORMANCE AUDIT. SO MOSS-ADAMS WAS
25	SELECTED BASED ON OUR EXPERIENCE WITH GOVERNMENTAL
	42
	42

1	AUDITING, WITH PERFORMANCE AUDITS, WITH GRANTS AND
2	CONTRACTING PROCESSES WITH GOVERNMENTS,
3	NOT-FOR-PROFIT ORGANIZATIONS, AND COMMERCIAL
4	ENTITIES, AS WELL AS OUR EXPERIENCE IN CONDUCTING
5	OPERATIONAL AUDITS.
6	THE SCOPE OF OUR WORK INCLUDED EXAMINATION
7	OF THE CORE FUNCTIONS OF CIRM. THESE INCLUDED THE
8	GRANT MAKING, PROCESSES RELATED TO LOANS,
9	CONTRACTING, AND TRACKING AND MONITORING OF
10	INTELLECTUAL PROPERTY. OUR WORK ALSO INCLUDED AN
11	ASSESSMENT OF THE ECONOMY, EFFICIENCY, AND
12	EFFECTIVENESS OF THE SUPPORTING FUNCTIONS AT CIRM.
13	AND THOSE INCLUDED EXECUTIVE LEADERSHIP, FINANCE,
14	HUMAN RESOURCES, INFORMATION TECHNOLOGY, LEGAL,
15	ADMINISTRATIVE SUPPORT, AND COMMUNICATIONS, THE
16	WHOLE SHOOTING MATCH, SO TO SPEAK.
17	OUR WORK SPANNED SIX MONTHS AND
18	ENCOMPASSED NEARLY A THOUSAND HOURS. THE SCOPE OF
19	OUR WORK DID NOT INCLUDE A VERY IMPORTANT ELEMENT,
20	CRITICAL ELEMENT, AND THAT'S AN ASSESSMENT OF THE
21	SCIENTIFIC ASPECTS OF THE CIRM'S WORK. YOU HAVE
22	OTHERS CONDUCTING THAT WORK.
23	THE AUDITING STANDARDS THAT WE FOLLOWED
24	WERE GENERALLY ACCEPTED GOVERNMENT AUDITING
25	STANDARDS WHICH EMANATE FROM THE GAO, GOVERNMENT
	43

1	ACCOUNTABILITY OFFICE, A FEDERAL AGENCY, WHICH
2	PRESCRIBED THE INDEPENDENCE AND OTHER STANDARDS
3	WHICH WE EMPLOYED IN THE CONDUCT OF OUR WORK. AND
4	SO WE'D, AGAIN, LIKE TO CONFIRM OUR INDEPENDENCE
5	FROM CIRM IN THE WORK THAT WE DID.
6	CIRM IS A VERY A RELATIVELY YOUNG
7	ORGANIZATION, AND WE WOULD EXPECT IT TO HAVE A
8	NUMBER OF FINDINGS RELATED TO PERFORMANCE AT THIS
9	STAGE OF ITS EXISTENCE. WE VIEW OUR REPORT AS
10	HAVING A VERY POSITIVE OUTCOME. THE CORE AREAS OF
11	GRANT MAKING, CONTRACTING, AND LENDING REVEALED NO
12	ISSUES WITH CONFORMITY, WITH POLICIES AND
13	PROCEDURES. THERE WERE NO FINDINGS IN THOSE KEY
14	AREAS WHICH ARE ADDRESSED BY THE IN THE
15	PERFORMANCE AUDIT; HOWEVER, THERE ARE SOME
16	OPPORTUNITIES FOR INCREASED EFFICIENCIES AND
17	IMPROVED EFFECTIVENESS.
18	OUR PROCESS CONSISTED OF SEVERAL STEPS.
19	THEY INCLUDED INTERVIEWING A SIGNIFICANT NUMBER OF
20	PEOPLE FROM THROUGHOUT THE ORGANIZATION IN A VARIETY
21	OF ROLES ACROSS EVERY FUNCTIONAL AREA INSIDE CIRM.
22	WE REVIEWED HUNDREDS OF DOCUMENTS, IT MAY EVEN
23	APPROACH THOUSANDS, TO UNDERSTAND POLICIES,
24	PROCEDURES, AND PROCESSES. WE THEN PERFORMED
25	STEP-BY-STEP WALK-THROUGHS WITH CIRM PERSONNEL TO
	44
	44

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

 OBSERVE THE PROCESSES AND CONTROLS TO ENSURE COMPLIANCE IN ALL THE AREAS OF THE CORE FUNCTIONS THAT WE WERE REVIEWING. AND THEN FOLLOWING THOSE WALK-THROUGHS, W SELECTED SAMPLES FROM POPULATIONS WITHIN THE CORE AREAS OF GRANTS, CONTRACTS, AND LOANS. WE EMPLOYED 	
 3 THAT WE WERE REVIEWING. 4 AND THEN FOLLOWING THOSE WALK-THROUGHS, W 5 SELECTED SAMPLES FROM POPULATIONS WITHIN THE CORE 6 AREAS OF GRANTS, CONTRACTS, AND LOANS. WE EMPLOYED 	
AND THEN FOLLOWING THOSE WALK-THROUGHS, W SELECTED SAMPLES FROM POPULATIONS WITHIN THE CORE AREAS OF GRANTS, CONTRACTS, AND LOANS. WE EMPLOYED	
5 SELECTED SAMPLES FROM POPULATIONS WITHIN THE CORE 6 AREAS OF GRANTS, CONTRACTS, AND LOANS. WE EMPLOYED	
6 AREAS OF GRANTS, CONTRACTS, AND LOANS. WE EMPLOYE)
)
7 STATISTICAL SAMPLING TECHNIQUES AND TESTED INTERNA	-
8 CONTROLS AND COMPLIANCE WITH POLICIES AND	
9 PROCEDURES.	
10 AMONG THE THINGS THAT WE NOTED DURING TH	Ξ
11 CONDUCT OF OUR WORK WERE THE PROFESSIONALISM, DRIV	Ξ,
12 AND FOCUS OF THE CIRM EMPLOYEES THAT WE INTERACTED	
13 WITH. WE SUBJECTED THEM TO CONSIDERABLE RIGOR	
14 DURING THE COURSE OF OUR AUDIT, AND WE REALLY	
15 APPRECIATED THEIR RESPONSIVENESS AND THEIR CANDOR	[N
16 DEALING WITH US ALONG THE WAY. THEY SEEM TO	
17 GENERALLY CARE ABOUT THEIR MISSION AND CREATED A	
18 DESIRE TO BE EFFICIENT AND EFFECTIVE STEWARDS OF T	ΙE
19 PUBLIC FUNDS.	
20 IN OUR WORK WE OBSERVED MANY DIFFERENT	
21 GOVERNMENT FUNDERS AND FIND THAT CIRM EXHIBITS MOR	Ξ
22 EFFECTIVE AND APPROPRIATE OVERSIGHT AND MONITORING	
23 THAN MANY, PERHAPS MOST THAT WE SEE. SO I'M GOING	
24 TO PASS THE BATON TO MARK STRANKA TO DISCUSS FURTH	ĒR
25 OUR OBSERVATIONS AND SUMMARIZE SOME OF OUR FINDING	5
45	

	BARRISTERS' REPORTING SERVICE
1	AND RECOMMENDATIONS AND THEN WE'LL TAKE SOME
2	QUESTIONS.
3	MR. TORRES: WOULD YOU REPEAT THAT LAST
4	LINE.
5	MS. CASE: PASSING THE BATON TO MARK.
6	MR. TORRES: NO. NO. THE LINE BEFORE
7	THAT.
8	MR. STERANKA: YOU'LL HEAR PLENTY OF GOOD
9	STUFF FROM ME.
10	MR. TORRES: ALL RIGHT.
11	MR. STERANKA: MR. CHAIR, VICE CHAIRS, AND
12	OTHER MEMBERS OF THE BOARD, IT'S A PLEASURE TO BE
13	BACK HERE. I ACTUALLY ATTENDED YOUR DECEMBER BOARD
14	MEETING AT CEDARS-SINAI, AND THAT WAS ACTUALLY QUITE
15	A MOVING EXPERIENCE GETTING TO HEAR ABOUT THE HEART
16	STEM CELL RESEARCH AND FROM THE DOCTORS AND
17	PATIENTS, AND THAT WAS REALLY QUITE EDUCATIONAL FOR
18	ME.
19	I WANT TO DO SOME STAGE SETTING BEFORE
20	TALKING ABOUT FINDINGS AND RECOMMENDATIONS BECAUSE
21	THE CONTEXT FOR DOING A PERFORMANCE AUDIT IS REALLY
22	AS IMPORTANT AS THE AUDIT ITSELF. AND AN AREA TO
23	START IS OUR WORK AND OUR ABILITY TO PROVIDE VALUE
24	TO YOU IS VERY MUCH PREDICATED ON THE EXPERIENCE
25	THAT WE HAVE IN WORKING WITH THE CLIENT FROM BOARD
	46

MEMBERS TO GRANTS WORKING GROUP MEMBERS TO YOUR
 SENIOR LEADERSHIP TEAM AND STAFF. AND I HAVE TO
 TELL YOU THEY WERE GREAT TO WORK WITH. THEY WERE
 COLLABORATIVE. THEY WERE EXTREMELY RESPONSIVE TO
 OUR NEEDS.

6 AS YOU PROBABLY ALL KNOW, CIRM WE WOULD 7 PUT IN THE CATEGORY AS ONE OF THOSE ORGANIZATIONS THAT GETS POKED AND PRODDED A LOT. OUR STUDY IS NOT 8 9 THE FIRST. I KNOW IT WON'T BE THE LAST. AND WE 10 KIND OF HATE TO BE A CONTRIBUTING FACTOR TO THAT BECAUSE IT TAKES A LOT OF EFFORT TO RESPOND TO THE 11 12 INFORMATION NEEDS OF AN ORGANIZATION LIKE OURS TO DO 13 THE WORK THAT WE DID. AND THE STAFF WAS REALLY JUST 14 GREAT IN WORKING WITH US, AND WE REALLY FEEL IT'S 15 INCUMBENT UPON US TO REALLY DELIVER VALUE FOR THE 16 TIME THAT THEY TAKE TO WORK WITH US AND THE MONEY THAT YOU SPEND ON US, AND WE HOPE THAT YOU FIND OUR 17 18 REPORT DOES, IN FACT, PROVIDE YOU VALUE.

19 SO AS BOARD MEMBERS, I'M GOING TO TRY TO 20 GIVE YOU WHAT I WOULD HOPE WOULD BE YOUR TAKEAWAYS 21 FROM OUR STUDY AND THE RESULTS. AND, AGAIN, A LOT 22 OF IT IS CONTEXTUAL. IT'S IMPORTANT FOR YOU TO KNOW 23 THAT WE HAD FREE REIN TO, WHAT I'D SAY, FOLLOW OUR 24 NOSE. SO WE GET IN, WE DO A LOT OF INTERVIEWS, WE 25 LOOK AT A LOT OF DOCUMENTS, AND WE'RE LOOKING FOR

47

1	WHERE WE CAN FIND WAYS FOR IMPROVED ECONOMY,
2	EFFICIENCY, AND EFFECTIVENESS.
3	AND THIS IS A VERY FAVORABLE REPORT. OUR
4	CLIENTS ARE ALWAYS SENSITIVE TO RESULTS OF A
5	PERFORMANCE AUDIT BECAUSE YOU ALWAYS THINK, WELL,
6	YOU'RE SAYING WE'RE NOT DOING SOMETHING RIGHT.
7	WELL, BY DEFINITION OUR JOB IS TO FIND OPPORTUNITIES
8	TO IMPROVE, AND THAT'S WHAT THESE ARE. THEY'RE
9	OPPORTUNITIES TO IMPROVE, TO BUILD UPON THE GOOD
10	WORK THAT YOU DO. THIS IS REALLY MORE OF A BUSINESS
11	FOCUS. IT'S CERTAINLY NOT A SCIENTIFIC FOCUS, AND A
12	LOT OF WHAT WE HAVE TO SAY IS ABOUT HELPING THE
13	ORGANIZATION TO BE MORE EFFICIENT, TO OPERATE EASIER
14	TO MAKE MANAGEMENT AND STAFF BETTER ABLE TO PERFORM
15	THE JOBS THAT THEY DO WITH TOOLS, WITH PROCESSES,
16	WITH TECHNOLOGY, AGAIN, JUST TO ENABLE LIFE TO BE
17	EASIER.
18	AND LASTLY, MAYBE CONTEXTUALLY, AN AUDIT
19	IS SOMETHING DONE AT A POINT IN TIME. AND I'VE
20	ALREADY HEARD TODAY, WE'RE ALREADY AWARE OF ANYWAY,
21	EXAMPLES OF THINGS THAT THE ORGANIZATION IS ALREADY
22	DOING IN RESPONSE TO FINDINGS AND RECOMMENDATIONS WE
23	HAD, THINGS THAT THEY WERE WORKING ON ANYWAY, THINGS
24	THAT HAVE TRANSPIRED DURING THE COURSE OF PREPARING
25	THE REPORT. AND SO WE'RE AT A POINT OF TIME OF
	40

48

1	FINDINGS AND RECOMMENDATIONS. YOU KIND OF HAVE TO
2	PUT A STAKE SOMEWHERE, AND I'M NOT EVEN SURE WHAT
3	DATE THAT ACTUALLY IS BECAUSE THINGS ARE ALWAYS
4	MOVING, AND OUR REPORT REFLECTS SOME THINGS THAT
5	HAVE ALREADY HAPPENED, AND IT REFLECTS SOME THINGS
6	THAT IT DOESN'T REFLECT SOME THINGS THAT HAVE
7	ALREADY HAPPENED, BUT THIS IS A VERY DYNAMIC
8	PROCESS. IT'S GREAT THAT THE ORGANIZATION IS
9	ALREADY ADDRESSING THINGS THAT ARE IN THE REPORT.
10	THAT'S REWARDING TO US, AND IT SHOULD BE REWARDING
11	TO YOU ALSO AS BOARD MEMBERS.
12	MAYBE ONE LAST THING IN TERMS OF PROCESS.
13	SO THERE'S A LOT OF DELIVERABLES AND STEPS IN THE
14	PROCESS OF A PERFORMANCE AUDIT, AND IT'S IMPORTANT
15	FOR YOU TO KNOW THAT IT BEGINS WITH AN AUDIT PLAN
16	THAT BASICALLY SAYS THIS IS WHAT WE'RE GOING TO LOOK
17	FOR, THIS IS HOW WE'RE GOING TO DO IT. IT'S VERY
18	SPECIFIC. ONCE WE GET IN AND START TO FORM
19	OBSERVATIONS AND FINDINGS, WE GO THROUGH A
20	VERIFICATION OF FACTS. SO ONCE WE HAVE FINDINGS, WE
21	MEET WITH STAFF AND MANAGEMENT AND BOARD CHAIR AND
22	VICE CHAIR AND MAKE SURE THAT WE'VE GOT IT RIGHT,
23	THAT WE HAVEN'T MISSED SOMETHING THAT WE SHOULD HAVE
24	CAUGHT, THAT WE HAVEN'T MISPORTRAYED SOMETHING, AND
25	REALLY MAKING SURE OUR FACTS ARE CORRECT.
	10

49

1	ONCE WE'RE THROUGH THAT POINT, WE DEVELOP
2	OUR RECOMMENDATIONS. WE, AGAIN, SORT OF GO THROUGH
3	THE PROCESS OF TESTING THE VIABILITY AND
4	REASONABLENESS OF THOSE RECOMMENDATIONS BECAUSE WE
5	DON'T WANT TO GIVE YOU TEXTBOOK ANSWERS. WE WANT TO
6	GIVE YOU THINGS THAT ARE PRACTICAL, THAT ARE
7	IMPLEMENTABLE FOR YOUR ORGANIZATION.
8	SO I THINK I WANT TO START HERE. THANK
9	YOU. I DIDN'T REALIZE YOU ALREADY GOT ME WHERE I
10	WANTED TO BE.
11	SO SOME OBSERVATIONS. WE WORK WITH
12	BUSINESSES, WE WORK WITH NOT-FOR-PROFITS, WE WORK
13	WITH GOVERNMENTS, LOTS OF ALL OF THE ABOVE,
14	HUNDREDS, IF NOT THOUSANDS. SO WE GET TO SEE A LOT.
15	WE WORK WITH START-UPS WHICH IS KIND OF WHAT CIRM
16	IS. YOU'RE STILL IN TRULY YOUR EARLY YEARS. WE
17	WORK WITH LOTS OF ENTITIES, GOVERNMENTAL ENTITIES,
18	THAT HAVE PROGRAMS THAT SUNSET. WHAT WE DON'T GET
19	TO WORK WITH ARE ORGANIZATIONS, A, AS SORT OF
20	COMPLICATED AS YOU ARE IN TERMS OF THE WORK THAT YOU
21	DO, BUT REALLY UNIQUE IS THE FACT THAT YOU ARE, IN
22	ESSENCE, STILL RAMPING UP YOUR ORGANIZATION, AND
23	THAT'S WHAT OUR STUDY LARGELY INDICATES BECAUSE
24	THERE ARE THOSE OPPORTUNITIES FOR IMPROVED
25	EFFICIENCY, BUT YOU'RE ALSO AT THE SAME TIME HAVING
	50

1	TO THINK ABOUT TECHNICALLY RAMPING DOWN AND WHAT
2	HAPPENS AT THE END OF THE FUNDING.
3	AND AS YOUR TRANSITION PLAN APPROPRIATELY
4	DOES, IT LOOKS AT ALTERNATIVES, BUT THAT IS A VERY
5	UNIQUE PLACE TO BE AND PROVIDES VERY UNIQUE
6	CHALLENGES TO AN ORGANIZATION TO, IN ESSENCE, BEING
7	RAMPING UP AND THINKING ABOUT RAMPING DOWN ALL AT
8	THE SAME TIME.
9	SO THAT IS VERY MUCH INHERENT IN OUR
10	FINDINGS AND RECOMMENDATIONS AND WHAT IMPACT THAT'S
11	HAVING ON THE ORGANIZATION. AND WHAT WE BELIEVE
12	WE'VE SEEN IS THAT AN ORGANIZATION HAS BEEN HIGHLY
13	FOCUSED, BEING EFFECTIVE ON BEING ABLE TO DO THE
14	BUSINESS THAT YOU DO, TO BE ABLE TO DISTRIBUTE
15	FUNDING TOWARDS YOUR MISSION, AND HAVE WORKED HARD
16	TO BE EFFECTIVELY DOING THAT YEAR IN AND YEAR OUT.
17	AND WHAT YOU SORT OF NOW HAVE A LITTLE BIT OF AN
18	OPPORTUNITY TO DO, ALTHOUGH IT'S NOT LIKE PEOPLE
19	HAVE TIME ON THEIR HANDS, BUT TO BE A LITTLE BIT
20	MORE FOCUSED NOW ON EFFICIENCY, ON HOW DO WE MAKE
21	THE PROCESS BY WHICH WE DO THESE THINGS EASIER. AND
22	YOU'LL HEAR SOME THEMES ABOUT DATA AND INFORMATION
23	AND DECISION-MAKING AND PERFORMANCE, AND THEY'RE ALL
24	TIED TO EFFICIENCY.
25	SO LET'S GO THROUGH SOME SPECIFIC
	51

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	FINDINGS. I BELIEVE YOU ALL HAVE A COPY OF OUR
2	REPORT. THE REPORT IS ORGANIZED BY THE CATEGORIES
3	REFLECTED ON THIS SLIDE. SO WE FIND COMPLIANCE,
4	PERFORMANCE, EFFICIENCY AND EFFECTIVENESS, HUMAN
5	CAPITAL, AND INFORMATION TECHNOLOGY. AS WE WENT
6	THROUGH OUR ASSESSMENT OF THE ORGANIZATION, THESE
7	ARE SORT OF THE THEMES OR THE BUCKETS IN WHICH WE
8	IDENTIFIED OPPORTUNITIES FOR THE ORGANIZATION TO
9	IMPROVE.

10 SO AS MARY MENTIONED, FROM COMPLIANCE, YOU 11 KNOW, THOSE WERE CHECKS DOWN THE BOX. YOU'RE FULLY 12 COMPLIANT WITH HOW YOU MANAGE YOUR GRANTS, MANAGE 13 YOUR LOANS, DEAL WITH YOUR CONTRACTS, HANDLE 14 INTELLECTUAL PROPERTY. ONE THING THAT WE HAVE FOUND 15 CERTAINLY IS THAT CIRM DOES NOT STAND STILL. THE 16 ORGANIZATION IS CONTINUALLY LOOKING AT HOW TO DO ITS 17 BUSINESS BETTER. A GOOD EXAMPLE OF THAT IS INTELLECTUAL PROPERTY. YOU KNOW, THERE WERE INITIAL 18 19 THOUGHTS ABOUT HOW WOULD BE THE BEST WAY TO COLLECT 20 INFORMATION RELATIVE TO IP. AND AS YOU'VE STARTED 21 TO GET MORE INTO THE PROCESS AND STILL AT THE VERY 22 NASCENT STAGE OF REALLY DEALING WITH INTELLECTUAL 23 PROPERTY AND CERTAINLY REVENUE ASSOCIATED WITH IT, 24 THE ORGANIZATION HAS LEARNED BETTER WAYS TO COLLECT 25 THAT INFORMATION AND IS, IN FACT, PURSUING THOSE

52

1	RELATIVE TO PERFORMANCE AND OUTCOMES.
2	SO THIS IS VERY MUCH A DATA-DRIVEN,
3	OUTCOME-BASED ORGANIZATION. AND CERTAINLY ONE OF
4	YOUR OPPORTUNITIES IS TO BETTER EQUIP MANAGEMENT,
5	BETTER EQUIP THE BOARD TO BE ABLE TO HAVE ACCESS TO
6	KEY PERFORMANCE DATA, OUTCOME-BASED INFORMATION THAT
7	IS JUST MORE READILY AVAILABLE. THE DATA IS THERE.
8	IT'S NOT THAT YOU'RE NOT COLLECTING IT. IT'S THAT
9	IT'S NOT TERRIBLY EASY TO GET YOUR HANDS ON IT. A
10	LOT OF WORK HAS TO GO INTO IT, AND IT REALLY
11	SHOULDN'T HAVE TO BE THAT COMPLICATED, THAT
12	TIME-CONSUMING, THAT MUCH OF AN EFFORT FOR YOUR
13	ORGANIZATION TO BE ABLE TO GENERATE THAT
14	INFORMATION.
15	FROM EFFICIENCY AND EFFECTIVENESS, A
16	COUPLE EXAMPLES. SO FROM AN EFFECTIVENESS
17	STANDPOINT, YOU HAVE A STRONG FOCUS ON DEVELOPING
18	BUSINESS WITH BIOPHARMACEUTICAL. SO ONE OF OUR
19	FINDINGS AND ASSOCIATED RECOMMENDATIONS IS
20	DEVELOPING A VERY SPECIFIC BUSINESS PLAN TO THAT
21	END. THAT'S A TOOL TO HELP YOU BE MORE EFFECTIVE,
22	TO ALIGN YOUR RESOURCES WITHIN THE ORGANIZATION THAT
23	HAVE THE CAPABILITIES TO INFLUENCE AND EFFECT THAT
24	TYPE OF BUSINESS.
25	AN EXAMPLE OF EFFICIENCY WOULD BE, FOR
	53

1	EXAMPLE, WITHIN YOUR FINANCE DEPARTMENT, YOU'RE
2	RELIANT ON THE STATE FOR A LOT OF YOUR FINANCIAL
3	INFORMATION. YOU DON'T HAVE YOUR OWN ACCOUNTING
4	SYSTEM. THERE'S A TREMENDOUS AMOUNT OF WORK THAT
5	HAS TO GO INTO PRODUCING THE INFORMATION THAT YOU
6	USE ON A DAY-TO-DAY BASIS, AND THAT COULD BE MADE
7	SIMPLER BY USING TECHNOLOGY. AND THAT SHOULD BE
8	SIMPLER. YOU SHOULDN'T GO INTO A ROOM AND SEE
9	STACKS OF PAPER AND KNOWING HOW MANY DIFFERENT
10	SOURCES YOU HAVE TO PULL INFORMATION FROM TO
11	ASSEMBLE A PARTICULAR REPORT. THAT'S NOT A KNOCK ON
12	THE AGENCY. THAT'S AN OPPORTUNITY TO BE ABLE TO BE
13	MORE EFFICIENT.
14	HUMAN CAPITAL, THIS REALLY GOES TO SOME OF
15	THE UNIQUENESS ABOUT YOUR SITUATION. BY DEFINITION,
16	HAVING TO THINK ABOUT RAMPING DOWN REALLY PUTS A
17	STRAIN ON HUMAN RESOURCES. JUST THE FACT THAT YOU
18	HAVE OPEN POSITIONS I THINK IN A WAY IS PARTLY
19	REFLECTIVE OF THAT. RECRUITING AND RETENTION FOR
20	YOUR STAFF IS REALLY A VERY IMPORTANT ISSUE FOR THIS
21	ORGANIZATION. IT WILL BECOME EVER MORE SO WITH EACH
22	YEAR THAT YOU GET CLOSER TO SUNSETTING. I KNOW
23	THERE'S EVERY HOPE THAT THE ORGANIZATION WILL
24	CONTINUE IN SOME FORM OR FASHION, BUT THE FACT OF
25	THE MATTER IS NONE OF US KNOWS WHAT THAT'S GOING TO
	54

54

1	
1	LOOK LIKE TODAY. SO IT'S REALLY IMPORTANT TO BE
2	ADDRESSING THE HUMAN CAPITAL ASPECT OF YOUR
3	ORGANIZATION IN THAT CONTEXT.
4	AND THEN, FINALLY, INFORMATION TECHNOLOGY.
5	I'M NOT A TECHNOLOGY GUY, BUT YOU HAVE I'LL JUST
6	FINISH AND THEN I'LL TAKE THAT. BUT YOU HAVE LOTS
7	OF OPPORTUNITY TO UTILIZE TECHNOLOGY, AGAIN, TO
8	ENABLE YOU TO BE MORE EFFICIENT. YOU'RE VERY MUCH
9	ON THE RIGHT TRACK. THERE'S A LOT GOING ON. YOU'RE
10	PROBABLY A LITTLE BIT BEHIND THE BALL ON IT BECAUSE
11	YOU COULD BE MAKING GREATER USE OF IT, BUT YOU'RE ON
12	THE RIGHT TRACK.
13	YES, QUESTION.
14	MR. SERRANO-SEWELL: YOU SAID WE COULD ASK
15	ALONG THE WAY. THANK YOU. THE ISSUE OF THE AGENCY
16	HAVING A SHELF LIFE, IF YOU WILL, WHICH YOU JUST
17	ADDRESSED IN TERMS OF RECRUITMENT, AND IT SORT OF
18	IMPACTS A LOT OF OTHER AREAS IN WHAT WE DO AS WELL,
19	SOMEWHAT UNSPOKEN BECAUSE IT'S A BIT OPAQUE WHEN
20	THAT DAY MIGHT HAPPEN, BUT IT WILL HAPPEN BARRING
21	SOMETHING ELSE. SO ASSUMING WE DON'T GET
22	RE-UPPED OR WHATEVER, JUST ASSUMING THAT THE SHELF
23	LIFE IS AND THAT WE WILL EXPIRE, ARE YOUR
24	RECOMMENDATIONS, SORT OF IS THAT EMBODIED WITHIN
25	YOUR REPORT LIKE YOU KNOW YOU WOULD HAVE TO CLOSE?
	55

1	WE'VE AUDITED OTHER ORGANIZATIONS THAT HAVE HAD A
2	SET TIME FRAME, AND THERE'S SPECIFIC THINGS YOU
3	SHOULD DO, ETC., ETC.
4	MR. STERANKA: THAT'S A GREAT QUESTION.
5	SO THE ANSWER IS KIND OF YES AND NO. YES IN THAT
6	ONE OF OUR RECOMMENDATIONS IS, AND YOU ALREADY HAVE
7	NOW A TRANSITION PLAN, AND THAT WOULD BE NO. 1 AN IS
8	FOR ANY ORGANIZATION THAT WE WORK WITH THAT HAS A
9	SHELF LIFE OR A PROGRAM THAT HAS A SHELF LIFE, WHICH
10	MANY PROGRAMS DO FUNDED BY TASK MEASURES. SO WHAT
11	ARE YOU GOING TO DO WHEN THAT HAPPENS? NO, WE
12	DIDN'T LOOK AT WHAT THOSE PARTICULAR SOLUTIONS
13	SHOULD BE BECAUSE THAT'S FRANKLY PREMATURE.
14	WHAT WE WOULD WANT TO SEE IS THAT THE
15	ORGANIZATION IS PREPARING FOR THAT. AND AS
16	IMPORTANTLY, COMMUNICATING TO YOUR EMPLOYEE BASE HOW
17	YOU'RE APPROACHING THAT, WHAT THE OPTIONS ARE
18	BECAUSE YOU WILL CONTINUE TO HAVE OPTIONS. THERE
19	WILL BE SOME TIME BEFORE SOMETHING IS SETTLED IN ON.
20	AND ONE OF OUR KEY CONCERNS RELATIVE TO
21	PERSONNEL IS THAT BY HUMAN NATURE PEOPLE SORT OF,
22	WHEN THEY HAVE TO FILL A VOID OF INFORMATION, THEY
23	TEND TO ASSUME THE WORST. WHAT'S THE WORST-CASE
24	SCENARIO? SO THE BEST WAY TO ADDRESS THAT IS BEING
25	VERY COMMUNICATIVE, VERY OPEN ABOUT WHAT ARE WE
	56
	50

1	DOING? WHAT ARE OUR OPTIONS? WHAT WE DO KNOW, WHAT
2	WE DON'T KNOW SO YOU'RE AT LEAST ELIMINATING THE
3	UNCERTAINTY IN TERMS OF GUESSING. YOU CAN'T
4	ELIMINATE THE UNCERTAINTY THAT YOU CAN'T DEVELOP A
5	SOLUTION FOR YET. BUT BEING, AS YOU ARE, BEING OPEN
6	ABOUT IT.
7	AS THAT EVOLVES, COMMUNICATING HOW IT'S
8	EVOLVING AND ALWAYS KEEPING IN MIND THE IMPACT THAT
9	IT CAN AND WILL HAVE ON YOUR PEOPLE, YOUR ABILITY TO
10	ATTRACT AS YOU WILL CONTINUE TO NEED TO, AND
11	CERTAINLY YOUR ABILITY TO RETAIN AS YOU WILL.
12	MR. SERRANO-SEWELL: LASTLY ON THAT TOPIC,
13	ONE WAY I MEAN CASE STUDIES, IF YOU WILL, IS THE
14	CLOSURE OF THE STATE'S REDEVELOPMENT AGENCIES. THAT
15	WAS SUDDEN. EVERYBODY KNEW IT. THEY DIDN'T THINK
16	IT WAS GOING TO HAPPEN. THEN IT DID HAPPEN AND MANY
17	AGENCIES, I BET SOME DID A BETTER JOB THAN OTHERS.
18	MR. STERANKA: ABSOLUTELY.
19	MR. SERRANO-SEWELL: AND THEY CERTAINLY
20	HAD TO DOWNSIZE AND KEEP THEIR CORE STAFF IN ONE WAY
21	OR ANOTHER. SO WE MIGHT LEARN FROM THAT.
22	MR. STERANKA: YOU MIGHT, BUT YOU
23	CERTAINLY HAVE THE BENEFIT OF YOU'RE VERY MUCH IN
24	FRONT OF THIS ISSUE. IT'S NOT GOING TO BE A
25	SURPRISE. IT'S JUST HOW IT'S GOING TO UNFOLD.
	57

1	THAT'S WHAT EVERYONE, I'M SURE, IS INTERESTED TO
2	SEE.
3	SO I'M GOING TO MOVE ON TO
4	RECOMMENDATIONS. AND I'M NOT GOING TO GO THROUGH
5	THESE, AND YOU OBVIOUSLY WOULDN'T EVEN BE ABLE TO
6	READ THEM ON THE SCREEN AS IT IS. WHAT I WANT TO
7	TALK ABOUT IS JUST SOME THEMES, PRIORITIES, HOW WE
8	ADDRESS THEM. SO WE BROKE THEM INTO THREE TIERS.
9	WE BELIEVE THAT ALL 27 RECOMMENDATIONS ARE ALL
10	IMPORTANT. WE HAVE IDENTIFIED WHERE WE THINK THAT
11	THERE IS A POTENTIAL EXTERNAL COST TO THE
12	ORGANIZATION. ALL OF THE CASES WHERE THERE'S A COST
13	IDENTIFIED, THEY'RE TECHNOLOGY RELATED. WITH YOUR
14	NEW HIRING OF AN I.T. DIRECTOR, SOME OF THAT MAY NOT
15	NEED TO BE EXTERNAL COST, WHICH IS GREAT.
16	SOME OF THE THEMES THAT I WOULD HOPE YOU
17	WOULD TAKE AWAY FROM THESE AS A BODY IS, AGAIN,
18	YOU'RE A VERY DATA-DRIVEN, OUTCOME-BASED
19	ORGANIZATION. AND A LOT OF OUR RECOMMENDATIONS ARE
20	REALLY GEARED TOWARDS BEING ABLE TO GENERATE DATA
21	MORE EASILY, HOW YOU COMMUNICATE THAT INFORMATION TO
22	YOUR VARIOUS AUDIENCES, HOW YOU CAN USE TECHNOLOGY
23	TO STREAMLINE THAT PROCESS, HOW YOU CAN INCORPORATE
24	THE USE OF PERFORMANCE METRICS THROUGHOUT YOUR DAILY
25	OPERATIONS FROM USING THEM IN STAFF MEETINGS TO
	FO

58

1	BEING ABLE TO MAKE DECISIONS AS A BOARD, TO HOW YOU
2	REFLECT THAT IN YOUR ANNUAL PLAN, IN GENERAL HOW YOU
3	COMMUNICATE PERFORMANCE AND PROGRESS TOWARDS THE
4	OUTCOMES TO ALL OF YOUR AUDIENCES. THOSE ARE ALL,
5	OF COURSE, PARAMOUNT TO YOUR BUSINESS.
6	A FEW TO JUST POINT OUT, AND, AGAIN, I
7	APOLOGIZE THAT YOU CERTAINLY CAN'T READ THIS ON
8	SCREEN. AS FAR AS A FEW ITEMS TO TAKE AWAY HERE FOR
9	TIER 1 RECOMMENDATIONS. SO WE TALK ABOUT GRANTS
10	OUTCOME TRACKING, AND THE WORK THAT THE ORGANIZATION
11	IS CURRENTLY DOING TO DEVELOP A DATABASE TO REALLY
12	AT THE FRONT END BE ABLE TO COLLECT THE DATA THAT'S
13	GOING TO TIE BACK TO YOUR OUTCOMES. AND BEING ABLE
14	TO PULL THAT WORK FORWARD AND BUILD IT INTO, WE'VE
15	USED THE TERM, A DIGITAL DASHBOARD, SOMETHING THAT
16	TYPICALLY A BUSINESS WOULD HAVE, AN EXECUTIVE TEAM
17	WOULD BE ABLE TO USE TO SORT OF KEEP THE PULSE ON
18	SOME OF THOSE KEY METRICS THAT YOU'RE, IN ESSENCE,
19	TRACKING CERTAINLY ON AN ANNUAL BASIS, BUT MAKING
20	THAT MORE READILY AVAILABLE ON MORE OF A DAY-TO-DAY
21	BASIS AND TRANSLATING THAT SAME TYPE OF INFORMATION
22	INTO A MORE PERFORMANCE-BASED ANNUAL REPORT.
23	DEVELOPMENT OF A COMMUNICATIONS PLAN,
24	WHICH I BELIEVE HAS ALREADY OCCURRED. SO THAT'S
25	GOING TO BE AN EXAMPLE OF THINGS THAT HAVE
	59
	55

1	TRANSPIRED DURING THE COURSE OF OUR STUDY.
2	MAKING GRANTS OUTCOME DATA NOT AN OPTION
3	IN TERMS OF PROGRESS REPORTS, BUT A REQUIREMENT.
4	THAT IS ALSO UNDER WAY, AND I BELIEVE INFORMATION
5	EITHER HAS ALREADY OR WILL BE PRESENTED TO THE BOARD
6	RELATIVE TO THAT.
7	ON THE NEXT GROUP OF RECOMMENDATIONS,
8	FIRST ONE ON THE LIST, DOCUMENT MANAGEMENT. SO
9	THIS, AGAIN, GOES BACK TO THIS ORGANIZATION, UNLIKE
10	MANY OTHERS, CERTAINLY UNLIKE MANY STATE AGENCIES,
11	IS GENERATING AN ENORMOUS AMOUNT OF CRITICAL
12	INFORMATION THAT MAYBE ONE COULD ARGUE IS GOING TO
13	BE IMPORTANT FOR GENERATIONS TO COME. PROTECTING
14	THAT INFORMATION, BEING ABLE TO ACCESS THAT
15	INFORMATION BOTH IN THE NEAR TERM AND THE LONG TERM
16	THROUGH A DOCUMENT MANAGEMENT SYSTEM IS QUITE
17	IMPORTANT TO THE ORGANIZATION. IT'S NOT SEXY. IT'S
18	NOT REALLY INTERESTING, DOCUMENT MANAGEMENT, BUT
19	THIS IS SOMETHING THAT WILL HELP YOU PROTECT THE
20	INFORMATION AND IS CERTAINLY SOMETHING WORTH
21	PURSUING.
22	DEALING WITH YOUR ABILITY TO REVIEW
23	PROGRESS REPORTS, YOUR SCIENTIFIC OFFICERS. SO ONE
24	OF OUR FINDINGS WAS YOU'RE REALLY NOT ABLE TO REVIEW
25	PROGRESS REPORTS QUITE AS TIMELY AS THE ORGANIZATION
	60
	00

-	
1	WOULD HOPE TO GIVEN THE OVERALL WORKLOAD. THAT'S
2	CORE TO YOUR BUSINESS, CORE TO BEING ABLE TO GLEAN
3	PROGRESS CERTAINLY ON THOSE, AND MAKING SURE THAT
4	YOU'RE RESOURCED, THAT YOU'RE USING TOOLS TO
5	OPTIMIZE YOUR ABILITY TO DO THAT.
6	A COUPLE EXAMPLES ON TIER II
7	RECOMMENDATIONS. THE THIRD ONE DOWN, WE TALK ABOUT
8	A FORMAL BUSINESS DEVELOPMENT PLAN, WHICH I
9	MENTIONED EARLIER, AGAIN, WITH A FOCUS TOWARDS THE
10	BIOPHARMACEUTICAL INDUSTRY. YOU HAVE SOME GREAT NEW
11	RESOURCES, NOT MAYBE SO NEW ANYMORE IN YOUR
12	ORGANIZATION, AT THE LEADERSHIP LEVEL WHO BRING
13	GREAT SKILL SETS. THIS IS JUST ALL ABOUT PUTTING A
14	PLAN TOGETHER. WHAT'S OUR GO TO MARKET STRATEGY?
15	WHO HAS WHAT RESPONSIBILITY WITHIN THE ORGANIZATION?
16	THINGS THAT YOU'RE DOING INHERENTLY, BUT
17	CRYSTALLIZING THOSE IN TERMS OF A PLAN.
18	GETTING ACCESS, WHICH YOU'VE ALREADY
19	REQUESTED, TO THE STATE CONTROLLER'S OFFICE FISCAL
20	SYSTEM. SO YOU RELY ON THE STATE FOR FISCAL
21	INFORMATION. YOU DON'T HAVE YOUR OWN FINANCIAL
22	SYSTEM. YOU'VE GOTTEN THAT THROUGH DEPARTMENT OF
23	GENERAL SERVICES RECENTLY READ ONLY ACCESS. THESE
24	ARE THINGS THAT WILL HELP YOUR FINANCE DEPARTMENT TO
25	BE MORE EFFICIENT, HAVE A REDUCED DUAL WORK WITH
	61

1 DATA.

2 AND MAYBE LAST, BUT NOT LEAST, AN EXAMPLE AT YOUR TIER III LEVEL. I MENTIONED A TRANSITION 3 4 PLAN AND HOW IMPORTANT THAT IS TO THE ORGANIZATION 5 ONGOING. I KNOW YOU ALREADY HAVE MAYBE WITH YOUR GOVERNANCE BOARD TO ADOPT A BOARD CODE OF CONDUCT. 6 7 THAT'S NOT RECOMMENDED BECAUSE WE HAVEN'T SEEN ANY ISSUES. IT'S JUST PRUDENT PRACTICE FOR A BOARD TO 8 9 HAVE A CODE OF CONDUCT IN PLACE. SO THAT'S KIND OF 10 JUST A REGULAR TYPE OF RECOMMENDATION. I THINK WITH THAT MAYBE I'LL STOP TALKING. 11 12 I DON'T WANT TO GET YOU TOO BEHIND IN YOUR SCHEDULE 13 HERE EARLY. ANY QUESTIONS, ANY OTHER QUESTIONS? 14 CHAIRMAN THOMAS: MR. SENATOR. 15 MR. TORRES: THANK YOU VERY MUCH FOR THAT 16 PRESENTATION. FOR THE NEW MEMBER OF THE BOARD AS 17 WELL AS FOR THE REMAINING MEMBERS OF THE BOARD, I THINK IT'S IMPORTANT TO PUT THIS WHOLE REPORT INTO 18 19 CONTEXT. THIS WAS NOT A SIMPLE PROCESS TO GET TO. 20 WITH THE HELP OF SCOTT TOCHER, JAMES HARRISON, AND 21 MYSELF, WORKING WITH THE PRESIDENT PRO TEM OF THE SENATE, DARRELL STEINBERG, AND ALSO WITH THE 22 23 MAJORITY LEADER, DEAN FLOREZ, AND, OF COURSE, SENATOR ELAINE ALQUIST, WHO WAS THE AUTHOR OF THE 24 25 BILL, AND OBVIOUSLY WORKING WITH THE CONTROLLER OF 62

1	THE STATE, IT WAS A VERY ARDUOUS PROCESS TO GET TO
2	THE POINT OF PUTTING A PERFORMANCE AUDIT REQUIREMENT
3	WITHIN SENATE BILL 1064.
4	AND THE REASONS FOR THAT IS THAT MOST
5	PEOPLE MAY NOT KNOW, BUT THIS AGENCY HAS MORE AUDITS
6	THAN ANY OTHER STATE AGENCY IN MY HISTORY AND THE
7	HISTORY OF THE STATE OF CALIFORNIA. WE HAVE AN
8	AUDIT THAT WE DO INTERNALLY. WE HAVE AN AUDIT
9	THAT'S REVIEWED BY THE CONTROLLER. THE CONTROLLER
10	DOES ITS OWN AUDIT REVIEW, AND WE REPORT TO THAT.
11	AND THEN WE REPORT TO THE CONTROLLER'S COMMITTEE,
12	WHICH IS LABELED FINANCIAL ACCOUNTABILITY COMMITTEE.
13	AND I MIGHT ADD THAT REPORT WAS GREETED WITH
14	TREMENDOUS SUPPORT AND A REAL CHANGE IN DIRECTION
15	BECAUSE OF OUR NEW CHAIR AND OBVIOUSLY OUR PRESIDENT
16	WORKING HARD TO MAKE SURE THAT WE ADDRESS THE ISSUES
17	THE CONTROLLER HAD RAISED WITHIN THAT REPORT.
18	SO IMPOSING ANOTHER AUDIT AND A
19	PERFORMANCE AUDIT WAS NOT AN EASY THING TO ACCEPT,
20	BUT WE DID. AND WE NEGOTIATED IT AND ACCEPTED IT
21	BECAUSE WE FELT AT THE END OF THE DAY TRANSPARENCY
22	WAS MUCH MORE IMPORTANT THAN STALLING AROUND OR
23	TRYING TO MAKE THE ARGUMENT THAT IT WOULD COST US
24	MORE. WE ALSO WANTED TO MAKE SURE THAT THIS
25	PERFORMANCE AUDIT WAS DONE ACCORDING TO STATE AND
	63

1	NATIONAL STANDARDS, WHICH YOU HAVE DONE EXPERTLY.
2	AND THIRDLY, I THINK IT'S IMPORTANT TO
3	POINT OUT THAT THIS PERFORMANCE AUDIT WAS ALSO
4	IMPORTANT TO LAY OUT TO THE REMAINING MEMBERS OF THE
5	LEGISLATURE, NEW AND RETURNING, THAT WE ARE A
6	TRANSPARENT AGENCY, THAT WE BELIEVE IN
7	ACCOUNTABILITY. AND OBVIOUSLY OUR EXPECTATIONS WERE
8	THAT THIS PERFORMANCE AUDIT, INTERNALLY WE KNEW WE'D
9	BE OKAY, AND COMPARATIVELY SPEAKING WE DID VERY WELL
10	IN TERMS OF HOW WE PERFORM AND HOW WE WILL CONTINUE
11	TO PERFORM, AND THE FACT THAT THIS AGENCY HAS ALSO
12	TAKEN VERY SPECIFIC STEPS TO ADDRESS THE ISSUES THAT
13	YOU HAD ALREADY RAISED, THE BOARD OF CONDUCT ISSUE
14	WHICH WAS NOT BASED ON ANY ISSUES THAT WERE RAISED
15	INTERNALLY, BUT A GOOD BEST PRACTICES FOR ANY
16	AGENCY.
17	IN RESPECT TO A COMMUNICATIONS PLAN, IT
18	TOOK US A WHILE TO GET TO THAT POINT, BUT WE'RE
19	THERE NOW WITH A GOOD DIRECTOR OF COMMUNICATIONS AND
20	PATIENT OUTREACH, KEVIN MCCORMACK. SO WE'VE MADE
21	TREMENDOUS STRIDES, BUT I THINK IT'S IMPORTANT FOR
22	THE BOARD TO UNDERSTAND THAT IT WAS NOT AN EASY
23	JOURNEY. AND NEGOTIATING THIS, AS JAMES AND SCOTT
24	WILL TELL YOU, WAS NOT AN EASY TASK, BUT IT WAS
25	DONE. AND I BELIEVE AT THE END OF THE DAY I'M GLAD
	64
	04

1	IT WAS DONE. AND I WANT TO THANK YOU AND YOUR
2	AGENCY FOR SHOWING THE TAXPAYERS THAT WE HAVE, THAT
3	WE ARE A FISCALLY RESPONSIBLE STATE AGENCY.
4	CHAIRMAN THOMAS: MR. GOLDBERG.
5	MR. GOLDBERG: THANK YOU FOR YOUR REPORT.
6	MY QUESTION IS YOU REFERENCE THAT YOU DO THIS FOR
7	HUNDREDS OF ORGANIZATIONS OF ALL DIFFERENT TYPES.
8	COULD YOU BE QUANTITATIVE AND TAKE A STAB AT WHAT
9	QUARTILE OR DECILE YOU WOULD RATE OUR PERFORMANCE?
10	MR. STERANKA: HOW DID WE KNOW THAT WAS
11	COMING? I WON'T BE QUITE AS COOPERATIVE AS YOU
12	WOULD LIKE. I WOULD SAY THAT YOU FAIRED VERY
13	FAVORABLY. I THINK THAT THAT'S A FAIR, A VERY FAIR
14	RANKING, RATING OF YOU, OF THE ORGANIZATION. I
15	DON'T KNOW THAT I WOULD GO TO QUARTILES NECESSARILY.
16	THIS IS A VERY FAVORABLE REPORT COMPARED TO OTHERS
17	THAT WE HAVE PROVIDED FOR OTHER CLIENTS.
18	MS. CASE: I JUST HAVE TO WEIGH IN ON
19	LITTLE BIT ON THAT. I WOULD SAY IN THE CORE AREAS
20	THAT YOU GUYS WERE SUPERLATIVE COMPARED TO MOST
21	OTHERS. BUT WHEN YOU WEIGH IN THE OPERATIONAL
22	OPPORTUNITIES FOR EFFICIENCY AND EFFECTIVENESS, I
23	THINK MARK'S COMMENT IS EXACTLY RIGHT ON. BUT THE
24	CORE COMPLIANCE AND INTERNAL CONTROL WORK THAT WE
25	DID WAS EXTREMELY GOOD, VERY WELL DESIGNED AND
	65

-	
1	IMPLEMENTED. NO FINDINGS. AND A GOVERNMENT AGENCY
2	OVERSEEING GRANTEES AND MONITORING PROGRESS AND
3	PROVIDING CONSULTATIONS TO THE GRANTEES, VERY
4	EXCELLENT JOB. AND THAT'S A KEY PIECE OF WHAT YOU
5	DO AND A KEY PIECE OF WHAT'S IN THE REQUIREMENT FOR
6	YOUR PERFORMANCE AUDIT.
7	MR. STERANKA: WAS THAT BETTER?
8	MR. GOLDBERG: NO COMMENT.
9	MR. STERANKA: FAIR ENOUGH.
10	CHAIRMAN THOMAS: DR. TROUNSON.
11	DR. TROUNSON: I'D JUST LIKE TO THANK MARK
12	AND HIS COLLEAGUES FOR BEING A GOOD TEAM TO WORK
13	WITH. AS ART SAID, WE'RE UNDER AN INCREDIBLE
14	PRESSURE TO DELIVER THE PROGRAM FOR CIRM, FOR THE
15	BOARD. AND WE WERE SITTING THROUGH THREE AUDITS
16	GOING ON SIMULTANEOUSLY. AND PARTICULARLY THE
17	PRESSURE ON AMY LEWIS AND GABE THOMPSON AND PAT
18	OLSON AND THE TEAM WAS REALLY, REALLY TOUGH. BUT
19	THEY KEPT UP THE PACE FOR ALL OF THE OTHER
20	ACTIVITIES, AND I THINK IT WAS REALLY HELPFUL THAT
21	MARK UNDERSTOOD THE PRESSURES THAT WE'RE UNDER AND
22	DID IT IN A WAY WHERE IT WAS OKAY TO DO.
23	I MEAN I ACTUALLY THOUGHT WE WERE GOING TO
24	RUN INTO TROUBLE BECAUSE IF IT HADN'T BEEN A
25	THOUGHTFUL GROUP OF PEOPLE, IT MIGHT HAVE HURT
	66

REALLY BADLY.

1

2 AND I WANT TO THANK IAN SWEEDLER FOR HIS 3 WORK. HE DID A TREMENDOUS JOB ON HELPING MAKE THE 4 CONNECTIONS TO SMOOTH THE WAY AND REALLY HELP GET 5 THE INFORMATION THAT YOU'RE LOOKING FOR. SO I THINK FROM BOTH SIDES, FROM WHAT I THOUGHT MIGHT BE REALLY 6 7 A DIFFICULT CHORE AND WOULD SET US WAY BEHIND ON 8 SOME OF OUR OTHER ACTIVITIES, WE MANAGED TO KEEP UP 9 OUR OWN PACE AND ADDRESS THE ISSUES THAT YOU NEEDED 10 TO HAVE ADDRESSED. SO I WANT TO THANK YOU FOR THAT AND THANK THE STAFF FOR ACTUALLY DOING IT WITH 11 12 REALLY GOOD HUMOR AND IN A VERY POSITIVE WAY. AND I 13 THANK GOODNESS BECAUSE IT COULD HAVE BEEN QUITE 14 DIFFICULT. AS I PREDICTED, I THINK, LAST YEAR, THIS 15 WAS GOING TO BE A TOUGH TIME FOR US. BUT THANK YOU 16 FOR BEING SENSITIVE AND BEING HELPFUL TO US, I 17 THINK. 18 AND I THINK THE RECOMMENDATIONS THAT YOU 19 MAKE ARE VERY USEFUL. SO SOME OF THEM ARE UNDER 20 CONSIDERATION ABOUT HOW WE CAN ACTUALLY DO THEM, BUT 21 MOST OF THEM ARE IN PROCESS ALREADY, AND WE'VE 22 IDENTIFIED THE KEY STAFF THAT WILL ACTUALLY DELIVER 23 ON THEM. 24 SO WE FEEL VERY GOOD ABOUT THIS AUDIT, AND 25 WE FEEL THAT WE'VE BEEN DONE OVER BY A REAL 67

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PROFESSIONAL GROUP OF PEOPLE IN A WAY THAT'S BEEN
2	VERY HELPFUL. SO THANK YOU TO YOU AND YOUR
3	COLLEAGUES.
4	MR. STERANKA: THANK YOU. YOU HAVE QUITE
5	A HIGH CALIBER GROUP HERE, SO WE HAD TO HAVE OUR ACT
6	TOGETHER TO KEEP UP WITH YOU.
7	CHAIRMAN THOMAS: THANK YOU FOR THOSE
8	COMMENTS, ALAN. I'D LIKE TO ADD TO THAT ON TOP OF
9	EVERYTHING ELSE. AS EVERYBODY KNOWS, THIS IS AN
10	EXTRAORDINARY YEAR IN TERMS OF NUMBERS OF RFA'S THAT
11	WE HAVE OUTSTANDING, THINGS TO EVALUATE, THINGS TO
12	REVIEW. SO WHEN YOU OVERLAY THREE AUDITS ON TOP OF
13	THAT, IT DOES POSE SOME SIGNIFICANT LOGISTICAL
14	CHALLENGES. AND I WANT TO ECHO WHAT ALAN SAID IN
15	CONGRATULATING EVERYBODY FOR COMPLETELY RISING TO
16	THE OCCASION ON THIS AND EVERYTHING ELSE WE'RE DOING
17	TO MAKE WHAT IS A VERY CHALLENGING YEAR GO
18	SEAMLESSLY. AND, MARK, THANK YOU VERY MUCH AS WELL.
19	DO WE HAVE ANY COMMENTS, CLOSING THOUGHTS?
20	WE REALLY APPRECIATE THIS. WE ARE DELIGHTED WITH
21	THE RESULTS. IT'S ALWAYS NICE TO HEAR THAT WE'RE ON
22	THE RIGHT TRACK AND ACTUALLY BETTER THAN THAT.
23	JAMES. THANK YOU. JAMES IS GIVING ME THE
24	EYE OVER THERE. SO DO WE HAVE ANY PUBLIC COMMENT ON
25	THIS PARTICULAR TOPIC? WELCOME, DON REED.

68

1	MR. REED: MY PLEASURE. I THINK THERE'S
2	SOMETHING THAT GOES A LITTLE BEYOND THAT. THIS
3	ORGANIZATION HAS BEEN AUDITED SO MANY TIMES, AND
4	EVERY TIME COMING UP SQUEAKY CLEAN. AND I FELT THAT
5	THERE'S SOMETHING MORE THAN THAT THAT NEEDED TO BE
6	SAID. AND THAT WAS WHY I WROTE THE FOLLOWING LETTER
7	WHICH WILL MAKE SENSE WHEN I GET TO THE END OF IT.
8	AS THE FATHER OF A PARALYZED YOUNG MAN,
9	I'M REMINDED EVERY DAY WHY CALIFORNIA APPROVED
10	PROPOSITION 71 AUTHORIZING THE SALE OF STATE BONDS
11	TO FUND THE PROGRAM OF STEM CELL RESEARCH. ROMAN
12	REED WAS 19 WHEN HIS NECK WAS BROKEN AT A COLLEGE
13	FOOTBALL GAME. TODAY AT 36 HE'S REMARKABLY
14	INDEPENDENT, DRIVING AN ADAPTED VAN, GRADUATE OF UC
15	BERKELEY, AND A FATHER OF THREE, BUT HE'S STILL
16	PARALYZED, AMONG THE 100 MILLION AMERICANS AFFLICTED
17	WITH A CHRONIC DISEASE DISABILITY.
18	CONSIDER THOSE AUDITS. ONE IN THREE U.S.
19	CITIZENS HAS AN INCURABLE ILLNESS OR INJURY. THIS
20	IS A PROBLEM WHICH COULD CRUSH A COUNTRY'S ECONOMY.
21	IN 2009 AMERICA SPENT 1.65 TRILLION ON CHRONIC
22	DISEASE, EXCEEDING THE ENTIRE NATIONAL DEBT FOR THAT
23	PERIOD OF TIME. AND FOR ALL THAT COLOSSAL
24	EXPENDITURE, NOT A SINGLE PERSON GOT WELL.
25	CHRONIC MEANS INCURABLE. THAT IS WHY
	69
	00

1	CALIFORNIA INVESTED IN THE \$6 BILLION STEM CELL
2	PROGRAM BECAUSE WE WANT TO HEAL OUR LOVED ONES, NOT
3	JUST MAINTAIN THEM IN THEIR MISERY. TODAY 12
4	SHINING NEW STEM CELL RESEARCH CENTERS ARE FOSTERING
5	A SYSTEMATIC QUEST FOR CURE, FORMING BIOMEDICAL
6	CLUSTERS UP AND DOWN THE STATE. WAS THIS EXPENSIVE?
7	OF COURSE. A WAR CANNOT BE FOUGHT FOR PENNIES, BUT
8	CALIFORNIA WAS CAREFUL TOO. WE DO NOT WANT TO
9	OVERSPEND ON CONSTRUCTION COST. THE GOVERNING BOARD
10	ADDED A CREATIVE FINANCIAL REQUIREMENT THAT
11	POTENTIAL SITES SHOULD COMPETE TO BRING OUTSIDE
12	MONEY WITH THEM. THIS LEVERAGED CIRM'S 271 MILLION
13	INTO 1.15 BILLION, FOUR TIMES OUR INVESTMENT, NEW
14	MONEY FOR THE GOLDEN STATE.
15	ALREADY THE PROGRAM HAS BENEFITED
16	CALIFORNIA BY EXPANDING BIOMEDICAL, ONE OF OUR
17	STATE'S FOUNDATIONAL INDUSTRIES. YOUNG PEOPLE CAN
18	LEARN A NEW TRADE AT THEIR LOCAL HIGH SCHOOLS AND
19	STATE COLLEGES BECAUSE OF A CIRM PROGRAM AVAILABLE
20	ONLINE AS PART OF THEIR EDUCATIONAL CURRICULA.
21	ADDITIONALLY, THE BRIDGES PROGRAM OFFERS A
22	WAY FOR TOPNOTCH, OFTEN FINANCIALLY DISADVANTAGED
23	STUDENTS TO WORK IN STEM CELL LABORATORIES GETTING
24	PRICELESS PRACTICAL EXPERIENCE TO BEGIN WHAT MIGHT
25	BECOME A FRUITFUL CAREER.
	70

70

1	THE CIRM HAS TRIED TO ANTICIPATE EVERY
2	NEED OF A NEW AND DEVELOPING FIELD ESTABLISHING
3	BASIC STEM CELL BIOLOGY PROGRAMS, BRINGING BOTH NEW
4	AND EXPERIENCED SCIENTISTS TO OUR FIELD, REACHING
5	OUT TO MAKE COOPERATIVE EFFORTS ACROSS THE COUNTRY
6	AND THE WORLD, DEVELOPING NEW TOOLS AND TECHNOLOGY,
7	FINDING WAYS TO ELIMINATE BOTTLENECKS, STUDYING
8	REGULATORY MINE FIELDS, LOAN PROGRAMS FOR BIOMEDICAL
9	MEDICINE, ESPECIALLY EXPENSIVE AND DIFFICULT
10	CLINICAL TRIALS, INVESTIGATING THE ENDLESS STRUGGLE
11	OVER INTELLECTUAL PROPERTY AND MUCH MORE.
12	CIRM'S CROWNING JEWEL IS A DISEASE TEAM
13	GRANT. EVERYTHING IS PREPARATION OF THESE HUGE AND
14	AMBITIOUS GRANTS UP TO \$20 MILLION EACH WITH THE
15	AMBITIOUS GOAL OF BRINGING HUMAN THERAPY TO CLINICAL
16	TRIALS WITHIN FOUR YEARS, AND WE HAVE 14 OF THEM.
17	WE ARE MAKING REALISTIC STEP-BY-STEP PROGRESS TOWARD
18	THIS GIGANTIC GOAL. ALREADY CIRM HAS ACHIEVED 1,000
19	PUBLISHED BREAKTHROUGHS, SCIENTIFIC PAPERS, EACH A
20	PIECE OF THE PUZZLE OF THE CURE. THIS LIBRARY OF
21	DOCUMENTATION THAT ONLY OFFERS PATIENT ADVOCATES FOR
22	PROGRESS, BUT ALSO CAUTIONS THOUGH IT DOES NOT WORK,
23	SO THAT RESEARCHERS CAN AVOID WASTING TIME AND
24	MONEY.
25	COLLABORATIONS ARE BEING FORGED. ALREADY
	71

1	130 TOP STEM CELL SCIENTISTS HAVE MOVED TO
2	CALIFORNIA, PERHAPS DRAWN BY THE CIRM PROGRAM.
3	BIOMEDICAL CLASSES ARE DEVELOPING. AND WHILE EVERY
4	CALIFORNIA DOLLAR MUST BE SPENT IN THE HOME STATE,
5	WE'RE GETTING MORE BANG FOR THE BUCK BY PARTNERING
6	WITH OTHER STATES AND COUNTRIES, 16 OF THEM.
7	ALREADY THESE NEW PARTNERS HAVE CONTRIBUTED MORE
8	THAN \$60 MILLION OF ADD-ON FUNDING AS WELL AS
9	INTELLECTUAL STRENGTH. THE JOB IS NOT DONE, BUT IT
10	IS WELL DONE. IT IS WELL BEGUN. LIKE FARMERS
11	BATTLING THE WILDERNESS, THE CIRM HAS CLEARED
12	GROUND, REMOVED BOULDERS, PLOWED AND PLANTING,
13	IRRIGATED AND WEEDED. TODAY'S SEEDS ARE BURSTING
14	OPEN BELOW GROUND. NEW SHOOTS ARE PUSHING UPWARDS
15	THROUGH THE SOIL, REACHING FOR THE SUN. THE
16	CALIFORNIA STEM CELL PROGRAM IS THE PRIDE OF THE
17	STATE, THE GLORY OF A NATION, AND A FRIEND TO ALL
18	THE WORLD.
19	AND THAT'S WHY IT IS AN HONOR AND DELIGHT
20	TO NOMINATE THE CALIFORNIA INSTITUTE FOR
21	REGENERATIVE MEDICINE FOR THE PAUL G. ROGERS
22	DISTINGUISHED ORGANIZATION LEGACY AWARD FROM
23	RESEARCH AMERICA WHICH WAS PREVIOUSLY WON BY THE
24	MARCH OF DIMES. THANK YOU.
25	(APPLAUSE.)
	72

BARRISTERS' REPORTING SERVICE CHAIRMAN THOMAS: THANK YOU VERY MUCH.

1	CHAIRMAN THOMAS: THANK YOU VERY MUCH,
2	DON. THAT WAS A TERRIFIC LETTER WHICH NEATLY
3	SUMMARIZES ALL THAT CIRM IS ABOUT. AND I WOULD
4	REQUEST IF YOU COULD SEND THAT TO MARIA AND HAVE
5	MARIA DISTRIBUTE TO ALL MEMBERS OF THE BOARD, THAT
6	WOULD BE GREATLY APPRECIATED. AS ALWAYS, OF COURSE,
7	PLEASE GIVE OUR BEST TO ROMAN.
8	OKAY. SO DO WE HAVE ANY OTHER QUESTIONS
9	FOR MARK? HEARING NONE, THANK YOU VERY MUCH. WE
10	APPRECIATE YOUR HARD WORK. AND WE WILL PROCEED
11	APACE IN ANALYZING AND IMPLEMENTING YOUR
12	SUGGESTIONS. SO THANK YOU VERY MUCH.
13	MR. STERANKA: THANK YOU. IT WAS A
14	PLEASURE.
15	CHAIRMAN THOMAS: WE WILL TAKE A
16	FIVE-MINUTE BREAK AT THIS POINT, AND WE'LL
17	RESUME YES. JAMES SAYS JUST FIVE MINUTES. THANK
18	YOU.
19	(A RECESS WAS TAKEN.)
20	CHAIRMAN THOMAS: COULD EVERYBODY PLEASE
21	TAKE THEIR SEATS. MARIA, YOU WANTED TO
22	MS. BONNEVILLE: I WANTED TO CONFIRM THAT
23	DR. MELMED WAS ON THE LINE. DR. MELMED. OR MAYBE
24	NOT ON THE LINE. OKAY. WE'LL FOLLOW UP.
25	CHAIRMAN THOMAS: OKAY. WE'RE
	73

1	RECONVENING. BEFORE WE START WITH THE NEXT ITEM, I
2	JUST WANTED TO NOTE FOR THE RECORD THAT WITH RESPECT
3	TO THE PERFORMANCE AUDIT, WE WILL BE BRINGING
4	BACK IAN SWEEDLER, SPEARHEADING THE EFFORT, WILL
5	BE BRINGING BACK TO THE BOARD A GAME PLAN AT OUR
6	JULY BOARD MEETING AS TO HOW TO IMPLEMENT THE
7	RECOMMENDATIONS SET FORTH IN THE PERFORMANCE AUDIT,
8	AND THAT WE WILL BE PERIODICALLY AFTER THAT COMING
9	BACK TO THE BOARD WITH SPECIFIC UPDATES. AND WE'LL,
10	OF COURSE, HAVE THAT AVAILABLE TO THE PUBLIC AS WELL
11	SO THAT EVERYBODY CAN TRACK HOW WE FOLLOW ALONG WITH
12	THE MANY RECOMMENDATIONS.
13	SO WITH THAT, LET'S TURN THIS OVER TO THE
14	NEXT ITEM, WHICH IS THE THIRD ROUND OF EARLY
15	TRANSLATION AWARDS. AS YOU KNOW, WE'VE HAD A NUMBER
16	OF THESE IN THE PAST THAT COMPRISES A SIGNIFICANT
17	PORTION OF THE 43 MAJOR AWARDS THAT WE'VE GIVEN TO
18	DATE. THIS IS, AS NOTED, THE THIRD ROUND OF EARLY
19	TRANSLATION AWARDS. AND I'D LIKE TO TURN THIS OVER
20	TO DR. SAMBRANO TO GIVE US CONTEXT ON THIS PROCESS.
21	DR. SAMBRANO: MR. CHAIR, THANK YOU VERY
22	MUCH. MEMBERS OF THE BOARD, MEMBERS OF THE PUBLIC,
23	I WANT TO JUST VERY BRIEFLY, I HAVE ABOUT TWO
24	MINUTES, AND I WILL TRY TO DO THIS WITHIN THAT TIME
25	IF I CAN, TO GIVE YOU A VERY BRIEF BACKGROUND AND
	74

1	OVERVIEW OF THE PROCESS AND JUST TO PROVIDE SOME
2	CONTEXT. THIS WILL NOT BE COMPREHENSIVE IN ANY WAY,
3	BUT I CAN ADDRESS ANY QUESTIONS SHOULD YOU HAVE
4	THEM.
5	SO IT'S IMPORTANT TO KNOW THAT AS WE BRING
6	THESE APPLICATIONS TO YOU, THAT ALL OF THE
7	APPLICATIONS UNDER CONSIDERATION BY THE ICOC, THE
8	GRANTS WORKING GROUP HAS CONDUCTED ALREADY A
9	THOROUGH SCIENTIFIC EVALUATION OF EACH APPLICATION
10	BASED ON THE REVIEW CRITERIA THAT ARE OUTLINED IN
11	THE RFA. AND ADDITIONALLY, IT HAS PERFORMED A
12	PROGRAMMATIC ASSESSMENT TO ARRIVE AT THE FUNDING
13	RECOMMENDATIONS MADE TO YOU.
14	AS YOU KNOW, THE GRANTS WORKING GROUP
15	ITSELF IS COMPOSED OF FIFTEEN SCIENTIFIC MEMBERS AND
16	SEVEN PATIENT ADVOCATE MEMBERS WHO ALSO SERVE ON
17	THIS BOARD. THE FIFTEEN SCIENTIFIC MEMBERS ARE
18	ASSIGNED BASED ON THE MOST RELEVANT EXPERTISE TO
19	THIS RFA. THAT EXPERTISE IS ENHANCED BY RECRUITMENT
20	OF ADDITIONAL SPECIALIST REVIEWERS WHO PROVIDE
21	EVALUATIONS, BUT DO NOT PROVIDE FINAL SCORES OR
22	VOTES.
23	SO IN THIS PARTICULAR RFA, WE HAD A TOTAL
24	OF 28 DIFFERENT SCIENTIFIC EXPERTS WHO CONTRIBUTED
25	TO THE REVIEW OF THE 41 APPLICATIONS COMING TO YOU.
	75
	/ 5

1	DURING THE GRANTS WORKING GROUP REVIEW
2	MEETING, ALL APPLICATIONS ARE DISCUSSED AND SCORED.
3	THERE IS NO TRIAGE. CIRM SCIENTIFIC STAFF TAKES
4	EXTENSIVE NOTES OF THE DISCUSSION WHICH, WHEN
5	COMBINED WITH THE REVIEWER CRITIQUES, HELPS
6	FORMULATE THE SUMMARIES THAT YOU SEE IN YOUR BOOKS.
7	NOW, EACH APPLICANT FOLLOWING THE REVIEW
8	AND THE GENERATION OF THE SUMMARIES RECEIVES A
9	REVIEW REPORT, AND THAT'S ABOUT TWO WEEKS BEFORE
10	THIS MEETING. THAT INCLUDES THE SCIENTIFIC SCORES,
11	THE RECOMMENDATION, THE SUMMARY OF THE REVIEW WHICH
12	WILL HIGHLIGHT THE STRENGTHS AND WEAKNESSES OF THE
13	PROPOSAL, AND THEN PRESENTS ANY SUGGESTED CONDITIONS
14	OR MODIFICATIONS.
15	THE REVIEW REPORT THAT IS SENT BY E-MAIL
16	ALSO DESCRIBES THE BASIC PROCESS FOR ADDRESSING
17	CONCERNS ABOUT THE REVIEW. SO APPLICANTS ARE
18	INSTRUCTED TO CONTACT THE SENIOR REVIEW OFFICER AS
19	THEIR FIRST STEP, BUT WE ALSO PROVIDE LINKS TO THE
20	GRANTS ADMINISTRATION POLICY WHICH DESCRIBES THE
21	FORMAL APPEALS PROCESS AND THE EXTRAORDINARY
22	PETITION POLICY. IT'S IMPORTANT TO REMEMBER THAT
23	THE FORMAL APPEALS PROCESS IS SEPARATE AND DISTINCT
24	FROM THE EXTRAORDINARY PETITION PROCESS.
25	FOR APPEALS, OR FORMAL APPEALS, IF THE
	70
	76

1	APPLICANT BELIEVES THAT A CONFLICT OF INTEREST AS
2	DEFINED UNDER THE GRANTS WORKING GROUP CONFLICT OF
3	INTEREST POLICY MIGHT HAVE HAD A NEGATIVE IMPACT ON
4	THE REVIEW, THE APPLICANT MAY CHOOSE TO PURSUE A
5	FORMAL APPEAL. DEMONSTRATION THAT A CONFLICT OF
6	INTEREST HAD A NEGATIVE IMPACT ON THE REVIEW PROCESS
7	AND RESULTED IN A FLAWED REVIEW IS THE ONLY GROUND
8	FOR A FORMAL APPEAL. AND THOSE APPEALS ARE MANAGED
9	BY THE CIRM PRESIDENT, LEGAL COUNSEL, SCIENTIFIC
10	STAFF, AND THE GRANTS WORKING GROUP REVIEW CHAIR.
11	NOW, ON THE OTHER HAND, IF THE APPLICANT
12	WISHES TO PETITION THE ICOC, THE APPLICANT MAY
13	SUBMIT AN EXTRAORDINARY PETITION. THE PETITION
14	POLICY DOES NOT LIMIT OR SPECIFY CIRCUMSTANCES UNDER
15	WHICH A PETITION CAN BE MADE, BUT IT IS INTENDED TO
16	AFFORD APPLICANTS AN OPPORTUNITY TO COMMUNICATE WITH
17	THE BOARD ABOUT THE REVIEW BASED ON WHAT THE
18	APPLICANT WOULD DEEM TO BE AN EXTRAORDINARY
19	CIRCUMSTANCE.
20	THE ICOC ESTABLISHED THIS POLICY TO MANAGE
21	AS BEST ONE CAN APPLICANT REQUESTS THAT MAY COME
22	FROM REVIEW. AND APPLICANTS ARE ASKED TO SUBMIT NOT
23	LESS THAN FIVE BUSINESS DAYS OF AN ICOC MEETING.
24	WHEN THEY ARE NOT, THEN WE LABEL THEM AS LATE.
25	NOW, IF AN EXTRAORDINARY PETITION HAS BEEN
	77

1	SUBMITTED BY THE APPLICANT, THE ICOC IS NOT REQUIRED
2	TO DISCUSS IT UNLESS A BOARD MEMBER HAS A SPECIFIC
3	QUESTION OR FEELS THAT THE PETITION MAY HAVE MERIT.
4	THE ICOC SCIENCE SUBCOMMITTEE PROVIDED THAT THE CIRM
5	STAFF SHOULD NOT PREPARE WRITTEN REBUTTALS TO
6	PETITIONS AND SHOULD PROVIDE WRITTEN RESPONSES ONLY
7	IN CASES WHERE CIRM STAFF BELIEVES THE PETITION HAS
8	MERIT. IN ALL CASES, HOWEVER, CIRM STAFF WILL BE
9	PREPARED TO ADDRESS ANY QUESTIONS OR CONCERNS THAT
10	BOARD MEMBERS MAY HAVE.
11	NOW, AS WE BRING THESE APPLICATIONS TO
12	YOU, WE'RE GOING TO BRING THE RECOMMENDATIONS OF THE
13	GRANTS WORKING GROUP FOR YOUR CONSIDERATION. YOU
14	CAN ALREADY CONSIDER OBVIOUSLY OTHER THINGS THAT MAY
15	IMPACT YOUR DECISION TO FUND OR NOT FUND
16	APPLICATIONS, SUCH AS THE AVAILABILITY OF FUNDS, THE
17	OVERALL GRANT PORTFOLIO, ANY STRATEGIC
18	CONSIDERATIONS, OR THE MISSION OF CIRM. AND SO WHAT
19	WE TRY TO DO IS PROVIDE YOU TOOLS THAT WILL HELP YOU
20	IN FORMULATING YOUR DECISION.
21	SO IN YOUR BINDERS YOU WILL FIND SEVERAL
22	THINGS. YOU WILL FIND A TABLE THAT LISTS THE
23	APPLICATIONS IN RANK ORDER. THAT TABLE SHOWS THE
24	APPLICATION NUMBER, THE TITLE OF THE PROJECT, THE
25	SCIENTIFIC SCORE, WHICH INCLUDES THE AVERAGE, THE
	78
	10

-	BARRISTERS REPORTING SERVICE
1	MEDIAN, STANDARD DEVIATION, AND RANGE OF INDIVIDUAL
2	SCORES, BY THE SCIENTIFIC MEMBERS OF THE WORKING
3	GROUP, THE AMOUNT REQUESTED FROM THE APPLICANT. AND
4	IF APPROPRIATE, WE'VE INCLUDED INFORMATION ABOUT THE
5	DISEASE AREA OR THE TARGET INDICATION THAT MIGHT
6	HELP YOU ASSESS THE OVERALL APPLICATIONS FROM THAT
7	PERSPECTIVE.
8	WE ALSO PROVIDE A COPY OF THE REVIEW
9	REPORT FOR EACH APPLICATION THAT HIGHLIGHTS THE
10	STRENGTHS AND WEAKNESSES. WE HAVE A COMPILATION OF
11	THE PROGRAMMATIC DISCUSSION, SECTIONS FROM THE
12	REVIEW REPORTS FOR YOUR QUICK REFERENCE. THAT WAY
13	YOU KNOW THAT THESE WERE DISCUSSED DURING THE
14	PROGRAMMATIC PORTION OF THE REVIEW. A COPY OF THE
15	CURRENT PORTFOLIO OF THE CIRM GRANTS FOR YOUR
16	REFERENCE SO THAT YOU CAN UTILIZE THAT AS A TOOL TO
17	COMPARE THE CURRENT PROPOSALS WITH WHAT CIRM IS
18	ALREADY FUNDING. AND THEN ANY EXTRAORDINARY
19	PETITIONS THAT WERE SUBMITTED BY APPLICANTS AND ANY
20	CIRM STAFF ASSESSMENTS, WHERE APPROPRIATE.
21	FOR THIS PARTICULAR RFA, WE RECEIVED THREE
22	EXTRAORDINARY PETITIONS. ONE OF THEM WAS LABELED
23	LATE, JUST FOR YOU TO NOTE. YOU SHOULD ALSO NOTE
24	THAT THERE ARE TWO AWARD CATEGORIES FOR THIS
25	PARTICULAR RFA, A DC AND DCF, WHICH DR. ARIE ABO

79

WILL DETAIL A LITTLE MORE, BUT JUST NOTE THAT THAT
 MEANS THAT THERE ARE ACTUALLY TWO TABLES IN YOUR
 BINDERS, ONE FOR EACH OF THESE CATEGORIES, BECAUSE
 THEY WERE REVIEWED SEPARATELY BY THE GRANTS WORKING
 GROUP.

6 SO TO GET US STARTED, DR. ARIE ABO IS 7 GOING TO PRESENT AN OVERVIEW THAT REMINDS US OF THE 8 OBJECTIVES AND FEATURES OF THE RFA. AND ONCE HE IS 9 DONE WITH THAT, WE ARE GOING TO SHOW YOU A DISPLAY 10 OF THE RANK ORDER ON THE OVERHEAD WHICH ESSENTIALLY 11 MIRRORS WHAT YOU HAVE IN YOUR BINDERS. FOR ANY OF 12 THE APPLICATIONS THAT ARE LISTED, MEMBERS OF THE 13 BOARD MAY REQUEST DISCUSSION OF THE APPLICATION TO INFORM YOUR DECISION. AND SO SCIENCE OFFICERS WILL 14 15 BE PREPARED TO PROVIDE A SYNOPSIS OF THE APPLICATION 16 THAT INCLUDES A SUMMARY OF THE STRENGTHS AND 17 WEAKNESSES NOTED BY REVIEWERS AND ADDRESS ANY OF 18 YOUR QUESTIONS. 19 IF THERE ARE ANY CONFIDENTIAL OR PROPRIETY

19 IF THERE ARE ANY CONFIDENTIAL OR PROPRIETY
20 INFORMATION, WE CAN DISCUSS THAT WITHIN A CLOSED
21 SESSION. SO I WILL STOP THERE AND I WILL LET DR.
22 ABO TAKE OVER HERE.

DR. ABO: THANK YOU, GIL. MR. CHAIRMAN,
MEMBERS OF THE ICOC, MEMBERS OF THE PUBLIC, CIRM
STAFF, I'M HERE TO REPORT THE RECOMMENDATION OF THE

80

1	GRANT WORKING GROUP FOR EARLY TRANSLATION III.
2	BEFORE I GO THROUGH THE RECOMMENDATION, I'D LIKE TO
3	REMIND YOU THAT FOCUS ON THE INITIATIVE OF THE EARLY
4	TRANSLATION PROGRAMS. THIS IS THE THIRD CYCLE OF
5	THE EARLY TRANSLATION III, AND I WAS HERE
6	APPROXIMATE A YEAR AGO, PRESENTED YOU THE CONCEPT.
7	AND FOR THOSE OF YOU THAT ARE NOT FAMILIAR WITH THIS
8	PROGRAM, THIS IS A PROGRAM THAT WAS DESIGNED TO
9	BRIDGE BASIC BIOLOGY TO CLINICAL TO IND-ENABLING
10	STUDIES. AS YOU CAN SEE HERE, IT FITS PERFECTLY IN
11	THE SPECTRUM OF OTHER PROGRAMS THAT WE HAVE AT CIRM
12	FROM STEM CELL BIOLOGY, BASIC RESEARCH PROGRAMS TO
13	DISEASE TEAM AND CLINICAL DEVELOPMENT PROGRAMS.
14	UNDER THIS INITIATIVE, WE DESIGNED TWO
15	TYPE OF AWARDS, THE DEVELOPMENT CANDIDATE AWARD, THE
16	DC AWARD, AND THE DEVELOPMENT CANDIDATE FEASIBILITY
17	AWARDS. AND THE REASON FOR THAT, WE WANTED TO
18	CREATE A SPACE TO PROJECT AN INVESTIGATOR THAT WANTS
19	TO TAKE THEIR EARLY HYPOTHESIS AND EARLY SCIENCE AND
20	BASIC RESEARCH TO BRING IT TO THERAPEUTIC
21	DEVELOPMENT TO ENTER TO THE TRANSLATIONAL SPACE.
22	SO TO TAKE A THERAPEUTIC CANDIDATE UNDER
23	THE DEVELOPMENT CANDIDATE FEASIBILITY, THE DCF, TO
24	IDENTIFY THE THERAPEUTIC CANDIDATE THAT COULD NOT
25	NECESSARILY MOVE ALL THE WAY TO CLINICAL
	81

1	DEVELOPMENT, BUT WILL BRING IT ALL THE WAY TO PROOF
2	OF CONCEPT.
3	SO SINCE A LOT OF THE APPLICANTS THAT WE
4	HAVE ARE ACADEMIC SCIENTISTS AND NOT A LOT OF THEM
5	ARE ENGAGED IN TRANSLATIONAL SCIENCE, THIS IS AN
6	OPPORTUNITY FOR THEM TO BE ENGAGED IN THIS PROCESS
7	AND REALLY BE PART OF THE MISSION OF CIRM.
8	UNDER THE DEVELOPMENT CANDIDATE AWARD,
9	WHICH IS A BIGGER TYPE OF AWARD, WE DESIGNED THE
10	PROCESS THAT ALLOWS INVESTIGATORS OR PROJECT TO TAKE
11	A THERAPEUTIC CANDIDATE ALL THE WAY TO IND-ENABLING
12	STAGE AND POTENTIALLY COULD MOVE IN THE LATER RFA,
13	IN THE DISEASE TEAM, TO CLINICAL DEVELOPMENT.
14	WE SET UP A FEW PRIORITIES FOR THIS RFA
15	WHERE WE WERE ASKING PROJECTS THAT ARE USING EITHER
16	STEM CELLS, PLURIPOTENT STEM CELLS FOR CELL
17	THERAPIES OR USING PLURIPOTENT STEM CELLS FOR
18	IDENTIFYING THERAPEUTIC CANDIDATES, ESSENTIALLY
19	CELLS, PLURIPOTENT DERIVATIVE CELLS THAT COULD BE
20	USED FOR DRUG SCREEN TO IDENTIFY THERAPEUTIC AGENT
21	THAT COULD BECOME DRUGS.
22	AND IN ADDITION, WE ADDED A CONSIDERATION
23	FOR THE PORTFOLIO. WE WILL ENCOURAGE APPLICATIONS
24	TO EXCUSE ME THE REVIEWERS TO ASSESS SOME OF
25	THE APPLICATION BASED ON THE PORTFOLIO
	82

CONSIDERATION; AND IF THERE IS AN APPLICATION THAT
 IS ALREADY REPRESENTED IN CIRM'S PORTFOLIO, WE
 REQUESTED IT TO BE COMPELLING AND INTERESTING
 PROJECT.

5 WE DEFINED THE SCOPE OF ACTIVITIES TO THE INVESTIGATORS AND THE REVIEWERS. AND CLEARLY OUT OF 6 7 SCOPE OF ACTIVITY WE DID NOT REALLY SEEK TO SUPPORT UNDER THIS RFA STUDIES THAT SUPPORT IND-ENABLING 8 9 STUDIES SUCH AS GMP PRODUCTION OR GLP TOXICOLOGY ON 10 CLINICAL STUDIES. WE HAVE OTHER PLACES, OTHER RFA TO SUPPORT THESE KIND OF STUDIES. AND WE DEFINED 11 12 VERY TIGHTLY THE SCOPE OF ACTIVITIES THAT WE WISH TO 13 SUPPORT, WHICH IS INCLUDING, AS YOU CAN SEE HERE IN 14 THE LEFT-HAND SIDE, CHARACTERIZATION OF THERAPEUTIC 15 CANDIDATES, RESEARCH PRODUCTION SCALE OF THERAPEUTIC 16 CANDIDATES, AND PROJECTS SUCH AS DISEASE IN THE DISH 17 AS WELL.

18AND WE DEFINED A SET OF SIX REVIEW19CRITERIA THAT I WILL GO VERY BRIEFLY THROUGH THEM.20THEY WERE PART OF THE RFA, AND WE PROVIDED THIS AND21DISCUSSED THIS VERY CLOSELY WITH THE REVIEWERS THE22CRITERIA THAT WE REALLY WANT TO FOCUS IN ORDER TO23IDENTIFY THE BEST APPLICANTS.

AND SO THE FIRST ONE, THE OBJECTIVE AND MILESTONES, WE CLEARLY WERE LOOKING FOR PROJECTS OR

1	APPLICATIONS THAT COULD ACHIEVE DEVELOPMENT
2	CANDIDATES AND DEVELOPMENT CANDIDATE FEASIBILITY.
3	WE ARE LOOKING FOR THE TARGET PRODUCT PROFILE THAT'S
4	SCIENTIFICALLY AND CLINICALLY REASONABLE AND DEFINED
5	MILESTONES THAT COULD BE TRACKED AND SUPPORT THE
6	STUDIES.
7	UNDER THE RATIONALE AND SIGNIFICANCE, WE
8	WERE LOOKING FOR PROJECTS THAT ADDRESS UNMET MEDICAL
9	NEEDS AND COULD LEAD TO SIGNIFICANT IMPROVED THERAPY
10	FOR THE PROPOSED DISEASE AND INJURY.
11	UNDER REVIEW CRITERIA NO. 3, THE RESEARCH
12	PROJECT AND FEASIBILITY AND DESIGN, WE ASKED
13	REVIEWERS TO PAY ATTENTION TO PRELIMINARY RESULTS TO
14	SEE IF THERE'S ANY COMPELLING DATA SUPPORTING THE
15	PROPOSED RESEARCH.
16	AND UNDER THE RESEARCH PLANS WE WERE
17	LOOKING FOR A FOCUSED PROPOSAL WITH WELL DESIGNED
18	AND ACHIEVE MILESTONES AND OBJECTIVES WITHIN THREE
19	YEARS PERIOD.
20	FOR REVIEW CRITERIA NO. 4, THE
21	QUALIFICATION OF THE TEAM, THE PI, THE CO-PI, AND
22	PARTNER PI, WE WERE LOOKING FOR A TEAM THAT IS
23	COMMITTED TO TRANSLATIONAL SCIENCE AND THEY HAVE THE
24	RELEVANT EXPERIENCE FOR THE TRANSLATION SCIENCE.
25	ESPECIALLY WE ASKED THE REVIEWERS TO PAY ATTENTION
	84
	70

1	FOR THE TRACK RECORD FOR THE PI AND THE CO-PI, THAT
2	THEY HAVE SUCCESSFUL RECORD IN PROPOSED
3	TRANSLATIONAL PROJECT BECAUSE THIS IS VERY IMPORTANT
4	AS SOME OF THE ACTIVITIES ARE DIFFERENT FROM BASIC
5	SCIENCE, AND WE'RE LOOKING FOR INVESTIGATOR THAT
6	COULD BRING THIS TO THE TABLE.
7	UNDER REVIEW CRITERIA NO. 5, THERE IS A
8	NUMBER OF THINGS LISTED HERE, BUT MOST IMPORTANTLY I
9	WOULD LIKE TO EMPHASIZE THAT WE WERE LOOKING FOR A
10	PROJECT THAT WOULD COME WITH A SET OF DOCUMENTS THAT
11	ALREADY SUPPORT THAT THEY HAVE THE MATERIAL TRANSFER
12	AGREEMENT, THE IP POSITION, THAT THEY COULD HAVE THE
13	REAGENTS THAT ARE NECESSARY TO DEVELOP FOR THE
14	PROJECT.
15	AND LASTLY, THEIR RESPONSIVENESS FOR THE
16	RFA, THE REVIEWER CRITERIA NO. 6. WE WERE ASKING
17	FOR REVIEWER TO ASSESS THE PROJECT BEST IF THEY
18	ADDRESS THE RFA OBJECTIVES, NAMELY, ACHIEVING A DC
19	AND DCF, AND THE USE OF STEM CELL FOR PROOF OF
20	CONCEPT FOR DEVELOPMENT CANDIDATE, AND IDENTIFY A
21	TARGET OF INTERVENTION IN CASE OF THE DC, AND
22	PORTFOLIO CONSIDERATIONS.
23	SO HAVING SAID THAT, I'M GOING TO SHOW YOU
24	NOW THE SCORE DISTRIBUTION FOR THE DC AWARDS. AS
25	YOU CAN SEE HERE FROM THIS HISTOGRAM, THE GRANT
	85
	60

WORKING GROUP DREW THE LINE AT SCORE OF 75 AND DEFINED THAT TIER NO. 1 ABOVE 75 AND TIER NO. 2 WAS DEFINED BETWEEN SCORE 45 TO 75. EVERYTHING THAT WAS THE INITIAL LINE THAT WAS DRAWN ON 75. EVERYTHING THAT WAS IN TIER II WAS DISCUSSED IN THE PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR.		
3DEFINED BETWEEN SCORE 45 TO 75. EVERYTHING THAT4WAS THE INITIAL LINE THAT WAS DRAWN ON 75.5EVERYTHING THAT WAS IN TIER II WAS DISCUSSED IN THE6PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING7GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR8TIER III.9SIMILARLY, FOR THE DC SCORE DISTRIBUTION,10THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS11DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND12SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE13DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER14I OR TO TIER III.15SO MY LAST SLIDE IS SHOWING THE16RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS17YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET18NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS19APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 1020DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE21NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC22THANK YOU. IF YOU HAVE ANY QUESTIONS,24I'LL BE HAPPY TO ADDRESS THEM.25CHAIRMAN THOMAS: ANY QUESTIONS FOR DR.	1	WORKING GROUP DREW THE LINE AT SCORE OF 75 AND
 WAS THE INITIAL LINE THAT WAS DRAWN ON 75. EVERYTHING THAT WAS IN TIER II WAS DISCUSSED IN THE PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	2	DEFINED THAT TIER NO. 1 ABOVE 75 AND TIER NO. 2 WAS
 EVERYTHING THAT WAS IN TIER II WAS DISCUSSED IN THE PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	3	DEFINED BETWEEN SCORE 45 TO 75. EVERYTHING THAT
 PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	4	WAS THE INITIAL LINE THAT WAS DRAWN ON 75.
 GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	5	EVERYTHING THAT WAS IN TIER II WAS DISCUSSED IN THE
 TIER III. SIMILARLY, FOR THE DC SCORE DISTRIBUTION, THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	6	PROGRAMMATIC DISCUSSION DURING THE GRANTS WORKING
 9 SIMILARLY, FOR THE DC SCORE DISTRIBUTION, 10 THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS 11 DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND 12 SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE 13 DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER 14 I OR TO TIER III. 15 SO MY LAST SLIDE IS SHOWING THE 16 RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS 17 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	7	GROUP AND WAS DECIDED EITHER TO MOVE TO TIER I OR
 10 THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS 11 DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND 12 SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE 13 DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER 14 I OR TO TIER III. 15 SO MY LAST SLIDE IS SHOWING THE 16 RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS 17 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	8	TIER III.
 11 DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND 12 SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE 13 DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER 14 I OR TO TIER III. 15 SO MY LAST SLIDE IS SHOWING THE 16 RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS 17 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	9	SIMILARLY, FOR THE DC SCORE DISTRIBUTION,
 SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	10	THE LINE FOR TIER I WAS DRAWN IN 75 AND TIER II WAS
 DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER I OR TO TIER III. SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	11	DEFINED BETWEEN 56, SCORE 56 TO FIVE. AND
 14 I OR TO TIER III. 15 SO MY LAST SLIDE IS SHOWING THE 16 RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS 17 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	12	SIMILARLY, PROGRAMS THAT WERE IN TIER II WERE
 SO MY LAST SLIDE IS SHOWING THE RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	13	DISCUSSED IN PROGRAMMATIC EITHER TO BE MOVED TO TIER
 16 RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS 17 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	14	I OR TO TIER III.
 YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	15	SO MY LAST SLIDE IS SHOWING THE
 18 NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS 19 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	16	RECOMMENDATION FOR THE GRANTS WORKING GROUP. AND AS
 APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	17	YOU CAN SEE FROM THIS TABLE, INITIALLY THE TARGET
 20 DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE 21 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC 22 THAT WILL BE CONVERTED TO A DCF. 23 THANK YOU. IF YOU HAVE ANY QUESTIONS, 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	18	NUMBER OF APPLICATIONS THAT WE WERE TARGETED AS
 NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	19	APPROVED BY THE BOARD WAS 95 MILLION, 50 DC AND 10
 THAT WILL BE CONVERTED TO A DCF. THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	20	DCF AWARDS. AND THE RECOMMENDED FOR FUNDING WERE
 THANK YOU. IF YOU HAVE ANY QUESTIONS, I'LL BE HAPPY TO ADDRESS THEM. CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	21	NINE DC AND TEN DCF WITH THE EXCEPTION OF ONE DC
 24 I'LL BE HAPPY TO ADDRESS THEM. 25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR. 	22	THAT WILL BE CONVERTED TO A DCF.
25 CHAIRMAN THOMAS: ANY QUESTIONS FOR DR.	23	THANK YOU. IF YOU HAVE ANY QUESTIONS,
	24	I'LL BE HAPPY TO ADDRESS THEM.
86	25	CHAIRMAN THOMAS: ANY QUESTIONS FOR DR.
		86

1

2 MR. HARRISON: BEFORE WE BEGIN DISCUSSING INDIVIDUAL APPLICATIONS, I'D LIKE TO JUST REMIND THE 3 BOARD OF TWO THINGS. ONE, YOU SHOULD EACH HAVE A 4 5 LIST OF THE APPLICATIONS BY APPLICATION NUMBER OF THE APPLICATIONS IN WHICH YOU HAVE A CONFLICT OF 6 7 INTEREST. SO IF THE BOARD BEGINS TO DISCUSS AN 8 APPLICATION IN WHICH YOU HAVE AN INTEREST, PLEASE 9 REFRAIN FROM PARTICIPATING IN THE DISCUSSION AS WELL AS THE VOTE. WE WILL NOT CALL YOU IF THERE'S A 10 11 MOTION ON THOSE APPLICATIONS DURING THE ROLL CALL 12 VOTE. 13 THE SECOND THING I WOULD LIKE TO REMIND 14 YOU, AS DR. SAMBRANO MENTIONED, THE BOARD DOES HAVE 15 THE OPPORTUNITY TO CONVENE IN CLOSED SESSION IF 16 NECESSARY TO DISCUSS PROPRIETARY INFORMATION. AND 17 ALTHOUGH IT'S SOMETIMES DIFFICULT TO KNOW IN THE 18 ABSTRACT WHAT INFORMATION WOULD CONSTITUTE 19 PROPRIETARY INFORMATION IN ANY PARTICULAR 20 APPLICATION, GENERALLY SPEAKING, WITH RESPECT TO

21 THESE APPLICATIONS, THE TYPE OF INFORMATION THAT

22 WOULD QUALIFY WOULD BE INFORMATION LIKE

- 23 PREPUBLICATION DATA OR OTHER INFORMATION WHICH IF
- 24 KNOWN TO AN APPLICANT'S COMPETITORS WOULD TEND TO
- 25 GIVE THE COMPETITORS AN ADVANTAGE. AND THAT COULD

1	INCLUDE, FOR EXAMPLE, SPECIFIC DETAILS REGARDING THE
2	THERAPEUTIC CANDIDATE OR THE RESEARCH PLAN; FOR
3	EXAMPLE, THE TIMELINES.
4	SO IF A BOARD MEMBER ASKS A QUESTION THAT
5	REQUIRES THE DISCLOSURE OF CONFIDENTIAL INFORMATION,
6	STAFF WILL MAKE A NOTE OF THAT, AND WE'LL HAVE AN
7	OPPORTUNITY TO DISCUSS THAT IN A CLOSED SESSION
8	SETTING.
9	CHAIRMAN THOMAS: THANK YOU, JAMES. I
10	BELIEVE ALL BOARD MEMBERS HAVE A CONFLICT OF
11	INTEREST SHEET. JAMES? MARIA?
12	MS. BONNEVILLE: THEY DO.
13	CHAIRMAN THOMAS: WHICH AT THE CONCLUSION
14	OF THE DISCUSSION ON THE ET AWARDS, WE NEED TO SIGN
15	AND MARIA WILL PICK THEM UP FROM EVERYBODY.
16	SO WITH THAT PROCEDURALLY IN PLACE, I'D
17	LIKE TO OPEN THE DISCUSSION ON THE PROPOSED AWARDS.
18	JOAN.
19	MS. SAMUELSON: I HAVE A QUESTION FIRST
20	FOR MAYBE ARIE. I'M NOT SURE. IT'S TO CLARIFY THE
21	TRANSLATIONAL PORTFOLIO. THIS IS EVERY GRANT THAT
22	WE HAVE OR ARE CURRENTLY FUNDING THAT ARE ATTEMPTING
23	TO MOVE TOWARD A THERAPEUTIC RESULT; IS THAT RIGHT?
24	DR. ABO: IT DEPENDS ON WHICH CATEGORY.
25	SO THE DC OR DCF, YEAH, YOU'RE TALKING ABOUT THE
	88

BARRISTERS' REPORTING SERVICE 1 APPLICATION THAT WERE RECOMMENDED OR ANY 2 APPLICATIONS? 3 MS. SAMUELSON: BOTH. YEAH. YEAH. 4 BECAUSE THIS GOES TO THE QUESTION OF PROGRAMMATIC 5 CONSIDERATIONS. 6 DR. OLSON: PERHAPS I COULD COMMENT ON 7 THAT. THE SET OF -- THE TRANSLATIONAL PORTFOLIO 8 THAT WAS PROVIDED TO YOU AS PART OF THE MATERIALS 9 INCLUDES ALL THE EARLY TRANSLATIONAL, ALL THE 10 DISEASE TEAM, ALL THE AWARDS THAT ARE ESSENTIALLY TARGETING -- ARE ATTEMPTING TO ADDRESS A THERAPEUTIC 11 12 OPTION. IN THE PARTICULAR HANDOUT THAT YOU 13 RECEIVED, IN WHITE ARE THOSE THAT ARE CURRENTLY PART 14 OF OUR PORTFOLIO. IN GRAY ARE THE ET III 15 APPLICATIONS, WHETHER DC -- TARGETING EITHER A 16 DEVELOPMENT CANDIDATE OR A PROOF OF CONCEPT THAT 17 WERE NOT RECOMMENDED BY THE GRANTS WORKING GROUP. AND IN GREEN ARE THE ET III EITHER DC OR DCF 18 19 APPLICATIONS THAT WERE RECOMMENDED BY THE GRANTS 20 WORKING GROUP. SO IT'S A CURRENT PORTFOLIO PLUS WHAT THE 21 22 FUTURE MIGHT LOOK LIKE DEPENDING ON THE BOARD'S 23 DECISIONS AS BASED ON THIS PARTICULAR SET OF 24 APPLICATIONS. 25 MS. SAMUELSON: AND THE MAJORITY,

89

1	SIGNIFICANT MAJORITY, OF THOSE ET III APPLICATIONS
2	THAT ARE NOW BEFORE US ARE NOT RECOMMENDED FOR
3	FUNDING, RIGHT? THIS IS SOUNDING LIKE A CROSS
4	EXAMINATION. I DON'T MEAN IT TO. I'M JUST TRYING
5	TO BE CLEAR.
6	DR. OLSON: I JUST SHOWED YOU THE FINAL
7	SLIDES THAT ARIE SHOWED YOU INDICATED, WHAT, ABOUT
8	HALF NO. IT'S 19. 19 TOTAL? IT'S ABOUT HALF OF
9	THEM. ABOUT HALF OF THEM ARE RECOMMENDED FOR
10	FUNDING, SO I DON'T THINK IT'S A FAIR STATEMENT TO
11	SAY THAT THE VAST MAJORITY.
12	MS. SAMUELSON: OKAY. YEAH. OKAY.
13	THANKS.
14	CHAIRMAN THOMAS: I'D LIKE TO OPEN THE
15	DISCUSSION. PERHAPS MR. SHEEHY, AS CHAIR OF THE
16	SCIENCE SUBCOMMITTEE, IF YOU COULD JUST GIVE A FEW
17	THOUGHTS ON THE GRANTS WORKING GROUP PROCESS FOR
18	THIS APPLICATION.
19	MR. SHEEHY: SURE. AND I THINK IT WAS A
20	ROBUST DISCUSSION THAT WE HAD IN PROGRAMMATIC
21	REVIEW. I DO THINK AS PEOPLE LOOK AT THIS, THEY'LL
22	SEE SOME MOVEMENT. AND I DON'T KNOW IF, FOR
23	EXAMPLE GIL, IS THERE A SEPARATE SHEET IN HERE
24	WITH THE PROGRAMMATIC? I KNOW THAT YOU HAVE A
25	SYNOPSIS OF THE PROGRAMMATIC.
	00
	90

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	BARRISTERS' REPORTING SERVICE
1	DR. SAMBRANO: YES. RIGHT. THERE SHOULD
2	BE A SHEET THAT'S A SUMMARY OF ALL THE PROGRAMMATIC
3	DISCUSSION. SO IT COMPILES IT FROM EACH OF THE
4	REVIEW REPORTS.
5	MR. SHEEHY: YEAH. PEOPLE SHOULD LOOK AT
6	THAT. I COULDN'T FIND IT IN MINE, BUT NONETHELESS,
7	THE PROGRAMMATIC PIECE IS ALSO APPENDED TO THE END
8	OF EACH APPLICATION. I DO THINK IT MIGHT SAVE SOME
9	DISCUSSION ON SOME OF THE OUTLIERS THAT GOT MOVED UP
10	TO TAKE A MINUTE AND LOOK AT THE PROGRAMMATIC
11	DISCUSSION. THIS WAS A GROUP OF REVIEWERS THAT TOOK
12	PROGRAMMATIC REVIEW VERY SERIOUSLY. AND THEY DID
13	MAKE A COUPLE OF RECOMMENDATIONS THAT INCLUDED
14	CONDITIONS.
15	NOW, IT'S UP TO STAFF TO ENSURE THAT THOSE
16	CONDITIONS ARE FOLLOWED. BUT WE DID NOT WANT TO
17	STOP SCIENCE THAT MIGHT HAVE A MEASURABLE IMPACT ON
18	DISEASE FROM GOING FORWARD BECAUSE THERE WAS A
19	SINGLE DEFECT THAT WAS READILY CURABLE BASED ON THE
20	ADVICE OF THIS, I THINK, VERY STRONG GROUP OF
21	REVIEWERS.
22	SO I DO HOPE THAT FOLKS WILL LOOK AT THE
23	PROGRAMMATIC DISCUSSION. IN GENERAL, THE SCORES
24	WERE REALLY GOOD. THIS IS A REALLY GOOD GROUP OF
25	APPLICATIONS. BUT I DON'T KNOW THAT WE NEED TO
	91

1	IF WE ARE GOING TO DISCUSS THOSE, I THINK PEOPLE
2	SHOULD FIRST LOOK AND SEE WHAT THE GRANTS REVIEW
3	GROUP DID IN PROGRAMMATIC REVIEW, WHY THEY DID IT,
4	IT MAKES SENSE, AND START FROM THAT BASIS BECAUSE
5	SOME OF THEM DID MAKE FAIRLY LARGE JUMPS, BUT THAT
6	WAS NOT BASED ON THE APPLICATION WITHOUT SOME
7	ADDITIONAL CONDITIONS BEING IMPOSED UPON THE
8	GRANTEE.
9	AND, AGAIN, WE CAN COUNT ON STAFF, I
10	THINK, DR. TROUNSON, YOU WOULD AGREE, TO MAKE SURE
11	THOSE CONDITIONS ARE FULFILLED IF THE GRANTS ARE
12	GOING TO GO FORWARD.
13	DR. TROUNSON: SURE, JEFF. WE CERTAINLY
14	HAVE HIGHLIGHTED THAT. AND SUBJECT TO THE DECISION
15	OF THE BOARD, WE WILL IMPLEMENT THOSE UNDER YOUR
16	INSTRUCTION. IF THERE'S FURTHER INSTRUCTION, WE'LL
17	TAKE THAT AS WELL.
18	MR. SHEEHY: AND JUST TO BE CLEAR, THERE'S
19	ACTUALLY ANOTHER CHART. SO YOU'RE LOOKING AT THIS
20	ONE AND THERE'S ALSO I DON'T KNOW IF YOU WANT TO
21	THROW THE OTHER ONE UP NOW. ARE WE GOING TO TAKE
22	THESE IN SEPARATE PILES?
23	CHAIRMAN THOMAS: YES. WE'RE GOING TO
24	ADDRESS THEM IN THE TWO TRANCHES HERE. SO THIS IS
25	THE DCF AWARDS.
	92
	JL

	BARRISTERS' REPORTING SERVICE
1	MR. SHEEHY: SO I WAS SPEAKING GENERICALLY
2	ACROSS BOTH CATEGORIES.
3	DR. SAMBRANO: I CAN SHOW YOU THE THIS
4	IS THEN THE DC.
5	MR. SHEEHY: YEAH. IF YOU LOOK, THE DC
6	HAD SOME IF YOU SHOW THE WHOLE THING, A COUPLE OF
7	MOVE-UPS. AND THAT'S JUST TO GIVE YOU A SENSE.
8	AGAIN, THIS WAS A VERY ROBUST DISCUSSION BY THE
9	GRANTS WORKING GROUP IN PROGRAMMATIC REVIEW. THAT'S
10	WHY WE HAD THAT DEGREE OF ACTIVITY, AND THIS IS A
11	GOOD PLACE FOR THAT KIND OF TO TAKE SOME RISK, I
12	THINK.
13	DR. SAMBRANO: JUST TO NOTE, THE
14	PROGRAMMATIC SUMMARIES WERE E-MAILED TO YOU. I
15	DON'T KNOW IF THAT WAS JUST NOW OR PREVIOUSLY. SO
16	IT SHOULD BE
17	MS. BONNEVILLE: IF YOU DON'T HAVE THEM,
18	WE'LL GET COPIES TO YOU.
19	MR. SHEEHY: AND YOU CAN LOOK AT THE
20	APPLICATION. THERE'S ACTUALLY A CATEGORY
21	"PROGRAMMATIC REVIEW," AND THAT GIVES YOU THAT
22	DISCUSSION THERE AS WELL.
23	CHAIRMAN THOMAS: GIL, DO I REMEMBER
24	CORRECTLY THAT IN ONE INSTANCE THERE WAS A DC THAT
25	WAS MOVED DOWN TO A DCF?
	93

1	DR. SAMBRANO: SO THERE IS A
2	RECOMMENDATION ON ONE OF THE DC APPLICATIONS TO
3	CONVERT IT TO A DCF. AND SO THAT ONE, WHEN WE GET
4	TO THE DC, OR I CAN JUST SHOW YOU, IT'S APPLICATION
5	5617. SO IT'S THIS ONE HERE. SO PART OF THE
6	DISCUSSION IN THE RECOMMENDATION WAS THAT IT WAS
7	RECOMMENDED IN PART BASED ON A CONVERSION TO A
8	DCF-TYPE AWARD.
9	CHAIRMAN THOMAS: OKAY. SO ARE THERE
10	WHICH DO WE HAVE UP HERE? OKAY. WE HAVE THE DCF
11	FIRST. ARE THERE ANY QUESTIONS OR COMMENTS WITH
12	RESPECT TO EITHER ANY OF THE RECOMMENDED AWARDS OR
13	WITH RESPECT TO ANY THAT ARE CURRENTLY NOT BEING
14	RECOMMENDED FOR FUNDING? YES, JOAN.
15	MS. SAMUELSON: DO WE HAVE THE RANGE OF
16	SCORES FOR THOSE NOT RECOMMENDED FOR FUNDING?
17	CHAIRMAN THOMAS: I THINK THAT WE SAW THEM
18	ON THE CHARTS.
19	DR. SAMBRANO: SO YOU HAVE SCORES SHOWN
20	FOR 60 AND ABOVE AND ANYTHING THAT'S IN TIER I. SO
21	NORMALLY WE DON'T SHOW THE SCORES FOR ANYTHING
22	THAT'S BELOW 60.
23	MS. SAMUELSON: DO YOU HAVE THAT RANGE?
24	DR. SAMBRANO: WE HAVE THE RANGE, BUT
25	WE I MEAN THAT GOES ALONG WITH THE SCORE. SO IF
	94

1	YOU HAVE ONE IN PARTICULAR THAT YOU WANT TO KNOW
2	ABOUT, WE CAN PROVIDE THAT TO YOU.
3	I THINK THE OTHER THING TO KNOW IS THAT
4	THESE ARE IN RANK ORDER BY AVERAGE SCORE. SO
5	BASICALLY THE ONES AT THE VERY BOTTOM ARE
6	ESSENTIALLY THE ONES THAT SCORED THE LOWEST. AND SO
7	THEY ARE IN THAT ORDER.
8	MS. SAMUELSON: I'M INTERESTED IN THE
9	SCORE FOR IT'S THE SPINAL CORD INJURY APPLICATION
10	THAT'S THE HIGHEST RANKING DCF, 5606.
11	DR. SAMBRANO: OKAY. SO THAT ONE THE
12	AVERAGE SCORE WAS A 54, THE MEDIAN IS A 55, THE
13	STANDARD DEVIATION IS 5, AND THE RANGE WAS 40, THE
14	LOWEST, AND 60, THE HIGHEST.
15	MS. SAMUELSON: SORRY. WHAT WAS THE
16	LOWEST?
17	DR. SAMBRANO: FORTY.
18	MS. SAMUELSON: ARE WE TAKING UP HEARING
19	THE EXTRAORDINARY PETITIONS NOW?
20	CHAIRMAN THOMAS: NO. WE'RE GOING TO DO
21	THAT AT THE CONCLUSION. ANY OTHER COMMENTS,
22	QUESTIONS ON THE DCF APPLICATIONS? DR. STEWARD.
23	DR. STEWARD: SO A QUESTION. AT WHAT
24	POINT WOULD YOU LIKE TO HAVE REQUESTS FOR
25	CONSIDERATION OF PROPRIETARY INFORMATION?
	0.F
	95

1CHAIRMAN THOMAS: MR. HARRISON.2MR. HARRISON: THE PROCEDURE THAT WE TRY3TO FOLLOW IS TO IDENTIFY THOSE APPLICATIONS IN WHICH4BOARD MEMBERS HAVE AN INTEREST, ASK SCIENTIFIC STAFF5TO MAKE A PRESENTATION. ALL OF THE INFORMATION THAT6CAN BE PROVIDED IN PUBLIC SESSION WILL BE PROVIDED7AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY8QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE9QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL10MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE11PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO12DISCUSS THAT PARTICULAR INFORMATION.13DR. STEWARD: SO WOULD IT, THEN, BE14APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION15AT THIS POINT IN TIME?16MR. HARRISON: YES.17DR. STEWARD: OKAY. SO JUST TO CONTINUE18DOWN JOAN'S TRACK, 5606.19CHAIRMAN THOMAS: DR. YAFFE.20DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE21BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED22A SCORE OF 54 AND WAS NOT RECOMMENDED FOR FUNDING.	
3TO FOLLOW IS TO IDENTIFY THOSE APPLICATIONS IN WHICH4BOARD MEMBERS HAVE AN INTEREST, ASK SCIENTIFIC STAFF5TO MAKE A PRESENTATION. ALL OF THE INFORMATION THAT6CAN BE PROVIDED IN PUBLIC SESSION WILL BE PROVIDED7AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY8QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE9QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL10MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE11PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO12DISCUSS THAT PARTICULAR INFORMATION.13DR. STEWARD: SO WOULD IT, THEN, BE14APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION15AT THIS POINT IN TIME?16MR. HARRISON: YES.17DR. STEWARD: OKAY. SO JUST TO CONTINUE18DOWN JOAN'S TRACK, 5606.19CHAIRMAN THOMAS: DR. YAFFE.20DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE21BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED	
 BOARD MEMBERS HAVE AN INTEREST, ASK SCIENTIFIC STAFF TO MAKE A PRESENTATION. ALL OF THE INFORMATION THAT CAN BE PROVIDED IN PUBLIC SESSION WILL BE PROVIDED AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO DISCUSS THAT PARTICULAR INFORMATION. DR. STEWARD: SO WOULD IT, THEN, BE APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION AT THIS POINT IN TIME? MR. HARRISON: YES. DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
5TO MAKE A PRESENTATION. ALL OF THE INFORMATION THAT6CAN BE PROVIDED IN PUBLIC SESSION WILL BE PROVIDED7AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY8QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE9QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL10MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE11PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO12DISCUSS THAT PARTICULAR INFORMATION.13DR. STEWARD: SO WOULD IT, THEN, BE14APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION15AT THIS POINT IN TIME?16MR. HARRISON: YES.17DR. STEWARD: OKAY. SO JUST TO CONTINUE18DOWN JOAN'S TRACK, 5606.19CHAIRMAN THOMAS: DR. YAFFE.20DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE21BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED	
 6 CAN BE PROVIDED IN PUBLIC SESSION WILL BE PROVIDED 7 AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY 8 QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE 9 QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL 10 MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE 11 PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO 12 DISCUSS THAT PARTICULAR INFORMATION. 13 DR. STEWARD: SO WOULD IT, THEN, BE 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 AT THAT POINT IN TIME, AND STAFF WILL ANSWER AS MANY QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO DISCUSS THAT PARTICULAR INFORMATION. DR. STEWARD: SO WOULD IT, THEN, BE APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION AT THIS POINT IN TIME? MR. HARRISON: YES. DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 8 QUESTIONS AS THEY CAN. TO THE EXTENT THAT THE 9 QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL 10 MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE 11 PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO 12 DISCUSS THAT PARTICULAR INFORMATION. 13 DR. STEWARD: SO WOULD IT, THEN, BE 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 9 QUESTIONS CALL FOR PROPRIETARY INFORMATION, WE'LL 10 MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE 11 PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO 12 DISCUSS THAT PARTICULAR INFORMATION. 13 DR. STEWARD: SO WOULD IT, THEN, BE 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 MAKE A NOTE OF THAT. AND THEN AFTER WE COMPLETE THE PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO DISCUSS THAT PARTICULAR INFORMATION. DR. STEWARD: SO WOULD IT, THEN, BE APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION AT THIS POINT IN TIME? MR. HARRISON: YES. DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 11 PUBLIC SESSION, WE'LL CONVENE IN CLOSED SESSION TO 12 DISCUSS THAT PARTICULAR INFORMATION. 13 DR. STEWARD: SO WOULD IT, THEN, BE 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 12 DISCUSS THAT PARTICULAR INFORMATION. 13 DR. STEWARD: SO WOULD IT, THEN, BE 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 DR. STEWARD: SO WOULD IT, THEN, BE APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION AT THIS POINT IN TIME? MR. HARRISON: YES. DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 14 APPROPRIATE TO RAISE APPLICATIONS FOR CONSIDERATION 15 AT THIS POINT IN TIME? 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 AT THIS POINT IN TIME? MR. HARRISON: YES. DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 16 MR. HARRISON: YES. 17 DR. STEWARD: OKAY. SO JUST TO CONTINUE 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 DR. STEWARD: OKAY. SO JUST TO CONTINUE DOWN JOAN'S TRACK, 5606. CHAIRMAN THOMAS: DR. YAFFE. DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 18 DOWN JOAN'S TRACK, 5606. 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
 19 CHAIRMAN THOMAS: DR. YAFFE. 20 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE 21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED 	
20DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE21BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED	
21 BOARD, APPLICATION 5606, AS YOU HEARD, THIS RECEIVED	
A SCORE OF 54 AND WAS NOT RECOMMENDED FOR FUNDING.	
23 THIS DEVELOPMENT CANDIDATE FEASIBILITY AWARD	
24 APPLICATION PROPOSES TO EVALUATE TRANSPLANTATION OF	
25 HUMAN EMBRYONIC STEM CELL-DERIVED INHIBITORY NEURON	
96	

1	
1	PRECURSORS AS A TREATMENT FOR BLADDER SPASTICITY AND
2	NEUROPATHIC PAIN ASSOCIATED WITH CHRONIC SPINAL CORD
3	INJURY.
4	THE APPLICANT HAS DEMONSTRATED THAT MURINE
5	INHIBITORY NERVE CELLS INTEGRATE INTO ADULT SPINAL
6	CORD AND IMPROVE SYMPTOMS IN AN ANIMAL MODEL OF
7	CHRONIC SPINAL CORD INJURY AND HAS RECENTLY
8	DEVELOPED METHODS TO CREATE HUMAN INHIBITORY
9	INTERNEURONS FROM EMBRYONIC STEM CELLS. THIS
10	PROPOSAL WILL CAPITALIZE ON RECENT DEVELOPMENTS AND
11	DETERMINE WHETHER HUMAN EMBRYONIC STEM CELL-DERIVED
12	INHIBITORY NERVE CELLS CAN BE SUCCESSFULLY
13	TRANSPLANTED INTO THE GRAY MATTER OF THE INJURED
14	SPINAL CORD IN A MOUSE MODEL OF SPINAL CORD INJURY
15	AND REDUCE NEUROGENIC BLADDER DYSFUNCTION AND
16	NEUROPATHIC PAIN.
17	MAJOR STRENGTHS IDENTIFIED BY THE
18	REVIEWERS IN THIS APPLICATION INCLUDE THE IMPORTANCE
19	AND SIGNIFICANCE OF THE GOAL AND THE RECOGNIZED
20	MEDICAL NEED, PROMISING PRELIMINARY DATA FROM MOUSE
21	STUDIES, AND AN EXCELLENT PI AND RESEARCH TEAM.
22	KEY WEAKNESSES IDENTIFIED BY REVIEWERS
23	INCLUDE SERIOUS CONCERNS ABOUT THE THERAPEUTIC
24	STRATEGY, IN PARTICULAR THE PROPOSED SITE OF CELL
25	TRANSPLANTATION, AND SERIOUS CONCERNS ALSO ABOUT
	97
	51

1	ASPECTS OF PROJECT FEASIBILITY, INCLUDING TIMING OF
2	POTENTIAL TREATMENTS, SURVIVAL AND ASSESSMENT OF
3	TRANSPLANTED CELLS, AND THE PURITY OF PROPOSED CELL
4	POPULATIONS.
5	THIS PROPOSAL WAS CONSIDERED DURING
6	PROGRAMMATIC DISCUSSION ALSO WHEN IT WAS RAISED
7	BECAUSE OF THE RECOGNIZED IMPORTANCE OF THE SPINAL
8	CORD INJURY AS AN IMPORTANT AREA FOR THE DEVELOPMENT
9	OF NEW THERAPIES. REVIEWERS REITERATED THE PROPOSED
10	STRENGTHS AND WEAKNESSES, AND A MOTION TO PROMOTE
11	THIS TO TIER I FAILED. BE HAPPY TO TAKE QUESTIONS
12	OR PROVIDE MORE DETAILS.
13	CHAIRMAN THOMAS: DR. STEWARD.
14	DR. STEWARD: IS IT APPROPRIATE TO ASK FOR
15	THE DISTRIBUTION OF VOTES ON THE MOTION TO MOVE IT
16	TO TIER I? IS THAT SOMETHING THAT WE CAN DO?
17	DR. YAFFE: DURING PROGRAMMATIC REVIEW?
18	DR. STEWARD: DURING PROGRAMMATIC.
19	DR. YAFFE: WE'RE LOOKING IT UP.
20	DR. STEWARD: OKAY. I REALIZE IT DIDN'T
21	HIT THE THRESHOLD.
22	DR. YAFFE: IT DID NOT HIT THE THRESHOLD
23	FOR A MINORITY REPORT.
24	CHAIRMAN THOMAS: WE'RE WAITING ON THAT
25	ANSWER.
	98

	BARRISTERS' REPORTING SERVICE
1	DR. STEWARD: SO IN THE MEANTIME, CAN YOU
2	EXPAND ANY ON THE ISSUE OF I'M LOOKING AT
3	THIS THE STRINGENCY OF THE LINEAGE MARKERS. IS
4	THERE ANYTHING MORE THAT CAN IT SEEMS LIKE
5	THAT
6	DR. YAFFE: THERE'S CONCERN ABOUT THAT. I
7	THINK TO DISCUSS SPECIFIC LINEAGE MARKERS, WE WOULD
8	HAVE TO DO THAT IN CLOSED SESSION.
9	DR. STEWARD: THAT'S WHAT I THOUGHT. AND
10	SO I'D LIKE TO ACTUALLY DO THAT.
11	DR. YAFFE: I SUSPECT THAT'S PROPRIETARY
12	INFORMATION.
13	ON THE MOTION TO ADVANCE TO TIER I, THERE
14	WERE 3 YESES AND 16 NAYS.
15	DR. STEWARD: THANK YOU.
16	CHAIRMAN THOMAS: ANY OTHER QUESTIONS FOR
17	DR. YAFFE? WE HAVE A PUBLIC COMMENT. MR. REED.
18	MR. REED: OBVIOUSLY IF THIS WAS IF I
19	WAS ON THE BOARD, I WOULD BE ONE OF THE ONES
20	DISQUALIFIED BECAUSE I HAVE A DEFINITE CONFLICT OF
21	INTEREST. THE INHIBITORS ARE NOT ONLY FOR PAIN.
22	THEY'RE FOR SPASTICITY WHICH I'VE SEEN FLING MY SON
23	OUT OF HIS WHEELCHAIR. THE PAIN THAT SOME PEOPLE GO
24	THROUGH WITH CHRONIC SPINAL CORD INJURY HAS BEEN
25	DESCRIBED AS HAVING YOUR SKIN SCRAPED OFF AND
	99

	BARRISTERS' REPORTING SERVICE
1	GASOLINE POURED ONTO YOUR FLESH.
2	I DON'T KNOW MUCH ABOUT THIS, THE
3	PROPOSAL, BUT THE NEED IS GIGANTIC. AND IF WE ARE
4	WELL UNDER BUDGET ON THIS, I WOULD HOPE THAT IT
5	WOULD BE CONSIDERED.
6	CHAIRMAN THOMAS: THANK YOU, DON. DR.
7	STEWARD.
8	DR. STEWARD: I THINK AT THIS POINT WHAT I
9	WOULD RECOMMEND IS THAT WE DEFER UNTIL WE CONSIDER
10	THE PROPRIETARY INFORMATION. IS THAT APPROPRIATE OR
11	WE COULD DISCUSS IT MORE NOW? WHAT WOULD BE THE
12	APPROPRIATE
13	MR. HARRISON: UNLESS MEMBERS HAVE OTHER
14	QUESTIONS APPROPRIATE FOR PUBLIC SESSION, WE'LL NOTE
15	THAT ITEM. AND WHEN WE CONVENE IN CLOSED SESSION,
16	WE'LL ADDRESS IT AT THAT POINT IN TIME. I'D SUGGEST
17	NOW THAT WE MOVE ON TO OTHER APPLICATIONS THAT
18	MEMBERS MIGHT HAVE AN INTEREST IN DISCUSSING.
19	CHAIRMAN THOMAS: ARE THERE ANY OTHER DCF
20	APPLICATIONS THAT ANY MEMBER OF THE BOARD WOULD LIKE
21	TO DISCUSS? HEARING NONE, PROCEDURALLY, MR.
22	HARRISON, DO WE WAIT ON A MOTION TO APPROVE ALL THE
23	DCF AWARDS PENDING DISCUSSION IN CLOSED SESSION ON
24	THIS ONE ITEM?
25	MR. HARRISON: YES. I'D RECOMMEND THAT WE
	100

1	GO THROUGH A PUBLIC SESSION DISCUSSION OF ALL THE
2	APPLICATIONS IN WHICH MEMBERS HAVE AN INTEREST.
3	THEN WE'LL KNOW WHAT ITEMS OF A CONFIDENTIAL NATURE
4	THAT WE NEED TO DISCUSS IN CLOSED SESSION. WE'LL
5	CONVENE IN CLOSED SESSION, AND THEN WE'LL RETURN TO
6	OPEN SESSION AND ENTERTAIN MOTIONS.
7	CHAIRMAN THOMAS: THANK YOU. OKAY. LET'S
8	MOVE ON NOW TO THE DC AWARDS. ARE THERE ANY
9	SPECIFIC APPLICATIONS THAT ANY MEMBERS OF THE BOARD
10	WOULD LIKE TO DISCUSS, EITHER THOSE MARKED AS
11	RECOMMENDED FOR FUNDING OR THOSE NOT RECOMMENDED?
12	MS. SAMUELSON: MR. CHAIRMAN?
13	THE COURT: YES, JOAN.
14	MS. SAMUELSON: NO. 5567, THE RETINAL
15	PROGENITOR CELLS FOR MACULAR DEGENERATION.
16	CHAIRMAN THOMAS: YES. WOULD YOU LIKE TO
17	HAVE STAFF PRESENT ON THAT?
18	MS. SAMUELSON: PLEASE.
19	CHAIRMAN THOMAS: YES. DR. SAMBRANO, WHO
20	IS THE
21	DR. SAMBRANO: IT'S DR. ABO.
22	CHAIRMAN THOMAS: DR. ABO WILL PRESENT.
23	THANK YOU.
24	DR. ABO: THIS PROJECT IS A DC
25	APPLICATION. THEY PROPOSE TO USE EMBRYONIC STEM
	101

1	CELLS-DERIVED RPE AND PHOTORECEPTORS PROGENITORS
2	GROWN TOGETHER AS A RETINAL SHEET. THEY WANT TO USE
3	THIS AS A COMBINATION THERAPY.
4	THE OBJECTIVE AND MILESTONES OF THIS
5	PROJECT WAS THE REVIEWERS SAID THAT THIS WORK IS IN
6	EARLY STAGE OF DEVELOPMENT. THEY WERE CONCERNED
7	ABOUT THE INABILITY TO SHOW EXPRESSION OF MATURE
8	RETINAL MARKERS AS DIFFERENTIATED CELLS. AND THEY
9	DID NOT HAVE A PLAN TO ASSESS DISTANCE MIGRATION OF
10	TRANSPLANTED CELLS BESIDE THE RETINA.
11	ALTHOUGH THEY FELT, ON THE RATIONALE AND
12	SIGNIFICANCE, THAT THIS PROPOSAL TARGETED UNMET
13	MEDICAL NEEDS FOR AMD.
14	THE REVIEWERS FELT THAT THE RESEARCH
15	PROJECT FEASIBILITY AND DESIGN WAS NOT SUFFICIENTLY
16	DEVELOPED AND LACK OF CRITICAL DETAILS, INSUFFICIENT
17	DESCRIPTIONS OF THE VISUAL ACUITY TEST WHICH IS
18	ESSENTIAL TO ASSESS SUCCESS OF TRANSPLANT, RETINAL
19	TRANSPLANT. NO ELECTROPHYSIOLOGY MEASUREMENT
20	INCLUDED, WHICH IS ESSENTIAL COMPONENT TO ASSESS
21	FUNCTIONALITY OF THE CELLS. THERE WAS NO PLAN TO
22	ASSESS POTENTIAL NEGATIVE EFFECTS SUCH AS PAIN. IT
23	WAS NOT CONSIDERED IN THIS PROPOSAL. AND IT WAS NOT
24	CLEAR HOW THEY ARE GOING TO INTERPRET THE
25	DESCRIPTIVE DATA.

	BARRISTERS' REPORTING SERVICE
1	THE PI, THEY FELT, IS STRONG, AND THERE
2	WAS SOME CONCERNS ABOUT 40 PERCENT USE OF THE
3	EFFORTS BY THE PI WAS NOT JUSTIFIABLE. THAT'S WHAT
4	THE REVIEWER FELT. AND THERE WAS CONCERNS
5	REGARDING
6	MS. SAMUELSON: WHAT WAS THAT LAST
7	COMMENT? SORRY.
8	DR. ABO: YOU KNOW, THE PI EFFORTS IN THE
9	PROJECT WAS 40 PERCENT, AND REVIEWERS FELT IT'S NOT
10	JUSTIFIABLE. AND THERE WERE CONCERNS
11	MS. SAMUELSON: UNJUSTIFIABLY LOW?
12	DR. ABO: NO. IT WAS TOO HIGH, THE
13	EFFORT. THAT'S WHAT THEY FELT. CONCERNS, AGAIN,
14	ABOUT THE BUDGET. THERE WERE ISSUES ASSOCIATED WITH
15	BUYING EQUIPMENT THAT SHOULD BE ALREADY IN PLACE.
16	AND THERE WAS NOT DEFINED ROLES FOR NUMEROUS OF THE
17	STAFF UNDER THIS PROPOSAL. SO THERE WAS A LOT OF
18	ISSUES.
19	AND OVERALL THEY FELT THAT THIS PROPOSAL
20	WAS NOT IN AN EARLY STAGE AND WAS NOT READY FOR
21	TO BE SUPPORTED BECAUSE IT NEEDS A LOT OF OTHER
22	ISSUES, AS I READ YOU ALL OF THIS.
23	CHAIRMAN THOMAS: JOAN, DO YOU HAVE ANY
24	OTHER QUESTIONS ON THIS ONE?
25	MS. SAMUELSON: NOT THAT ARE POPPING UP
	103

	BARRISTERS' REPORTING SERVICE
1	RIGHT THIS SECOND. I'M SURE I WILL IF I REFLECT ON
2	IT. BUT OUR COMMENTS, RESPONSE OF COMMENTS COME
3	LATER; IS THAT RIGHT?
4	CHAIRMAN THOMAS: I THINK WE WANT TO
5	DISCUSS NOW, IF WE CAN, WHILE WE'RE ON THE TOPIC.
6	MS. SAMUELSON: OKAY. I GUESS THE FIRST
7	POINT TO MAKE IS THAT THERE'S VERY LITTLE IN THE
8	PORTFOLIO. I'M TRYING TO FIND IT.
9	DR. ABO: WE HAVE TWO PROJECTS ON AMD IN
10	THE PORTFOLIO.
11	MS. SAMUELSON: PARDON? COULD YOU SPEAK
12	UP A LITTLE BIT?
13	DR. ABO: UNDER THE EYE DISEASES IN THE
14	PORTFOLIO, WE HAVE TWO PROGRAMS IN AMD. ONE IS AN
15	IND-ENABLING DISEASE TEAM I AGE-RELATED MACULAR
16	DEGENERATION, AND THE OTHER ONE IS EARLY TRANSLATION
17	1 DC AWARD. AND THERE IS A THIRD ONE. IT'S A DC
18	AWARD AS WELL. SO THERE'S THREE APPROACHES IN THE
19	TRANSLATIONAL PORTFOLIO TARGETING THE SAME DISEASE
20	WITH SIMILAR APPROACHES USING RPE CELLS AND TO CELL
21	TRANSPLANT.
22	MS. SAMUELSON: IS THAT REGARDED BY STAFF
23	AS A PROBLEM, THAT THEY'RE SIMILAR?
24	DR. ABO: THE APPROACH IN THIS PROPOSAL
25	WAS NOT IDENTICAL. AS I RECALL FROM THE REVIEW,
	104

-	
1	DURING THE REVIEW SESSION, THE FACT THAT THEY WANT
2	TO USE A COMBINATION OF PHOTORECEPTORS AND RPE WAS
3	ATTRACTIVE AS PART OF THE APPROACH, ALTHOUGH THE
4	REVIEWERS, AS I SAID, FELT THAT THE SCIENCE WAS NOT
5	THERE AND THAT THE PROPOSAL WAS TOO EARLY STAGE.
6	THEY WERE MISSING LOT OF DETAIL, THE RIGHT TEST TO
7	REALLY ASSESS THE SUCCESS OF THIS APPROACH. THAT
8	WAS THE MAIN CRITICISM.
9	BUT AS I SAID, THE APPROACH IS DIFFERENT
10	THAN JUST TAKING WHAT WE HAVE ON THE PORTFOLIO, JUST
11	RPE CELLS TRANSPLANTED IN THE RETINA. HERE THERE IS
12	A COMBINATION OF PRODUCT OF A COMBINATION OF RPE
13	PLUS PHOTORECEPTOR CELLS.
14	MS. SAMUELSON: AND THAT WOULD BE THE WAY
15	IT ENDS UP WORKING AS OPPOSED TO THE OTHERS WHICH
16	ARE DIFFERENT, RIGHT?
17	DR. ABO: IT COULD BE. IF IT WAS IF
18	THE SCIENCE WAS READY, AS THE REVIEWERS SAID, THIS
19	PROBABLY COULD BE A VERY ATTRACTIVE PROJECT.
20	MS. SAMUELSON: AND GIVEN THAT THIS IS
21	EARLY TRANSLATION AND IT'S JUST A FEASIBILITY AWARD,
22	ISN'T THIS
23	DR. ABO: NO. THIS IS A DC AWARD.
24	MS. SAMUELSON: EVEN SO, THIS IS THE FIRST
25	EFFORT TO TRY TO TAKE BASIC SCIENCE AND COME UP WITH
	105

1	A HYPOTHESIS THAT CAN LEAD TO SOMETHING. ISN'T THAT
2	WHAT THIS PART OF OUR GRANT PORTFOLIO IS TRYING TO
3	DO WITH THE EARLY TRANSLATION AWARD? THAT'S MY
4	UNDERSTANDING OF IT. AND I SHOULDN'T BE
5	INTERROGATING YOU ABOUT IT.
6	DR. ABO: NO. THE REVIEWER IS THE ONE
7	THAT MADE THE DECISION. I'M JUST COMMUNICATING
8	THEIR MESSAGE.
9	MS. SAMUELSON: I'M NOT GOING TO SHOOT THE
10	MESSENGER. THIS IS OBVIOUSLY AN ENORMOUSLY
11	IMPORTANT PART OF OUR PORTFOLIO. I SPENT LAST
12	WEEKEND WITH A WOMAN WITH MACULAR DEGENERATION, AND
13	SHE CAN SEE A LITTLE BIT OUT OF THE FAR RIGHT CORNER
14	OF HER EYE AND THAT'S ALL. IT DESERVES ROBUST
15	ATTENTION, AND I DON'T THINK THAT'S WHAT WE HAVE IN
16	OUR PORTFOLIO NOW. SO IMPORTANT NEW IDEAS DESERVE
17	FUNDING, AND IT SEEMS TO ME THAT THIS HAS THAT, AND
18	THAT IN EARLY TRANSLATION WE SHOULDN'T BE EXPECTING
19	PERFECTION. THAT IS A POINT AT WHICH WE'RE TAKING A
20	SERIES OF UNKNOWNS AND TRYING TO TURN THEM INTO A
21	KNOWN COMMODITY THERAPY.
22	AND SO TO CRITICIZE IT AS NOT REALLY READY
23	FOR PRIME TIME IS NOT TO ACCEPT THIS PART OF THE
24	PORTFOLIO, I THINK. I THINK IT'S IMPORTANT TO PUT
25	THE FUNDING TO IT. AND SO I THINK WE SHOULD BE
	106

	BARRISTERS' REPORTING SERVICE
1	DOING IT.
2	CHAIRMAN THOMAS: DR. PRIETO AND THEN DR.
3	TROUNSON.
4	DR. PRIETO: I'M TRYING TO REMEMBER SOME
5	OF THE DISCUSSION AROUND THIS APPLICATION. BUT
6	THERE ARE A COUPLE OF POINTS ON THE FEASIBILITY AND
7	DESIGN THAT WERE BROUGHT UP AS CRITICISMS THAT YOU
8	WOULD QUESTION. THE FIRST POINT, THAT OUTCOME
9	MEASURES WERE INSUFFICIENTLY DESCRIBED. AND THEN
10	RELATED TO THAT, THERE'S INSUFFICIENT DESCRIPTION OF
11	THE VISUAL ACUITY TEST WHICH IS PARTICULARLY
12	IMPORTANT FOR EVALUATING THE SUCCESS OF THE
13	TRANSPLANTS. I THINK THAT'S OBVIOUS, BUT IT SEEMS
14	TO ME THAT VISUAL ACUITY TESTING AND THE ASSESSMENT
15	OF VISUAL ACUITY IS A VERY WELL ESTABLISHED AND
16	MATURE TECHNOLOGY WITH VALIDATED INSTRUMENTS THAT
17	HAVE BEEN IN USE FOREVER.
18	I'M NOT SURE THAT I WOULD NECESSARILY
19	EXPECT THAT TO BE LAID OUT IN GREAT DETAIL,
20	PARTICULARLY GIVEN THAT WE GIVE SOME SPACE
21	CONSTRAINTS TO AN APPLICANT.
22	CHAIRMAN THOMAS: DR. TROUNSON.
23	DR. TROUNSON: WELL, I THINK THE IMPORTANT
24	PART IS TO REALLY REFLECT ON WHAT THEY'RE TRYING TO
25	ACHIEVE WITH WHAT TOOLS THEY'VE GOT. I THINK THIS

1	STUDY PROBABLY DESERVES A LITTLE BIT MORE A BIT
2	MORE DEVELOPMENT. YOU'VE GOT TO ACTUALLY PRODUCE
3	RETINAL EPITHELIAL CELLS, WHICH ARE GENERALLY WHERE
4	THE FIELD IS REASONABLY COMFORTABLE. AND THEN ON
5	TOP OF THAT, YOU GOT TO DEVELOP PHOTORECEPTOR CELLS.
6	AND THE CONCERNS REALLY ARE THE SCIENTISTS BELIEVE
7	THAT THERE REALLY WASN'T IT DIDN'T REALLY HAVE
8	THE TOOLS TO GET TO THOSE ENDPOINTS. AND PERHAPS A
9	LITTLE MORE TIME MIGHT MAKE IT MORE PERSUASIVE.
10	BUT I THINK WHEN YOU LOOK AT THE SCIENCE
11	OF SOME OF THESE PROJECTS, YOU'VE GOT TO BE
12	COMFORTABLE THAT THEY CAN ACTUALLY DO SOMETHING AS
13	COMPLEX AS THIS IN THE TIME FRAME. AND THE
14	SCIENTISTS CLEARLY DIDN'T THINK THAT THE TOOLS WERE
15	THERE IN THIS PARTICULAR STUDY TO COMPLETE IT.
16	SO I MEAN IT'S REALLY MORE ABOUT THE
17	SCIENCE BEING READY. IN SOME OF THE OTHER STUDIES
18	THAT WE'VE ALREADY GOT GOING IN THIS AREA, THEY'RE
19	WELL AND TRULY MATURE AND THEY'RE IN GOOD
20	DEVELOPMENT PHASES. BUT THIS ONE SOUNDED LIKE IT
21	REALLY DID NEED A LITTLE BIT MORE TIME TO SORT OF BE
22	PERSUASIVE THAT YOU COULD GET BOTH THESE CELL TYPES
23	TO DEVELOP IN SITU WITH THIS PARTICULAR APPLICATION.
24	CHAIRMAN THOMAS: JOAN.
25	MS. SAMUELSON: THE APPLICATION DID GET A
	108
	TOO

1	63, WHICH IS HIGHER THAN SOME OF THE OTHER GRANTS
2	THAT ARE RECOMMENDED FOR FUNDING. SO IT SEEMS TO ME
3	IT'S NOT STRICTLY A DEFICIT IN SCIENTIFIC MERIT, BUT
4	MORE A REFLECTION OF THE CHALLENGES THAT FACE THESE
5	INVESTIGATORS AS THEY'RE TRYING TO SOLVE AN
6	INTRACTABLE PROBLEM THAT HAS NO THERAPEUTIC
7	TREATMENT NOW. THAT'S THE HIGH BAR THAT THE
8	INITIATIVE GIVES US TO ACHIEVE, TO SUCCEED, TO TAKE
9	INCURABLE DISORDERS AND MAKE THEM CURABLE.
10	AND I KNOW IN PARKINSON'S MOST OF THE TIME
11	IT TAKES LONGER THAN THREE YEARS TO ADDRESS A
12	PROPOSED THERAPY AND FIGURE OUT HOW TO DEVELOP IT
13	ENOUGH THAT IT IS READY FOR A CLINICAL TRIAL. AND
14	WE'VE PUT THIS LIMIT OF THREE YEARS ON THESE GRANTS,
15	AND I DON'T THINK IT'S ALWAYS REFLECTIVE OF THE
16	TOUGH WORK THAT'S GOT TO BE DONE, AND THAT THAT MAY
17	BE THE CASE IN THIS CASE, AND THAT THAT'S WHAT'S
18	GOING ON WITH THE SCORE, THAT IT IS JUST UNDULY
19	DIFFICULT AND THAT IT DOESN'T REFLECT THE QUALITY OF
20	THE IDEA AND OF THE INVESTIGATORS AND OF HOW HARD
21	THEY'RE GOING TO WORK. AND IF WE CAN BENEFIT FROM
22	WHATEVER SCIENTIFIC ADVANCES COME FROM THOSE THREE
23	OR MORE YEARS OF WORK, TERRIFIC. IT WILL BE GREAT
24	USE OF OUR FUNDS.
25	DR. ABO: I JUST WANT TO EMPHASIZE THAT
	109

1	THIS WAS AN AWARD THAT WAS SUBMITTED UNDER OUR
2	DEVELOPMENT CANDIDATE AWARDS. WE HAVE THE SPACE FOR
3	THIS KIND OF STUDY WHICH IS A DCF AWARDS. IT'S A
4	LOWER EARLY STAGE PROJECT THAT COULD BE DEVELOPED
5	INTO THE DEVELOPMENT CANDIDATE. SO IT'S NOT JUST
6	THREE YEARS PROGRAM. ONE COULD ENTER INTO THE DCF,
7	GENERATE SOME DATA, AND AFTER A YEAR, TWO YEARS, OR
8	EVEN DURING THE PROCESS USE THE DATA AS PRELIMINARY
9	DATA TO APPLY FOR A DC AWARD. SO IT'S ABOUT SIX
10	YEARS PROGRAM. YOU CAN LOOK AT IT AS THAT'S WHAT WE
11	TRY TO ACHIEVE.
12	SO WE ASKED THE REVIEWERS TO ASSESS THIS
13	PROJECT AS A DEVELOPMENT CANDIDATE AWARD, NOT AS A
14	PROOF OF CONCEPT TYPE OF AWARD. AND THAT'S THE
15	RESPONSIBILITY OF THE APPLICANT TO UNDERSTAND THE
16	DIFFERENCES BETWEEN THESE TWO TYPE OF AWARDS WHEN
17	THEY APPLY FOR IT.
18	MS. SAMUELSON: RIGHT. AND I GUESS AT
19	THIS POINT WATCHING HOW THOSE TWO CATEGORIES WORK,
20	SOMETIMES THERE ARE THINGS THAT FALL THROUGH THE
21	CRACKS. I THINK IT'S TERRIFIC THAT THEY ARE
22	SUFFICIENTLY AMBITIOUS AND CONFIDENT ABOUT THEIR
23	HYPOTHESIS THAT THEY REALLY WANT TO BE AGGRESSIVE
24	ABOUT WORKING IT. AND IT'S A LOT MORE MONEY, AND
25	THE DIFFICULTY OF THE WORK IS SUFFICIENTLY IS
	110

1	SUFFICIENT TO JUSTIFY THAT MUCH MONEY. MAYBE
2	THEY'RE UNDULY AMBITIOUS IN THAT TIME FRAME, BUT IT
3	MAY MEAN THAT THAT EXTRA MONEY AND THE DEMANDS OF A
4	DC AS OPPOSED TO A DCF WILL GET MORE WORK DONE. AND
5	THAT'S ALL A GOOD THING.
6	CHAIRMAN THOMAS: PROCEDURALLY, DR. ABO,
7	FOR PURPOSES OF DISCUSSION, IS ONE OPTION HERE TO
8	PROPOSE THAT THE AWARD POTENTIALLY WOULD BE REDUCED
9	TO A DCF AWARD, WHICH WOULD THEN INVOLVE
10	REDEFINITION OF SCOPE, FUNDING, ETC.? DO WE HAVE
11	THAT AS AN OPTION HERE?
12	MR. SHEEHY: JUST AS A POINT, THE GRANTS
13	WORKING GROUP HAD THAT OPTION IN THE PROGRAMMATIC
14	REVIEW. SO THAT YEAH. THEY COULD HAVE DONE THAT
15	IF THEY THOUGHT THAT THAT PROPOSAL COULD HAVE
16	MERITED THAT TYPE OF APPROACH.
17	DR. SAMBRANO: SO THE OPTION WAS
18	AVAILABLE, AS MR. SHEEHY SAYS, WITH THE GRANTS
19	WORKING GROUP. AND THEY ACTUALLY DID MAKE THAT
20	RECOMMENDATION IN ONE CASE. AS WE ALSO ALERTED THE
21	GRANTS WORKING GROUP, ON DOING THIS, ONE HAS TO BE
22	VERY CAUTIOUS ABOUT MAKING SUCH A CHANGE. NOT ONLY
23	IS THE AWARD AMOUNT DIFFERENT, YOU WANT TO MAKE SURE
24	THAT BY REDUCING THE AWARD AMOUNT AND PUTTING IT
25	INTO A DIFFERENT CATEGORY, THAT IT IN SOME WAY
	111

1	DOESN'T THEN PREVENT APPLICANTS FROM BEING ABLE TO
2	PURSUE THE STUDIES GIVEN THE SIGNIFICANT DIFFERENCES
3	IN THE AWARD TYPE. SO ONE HAS TO, I THINK, JUST
4	TREAD VERY CAREFULLY IN DOING THAT.
5	CHAIRMAN THOMAS: THANK YOU. DR. FEIGAL.
6	DR. FEIGAL: YEAH. I JUST WANT TO MAKE A
7	COMMENT. IT'S NOT SPECIFIC TO THIS PROPOSAL, BUT
8	JUST IN GENERAL. I THINK IT'S REALLY HARD IF WE
9	MAKE SUGGESTIONS TO CHANGE THE BUDGET, CHANGE THE
10	SCOPE, GREATLY REVISE WHAT THE APPLICANT INTENDED TO
11	PRESENT. AND I THINK THERE'S NOT JUST THIS ONE, BUT
12	PROBABLY MULTIPLE ONES THAT THAT COULD BE SUGGESTED
13	FOR. BUT I THINK THAT'S A VERY DIFFERENT WAY OF
14	APPROACHING HOW TO LOOK AT THESE APPLICATIONS THAT
15	COME IN.
16	I THINK, AS JEFF POINTED OUT, THERE IS A
17	PROGRAMMATIC DISCUSSION THAT TAKES PLACE WHERE SOME
18	OF THESE OPTIONS ARE DISCUSSED. AND YOU HEARD WHAT
19	THE PROPOSAL WAS AND THE REASONS WHY THEY MAY OR MAY
20	NOT HAVE WANTED TO DO IT. BUT I JUST THINK FOR THE
21	BOARD TO SUGGEST IT'S CERTAINLY AN OPTION YOU CAN
22	SUGGEST, BUT I WOULD JUST CAUTION YOU THAT I THINK
23	THAT'S A VERY HARD ROAD TO GO DOWN IF THE BOARD IS
24	SUGGESTING REVISING THE SCOPE AND REVISING THE
25	BUDGET. JUST AN OPINION. I JUST WANTED TO PUT THAT
	112

1 OUT. 2 MS. SAMUELSON: AND THAT IS NOT WHAT I'M 3 SUGGESTING. I'M SUGGESTING THAT THE FACT THAT THIS 4 GRANT APPLICATION MAY NOT SEEM PERFECT AND AN OVERLY 5 DEMANDING SET OF CRITERIA IN THE CONTEXT OF THE DIFFICULTY OF SCIENTIFIC ADVANCES IN THIS VERY 6 7 DIFFICULT FIELD AND THAT THE MISSION OF OUR 8 PROGRAMMATIC DISCUSSION IS TO LOOK FOR SITUATIONS 9 WHERE IMPORTANT ADVANCES COULD BE MADE THAT AREN'T 10 NECESSARILY SATISFYING THE LETTER OF THE LAW IN EVERY INSTANCE. THAT'S WHERE WE ARE SUPPOSED TO BE 11 12 ACTING. 13 CHAIRMAN THOMAS: MR. SHEEHY. MR. SHEEHY: YOU KNOW, MAYBE ONE WAY TO 14 15 KIND OF BRING THIS DISCUSSION TO A CLOSE MIGHT JUST 16 BE TO HAVE A VOTE. I MEAN A MOTION AND A VOTE. I 17 JUST DON'T -- I DON'T KNOW. I MEAN JUST AS A SUGGESTION TO THE CHAIR AND TO JOAN, MAYBE THAT'S A 18 19 GOOD WAY. 20 CHAIRMAN THOMAS: I THINK WHAT WE DECIDED TO DO WAS TO WITHHOLD ANY MOTIONS OR ANY VOTES UNTIL 21 22 WE HAVE OUR CLOSED SESSION AND THEN COME BACK AND 23 CAN ENTERTAIN ANY MOTIONS AND VOTES AT THAT POINT. 24 SO ARE THERE ANY OTHER COMMENTS ON ANY OF THE 25 AWARDS? DR. VUORI.

1	DR. VUORI: I HAVE A QUESTION ON THE
2	APPLICATION 5541. ACTUALLY I HAVE READ THE
3	COMMENTARY IN THE BOOKLET, AND I HAVE ONE SPECIFIC
4	QUESTION THAT I THINK HELPS ME TO PUT THE COMMENTS
5	IN PERSPECTIVE. AND THAT IS WHAT TYPE OF SOLID
6	TUMOR IS PROPOSED TO BEING STUDIED HERE?
7	DR. ABO: I THINK IT'S PANCREATIC CANCER.
8	THE FIRST ONE DISCUSSES PANCREATIC CANCER.
9	DR. VUORI: 5541 FOCUSES ON PANCREATIC
10	CANCER SPECIFICALLY?
11	DR. ABO: I HAVE TO LOOK. IS THAT
12	CONFIDENTIAL INFORMATION BECAUSE IT'S NOT IN THE
13	PUBLIC ABSTRACT?
14	DR. OLSON: I THINK THAT'S OKAY.
15	DR. ABO: STRONG ACTIVITY IN PRECLINICAL
16	MODEL FOR PANCREATIC CANCER. THAT'S THE AREA THAT
17	THEY FEEL THAT THEY CAN GO FORWARD WITH THIS
18	APPROACH.
19	DR. VUORI: SO I WOULD LIKE TO MOVE THIS
20	APPLICATION TO BE DISCUSSED IN THE CLOSED SESSION
21	REGARDING ITS STUDY DESIGN.
22	DR. PRIETO: ANOTHER APPLICATION WHEN
23	WE'RE READY FOR THAT.
24	CHAIRMAN THOMAS: IS THERE ANY OTHER
25	COMMENTS ON THIS PARTICULAR APPLICATION? HEARING
	114
	114

	BARRISTERS' REPORTING SERVICE
1	NONE, DR. PRIETO.
2	DR. PRIETO: YEAH. I'D ALSO LIKE TO BRING
3	UP 5660.
4	CHAIRMAN THOMAS: PLEASE PROCEED.
5	DR. CANET-AVILES: I WOULD LIKE TO REVIEW
6	THE SUMMARY FIRST. THIS APPLICATION IS FOR THE
7	DEVELOPMENT CANDIDATE, AND IT'S FOCUSED ON HUMAN
8	EMBRYONIC STEM CELL-DERIVED NEUROPROGENITOR CELL
9	THERAPY FOR STROKE. THE APPLICANT PROPOSED TO
10	TRANSIENTLY AND EX VIVO GENETICALLY MODIFY HUMAN
11	EMBRYONIC STEM CELLS TO DERIVE NEURAL PRECURSOR
12	CELLS, PROGENITOR CELLS, TO IMPROVE SURVIVAL AND
13	DIFFERENTIATION INTO NEURONS FOLLOWING TRANSPLANT
14	INTO THE STROKE BRAIN.
15	HE PROPOSED FOUR MILESTONES. THE FIRST
16	ONE WAS TO TRANSDUCE THE HUMAN EMBRYONIC STEM
17	CELL-DERIVED NEUROPROGENITOR CELLS WITH A VIRAL
18	VECTOR AND VERIFY NEUROGENESIS IN VITRO.
19	THE SECOND ONE WAS TO TRANSPLANT THESE
20	CELLS INTO IN ANIMAL MODELS OF A STROKE.
21	THE THIRD ONE WAS TO ANALYZE THESE ANIMALS
22	TO VERIFY NEURONAL DIFFERENTIATION AND INTEGRATION
23	IN VIVO. AND LASTLY, THE FOURTH MILESTONE WAS TO
24	ANALYZE THE BEHAVIOR OF THESE ANIMALS TO DETERMINE
25	IF THESE CELLS COULD AMELIORATE THE STROKE-INDUCED
	115

DEFICITS.

1

2 THE MAJOR KEY CON OF THIS APPLICATION, IT 3 WAS THE STRONG OPINION OF THE GRANTS WORKING GROUP, 4 IT WAS UNDER THE OBJECTIVE AND MILESTONES, WAS THAT 5 THE PROJECT COULD BE READY TO ADVANCE INTO IND-ENABLING STUDIES IN THE THREE YEARS. BASED ON 6 7 THE APPLICATION, AND THIS IS KEY, THEY DID NOT 8 PROPOSE THE KEY ACTIVITIES LISTED IN THE RFA FOR 9 ACHIEVING DEVELOPMENT CANDIDATE. IF YOU LOOK AT THE 10 RFA, YOU CAN FIND THIS ON PAGE 3 OF THE RFA. 11 BASICALLY THERE WERE NO STUDIES PROPOSED TO 12 CHARACTERIZE THIS POPULATION THAT THEY ARE PROPOSING 13 TO DERIVE. 14 IN TERMS OF RATIONALE AND SIGNIFICANCE, IT'S INDEED A VERY SIGNIFICANT PROBLEM THAT SOCIETY 15 16 FACES. STROKE CAUSES IRREVERSIBLE DAMAGE TO THE 17 BRAIN, AND THERE ARE CURRENTLY FEW TREATMENTS, FEW 18 EFFECTIVE TREATMENTS. ANY STEM CELL-BASED 19 RESTORATION OF THE CENTRAL NERVOUS SYSTEM COULD BE A 20 MAJOR ADVANCEMENT IN STROKE THERAPY. 21 IN TERMS OF FEASIBILITY AND DESIGN, THE 22 GRANTS WORKING GROUP FOUND THAT THE PRECLINICAL 23 ANIMAL STUDIES, WHICH ARE THE BULK OF THIS PROPOSAL, 24 ARE NOT FEASIBLE OVER THE COURSE OF THE THREE-YEAR 25 AWARD. BASICALLY THEY PROPOSED TO CONDUCT THE 116

1	STUDIES WITH RESOURCES IN THE TIME AND WITH THE
2	RESOURCES THEY HAVE ALLOTTED, THEY ARE NOT FEASIBLE.
3	AND I DON'T KNOW IF IT'S PROPRIETARY INFORMATION THE
4	AMOUNT OF ANIMALS PROPOSED. THEY PROPOSE TO DO
5	THESE STUDIES IN TWO YEARS AND IT WAS A HUGE NUMBER.
6	AND IF IT'S CONSIDERED CONFIDENTIAL, I CAN TALK
7	ABOUT IT IN CLOSED DOORS LATER. BUT THAT WAS ONE OF
8	THE MAJOR CONS.
9	A MOTION WAS MADE TO MOVE THIS APPLICATION
10	TO TIER III, NOT RECOMMENDED FOR FUNDING, AND THE
11	MOTION CARRIED. ARE THERE ANY QUESTIONS SPECIFIC?
12	MS. SAMUELSON: QUESTION, ROSA. THE
13	NUMBER OF ANIMALS TO BE TESTED AT A CERTAIN TIME
14	FRAME WAS REGARDED AS REALLY AMBITIOUS?
15	DR. CANET-AVILES: SO THE NUMBER OF
16	ANIMALS WAS GOING TO BE IN TWO YEARS WAS GOING TO
17	COME UP TO APPROXIMATELY 10,000 ANIMALS, WHICH MEANT
18	THAT YOU WERE GOING TO BE WORKING WITH ABOUT AN
19	AVERAGE OF 15 ANIMALS PER DAY. AND YOU HAVE TO DO
20	ALL THE, LIKE, SURGERY IN ORDER TO INDUCE THE STROKE
21	AND EVERYTHING. SO THAT WAS NOT SEEN AS FEASIBLE.
22	BUT MORE THAN THAT IF YOU JUST GIVE ME A MOMENT.
23	DR. STEWARD: I'M SORRY. COULD I SUGGEST
24	THAT THE DISCUSSION OF ANIMAL USE AND NUMBERS, THAT
25	REALLY STRIKES ME AS BEING PROPRIETARY.
	117

BARRISTERS' REPORTING SERVICE 1 CHAIRMAN THOMAS: MR. HARRISON. 2 MR. HARRISON: WE CAN DISCUSS THAT FURTHER 3 IN CLOSED SESSION. 4 CHAIRMAN THOMAS: THANK YOU. ANY OTHER 5 QUESTIONS OF ROSA ON THIS APPLICATION? IT NOW SOUNDS LIKE THREE --6 7 DR. PRIETO: IT IS A QUESTION. BUT THIS IS THE SUBJECT OF AN EXTRAORDINARY PETITION WHICH 8 9 ADDRESS SEVERAL OF THESE POINTS DIRECTLY. SO WE'LL 10 DISCUSS THAT IN CLOSED SESSION, INCLUDING THE 11 QUESTIONS OF THE ANIMAL USAGE AND FEASIBILITY OF 12 THAT. 13 DR. CANET-AVILES: THAT'S ONE OF THE 14 POINTS RAISED. 15 CHAIRMAN THOMAS: IS THAT OKAY, MR. 16 HARRISON? 17 MR. HARRISON: WITH RESPECT TO THE STUDY 18 DESIGN AND THE USE OF ANIMALS, YES. IF THERE ARE 19 OTHER POINTS THAT YOU'D LIKE TO DISCUSS IN THE 20 EXTRAORDINARY PETITION THAT DON'T FALL INTO THE 21 CATEGORY OF BEING PROPRIETARY, THEY CAN BE ADDRESSED 22 NOW. 23 DR. PRIETO: WELL, THE EXTRAORDINARY 24 PETITION DOES CALL INTO QUESTION FACTUAL ERRORS OR 25 POTENTIAL FACTUAL ERRORS IN THE REVIEW, INCLUDING 118

1	THAT IN OUR SUMMARY HERE THE RESEARCH PLAN DOES NOT
2	INCLUDE A THOROUGH INVESTIGATION OF SAFETY ENDPOINTS
3	AND, IN PARTICULAR, THE POTENTIAL FOR NEWLY
4	TRANSPLANTED NEURONS TO CAUSE ABNORMAL ACTIVITY, AND
5	SEIZURE SHOULD BE EXAMINED.
6	I THINK I CAN MENTION THE REVIEWER'S NAME
7	IF THERE'S AN EXTRAORDINARY PETITION. THE
8	INVESTIGATOR'S NAME, IT'S STUART LIPTON FROM THE
9	SANFORD-BURNHAM, AND HE DOES DIRECTLY ADDRESS THAT
10	QUESTION, THAT THIS IS NOT FACTUALLY CORRECT, THAT
11	THERE'S AN ENTIRE SECTION IN THE GRANT ABOUT
12	MONITORING ELECTRICAL ACTIVITY IN THESE CELLS
13	USING HE DESCRIBES THE TECHNIQUES. IN THE THIRD
14	MILESTONE THERE'S A WHOLE SECTION OF THE PRELIMINARY
15	DATA ON THOSE EXPERIMENTS.
16	IT KIND OF BRINGS INTO QUESTION: DO WE
17	ALWAYS HAVE THE APPROPRIATE EXPERTISE IN OUR REVIEW
18	SESSION, PEOPLE WITH FAMILIARITY OF THE CLINICAL
19	ISSUES AND SUCH?
20	CHAIRMAN THOMAS: DR. STEWARD.
21	DR. STEWARD: JUST IN PRINCIPLE AND SORT
22	OF IRRESPECTIVE OF THIS APPLICATION, I WOULD SUGGEST
23	THAT IF THERE ARE CLAIMS OF DISCREPANCIES OF FACT,
24	THAT THAT REQUIRES US TO REALLY DRILL DOWN A LITTLE
25	BIT MORE INTO THE DETAILS OF THE APPLICATION AND,
	119
	±±3

1	THEREFORE, IT IS PROPRIETARY, AND THAT THAT SHOULD
2	BE SOMETHING THAT WE COULD DO IN CLOSED SESSION.
3	CHAIRMAN THOMAS: MR. HARRISON IS NODDING
4	IN THE AFFIRMATIVE. ANY OTHER COMMENTS ON THIS
5	PARTICULAR APPLICATION?
6	DR. STEWARD: JUST IF WE COULD GET THE
7	DISTRIBUTION OF VOTES ON THE MOTION TO MOVE TO TIER
8	I. MAYBE LATER, BUT AT SOME POINT.
9	CHAIRMAN THOMAS: WE CAN GET THAT NOW.
10	THAT'S AN OPEN SESSION QUESTION.
11	DR. CANET-AVILES: SORRY. THERE WAS NO
12	MOTION TO TIER I. IT WAS TO TIER III.
13	DR. STEWARD: OKAY.
14	DR. CANET-AVILES: IT WAS FROM TIER II TO
15	TIER III.
16	DR. STEWARD: WELL, PROBABLY IT WOULD BE
17	USEFUL TO HAVE THAT.
18	DR. CANET-AVILES: I WILL GET IT TO YOU.
19	MR. SWEEDLER: I HAVE THAT INFORMATION.
20	IT WAS MOVED DOWN BY A VOTE OF 18 AYE VOTES TO TWO
21	NO VOTES.
22	DR. STEWARD: THANK YOU.
23	CHAIRMAN THOMAS: THANK YOU, ROSA. ARE
24	THERE ANY COMMENTS OR QUESTIONS ABOUT OTHER
25	APPLICATIONS? MR. SHEEHY.
	120
	120

i i	
1	MR. SHEEHY: COULD WE TAKE A LOOK AT 5626?
2	JUST LOOKING AT THE NUMBERS, IT HAS A HIGH STANDARD
3	DEVIATION, AND THEN ITS MEDIAN SCORE IS 75, WHICH IS
4	ACTUALLY HIGHER IN A MEDIAN SENSE THAN THE THREE
5	ABOVE IT. AND IT SEEMS AS THOUGH I MEAN I LOOK
6	AT THE REVIEW, AND THE REVIEW SEEMS TO FOCUS ON
7	PROBABLY THE 40, AND I DON'T KNOW IF IT REALLY
8	ADDRESSES WHY THE MEDIAN WAS 75. I MEAN THERE SEEMS
9	TO BE SOME DISPUTE AS TO WHETHER THESE CELLS ARE THE
10	BEST CELLS IN HEART DISEASE, BUT THAT SEEMS TO BE A
11	LIVE DEBATE. AND ARE WE PREMATURELY KIND OF FALLING
12	ON ONE SIDE OF THAT DEBATE, THAT THE MESENCHYMAL
13	STEM CELLS ARE NOT GOING TO BE THE GREAT CELLS TO
14	PUT IN FOR HEART DISEASE? ARE WE KIND OF
15	ARBITRARILY MAKING THAT DECISION WHEN IT SEEMS LIKE
16	A SUBSTANTIAL NUMBER OF THE REVIEWERS WERE
17	COMFORTABLE WITH US MAKING THAT BET?
18	AND IT SEEMS LIKE THE KEY THING HERE IS
19	THE MATRIX THAT'S GOING TO HOLD THEM IN PLACE. WE
20	REALLY MIGHT NOT KNOW THE ANSWER UNTIL WE PUT IN
21	SOMETHING THAT HOLDS THOSE CELLS IN PLACE AND WE CAN
22	SEE WHAT HAPPENS.
23	WE DID HAVE THAT GREAT PRESENTATION AT
24	CEDARS-SINAI, SO WE DO KNOW THAT CELLS GOING INTO
25	THE HEART DO SEEM TO BE DOING SOME STUFF. SO MAYBE
	121

BARRISTERS' REPORTING SERVICE 1 INSIGHTS. 2 CHAIRMAN THOMAS: YES, PLEASE PROCEED. DR. COLLINS: GOOD MORNING, MR. CHAIRMAN 3 4 AND MEMBERS OF THE BOARD AND PUBLIC. I'D LIKE TO 5 JUST BRIEFLY PRESENT TO YOU A SYNOPSIS OF THIS 6 APPLICATION, AND THEN I WILL GO THROUGH THE KEY 7 POINTS THAT CAME UP IN THE REVIEW. 8 SO THIS IS A DEVELOPMENT CANDIDATE 9 PROPOSAL, AND I MAY SAY DC LATER, BUT I'LL TRY TO 10 STICK WITH DC, WITH DEVELOPMENT CANDIDATE, TO 11 EVALUATE DONOR-DERIVED BONE MARROW MESENCHYMAL STEM 12 CELLS ON AN FDA-APPROVED BIOLOGICAL SCAFFOLD OR CELL 13 CARRIER FOR THE TREATMENT OF CHRONIC HEART ATTACKS. AND THE RATIONALE BEHIND ADDING THIS CARRIER IS TO 14 15 KEEP THE CELLS AT THE DESIRED TRANSPLANT SITE AND 16 ENHANCE THE THERAPEUTIC IMPACT OF THE STEM CELLS BY 17 RETAINING THEM IN PLACE. SO JUST BRIEFLY, THE PLAN IS TO DEVELOP 18 19 AND CHARACTERIZE THIS DEVICE IN VITRO AND THEN 20 PERFORM IN VIVO SAFETY AND EFFICACY TESTING. AND AS FAR AS THE EVALUATION OF THE GRANTS WORKING GROUP, 21 22 THIS IS A PROPOSAL FROM AN ACCOMPLISHED CARDIAC SURGEON, THAT'S ONE OF THE STRENGTHS, WITH CLINICAL 23 24 EXPERIENCE USING THE PROPOSED SCAFFOLD. THE TEAM 25 ITSELF IS TRANSLATIONALLY FOCUSED AND HAS STEM CELL

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	BARRISTERS' REPORTING SERVICE
1	AND MANUFACTURING EXPERTISE.
2	AND THE PANEL DID NOTE THAT THE
3	APPLICATION WAS CLEARLY WRITTEN WITH APPROPRIATE
4	MILESTONES AND SUCCESS CRITERIA. SO THOSE WERE THE
5	STRENGTHS. AND IN ADDITION, THE UNMET MEDICAL NEED
6	IN HEART FAILURE IS OBVIOUSLY COMPELLING.
7	HOWEVER, THE GRANTS WORKING GROUP HAD
8	THREE MAIN CONCERNS REGARDING THE PROPOSAL THAT
9	RESULTED IN THE RECOMMENDATION NOT TO FUND THE
10	PROGRAM. AND THE FIRST, I THINK, AND KEY
11	RESERVATION WAS THAT THEY FOUND THE PROGRAM TO BE
12	PREMATURE. AS ALREADY MENTIONED, PRELIMINARY DATA
13	AND FEASIBILITY ARE IMPORTANT FOR THESE DEVELOPMENT
14	CANDIDATE AWARDS. AND THIS WAS PART OF THE REVIEW
15	CRITERIA.
16	AND THE PANEL NOTED THAT THE PROPOSAL
17	THE APPLICATION LOOKED AT PRELIMINARY DATA USING THE
18	PROPOSED CANDIDATE IN THE CHRONIC HEART DISEASE
19	MODEL. SO THEY WERE A LITTLE BIT CONCERNED THAT THE
20	DATA THERE TO SHOW THAT PERHAPS THIS PRODUCT WOULD
21	BE MORE EFFECTIVE THAN EITHER COMPONENT ALONE WAS
22	LACKING.
23	AND THIS CONCERN MAY HAVE BEEN MAGNIFIED
24	BY UNCERTAINTY THAT YOU MENTIONED, MR. SHEEHY, THAT
25	MSC'S ARE THE BEST CHOICE FOR REPAIRING CHRONICALLY
	123

1	DAMAGED HEARTS GIVEN THAT THIS IS A WELL-STUDIED
2	CELL TYPE IN THIS DISEASE AND THE DATA HAVE BEEN A
3	BIT CONFLICTING TO DATE.
4	AND FINALLY, THERE WAS DISCUSSION THAT THE
5	PANEL DIDN'T FIND THAT THE DC WAS PARTICULARLY
6	NOVEL. AGAIN, I MENTIONED THAT IT WAS WELL STUDIED.
7	AND THE PANEL WAS NOT CLEAR THAT ATTEMPTS TO RETAIN
8	THE CELLS AT THAT TIME THE TRANSPLANTATION SITE
9	WOULD REALLY IMPROVE THEIR EFFECT. AND I THINK
10	REALLY THAT DATA WAS WHAT THEY WOULD HAVE LIKED TO
11	SEE TO FEEL MORE COMFORTABLE WITH RECOMMENDING IT.
12	SO THOSE WERE THE KEY REASONS FROM THE
13	REVIEW THAT IT WASN'T RECOMMENDED FOR FUNDING.
14	CHAIRMAN THOMAS: MR. SHEEHY.
15	MR. SHEEHY: WELL, JUST A COUPLE OF
16	POINTS. ONE, IT DOESN'T SEEM LIKE WE HAVE ANY
17	CARDIAC MSC WORK GOING ON. I THINK I'M CORRECT IN
18	THAT. AND I THINK, I MEAN I'M NOT AN EXPERT ON
19	THIS, BUT MSC'S SEEM TO BE MOVING FAIRLY I MEAN
20	HAVING SAT THROUGH THESE REVIEWS, SEEM TO BE VERY
21	TRANSPLANTABLE RIGHT NOW. THEY'RE NOT IMMUNOGENIC.
22	THEY'RE NOT TUMOROGENIC. SO IT DOES ADDRESS PERHAPS
23	A GAP IN OUR PORTFOLIO. AND I WONDER TO WHAT DEGREE
24	THE NOVELTY WAS A NEGATIVE AND THAT MAYBE OTHER
25	PEOPLE ARE DOING THIS. MAYBE THIS IS SOMETHING WE
	124

	BARRISTERS' REPORTING SERVICE
1	MIGHT WANT TO DO. MAYBE WE COULD GET THERE FIRST.
2	BE A NICE HOME RUN FOR US IF WE DID, I THINK.
3	DR. COLLINS: I THINK THE POINT WITH THE
4	NOVELTY I'M SORRY.
5	MR. SHEEHY: NO. GO AHEAD, PLEASE.
6	DR. COLLINS: I THINK THE POINT WITH THE
7	NOVELTY WAS THAT IT'S NOT JUST WHO'S DOING IT, THAT
8	THIS HAS BEEN WELL STUDIED TO THE POINT THERE HAVE
9	BEEN A NUMBER OF CLINICAL TRIALS, INCLUDING WELL,
10	ANYWAYS, I THINK THAT WAS THE KEY POINT.
11	MR. SHEEHY: BUT ISN'T THE DATA KIND OF
12	CONFLICTING? SOME SHOW SOME EFFECT FROM HAVING THE
13	MSC'S THERE AND SOME SHOW NO EFFECT.
14	DR. COLLINS: EXACTLY.
15	MR. SHEEHY: AND SO THEIR HYPOTHESIS IS IF
16	WE JUST KEEP THE CELLS THERE, WE MIGHT GET AN
17	EFFECT. SO HE'S GOT A RELATIVELY SAFE CELL
18	POPULATION, GOOD BIOMATERIAL TO HOLD THEM THERE. I
19	THINK THIS IS A SAFE, APPROVED PRODUCT.
20	DR. COLLINS: THE MATERIAL IS APPROVED.
21	MR. SHEEHY: AND THEN I LOOK AT THE MEDIAN
22	SCORE OF 75, AND TO ME THIS SUGGESTS ONE WHERE WE
23	MIGHT PERSONALLY, AND WE'RE NOT MAKING MOTIONS
24	NOW, BUT WE MIGHT WANT TO TAKE A LOOK AT PERHAPS
25	TAKING A RISK ON THIS. AND THE CELL TYPE WE DON'T
	125

1	HAVE IN OUR PORTFOLIO FOR THIS PARTICULAR APPROACH.
2	CHAIRMAN THOMAS: DR. TROUNSON.
3	DR. TROUNSON: JUST IN A GENERAL SENSE,
4	JEFF, THE MSC'S USUALLY DON'T LAST VERY LONG.
5	THEY'RE GONE IN A COUPLE OF DAYS. AND SO I THINK
6	ONE OF THE CONCERNS OF THE REVIEWERS WAS SAYING,
7	WELL, WOULDN'T THAT BE THE SAME IN THIS SITUATION?
8	TELL US THAT THE SCAFFOLD SEEDED WITH THIS IS
9	BETTER. AND THAT'S WHAT WE DIDN'T HAVE. YOU PUT
10	THE SCAFFOLD ON, MIGHT BE JUST AS GOOD AS ADDING THE
11	CELLS. SO THAT WAS IT WAS DEFICIENT IN THAT
12	REGARD.
13	SO I THINK THE INJECTION FRACTION STUDIES
14	WITH DIFFERENT COMPANIES IS UP AND DOWN, YES, BUT
15	THERE'S USUALLY SOME MERIT FOR HAVING THOSE MSC'S.
16	WE HAVE NO IDEA WHAT THAT MECHANISM IS, OF COURSE,
17	WHICH IS A LITTLE CONCERNING, BUT I THINK THE REAL
18	ISSUE WHERE THE REVIEWERS WERE REALLY SORT OF
19	STRUGGLING WAS, WELL, IS IT REALLY BETTER THAN JUST
20	HAVING THE SCAFFOLD. THE SCAFFOLD THERE WOULD
21	ATTRACT ENDOGENOUS CELLS AS WELL, AND SO WONDERED
22	WHERE THE BENEFIT WAS. AND IF THEY COULD SHOW THEM
23	THE BENEFIT, I THINK, IT WOULD HAVE HELPED
24	CONSIDERABLY. THAT'S THE WAY I RECALL THE
25	DISCUSSION.

1	MR. SHEEHY: MIGHT NOT HAVING THOSE MSC'S
2	WITH THEIR KIND OF SOMEWHAT MAGIC PROPERTY IN THE
3	ENDOGENOUS CELLS, WHICH SEEMS LIKE IF MSC'S ARE
4	DOING SOMETHING, THEY'RE DOING SOMETHING ON THE
5	ENDOGENOUS CELLS HAVING THAT TRAFFICKING AND THEN
6	THE MSC'S WITH THEIR KIND OF PRESENCE THERE, EVEN IF
7	THEY'RE NOT THERE FOR A LONG TIME. I MEAN JUST
8	DR. TROUNSON: THAT'S TRUE. JUST TO
9	REMIND YOU, ALSO, THAT THE GROUP AT CEDARS-SINAI
10	COMPARED MSC'S AND MONONUCLEOCYTES WITH THE CARDIAC
11	CELLS, AND THERE WAS REALLY A VERY BIG DIFFERENCE IN
12	THEIR STUDIES. I'D LIKE TO SEE THAT REPEATED BY
13	OTHERS, BUT IT LOOKS LIKE, IF WE'RE ON THE TRACK,
14	WE'RE KIND OF ON THE TRACK WITH A BETTER COMPOUND
15	GIVEN THAT PARTICULAR STUDY. AS I SAID, I'D LIKE TO
16	SEE THAT REPEATED. BUT IT LOOKED MUCH BETTER TO
17	UTILIZE THE HEART THE HEART-TYPE CELLS RATHER
18	THAN THE MSC'S.
19	MR. SHEEHY: THOSE DON'T PERSIST EITHER,
20	RIGHT?
21	DR. TROUNSON: NO. NO. THAT'S TRUE. NO,
22	THAT'S RIGHT. THAT I AGREE. THAT I AGREE.
23	CHAIRMAN THOMAS: DR. STEWARD.
24	DR. STEWARD: COULD YOU REMIND US, THERE'S
25	ONE COMMENT IN HERE ABOUT LACKS LETTERS OF SUPPORT
	127

BARRISTERS' REPORTING SERVICE FROM CO-INVESTIGATORS. COULD I COMMENT? I DON'T REMEMBER THE DEGREE TO WHICH THAT INFLUENCED THE OVERALL SCORE. DR. COLLINS: SO THAT WAS DISCUSSED. I DON'T RECALL IT BEING A KEY CRITICISM. ARE YOU GETTING TO ANY OTHER DOCUMENT OR JUST THE --DR. STEWARD: WELL, YEAH, BECAUSE ACTUALLY -- SO I REALIZE THAT WE'RE NOT OFFICIALLY CONSIDERING THE EXTRAORDINARY PETITIONS, BUT THE

1

2

3

4

5

6

7

8

9

10

11 DOES HAVE THAT, AND I JUST WANTED TO RAISE THAT AS 12 AN ISSUE IF THAT WAS A MAJOR FACTOR.

EXTRAORDINARY PETITION THAT RELATES TO THIS GRANT

13DR. COLLINS: SO I THINK REALLY THE KEY14FACTOR WAS THAT THE PROPOSAL WAS A BIT PREMATURE AND15THERE WERE SOME CONCERNS ABOUT, AS WE DISCUSSED, THE16SELECTED THERAPEUTIC CELL TYPE.

17 BUT TO THE PETITION, A PETITION WAS 18 RECEIVED, IT WAS RECEIVED LATE, BUT IT WAS 19 DOCUMENTING BOTH SUPPORT FROM MANUFACTURER OF THE 20 SCAFFOLD AS WELL AS MATERIAL TRANSFER AGREEMENT FROM 21 THE PRODUCER OF THE SCAFFOLD TO PROVIDE THIS 22 MATERIAL AS WELL AS TECHNICAL EXPERTISE FOR THE 23 PROPOSED PROGRAM. AND THAT WAS RECEIVED. 24 DR. STEWARD: IF I COULD JUST COMMENT. I 25 WILL CONFESS THAT I NORMALLY DON'T LIKE THE

1	EXTRAORDINARY PETITIONS BECAUSE THEY VERY OFTEN
2	ARGUE WITH THE REVIEWERS ABOUT POINTS THAT REALLY
3	ARE VERY DIFFICULT TO ADJUDICATE IN A SETTING LIKE
4	THIS. IN THIS CASE, HOWEVER, THE EXTRAORDINARY
5	PETITION PERTAINS TO SOMETHING THAT ACTUALLY DID
6	SHOW UP IN THE REVIEW AND REALLY IS AN MTA THAT
7	WASN'T EXECUTED AT THE TIME. SO I JUST WANTED TO
8	POINT THAT OUT JUST TO SAY IF IT WAS A KEY FACTOR,
9	THAT THAT APPEARS TO BE IN PLACE NOW. IS THAT
10	CORRECT?
11	DR. COLLINS: YES, THAT'S CORRECT.
12	DR. STEWARD: OKAY.
13	CHAIRMAN THOMAS: ANY OTHER COMMENTS ON
14	THIS APPLICATION? THANK YOU. ANY OTHER COMMENTS ON
15	ANY OTHER DC APPLICATION NOT YET DISCUSSED? HEARING
16	NONE, MR. HARRISON, PERHAPS YOU COULD DESCRIBE THE
17	NEXT STEP WITH RESPECT TO CLOSED SESSION.
18	MR. HARRISON: YES. BUT BEFORE WE GO TO
19	CLOSED SESSION, I UNDERSTAND THAT THERE IS A MEMBER
20	OF THE PUBLIC PRESENT IN SAN DIEGO WITH DUANE ROTH
21	WHO WOULD LIKE TO OFFER A COMMENT ABOUT AN
22	APPLICATION THAT HAS NOT YET BEEN DISCUSSED. SO
23	PERHAPS WE COULD OFFER THAT OPPORTUNITY FIRST AND
24	THEN CONVENE IN CLOSED SESSION SO WE MAKE SURE THAT
25	WE'VE COVERED EVERYTHING WE NEED TO.
	129
	169

1	
1	CHAIRMAN THOMAS: CERTAINLY.
2	MR. ROTH: SO I HAVE SOME MEMBERS OF THE
3	PUBLIC THAT DID SUBMIT AN EXTRAORDINARY PETITION,
4	AND THEY WOULD LIKE TO MAKE A COMMENT. SO I'LL TURN
5	IT OVER TO THEM.
6	DR. CHU: GOOD MORNING, EVERYONE. THIS IS
7	DR. PETER CHU AND THE PRESIDENT AND CO-FOUNDER OF
8	ECLIPSE THERAPEUTICS. WE SUBMITTED GRANT NUMBER
9	TR3-05730. IT RECEIVED A BORDERLINE SCORE AND WAS
10	NOT APPROVED FOR FUNDING. SO WE DID SUBMIT A
11	PETITION WHICH IS, I THINK, ON THE AGENDA AS ONE OF
12	THE THREE PETITIONS.
13	I'D JUST LIKE TO SORT OF SUMMARIZE SORT OF
14	OUR ARGUMENT HERE. SO ECLIPSE IS A SAN DIEGO
15	BIOTECH COMPANY FOCUSED ON DEVELOPING A VERY
16	PROMISING DRUG TARGETING CANCER STEM CELLS THAT CAN
17	TREAT NOT ONLY COLON CANCER, BUT MOST OTHER SOLID
18	CANCERS, SUCH AS BREAST, PROSTATE, PANCREATIC, AND
19	LUNG CANCER. THESE ARE DISEASES THAT AFFECT
20	MILLIONS OF AMERICANS EVERY YEAR. WE'RE A SPIN-OUT
21	OF BIOGEN IDEC, A MAJOR BIOTECH COMPANY THAT CHOSE
22	TO EXIT CANCER R&D AND CLOSE ITS SAN DIEGO SITES.
23	SO AT ECLIPSE WE'RE ACTUALLY CAPITALIZING
24	ON MILLIONS OF DOLLARS AND SEVEN YEARS AT BIOGEN
25	IDEC PREVIOUSLY INVESTED IN THIS CANCER STEM CELL
	130
	150

1	AND ANTIBODY PROGRAM. SO AS A RESULT WE ACTUALLY
2	HAVE A VERY ADVANCED PRECLINICAL STAGE CANCER STEM
3	CELL DRUG POISED TO ENTER THE CLINIC WITHIN 18
4	MONTHS. SO WE BELIEVE THIS WOULD BE AN EXCELLENT
5	OPPORTUNITY FOR CIRM TO PARTNER WITH AND BE
6	ASSOCIATED WITH A VERY EXCITING, VERY PROMISING DRUG
7	THAT WOULD BE TESTED IN PATIENTS IN THE VERY NEAR
8	FUTURE.
9	SO WE HAVE PRECLINICAL STUDIES THAT HAVE
10	SHOWN VERY GOOD RESULTS, SIGNIFICANT INHIBITION OF
11	PRIMARY COLORECTAL TUMOR MODELS. THESE ARE TUMORS
12	DIRECTLY FROM THE PATIENTS. AND MORE IMPORTANTLY,
13	WE HAVE SHOWN SIGNIFICANTLY INCREASED SURVIVAL OF
14	THE ANIMALS IN THESE STUDIES. VERY IMPORTANTLY,
15	WE'VE RECENTLY SHOWN THAT OUR DRUG ACTUALLY DOES
16	REDUCE THE FREQUENCY OF CANCER STEM CELLS IN THESE
17	MODELS. SO, IN FACT, WHEN WE TREAT THESE TUMORS,
18	TAKE THEM OUT AND REIMPLANT THEM INTO THE MICE, THEY
19	EITHER DO NOT GROW OR GROW VERY POORLY. IN
20	CONTRAST, THE CONTROL OR CHEMO-TREATED TUMORS GROW
21	IN A HUNDRED PERCENT OF THE ANIMALS AND, IN FACT,
22	THEY GROW MUCH, MUCH FASTER.
23	SO WE FILED THIS PETITION, AS I MENTIONED,
24	BECAUSE WE HAD THE BORDERLINE SCORE. SO AS YOU WILL
25	READ IN OUR PETITION LETTER, SINCE WE SUBMITTED THIS
	131

1	APPLICATION, WE'VE MADE VERY GOOD PROGRESS ON OUR
2	DRUG PROGRAM. WE'VE ACTUALLY MOVED FASTER THAN WE
3	HAD EXPECTED. WE HAVE SELECTED A LEAD DRUG
4	CANDIDATE ALREADY. SO WE'VE BEEN ABLE TO MOVE UP
5	OUR TIMELINES. AND AS I MENTIONED, WE'RE ON TRACK
6	TO BE IN THE CLINIC WITHIN 18 MONTHS. SO WE'VE
7	ACTUALLY COMPLETED MILESTONE ONE IN THIS GRANT AND
8	WILL ACTUALLY NOT BE NEEDING THE FULL BUDGET THAT WE
9	ORIGINALLY REQUESTED.
10	SOMETHING OF NOTE, MENTIONING THAT WE HAD
11	A STRONG LETTER OF SUPPORT FROM PROFESSOR HANS
12	CLEAVERS ON THIS GRANT. HE'S THE WORLD'S EXPERT ON
13	COLON STEM CELL BIOLOGY. I KNOW HE'S WELL-KNOWN AND
14	HIGHLY RESPECTED BY MANY OF THOSE AT CIRM. AND HE
15	ONLY AGREED TO JOIN OUR ADVISORY BOARD AFTER SEEING
16	OUR DATA. HE'S ACTUALLY NOT ON ANY OTHER CANCER
17	ADVISORY BOARDS. WE'RE THE ONLY ONE. SO I THINK
18	THAT SPEAKS VERY HIGHLY OF THE PROMISE OF OUR DRUG.
19	SO WE DO BELIEVE THERE'S
20	MR. ROTH: GO AHEAD, J.T.
21	CHAIRMAN THOMAS: SORRY, DUANE.
22	MR. ROTH: OH, I THOUGHT SOMEBODY WAS
23	TRYING TO INTERRUPT.
24	CHAIRMAN THOMAS: NO.
25	DR. CHU: SO WE DO BELIEVE WE HAVE AN
	132

1	EXTRAORDINARY CIRCUMSTANCE HERE WHICH IS A VALID
2	REASON TO HAVE OUR GRANT APPROVED, WHICH IS SORT OF
3	THE FINAL RECOMMENDATION OF THE REVIEW COMMITTEE WAS
4	THAT WE HAD NOT DEMONSTRATED THAT WE WERE ABLE TO
5	REDUCE THE CANCER STEM CELLS WITH OUR DRUG IN VIVO,
6	AND THEY RECOMMENDED THAT THEY WOULD HAVE LIKED TO
7	HAVE SEEN THAT DATA. WE ACTUALLY, AS I MENTIONED,
8	HAVE GENERATED THAT DATA IN THE LAST SINCE THE
9	GRANT WAS SUBMITTED, WE ACTUALLY ATTEMPTED TO SUBMIT
10	THIS DATA LAST MONTH TO CIRM ALTHOUGH WE WERE TOLD
11	THAT OUR GRANT HAD ALREADY BEEN REVIEWED. AND
12	ESSENTIALLY SINCE WE SUBMITTED THE GRANT, WE ARE IN
13	THE PROCESS OF TRANSFERRING ALL OUR ASSETS FROM
14	BIOGEN IDEC FROM THEIR FREEZERS TO OUR NEW LAB IN
15	SAN DIEGO. SO WE WEREN'T ABLE TO DO THESE
16	EXPERIMENTS AT THE TIME; BUT, AS I MENTIONED, SINCE
17	THE GRANT HAS BEEN SUBMITTED, WE HAVE DONE THOSE
18	EXPERIMENTS, AND THE DATA HAS BEEN VERY POSITIVE.
19	SO WE BELIEVE THAT THAT'S A VERY VALID
20	REASON FOR THIS PETITION. I'D JUST LIKE TO CLOSE BY
21	SAYING THAT WE ALSO HAVE A VERY STRONG TEAM THAT
22	WE'VE ASSEMBLED AT ECLIPSE. OUR EMPLOYEES HAVE LED
23	PROGRAMS THAT HAVE LED TO EIGHT FDA DRUG APPROVALS
24	AND OVER 15 IND APPROVALS, SO WE BELIEVE WE HAVE THE
25	TRACK RECORD AND THE CREDIBILITY TO SUCCEED IN THIS
	133

	BARRISTERS' REPORTING SERVICE
1	DRUG. AND WE REALLY WOULD LIKE TO WORK WITH CIRM ON
2	THIS DRUG PROGRAM.
3	MR. ROTH: OKAY, J.T.
4	CHAIRMAN THOMAS: OKAY. THANK YOU, DR.
5	CHU. THANK YOU, DUANE. MR. HARRISON.
6	MR. HARRISON: I BELIEVE WE HAVE ONE
7	MEMBER OF THE PUBLIC PRESENT WITH US HERE WHO WOULD
8	LIKE TO MAKE A COMMENT BEFORE WE CONVENE IN CLOSED
9	SESSION. JUST A REMINDER, COMMENTERS SHOULD LIMIT
10	THEMSELVES TO THREE MINUTES PLEASE.
11	DR. BOYD: THANK YOU VERY MUCH. MR.
12	CHAIRMAN, MEMBERS OF THE BOARD, I'M DR. DOUGLAS
13	BOYD. I'M THE PRINCIPAL INVESTIGATOR OF GRANT
14	NUMBER 05626, EXTRACELLULAR MATRIX BY SCAFFOLDS
15	AUGMENTED WITH HUMAN STEM CELLS FOR CARDIOVASCULAR
16	REPAIR. I'D JUST LIKE TO ADDRESS THE BOARD
17	ESSENTIALLY WITH THREE ISSUES THAT I HAD AND TO
18	CLARIFY WITH REGARDS TO THIS GRANT APPLICATION.
19	SO ONE OF MY COLLEAGUES THAT ARE CLOSE,
20	SANDRA GUARD (PHONETIC) AND MY OTHER COLLEAGUE JAN
21	NOLTA, THEY'RE HERE PRESENT WITH ME TODAY. I'D
22	FIRST LIKE TO THANK THE COMMITTEE FOR THEIR
23	INVOLVEMENT AND ALL THE TIME THEY'VE SPENT IN THIS
24	UNIQUE AND VISIONARY ORGANIZATION. IT ENABLES
25	RESEARCHERS LIKE US TO REALLY GET THE JOB DONE, BUT,
	134

1	MORE IMPORTANTLY, IT BRINGS PROMISE TO THE 16
2	MILLION AMERICANS THAT HAVE CARDIOVASCULAR DISEASE.
3	I'M JUST A SIMPLE CARDIAC SURGEON. SO
4	WHEN I SPEAK TO OTHER ESTEEMED SCIENTISTS AND
5	BRILLIANT PEOPLE, I'M JUST REALLY A PLUMBER. THE
6	FACT IS THAT ONE THING I DO HAVE THE ADVANTAGE OF IS
7	BEING IN THE OPERATING ROOM EVERY DAY AND DEALING
8	WITH THESE PATIENTS. I CAN TELL YOU THAT THE GAP
9	BETWEEN BASIC SCIENCE AND CLINICAL UTILITY IS
10	ENORMOUS. BUT I CAN TELL YOU THAT EVERY DAY THAT
11	SIX YEARS AGO I IMPLANTED THE FIRST HUMAN BY
12	SCAFFOLD FOR CARDIOVASCULAR REPAIR AND REGENERATION.
13	I USE THAT IN MY PRACTICE REGULARLY, AND I HAVE
14	GREAT FAMILIARITY WITH THAT. WHAT I CAN TELL YOU IS
15	THAT IT BRINGS GREAT PROMISE TO THE MILLIONS OF
16	PEOPLE THAT DO HAVE HEART DISEASE.
17	THE OTHER THING IS REGARDING THE THREE
18	ISSUES REGARDING OUR APPLICATION. THE FIRST THING,
19	ONE OF THE MAIN CRITICISMS OF OUR GRANT WAS THAT OUR
20	APPLICATION LACKED LETTERS OF SUPPORT FROM INDUSTRY.
21	AND THAT WAS REALLY MY SHORTFALL. WHAT I'D LIKE TO
22	MAKE CLEAR TO THE BOARD IS THAT OUR INDUSTRY PARTNER
23	IS COOK BIOTECH, A \$500 MILLION INDUSTRY. COOK
24	BIOTECH PRODUCED THE WORLD'S FIRST BIOLOGICS ECM
25	BIOSCAFFOLD AND HAS THE MOST EXPERIENCE IN PRODUCING
	135

1	THIS, AND IS FULLY ENDORSED AND IS EXCITED AND
2	BACKING US IN THIS ENDEAVOR. THEY ARE A HUNDRED
3	PERCENT BEHIND US. AND WE HAVE DOCUMENTED THAT IN
4	OUR RECENT LETTER.
5	OF CONCERN TO ME WAS THAT IT WAS MENTIONED
6	IN THE REVIEWER'S REPORT THAT THIS LACK OF
7	COLLABORATION INCREASED THE RISK OF THIS PROJECT. I
8	WANT TO ASSURE THE BOARD THAT WE HAVE FULL AND
9	UNYIELDING SUPPORT BY THE WORLD'S NO. 1 PRODUCER OF
10	BIOLOGIC SCAFFOLDS.
11	THE SECOND THING I'D LIKE TO ADDRESS IS I
12	UNDERSTAND THERE'S A PANEL DEBATE ABOUT THE CHOICE
13	OF MESENCHYMAL STEM CELLS FOR THE DEVELOPMENT
14	CANDIDATE AND HOW THAT THERE'S A PLUS-MINUS EFFECT
15	MENTIONED ON THE EFFICACY. I COULDN'T AGREE MORE.
16	AND THE REASON WHY IS THAT THE IDEA OF A PARADIGM OF
17	CELLS ALONE FOR CARDIAC REGENERATION IN OUR OWN
18	EXPERIENCE AND IN OUR OWN PRELIMINARY RESULTS SHOW
19	THAT CELLS ALONE FOR CARDIAC REGENERATION ARE
20	PROBABLY NOT THE RIGHT WAY TO GO. AND THE
21	COMBINATION WITH A SCAFFOLD, WE BELIEVE, HAS GREAT
22	PROMISE AND, THEREFORE, IS THE FOCUS OF OUR
23	INVESTIGATIVE EFFORTS.
24	SO WE FEEL THAT THE COMBINATION OF STEM
25	CELLS AND SCAFFOLDS IS REALLY A VERY, VERY NOVEL
	136

1	APPROACH THAT REALLY SHOULD BE GIVEN STRONG
2	CONSIDERATION BY THE BOARD.
3	I CAN TELL YOU THAT THREE MONTHS AGO I HAD
4	A PATIENT THAT I WAS CALLED TO SEE IN THE INTENSIVE
5	CARE UNIT. SHE WAS DYING. SHE'S A 31-YEAR-OLD
6	MOTHER WITH TWO CHILDREN. SHE HAD INFECTIONS IN HER
7	LUNGS BECAUSE SHE HAD A MASSIVELY INFECTED VALVE
8	SEEDING HER LUNGS. I BROUGHT HER TO THE OPERATING
9	ROOM AS A LAST HOPE. HER HEART PUMP WAS FAILING.
10	THE ONLY OPPORTUNITY TO SAVE HER LIFE WAS TO PUT IN
11	AN ARTIFICIAL VALVE. UNFORTUNATELY, IF YOU PUT AN
12	ARTIFICIAL VALVE INSIDE AN INFECTED SITE, THEY
13	IMMEDIATELY GET REINFECTION AND THE PATIENT IS
14	DOOMED TO DIE.
15	BECAUSE OF OUR RESEARCH IN REGENERATIVE
16	MEDICINE, I CHOSE TO DO A VERY, VERY NOVEL AND
17	RADICAL PROCEDURE. AND THAT WAS OUR TEAM REBUILT A
18	HUMAN HEART VALVE IN THE OPERATING ROOM AND
19	IMPLANTED IT. THIS WAS THREE MONTHS AGO. THE
20	PATIENT IS NOW HOME AND ECHO SHOWS THAT SHE'S
21	COMPLETELY REGENERATED HER VALVE. AND THIS IS GOING
22	TO BE REPORTED IN THE NEXT SIX WEEKS AT AN
23	INTERNATIONAL CONFERENCE.
24	THESE KIND OF THINGS ALSO THAT MAY HAVE
25	BEEN OVERLOOKED IN OUR REPORT WAS THAT OUR
	137
	LJ/

1	PRELIMINARY STUDIES DID, IN FACT, SHOW A DECREASE IN
2	INFLAMMATION SURROUNDING THE REGENERATIVE PROCESS
3	WHEN YOU ADD MESENCHYMAL STEM CELLS TO MATRIX. AND
4	I THINK THIS IS VERY, VERY IMPORTANT. AS WE ALL
5	KNOW, INFLAMMATION IS ONE OF THE ACHILLES HEELS OF
6	REGENERATION.
7	IN SUMMARY, I'D LIKE TO SAY THAT OUR GRANT
8	ADDRESSES THE NO. 1 CAUSE OF DISEASE AND CAUSE OF
9	DEATH IN CALIFORNIA AND THE UNITED STATES. WE HAVE
10	DIRECTLY ADDRESSED THE REVIEW PANEL'S CONCERN
11	REGARDING OUR COLLABORATIVE SUPPORT. AND, IN FACT,
12	WE HAVE THE STRONGEST INDUSTRY SUPPORT POSSIBLY
13	AVAILABLE IN THIS BIOSCAFFOLD STEM CELL EFFORT.
14	WE HAVE THE TOOLS TO GET THE JOB DONE. WE
15	HAVE THE FACILITIES, WE HAVE WORLD-CLASS FACILITIES,
16	WE HAVE THE SURGEONS AND THE STAFF TO DO THE SURGERY
17	AND GET THE RESEARCH DONE, BUT ALSO WE HAVE THE
18	EXPERIENCE IN USING THIS SCAFFOLD EVERY DAY. I
19	REALLY HOPE THAT THE BOARD WILL RECONSIDER FUNDING
20	FOR OUR PROJECT. THANK YOU.
21	CHAIRMAN THOMAS: THANK YOU, DR. BOYD.
22	DR. OLSON.
23	DR. OLSON: I JUST WANTED TO BRING ONE
24	THING TO THE BOARD'S ATTENTION BECAUSE IT HAS NOT
25	COME UP IN DISCUSSION. AND IF YOU WILL NOTE ON THE,
	138

1	AND I BELIEVE DR. ABO BROUGHT THIS UP IN HIS
2	PRESENTATION, IT'S ALSO OBVIOUS UP THERE THAT
3	APPLICATION NO. TR3-05617 WAS ACTUALLY RECOMMENDED
4	IN PROGRAMMATIC REVIEW BY THE GRANTS WORKING GROUP
5	TO BE FUNDED AS A DEVELOPMENT CANDIDATE FEASIBILITY
6	AWARD.
7	I WOULD LIKE TO OFFER A STAFF
8	RECOMMENDATION INSTEAD. NOW, IF YOU WOULD LIKE ME
9	TO GO INTO THIS, BUT THE REASON AND MAYBE I'D
10	BETTER GIVE YOU A BIT OF BACKGROUND SO YOU
11	UNDERSTAND THE BASIS FOR THE STAFF RECOMMENDATION.
12	SO WHAT THIS AWARD IS, IT'S A DEVELOPMENT CANDIDATE
13	AWARD FOCUSED ON IDENTIFYING SMALL MOLECULE DRUGS
14	FOR THE TREATMENT OF MULTIPLE SCLEROSIS.
15	THE APPLICANT PROPOSES TO IDENTIFY SMALL
16	MOLECULE DRUGS THAT REMYELINATE AXONS. THEY'VE
17	PROPOSED SIX MILESTONES, BUT BASICALLY THESE
18	MILESTONES FALL IN TWO CLASSES. THEY HAVE SCREENED
19	USING THEIR ASSAY A SET OF BIOLOGICALLY ACTIVE
20	COMPOUNDS INCLUDING KNOWN DRUGS AND HAVE IDENTIFIED
21	SEVERAL, ONE OF WHICH IS A DRUG FDA APPROVED IN
22	CLINICAL USE. AND MUCH OF THEIR PRELIMINARY DATA IS
23	DIRECTED TO THAT DRUG.
24	OKAY. THEY HAVE ALSO CONDUCTED A SCREEN
25	WITH WHOLLY NOVEL COMPOUNDS AND HAVE IDENTIFIED A
	139
	L)3

-	
1	NUMBER OF WHAT I'LL CALL HITS, NEW SCAFFOLDS. AND
2	SO THE PROPOSAL ESSENTIALLY IS BIFURCATED IN TWO
3	SENSES. IT'S BASICALLY DOING THE WORK ON THE
4	ALREADY APPROVED DRUGS THAT HAVE SHOWN TO BE
5	POSITIVE IN THIS INDICATION, SO CONDUCTING THE
6	PRECLINICAL STUDIES, MOVING THEM FORWARD, OR DOING
7	THE OPTIMIZATION ON THE HITS, WHICH INVOLVES SAR
8	STUDIES. IN OTHER WORDS, THOSE ARE MUCH FURTHER
9	BEHIND. THEY'RE NOT APPROVED FOR ANOTHER
10	INDICATION. THEY DON'T HAVE A RECORD OF TOXICITY.
11	SO ESSENTIALLY WHAT THE GRANTS WORKING
12	GROUP WAS EXCITED ABOUT AND WHAT THEY WANTED TO DO
13	IS THEY WANTED THEM TO MOVE FORWARD WITH ESSENTIALLY
14	THE APPROVED DRUG CANDIDATE, THE APPROVED COMPOUNDS.
15	AND THAT'S WHERE THE RECOMMENDATION WAS FOCUSED.
16	SO ALTHOUGH I THINK STAFF, IF YOU LOOK AT
17	THE PROGRAMMATIC DISCUSSION, YOU CAN SEE THAT STAFF
18	TRIED TO INDICATE THAT THE DCF AWARD WAS FOCUSED ON
19	ESSENTIALLY PROOF OF CONCEPT; WHEREAS, THIS INITIAL
20	CLASS OF APPROVED DRUGS THAT ARE ACTIVE IN THIS
21	INDICATION CLEARLY ALREADY SHOW PROOF OF CONCEPT.
22	SO WHAT THE STAFF MODIFICATION THAT I JUST WANT TO
23	OFFER FOR YOUR CONSIDERATION, AND THE REASON I'M
24	OFFERING IT NOW IS IF THERE WOULD WANT TO BE ANY
25	FURTHER DISCUSSION OF THIS, IS THAT, IN FACT, THIS
	140

-	
1	STAY AS A DC AWARD, BUT THAT THE FOCUS WOULD BE ON
2	THE DRUG ALREADY IDENTIFIED AND THE SET OF
3	BIOLOGICALLY I MEAN THIS DRUG ALREADY IDENTIFIED
4	HAS GOOD PHARMACOLOGIC PROPERTIES. IT'S GOT
5	EVERYTHING YOU'D EXPECT. OKAY. AND THE FOCUS WOULD
6	BE ON MOVING THAT FORWARD AS A DC, AND THE BUDGET
7	WOULD BE ADJUSTED ACCORDINGLY.
8	NOW, AS I SAY, IF YOU READ THE
9	PROGRAMMATIC, THERE ARE OTHER ISSUES WITH REVIEWERS
10	WERE PLUS AND MINUS ON THE DCF RECOMMENDATION, BUT
11	THAT IS THE STAFF AMENDMENT, TO CONSIDER IT AS A DC
12	AWARD RATHER THAN A DCF WITH A REDUCED BUDGET.
13	CHAIRMAN THOMAS: DR. BRYANT.
14	DR. BRYANT: I'M SORRY. I MISSED THE
15	NUMBER OF THE AWARD, AND I'VE GOT SEVERAL CONFLICTS,
16	SO I WANT TO MAKE SURE I DON'T COMMENT ON SOMETHING
17	INAPPROPRIATE.
18	DR. OLSON: 5617.
19	DR. BRYANT: THANK YOU.
20	CHAIRMAN THOMAS: DR. LUBIN.
21	DR. LUBIN: SO JUST SUMMARIZE ONCE MORE
22	WHY YOU'RE MAKING THIS SUGGESTION TO US.
23	DR. OLSON: BECAUSE THE GOAL OF A
24	DEVELOPMENT CANDIDATE FEASIBILITY AWARD IS SIMPLY TO
25	GET INITIAL PROOF OF CONCEPT OF A HYPOTHESIS. THEY
	141

1	ARE PAST THAT STAGE. THEY COULD PRETTY THIS
2	COULD PROBABLY BE PRETTY EASILY MOVED INTO THE
3	CLINIC IN A COUPLE OF YEARS.
4	MR. SERRANO-SEWELL: (INAUDIBLE).
5	DR. OLSON: IF YOU LOOK AT THE I THINK
6	THEY WERE JUST LOOKING AT THE MONEY ISSUE. AND THEY
7	WERE SAYING, WELL, YOU WON'T NEED ALL THE FUNDING
8	NECESSARY FOR A DC AWARD TO DO THIS REDUCED SET OF
9	ACTIVITIES. AND WE DID TRY IT WAS BROUGHT UP AT
10	THE GRANTS WORKING GROUP MEETING AND IS CAPTURED IN
11	THE PROGRAMMATIC DISCUSSION. AND SO AS I SAY, THE
12	INTENT WAS TO MOVE WITH ALL SPEED TOWARDS VALIDATING
13	IT.
14	NOW, THERE ARE OTHER THERE ARE OTHER
15	POINTS. I'VE NOT GONE INTO THE WHOLE DISCUSSION.
16	BUT THE RECOMMENDATION I THINK I WOULD SAY I
17	CAPTURED THE SPIRIT OF WHAT THE GRANTS WORKING GROUP
18	WANTED THROUGH THIS PROPOSED MODIFICATION.
19	DR. BRYANT: I WAS JUST GOING TO ASK IF
20	THERE WERE ANY SPECIFIC CRITICISMS THAT WERE MADE OF
21	THE OTHER PART OF THE PROPOSAL.
22	DR. OLSON: I WOULD BE HAPPY TO GO THROUGH
23	THE SUMMARY IF YOU WOULD LIKE. SO I THINK I'VE
24	OUTLINED WHAT THE PROPOSAL IS ABOUT.
25	I THINK THE MAIN FIRST, LET ME SAY THAT
	142

1	THE RESEARCH TEAM WAS PERCEIVED TO BE STRONG,
2	PARTICULARLY IN THE AREA OF SMALL MOLECULE DRUG
3	DISCOVERY AND OPTIMIZATION. THAT'S CLEARLY
4	THAT'S WHAT THEY DO. THAT'S A STRENGTH OF THEIRS.
5	THEY'RE DEFINITELY TRANSLATIONALLY FOCUSED. THEY'VE
6	DONE THIS KIND OF THING BEFORE.
7	WITH RESPECT TO THE TEAM, THE GRANTS
8	WORKING GROUP DID HAVE SO THIS DRUG IS FOR THE
9	TREATMENT OF MS. I BELIEVE I SAID THAT. THEY WOULD
10	HAVE LIKED TO SEE A CLINICAL MS PHYSICIAN ON THE
11	TEAM BECAUSE OF THE ISSUES ASSOCIATED WITH THE
12	DIFFERENT TYPES OF MS AND THE KINDS OF DRUGS, AND
13	THAT GETS TO PROBABLY THE OTHER ISSUE.
14	SO THERE WAS SOME QUESTION ABOUT THE
15	THEY CONSIDERED THAT THE OBJECTIVE OF TARGETING
16	OPC SO WHAT THIS DRUG THAT THEY'RE SCREENING FOR
17	IS DIFFERENTIATION OF AN OLIGODENDROCYTE PROGENITOR
18	POPULATION INTO MATURE OLIGODENDROCYTES. SO THEY'RE
19	LOOKING FOR A SMALL MOLECULE THAT WILL ESSENTIALLY
20	SAY PROGENITOR BECOME A FULLY MATURE CELL. BECAUSE
21	ONE OF THE KEY ISSUES IN MULTIPLE SCLEROSIS IS YOU
22	GET OLIGODENDROCYTE PROGENITORS AT THE SITE OF
23	LESION, BUT THEY DON'T DIFFERENTIATE. AND SO THEY
24	SAID, WELL, OKAY, IF WE DEVELOPED A SCREEN TO SELECT
25	FOR SMALL MOLECULES THAT DID THAT, THAT WOULD BE

143

-	3002.
2	THEY, HOWEVER, WERE CONCERNED ABOUT DRUGS
3	THAT, IN FACT, STIMULATE OPC DIFFERENTIATION
4	BECAUSE, IF YOU THINK ABOUT IT, WHEN YOU GIVE A
5	SMALL MOLECULE, WHAT YOU DO IS YOU TARGET THE
6	PROGENITORS NO MATTER WHERE THEY ARE. AND SO THERE
7	WAS SOME CONCERN ABOUT DO YOU RUN THE RISK OF
8	DEPLETING A PROGENITOR POPULATION BY GIVING THIS
9	DRUG? SO THERE WERE A BIT OF ISSUES WITH THE
10	RATIONALE, AND THAT REALLY WAS THE MAIN CONCERN WITH
11	THE RATIONALE IS THAT IS THIS HYPOTHESIS POTENTIALLY
12	DANGEROUS, AND THAT'S JUST SOMETHING THAT YOU CAN'T
13	KNOW RIGHT OFF THE BAT.
14	BUT THE PRECLINICAL DATA, AT LEAST IN
15	SUPPORT OF THIS, THEY CONSIDERED TO BE GOOD. THEY
16	WERE I MEAN THE TREATMENT OPTIONS FOR MULTIPLE
17	SCLEROSIS ARE NOT GOOD. AND SO I THINK IT WAS A
18	BALANCE IN THEIR MIND AS WANTING TO MOVE FORWARD
19	WITH SOMETHING THAT MIGHT OFFER AN OPTION VERSUS
20	CONCERNS ABOUT ESSENTIALLY THE SCIENTIFIC RATIONALE
21	BEHIND THIS.
22	CHAIRMAN THOMAS: DR. STEWARD.
23	DR. STEWARD: PAT, I WAS ACTUALLY JUST
24	LOOKING AT THIS. AND SO I GUESS THE BIG DIFFERENCE
25	BETWEEN A DF AND A DCF IS REALLY THE BRINGING THIS
	144

1	TO THE CLINIC. AND THE ONE COMMENT
2	DR. OLSON: IT'S BRINGING IT TO SO IT
3	MOVES INTO THE REGULATED DEVELOPMENT ENVIRONMENT.
4	DR. STEWARD: RIGHT. AND JUST TO SAY, THE
5	COMMENT HERE, THAT SPECIFIC EXPERTISE IN MS WOULD BE
6	REQUIRED FOR THE SUCCESSFUL EXECUTION, THEY WANT
7	SOMEBODY WHO'S REALLY A CLINICIAN IN MS, RIGHT?
8	DR. OLSON: THEY WOULD LIKE SOMEONE LIKE
9	THAT TO ADVISE ON, I THINK, SORT OF MS BIOLOGY OR
10	CLINICAL THINGS. THEY THINK THAT THERE ARE
11	SUBTLETIES ASSOCIATED WITH THAT THAT WAS IMPORTANT
12	IN THIS CONTEXT.
13	DR. STEWARD: WAS THAT PART OF THE REASON
14	THAT IT WAS RECOMMENDED AS A DCF, THAT THEY DIDN'T
15	REALLY HAVE THAT EXPERTISE IN PLACE AND, THEREFORE,
16	IT WAS A VERY RISKY THING TO MOVE FORWARD IN THE WAY
17	THAT THEY WERE PLANNING?
18	DR. OLSON: THAT EXPERTISE WOULD BE LESS
19	RELEVANT AS A DCF THAN AS A DC.
20	DR. STEWARD: OKAY.
21	DR. PIZZO: I JUST WANT TO FOLLOW UP ON
22	THE POINT THAT WAS JUST MADE. FROM OTHER STUDIES AT
23	LEAST I'VE BECOME AWARE OF, THE ISSUE OF MS IS A
24	VERY COMPLICATED STORY, AS YOU KNOW.
25	DR. OLSON: YES. ALSO TRUE.
	145

BARRISTERS' REPORTING SERVICE 1 DR. PIZZO: AND I THINK TO THE POINT THAT 2 WAS JUST BEING MADE, IT'S VERY HETEROGENEOUS. 3 DR. OLSON: YES. 4 DR. PIZZO: THE DEFINITION IS VERY 5 VARIEGATED. AND I THINK THAT IT'S REALLY IMPERATIVE TO MAKE SURE THAT THERE IS EXPERTISE ON THE CLINICAL 6 7 TEAM. OTHERWISE IT CAN BECOME A VERY ALTERED 8 **RESPONSE**. 9 DR. OLSON: YES. I'M SORRY. THAT IS PART 10 OF THE -- I DID NOT CHANGE THAT PART OF THE 11 RECOMMENDATION. I THINK THAT BOTH THE STAFF 12 RECOMMENDATION AS WELL AS THE RECOMMENDATION OF THE 13 GRANTS WORKING GROUP WOULD BE THAT THAT TYPE OF EXPERTISE SHOULD BE PART OF THE TEAM IF THIS MOVES 14 15 FORWARD IN WHATEVER FORM. 16 DR. PIZZO: CAN WE SAY MUST? 17 DR. OLSON: WE CAN SAY MUST. 18 CHAIRMAN THOMAS: MR. SHEEHY. 19 MR. SHEEHY: I WOULD JUST LIKE TO SAY, PER 20 MY RECOLLECTION, DR. OLSON'S RECOMMENDATION IS VERY CONSISTENT WITH THE SPIRIT OF WHAT THE GRANTS 21 22 WORKING GROUP WAS TRYING TO ACCOMPLISH. I MEAN YOU 23 HAVE BASICALLY AN OFF-THE-SHELF DRUG THAT SEEMS TO HAVE SOME MEASURABLE IMPACT ON MS WHERE WE'RE NOT 24 25 REALLY INVESTED AT ALL AT THIS POINT. AND THE IDEA 146

_...

1	WAS TO GET THAT AS QUICKLY INTO THE CLINIC AS
2	POSSIBLE. AND SO I THINK WHAT DR. OLSON IS
3	PROPOSING IS QUITE IN LINE WITH THAT.
4	CHAIRMAN THOMAS: DR. BRYANT.
5	DR. BRYANT: I JUST HAVE ONE MORE COMMENT
6	ON THAT, ON THE REASON FOR NOT PREFERRING THE SECOND
7	PART, THE MORE EXPLORATORY PART. AND THAT IS ARE
8	THERE NO ANIMAL STUDIES THAT ADDRESS THE ISSUE OF
9	WHEN YOU GIVE THESE KIND OF DRUGS TO ANIMALS, THAT
10	IT DEPLETES THE STEM CELL POPULATION OR NOT? IF
11	NOT, THEN I COMPLETELY AGREE WITH IT. BUT I MEAN
12	SURELY THERE MUST BE SOME.
13	DR. OLSON: I CAN STATE THAT TWO COMMON
14	PRECLINICAL MS MODELS WERE PERFORMED WITH ONE OF THE
15	LEAD COMPOUNDS. NOW, THEY DID NOT I CAN ALSO
16	STATE THAT THEY DID NOT SPECIFICALLY ADDRESS THAT
17	ISSUE. I'M NOT SURE HOW READILY THAT COULD BE
18	ADDRESSED IN A MODEL, NOR CAN I SPEAK TO THE FACT
19	HOW EXTRAPOLATABLE IT WOULD BE, BUT THAT'S ALWAYS
20	TRUE.
21	CHAIRMAN THOMAS: OKAY. SEEING NO FURTHER
22	COMMENT, ARE THERE ANY COMMENTS ABOUT ANY OTHER DC
23	AWARDS? SEEING NONE, I THINK WE'RE NOW READY TO
24	ADJOURN INTO CLOSED SESSION. WE HAVE BOX LUNCHES
25	AVAILABLE IN THE OTHER ROOM ACROSS THE HALL AND
	147
	14/

1	WOULD REQUEST THAT BOARD MEMBERS EAT THEIR LUNCH
2	OVER THERE. WE'LL DO A WORKING LUNCH CLOSED
3	SESSION. MR. HARRISON.
4	MR. HARRISON: THE BOARD WILL BE CONVENING
5	IN CLOSED SESSION TO CONSIDER PROPRIETARY
6	INFORMATION RELATED TO APPLICATIONS FOR CIRM EARLY
7	TRANSLATION III AWARDS PURSUANT TO HEALTH AND SAFETY
8	CODE SECTION 125290.30(F)(3)(B) AND (C). AND
9	HOPEFULLY WE WILL TRY TO LIMIT OUR CLOSED SESSION TO
10	APPROXIMATELY 45 MINUTES AT A MAXIMUM BECAUSE WE
11	HAVE A LOT OF WORK TO ACCOMPLISH THIS AFTERNOON.
12	CHAIRMAN THOMAS: THANK YOU. SO IF
13	EVERYBODY COULD PROCEED ACROSS THE HALL WITH ALL
14	DELIBERATE SPEED, THAT WOULD BE APPRECIATED.
15	(A RECESS WAS TAKEN.)
16	CHAIRMAN THOMAS: OKAY. WE ARE NOW
17	RECONVENING IN OPEN SESSION. WE HAVE CONCLUDED THE
18	CLOSED SESSION DISCUSSION ON THE THREE APPLICATIONS
19	IDENTIFIED IN THE EARLIER SESSION AND ARE NOW BACK,
20	FOLLOWING WHAT I THINK HAS BEEN A DETAILED AND
21	ROBUST CONSIDERATION OF ALL OF THE AWARDS, READY TO
22	HAVE MOTIONS WITH RESPECT TO APPROVAL.
23	FIRST OF ALL, ARE THERE IS THERE A
24	MOTION TO APPROVE YES, JAMES. YOU'RE LOOKING AT
25	ME.
	148

1	MR. HARRISON: I WAS JUST GOING TO SUGGEST
2	THAT YOU REQUEST ANY MOTIONS TO MOVE APPLICATIONS
3	FROM TIER III TO TIER I. AND THEN ONCE WE'VE
4	EXHAUSTED THOSE MOTIONS, YOU CAN ASK FOR MOTIONS TO
5	MOVE APPLICATIONS OUT OF TIER I TO TIER III. AND
6	THEN WE'LL TAKE OMNIBUS MOTIONS ON THE AWARDS.
7	CHAIRMAN THOMAS: THAT WAS PRECISELY WHERE
8	I WAS HEADED, MR. HARRISON.
9	MR. HARRISON: I'M SORRY I INTERRUPTED
10	YOU.
11	CHAIRMAN THOMAS: LET THE RECORD REFLECT.
12	SO DO WE HAVE ANY MOTIONS TO MOVE ANY OF THE
13	CURRENTLY TIER III PROPOSALS? YES, DR. SAMBRANO.
14	DR. SAMBRANO: I DON'T KNOW IF YOU WANT TO
15	DO THEM IN THAT ORDER, DCF FIRST AND DC.
16	CHAIRMAN THOMAS: YES. WHY DON'T WE DO
17	THAT. IT'S A GOOD IDEA. OKAY. ARE THERE ANY
18	RECOMMENDATIONS TO MOVE ANY OF THE CURRENTLY TIER
19	III PROPOSALS ON THE DCF LIST UP TO TIER I?
20	MS. SAMUELSON: MR. CHAIRMAN, WOULD IT BE
21	POSSIBLE TO JUST, SO WE'RE ALL ON THE SAME PAGE, GET
22	A BRIEF LIST OF THOSE THAT ARE ELIGIBLE FOR FURTHER
23	DISCUSSION? WE'RE DOWN TO A SHORT LIST, AREN'T WE?
24	CHAIRMAN THOMAS: WELL, IF WE ARE
25	CONFINING THAT TO THE PROPOSALS THAT WERE DISCUSSED
	140
	149

	BARRISTERS' REPORTING SERVICE
1	IN CLOSED SESSION.
2	MS. SAMUELSON: I THINK IN COMBINATION
3	WITH THE DISCUSSION BEFORE.
4	CHAIRMAN THOMAS: YES. AND THOSE THAT
5	WERE THE SUBJECT OF EXTRAORDINARY PETITIONS THAT
6	WERE NOT DISCUSSED IN CLOSED SESSION. COULD WE HAVE
7	SOMEBODY GIVE US THAT LIST? YES. MR. HARRISON.
8	MR. HARRISON: THE APPLICATIONS THAT WERE
9	DISCUSSED IN OPEN SESSION WERE 5606, 5567.
10	MS. GIBBONS: IS THERE A TWO- OR
11	THREE-WORD DESCRIPTION THAT WOULD TRIGGER IT FOR US
12	BECAUSE
13	DR. SAMBRANO: SO I CAN READ THE TITLE FOR
14	5606. THAT WAS HUMAN ES CELL-DERIVED MGE INHIBITORY
15	INTERNEURON TRANSPLANTATION FOR SPINAL CORD INJURY.
16	DR. STEWARD: AND COULD WE ACTUALLY
17	CONSIDER THEM DCF BY CATEGORY? AND THEN IF YOU
18	COULD DO THE SAME THING WHEN WE COME TO THE DC?
19	MS. SAMUELSON: AND THE PRINCIPAL
20	INVESTIGATOR OR THE INSTITUTION.
21	DR. SAMBRANO: WE CAN'T REVEAL THAT
22	INFORMATION IN PUBLIC. SO THAT WAS DCF. SO, JAMES,
23	I WILL READ THE TITLE IF YOU READ THE APPLICATION
24	NUMBER.
25	MR. HARRISON: THE NEXT WAS 5567.
	150

BARRISTERS' REPORTING SERVICE 1 DR. SAMBRANO: SO I THINK THAT WAS A DCF. 2 I'M SORRY. DC. 5567 IS TRANSPLANTATION OF STEM 3 CELL-DERIVED RETINAL PROGENITOR AND RPE SHEETS TO 4 RESTORE VISION. 5 DR. STEWARD: ISN'T THAT A DC? DR. SAMBRANO: YES. SORRY. IT WAS A DC. 6 7 CHAIRMAN THOMAS: LET'S TRY TO CONFINE THIS FIRST TO THE DCF LIST. 8 9 DR. PRIETO: ARE THERE ANY OTHER DCF'S 10 THAT ANYONE ELSE WANTS TO BRING UP OR DISCUSS? THAT'S, I THINK, THE QUESTION OS IS ASKING AND I'M 11 12 CURIOUS. 13 DR. STEWARD: SO I DO --CHAIRMAN THOMAS: DR. STEWARD. 14 15 DR. STEWARD: IF I MAY. I DO WANT TO 16 RAISE 5606, AND I GUESS IN ORDER TO DO THAT, I'M 17 GOING TO MOVE THAT IT BE MOVED TO TIER I. I'LL SAY THAT AT THE END OF THE DISCUSSION -- I WANT TO HEAR 18 19 REALLY WHAT EVERYBODY HAS TO SAY ABOUT THAT; BUT AT 20 THE END OF THE DISCUSSION, I MAY VERY WELL VOTE 21 AGAINST MY OWN MOTION, BUT JUST TO SAY THAT. 22 DR. PRIETO: I'LL SECOND. 23 CHAIRMAN THOMAS: THANK YOU. DISCUSSION 24 ON THE TOPIC? DR. STEWARD. 25 DR. STEWARD: SO THIS IS A GRANT TO TEST A 151

1	DEVELOPMENT CANDIDATE FOR SPINAL CORD INJURY. THE
1 2	
	TARGET IS BLADDER SPASTICITY AND NEUROPATHIC PAIN.
3	AND THE IDEA IS THAT THESE DISORDERS THAT ARE VERY,
4	VERY CRITICAL AFTER SPINAL CORD INJURY ARE DUE, IN
5	PART, TO THE LOSS OF INHIBITORY INTERNEURONS. SO
6	THE IDEA HERE IS THAT AS A CONSEQUENCE OF LOSS OF
7	THESE NEURONS, THE SPINAL CORD IS FIRING WILDLY.
8	AND THAT IS THE REASON FOR THESE NEUROPATHIC PAIN
9	SYNDROMES IN PART AND ALSO THE CAUSE OF BLADDER
10	SPASTICITY WHICH IS A MAJOR DEBILITATING PART OF
11	SPINAL CORD INJURY.
12	THE ISSUE IS THAT PEOPLE WITH SPINAL CORD
13	INJURY CAN'T CONTROL THEIR BLADDER; BUT MORE THAN
14	THAT, THERE'S SOMETHING CALLED DETRUSOR SPHINCTER
15	DYSSYNERGIA. SO BASICALLY THE SPHINCTER STAYS
16	CLOSED AND THE BLADDER IS PUMPING AWAY AND YOU CAN'T
17	EXPEL URINE. AND AS A CONSEQUENCE, THE URINE IS
18	PROPELLED BACK UP INTO THE KIDNEYS. AND THAT IS A
19	MAJOR CAUSE OF URINARY TRACT INFECTIONS AND OTHER
20	URINARY DISORDERS.
21	SO HAVING SOMETHING TO SOLVE THESE ISSUES,
22	AND ESPECIALLY BLADDER, WOULD REALLY BE A HUGE
23	THING.
24	THE MAJOR CRITICISMS WERE, NO. 1, THERE
25	REALLY WASN'T ANY PRELIMINARY EVIDENCE INDICATING
	152
I	

1	THE FEASIBILITY OF THE BLADDER STUDIES. AND WHAT WE
2	CONSIDERED IN THE CLOSED SESSION WAS ONE OF THE
3	COMMENTS THAT THE MARKERS FOR THE CELLS WERE NOT
4	SUFFICIENTLY STRINGENT TO BE ABLE TO IDENTIFY THE
5	CELL POPULATIONS THAT WERE BEING TRANSPLANTED. THEY
6	REPORTED THAT THERE WAS A LEVEL OF CONTAMINATION.
7	MY MEMORY IS IT'S AROUND 30 PERCENT. AND THE ISSUE
8	IS HOW MANY WHAT ARE THESE CELLS AND WHAT ARE
9	THEY LIKELY TO DO?
10	AND SO IDENTIFYING THESE NONTARGET CELLS,
11	NONINHIBITORY NEURONS, IS IMPORTANT, BUT IT'S ALSO
12	IMPORTANT TO IDENTIFY THE INHIBITORY NEURONS. AND
13	SO THE REVIEWER'S COMMENT WAS THAT THE MARKERS WERE
14	NOT SUFFICIENTLY STRINGENT.
15	WE DID LOOK AT THAT IN CLOSED SESSION.
16	THE MARKERS ARE PROPRIETARY INFORMATION, AND WE
17	FOUND NO BASIS TO ARGUE WITH THE REVIEWER'S
18	CONCLUSIONS REGARDING THOSE MARKERS.
19	DR. PIZZO: CAN I JUST MAKE ONE ADDENDUM
20	TO THAT, WHICH IS SOME OF THE MARKERS ARE NOT
21	NEUROSPECIFIC AS WELL.
22	CHAIRMAN THOMAS: ANY OTHER COMMENTS ON
23	THIS APPLICATION? SO DO WE NEED A ROLL CALL
24	VOTE. FIRST OF ALL, WE HAVE COMMENT FROM A MEMBER
25	OF THE PUBLIC. MR. REED. NO. THANK YOU.
	153

BARRISTERS' REPORTING SERVICE 1 MS. SAMUELSON: ISN'T THERE AN 2 EXTRAORDINARY PETITION ON THIS ONE? 3 DR. STEWARD: THERE WAS NO EXTRAORDINARY 4 PETITION. 5 CHAIRMAN THOMAS: NOT ON THIS ONE. SO, 6 MARIA, WOULD YOU PLEASE CALL THE ROLL. 7 MR. HARRISON: JUST TO RESTATE THE MOTION IS TO MOVE APPLICATION 5606 TO TIER I. 8 9 DR. STEWARD: I'M SORRY. IF I MAY. DON 10 REED ALREADY HAD PUBLIC COMMENT REGARDING THIS 11 BEFORE THE BREAK, AND THIS WAS THE APPLICATION ON 12 WHICH HE WAS MAKING --13 CHAIRMAN THOMAS: YES, I'M AWARE OF THAT. 14 I WAS JUST WONDERING IF HE WANTED TO REITERATE 15 ANYTHING. THANK YOU. OKAY. MARIA. 16 MS. BONNEVILLE: ROBERT BIRGENEAU. 17 DR. BIRGENEAU: YES. MS. BONNEVILLE: DAVID BRENNER. SUSAN 18 19 BRYANT. 20 DR. BRYANT: YES. 21 MS. BONNEVILLE: KEN BURTIS. DR. BURTIS: YES. 22 23 MS. BONNEVILLE: MICHAEL FRIEDMAN. DR. FRIEDMAN: YES. 24 25 MS. BONNEVILLE: LEEZA GIBBONS. 154

	BARRISTERS' REPORTING SERVICE
1	MS. GIBBONS: YES.
2	MS. BONNEVILLE: MICHAEL GOLDBERG.
3	MR. GOLDBERG: YES.
4	MS. BONNEVILLE: STEVE JUELSGAARD.
5	DR. JUELSGAARD: NO.
6	MS. BONNEVILLE: BERT LUBIN.
7	DR. LUBIN: NO.
8	MS. BONNEVILLE: MICHAEL MARLETTA.
9	DR. MARLETTA: NO.
10	MS. BONNEVILLE: SHLOMO MELMED. PHIL
11	PIZZO.
12	DR. PIZZO: NO.
13	MS. BONNEVILLE: FRANCISCO PRIETO.
14	DR. PRIETO: YES.
15	MS. BONNEVILLE: ELIZABETH FINI. ROBERT
16	QUINT.
17	DR. QUINT: NO.
18	MS. BONNEVILLE: DUANE ROTH. JOAN
19	SAMUELSON.
20	MS. SAMUELSON: YES.
21	MS. BONNEVILLE: DAVID SERRANO-SEWELL.
22	MR. SERRANO-SEWELL: YES.
23	MS. BONNEVILLE: JONATHAN SHESTACK. OS
24	STEWARD.
25	DR. STEWARD: YES.
	155
	T))

	BARRISTERS' REPORTING SERVICE
1	MS. BONNEVILLE: JONATHAN THOMAS.
2	CHAIRMAN THOMAS: YES.
3	MS. BONNEVILLE: ART TORRES.
4	MR. TORRES: AYE.
5	MS. BONNEVILLE: CHRISTINA VUORI.
6	DR. VUORI: YES.
7	MS. BONNEVILLE: EUGENE WASHINGTON.
8	CHAIRMAN THOMAS: MR. HARRISON.
9	MR. HARRISON: JUST GIVE US ONE MOMENT TO
10	MAKE SURE WE HAVE THE CORRECT TABULATION. THANK
11	YOU. SO THAT MOTION PASSES BY A VOTE OF 13 TO FIVE.
12	CHAIRMAN THOMAS: THANK YOU, MR. HARRISON.
13	DOES THAT EXHAUST THE LIST OF DCF CANDIDATES? OKAY.
14	COULD YOU NOW RECITE IN ORDER HERE THE DC CANDIDATES
15	FOR POSSIBLE CONSIDERATION TO MOVE FROM TIER III TO
16	TIER I.
17	MR. HARRISON: THE FIRST THAT WAS
18	DISCUSSED WAS 5567.
19	DR. SAMBRANO: SO 5567 WAS TRANSPLANTATION
20	OF STEM CELL-DERIVED RETINAL PROGENITOR AND RPE
21	SHEETS TO RESTORE VISION.
22	CHAIRMAN THOMAS: IS THERE A MOTION TO
23	MOVE THIS FROM TIER III TO TIER I?
24	MS. SAMUELSON: YES.
25	CHAIRMAN THOMAS: MOVED BY JOAN SAMUELSON.
	156

	BARRISTERS' REPORTING SERVICE
1	IS THERE A SECOND?
2	DR. PRIETO: WELL, JUST TO KEEP THE
3	DISCUSSION GOING, I'LL SECOND.
4	CHAIRMAN THOMAS: SECOND BY DR. PRIETO.
5	SO DISCUSSION. JOAN.
6	MS. SAMUELSON: IT WOULD BE REPEATING
7	EVERYTHING I SAID BEFORE THE CLOSED SESSION.
8	THINKING OF SORRY. I THOUGHT I'D HAVE A SECOND
9	TO GET BACK TO THIS ONE. AND I DON'T KNOW WHERE MY
10	NOTES ON IT ARE.
11	CHAIRMAN THOMAS: PERHAPS DR. PRIETO COULD
12	STEP IN WHILE YOU'RE
13	MS. SAMUELSON: THAT WOULD BE NICE.
14	DR. PRIETO: WAS THIS DISCUSSED DURING
15	WAS THERE ANY PROPRIETARY INFORMATION BROUGHT UP IN
16	THE CLOSED SESSION? I DIDN'T THINK I HEARD ANY.
17	ONE OF THE ISSUES MAY BE SCIENTIFIC STAFF
18	COULD TALK A LITTLE BIT MORE ABOUT THIS BECAUSE IT
19	APPLIES TO ANOTHER APPLICATION THAT WE'LL BE VOTING
20	ON EXCUSE ME A SECOND THE CHARACTERIZATION
21	WORK THAT HAS BEEN DONE AND WHETHER THAT'S REALLY
22	ADEQUATE FOR THEM TO MEET THEIR TIMELINES.
23	DR. ABO: SO JUST TO REMIND YOU, PART OF
24	THE DISCUSSION THAT JOAN BROUGHT UP, THERE WERE
25	THREE OTHER AMD PROJECTS IN THE PORTFOLIO, BUT THE
	157

1	MAIN CONCERN OF THE REVIEWERS WERE THAT THEY FELT
2	THIS IS AN EARLY STAGE, UNDERDEVELOPED PROPOSAL.
3	THERE WAS CONCERN ASSOCIATED WITH EXPRESSION MARKERS
4	FOR THE RETINAL MARKERS. THEY DID NOT CONSIDER
5	POSSIBILITY OF SURVIVAL OF ENDOGENOUS NEURONS. BUT
6	THE MAIN CONCERNS WERE NOT SUFFICIENT, AS I SAID,
7	DEVELOPED AND LACK OF CRITICAL DETAILS, INSUFFICIENT
8	DESCRIPTION OF VISUAL ACUITY TESTS IN ANIMALS. THAT
9	WAS ALL PRECLINICAL STUDIES. NO ELECTROPHYSIOLOGY
10	MEASUREMENT, WHICH IS VERY IMPORTANT TO CELL
11	CHARACTERIZATION. AND POTENTIAL NEGATIVE EFFECT AND
12	PAIN WAS NOT CONSIDERED AND OTHER ISSUES.
13	AND SOME ISSUES ON QUALIFICATION OF THE
14	PI, AS I MENTIONED, THAT IT SEEMS UNJUSTIFIABLE TO
15	CHARGE 40-PERCENT EFFORT FOR THE PI. AND THERE'S
16	SOME ISSUES WITH BUDGET ASSOCIATED WITH EQUIPMENT
17	AND THE ROLE OF SOME OF THE STAFF THAT WERE PROPOSED
18	TO BE PART OF THIS STUDY.
19	DR. PRIETO: JUST REMEMBERING THIS, AS I
20	RECALL, ACTUALLY THE QUALIFICATIONS OF THE PI WERE
21	THOUGHT TO BE PRETTY STRONG. SOMEONE WHO'S A
22	WELL-KNOWN LEADER IN THE FIELD, BUT THERE WERE
23	SIGNIFICANT QUESTIONS IN THE GRANTS REVIEW ABOUT THE
24	BUDGET AND THE AMOUNT ALLOCATED TO SOME OF THE
25	EFFORTS.
	158
	017

	BARRISTERS' REPORTING SERVICE
1	MR. TORRES: THE ITEM NUMBER AGAIN?
2	DR. PRIETO: 5567, MACULAR DEGENERATION.
3	MS. SAMUELSON: AND THIS HAD A SCORE OF
4	63; IS THAT RIGHT? I THINK. IN WHICH CASE
5	DR. ABO: RPE WAS THE PHOTORECEPTOR SHEET
6	WHICH BRINGS A DIFFERENT LEVEL OF COMPLEXITY AND
7	POTENTIALLY COULD BE AN IMPORTANT UNMET NEED. THE
8	APPROACH IS NOVEL AND IS DIFFERENT THAN WHAT WE HAVE
9	IN THE PORTFOLIO RIGHT NOW.
10	MS. SAMUELSON: AND AS I'M HEARING IT, I'M
11	SCRAMBLING MY METAPHORS HERE, I'M LISTENING THROUGH
12	THE LENS OF PROP 71, WHICH SAYS THAT OUR MISSION IS
13	TO DEVELOP REGENERATIVE MEDICAL TREATMENTS AND CURES
14	SO THAT WE CAN SWITCH AWAY FROM MAINTENANCE TOWARD
15	PREVENTION AND CURES. AND THIS IS A CASE WHERE I
16	SUPPOSE MOST OF THE PEOPLE HAVE NO THERAPEUTIC
17	ALTERNATIVE AND SIMPLY BECOME BLIND. AND SO THERE'S
18	GREAT URGENCY PER OUR PROGRAMMATIC MISSION, AND
19	THAT'S WHAT WE NEED TO BE THINKING ABOUT AT THE END
20	OF EVERY DISCUSSION PER PROP 71, NOT IS EVERY BOX
21	CHECKED, BUT IS THERE A REASONABLE POSSIBILITY THAT
22	THIS WILL PRODUCE THIS TREATMENT OR EVEN JUST
23	ADVANCE THE SCIENCE IN SOME SIGNIFICANT WAY SO THAT
24	SOMETHING WILL, WHICH IS PROBABLY THE MOST FREQUENT
25	WAY THAT STUFF DEVELOPS, RIGHT. THAT'S MY

159

1	PERSPECTIVE WITH PARKINSON'S, THAT THERE'S SOME
2	ADVANCE MADE BY A TEAM SOMEWHERE IN THE UNITED
3	STATES AND THEN BY ONE IN EUROPE AND SO ON AND THEY
4	BUILD OFF EACH OTHER'S WORK. AND WE WANT TO GET
5	THERE AS SOON AS HUMANLY POSSIBLE. THAT'S THE OTHER
6	LANGUAGE FROM THE STATUTE.

7 SO HERE WE'RE TRYING TO ADDRESS BLINDNESS, 8 AND THEY'RE TRYING TO BE AMBITIOUS ABOUT IT AND GO 9 AT IT FROM A DC PERSPECTIVE SO THEY'LL GET MORE 10 MONEY. AND IT'S AN INTRACTABLE PROBLEM. SO IT MAY 11 TAKE LONGER THAN THREE YEARS. THAT JUST DOESN'T 12 STRIKE ME AS A FATAL FLAW, NOR DO ANY OF THE OTHER 13 CRITICISMS WHEN AT THE SAME TIME THEY'RE SAYING THAT 14 THESE IDEAS ARE IMPORTANT AND NEW AND THAT THE TEAM 15 IS EFFECTIVE. THEN THAT SOUNDS LIKE THE ELEMENTS OF 16 SUCCESS. IT MAY NOT BE EXACTLY THE RESULT THAT THEY 17 ORIGINALLY PREDICT, BUT HOW OFTEN IS IT? THAT SEEMS TO BE THE WAY SCIENCE WORKS FROM MY PERCH. 18 SO I 19 RECOMMEND FUNDING, MOVING IT TO TIER I. 20 DR. MARLETTA: COULD I MAKE A COMMENT? 21 CHAIRMAN THOMAS: CERTAINLY. DR. 22 MARLETTA. 23 DR. MARLETTA: IT'S AGAINST WHAT I SAID I 24 WOULD DO TODAY. I PROMISED MYSELF. BUT THOSE THAT 25 KNOW ME KNOW THAT IT'S ALMOST IMPOSSIBLE FOR ME TO 160

1	SIT HERE WITH A MICROPHONE IN FRONT OF ME AND NOT
2	SAY SOMETHING. SO I JUST WANT TO YOU KNOW, WHAT
3	WE DON'T HAVE, WHAT I FIND THAT I DON'T HAVE THAT I
4	WOULD NEED IS I DIDN'T READ THE PROPOSAL. I CAN
5	ONLY LOOK AT THE REVIEWER REPORT. AND WHAT I READ
6	IN THE REVIEWER REPORT, THE VERY FIRST COMMENT IS A
7	SERIOUS I'M READING FROM IT A SERIOUS CONCERN
8	IS THE INABILITY TO SHOW ANY EXPRESSION OF MATURE
9	RETINAL MARKERS IN THE COMPOSITE HSEC-DERIVED
10	RETINAL SHEETS. IT'S UNCLEAR WHETHER ADDITIONAL
11	OPTIMIZATION WILL SUCCESSFULLY ACCOMPLISH THE GOAL
12	OF THIS DIFFERENTIATION AND HOW LONG IT WILL TAKE.
13	SO TO ME THIS SOUNDS LIKE A FATAL FLAW.
14	THEY CAN'T EXPRESS MARKERS ON THE CELLS TO KNOW THAT
15	THEY HAVE CELLS THEY CAN DO ANYTHING WITH. SO WITH
16	ALL DUE RESPECT TO THE UNMET MEDICAL NEED, I'M
17	AFRAID THAT STEP ONE, THEY'RE NOT EVEN ON THE MAP.
18	AND THEY WON'T BE ABLE TO DO ANY OF THE EXPERIMENTS
19	THAT THEY PROPOSE TO DO. SO IT JUST SOUNDS TO ME
20	LIKE A SERIOUS FATAL FLAW.
21	MS. SAMUELSON: MY QUESTION IN RESPONSE IS
22	THAT I THINK THIS IS AN IMPORTANT DISCUSSION. I
23	APPRECIATE YOU JUMPING IN BECAUSE THIS IS WHAT WE
24	FACE EVERY TIME, IT SEEMS TO ME. HOW MUCH OF THAT
25	IS SIMPLY THE PROCESS OF SCIENTIFIC EXPERIMENTATION,
	161

1	WHICH IS IN THE NATURE OF HOW CURES AND EFFECTIVE
2	TREATMENTS ARE REACHED? THEY'VE GOT A HYPOTHESIS
3	AND THEY DON'T HAVE ALL THE DATA YET.
4	DR. MARLETTA: MY CONCERN IS I APPRECIATE
5	THE HYPOTHESIS AND THEY HAVE A SERIES OF EXPERIMENTS
6	PROPOSED THAT ARE BOTH RISKY AND COULD BE QUITE
7	INFORMATIVE, BUT MY POINT IS, FROM WHAT I READ IN
8	FRONT OF ME, AS LIMITED AS THAT IS, THAT THEY CANNOT
9	EVEN BEGIN THE EXPERIMENTS.
10	CHAIRMAN THOMAS: DR. STEWARD.
11	DR. STEWARD: YEAH. I'D GO BACK, I THINK,
12	TO YOUR COMMENTS BEFORE LUNCH, JOAN. I MEAN AM I
13	IN CONFLICT ON THIS? OOPS. SORRY.
14	CHAIRMAN THOMAS: LEEZA.
15	MS. GIBBONS: JOAN, I THINK YOU HIT IT.
16	THIS REPRESENTS THAT CONFLICT THAT WE HAVE BETWEEN
17	BEING RESPONSIBLE AND BEING AGGRESSIVE, RECOGNIZING
18	THE VERY NATURE OF SCIENCE FOR, I'LL SPEAK FOR
19	MYSELF, BEING A LAYPERSON, MEANING SO MANY TIMES IT
20	ENDS UP IN A DEAD END WHICH ULTIMATELY THE NO IS THE
21	ANSWER THAT GETS US TO THE BREAKTHROUGH. AND THEN
22	WANTING TO MAKE SURE THAT WE TAKE SERIOUSLY, AS WE
23	DO, THE GREAT RESPECT THAT WE HAVE FOR STAFF AND THE
24	REVIEWERS AND ALL THE EXTRAORDINARY AMOUNT OF WORK
25	THAT GOES INTO THESE RECOMMENDATIONS BEFORE THEY GET
	162
	TOC

BARRISTERS' REPORTING SERVICE 1 TO US. 2 CAN WE BE REMINDED OF THE SCORES FOR THIS ONE AGAIN. PLEASE? 3 4 DR. SAMBRANO: SO THE SCORES ARE UP ON THE 5 SCREEN. THE SCORE WAS A 63. MS. GIBBONS: OKAY. WAS THAT A DIG AT MY 6 7 EYESIGHT RIGHT THERE? DR. SAMBRANO: NO, IT WAS NOT INTENDED AS 8 9 SUCH. 10 MR. TORRES: NOT LEEZA IN THIS CATEGORY, 11 BUT I'M CHRONOLOGICALLY GIFTED. AND I STILL CAN'T SEE THESE NUMBERS. IT'S VERY DIFFICULT. 12 13 DR. SAMBRANO: LET'S RETRACT THAT LAST 14 STATEMENT OF MINE. AND I WILL JUST READ TO YOU THE SCORES. SO THE SCORE, THE AVERAGE SCORE WAS A 63, 15 16 THE MEDIAN WAS A 60, THE STANDARD DEVIATION IS A 5, 17 AND THE RANGE IS FROM 55 TO 75. CHAIRMAN THOMAS: SEEING NO FURTHER 18 19 DISCUSSION, MARIA, WILL YOU PLEASE -- DO WE HAVE ANY 20 PUBLIC COMMENT ON THIS? SEEING NONE, MARIA, PLEASE 21 CALL THE ROLL. 22 MS. BONNEVILLE: ROBERT BIRGENEAU. 23 DR. BIRGENEAU: NO. 24 MS. BONNEVILLE: DAVID BRENNER. KEN 25 BURTIS. 163

	BA	RRISTERS' REP	PORTING SERVICE
1	DR	. BURTIS: NO.	
2	MS	. BONNEVILLE:	MARCY FEIT.
3	MS	. FEIT: NO.	
4	MS	. BONNEVILLE:	MICHAEL FRIEDMAN.
5	DR	. FRIEDMAN: N	0.
6	MS	. BONNEVILLE:	LEEZA GIBBONS.
7	MS	. GIBBONS: NO	
8	MS	. BONNEVILLE:	MICHAEL GOLDBERG.
9	MR	. GOLDBERG: N	0.
10	MS	. BONNEVILLE:	SAM HAWGOOD.
11	DR	. HAWGOOD: NO	
12	MS	. BONNEVILLE:	STEVE JUELSGAARD.
13	DR	. JUELSGAARD:	NO.
14	MS	. BONNEVILLE:	BERT LUBIN.
15	DR	. LUBIN: NO.	
16	MS	. BONNEVILLE:	MICHAEL MARLETTA.
17	DR	. MARLETTA: N	0.
18	MS	. BONNEVILLE:	SHLOMO MELMED. PHIL
19	PIZZO.		
20	DR	. PIZZO: NO.	
21	MS	. BONNEVILLE:	FRANCISCO PRIETO.
22	DR	. PRIETO: NO.	
23	MS	. BONNEVILLE:	ELIZABETH FINI.
24	DR	. FINI: NO.	
25	MS	. BONNEVILLE:	ROBERT QUINT.
		16	54
		I	· ·

	BARRISTERS' REPORTING SERVICE
1	DR. QUINT: NO.
2	MS. BONNEVILLE: DUANE ROTH.
3	MR. ROTH: NO.
4	MS. BONNEVILLE: JOAN SAMUELSON.
5	MS. SAMUELSON: YES.
6	MS. BONNEVILLE: DAVID SERRANO-SEWELL.
7	MR. SERRANO-SEWELL: NO.
8	MS. BONNEVILLE: JEFF SHEEHY.
9	MR. SHEEHY: NO.
10	MS. BONNEVILLE: JONATHAN SHESTACK.
11	JONATHAN THOMAS.
12	CHAIRMAN THOMAS: NO.
13	MS. BONNEVILLE: ART TORRES.
14	MR. TORRES: NO.
15	MS. BONNEVILLE: CHRISTINA VUORI.
16	DR. VUORI: NO.
17	MS. BONNEVILLE: EUGENE WASHINGTON.
18	MR. HARRISON: THAT MOTION FAILS BY A VOTE
19	OF ONE YES VOTE AND 20 NO VOTES.
20	CHAIRMAN THOMAS: JAMES, DO WE HAVE
21	ANOTHER DC CANDIDATE?
22	MR. HARRISON: APPLICATION NO. 5541.
23	DR. SAMBRANO: SO THAT ONE WAS SELECTION
24	OF ANTI-R-SPONDIN ANTIBODY FOR TARGETING CANCER STEM
25	CELLS.
	165
	165

BARRISTERS' REPORTING SERVICE 1 CHAIRMAN THOMAS: IS THERE A MOTION THAT 2 WE MOVE IT FROM TIER III TO TIER I? HEARING NONE, 3 JAMES, ARE THERE ANY OTHERS? 4 MR. HARRISON: THE NEXT APPLICATION IS NO. 5 5660. 6 DR. SAMBRANO: THAT WAS PROGRAMMING HUMAN 7 ESC-DERIVED NEURAL STEM CELLS WITH MEF2C4 8 TRANSPLANTATION IN STROKE. CHAIRMAN THOMAS: IS THERE A MOTION TO 9 10 MOVE THIS FROM TIER III TO TIER I? 11 DR. PRIETO: SO MOVED. 12 CHAIRMAN THOMAS: SECOND? I'LL SECOND FOR 13 PURPOSES OF DISCUSSION. DR. PRIETO. DR. PRIETO: SO THIS ONE, AS I EXPECT MOST 14 15 OF YOU HAVE READ BY NOW, IS THE SUBJECT OF AN 16 EXTRAORDINARY PETITION. THE PETITIONER, LET ME TURN 17 TO THE LETTER, STUART LIPTON AT THE SANFORD BURNHAM, QUESTIONS SOME OF THE FACTUAL POINTS MADE OR 18 19 ASSERTED BY THE REVIEWERS DURING THE REVIEW. 20 QUESTIONS WERE RAISED IN CLOSED SESSION ABOUT SOME OF THE TECHNICAL ASPECTS OF THIS AND WHETHER 21 22 PRELIMINARY WORK HAS BEEN DONE THAT REALLY WOULD 23 ALLOW THEM TO DO WHAT HE SAYS HE CAN DO. 24 I WAS IMPRESSED THAT IF ANYONE CAN DO THIS 25 WORK THIS AMBITIOUS AND DIFFICULT, IT WOULD HAVE 166

1	HUGE CLINICAL SIGNIFICANCE AND THAT HE IS PROBABLY
2	OR HIS GROUP IS PROBABLY A GROUP THAT COULD DO IT IF
3	ANYONE CAN.
4	ONE OF THE ISSUES THAT WAS RAISED IS A
5	CLINICAL ONE, SO I WANTED TO SPEAK TO THAT A LITTLE
6	BIT ABOUT THE TIMING. AND THIS DID COME UP IN THE
7	REVIEW. THEY'RE PROPOSING TO INTERVENE A WEEK AFTER
8	THE STROKE, IN THEIR CASE THE STROKE THAT THEY
9	CREATE IN THEIR ANIMAL MODEL. QUESTION WAS RAISED
10	WHETHER THAT'S APPROPRIATE BECAUSE STROKE HAS A HUGE
11	VARIABILITY IN ITS CLINICAL OUTCOME AND EXPRESSION,
12	AND THAT CAN TAKE QUITE A WHILE TO BE APPARENT. I
13	READ THIS AS THEY'RE TRYING TO BALANCE THE ATTEMPT
14	TO INTERVENE AT A POINT THAT'S EARLY ENOUGH WHERE
15	YOU COULD MAKE A DIFFERENCE, BUT FAR ENOUGH ALONG
16	THAT THE STROKE IS IN SOME SENSE ESTABLISHED.
17	AND AS HE POINTS OUT, THAT CLINICALLY,
18	QUOTING FROM HIS PETITION, CLINICALLY MOST STROKES
19	ARE COMPLETED BY THE END OF ONE WEEK. AND THAT'S
20	CERTAINLY TRUE ANATOMICALLY AND IN TERMS OF JUST THE
21	IMMEDIATE PHYSICAL EFFECT OF THE STROKE. THE
22	EXPRESSION OF THE STROKE IN TERMS OF THE ACTUAL
23	CLINICAL OUTCOME CAN VARY TREMENDOUSLY DEPENDING ON
24	THE PREEXISTING HEALTH OF THE PERSON WHO SUFFERS THE
25	STROKE, THEIR OWN MOTIVATION, PSYCHOLOGICAL FACTORS,
	167

1	AND THERE'S A HUGE NUMBER OF VARIABLES. BUT I THINK
2	THAT THIS IS AS VALID A TIME POINT AS ANY OTHER TO
3	PICK, AND I THINK HE MAKES A GOOD ARGUMENT FOR IT.
4	THE NUMBERS OF ANIMALS THAT THEY HAVE TO
5	USE AND THE SIZE OF THEIR PROJECT IS LARGE, AND SOME
6	OF THE PRELIMINARY WORK HAS PERHAPS NOT BEEN CARRIED
7	AS FAR AS ALONG AS WE'D LIKE TO SEE IN THE
8	PRELIMINARY DATA, BUT I THINK THAT THIS IS A
9	MERITORIOUS APPLICATION, AND I WOULD URGE US TO MOVE
10	IT UP TO TIER I.
11	CHAIRMAN THOMAS: DEAN HAWGOOD.
12	MS. SAMUELSON: DOES IT NEED A SECOND?
13	DR. HAWGOOD: I THINK ONE OF THE CONCERNS
14	THAT THE REVIEWERS ALSO RAISED THAT IS IMPORTANT IS
15	LACK OF COMPELLING PRELIMINARY DATA FOR THE
16	PARTICULAR CELL TYPE AND THE PARTICULAR VIRAL VECTOR
17	THAT IS BEING USED. THE PROOF OF PRINCIPLE WORK IS
18	DONE WITH A MURINE EMBRYONIC STEM CELL LINE AND A
19	LENTI VECTOR, AND THE PROPOSAL IS HUMAN CELLS WITH
20	AN ADENOVIRAL VECTOR. AND FOR A THREE-YEAR PROJECT,
21	THE CELL CHARACTERIZATION IS NOT YET COMPLETE. AND
22	SO I THINK THAT RAISED QUESTIONS OF FEASIBILITY AS
23	WELL.
24	CHAIRMAN THOMAS: IS THERE ANY OTHER
25	DISCUSSION BY MEMBERS OF THE BOARD? ANY PUBLIC
	168

	BARRISTERS' REPORTING SERVICE
1	COMMENT? DON REED.
2	MR. REED: THIS RAISES TO ME A VERY
3	INTERESTING QUESTION ON THE TIMING. WHEN MY SON WAS
4	FIRST INJURED, WE TRIED TO GET HIM INTO A CLINICAL
5	STUDY ON SYGEN, A GANGLIOSIDE GM1 OF DRIED-UP COW
6	BRAINS. AND IT WAS DONE UNDER FDA AUSPICES, BUT WE
7	MISSED THE DEADLINE BY ONE HOUR. WE HAD TO BE 72
8	HOURS. WE GOT THERE 73. SO THE TIMING EVER SINCE
9	HAS STRUCK ME AS HUGELY IMPORTANT TO A LOT OF
10	NEUROLOGICAL CONDITIONS. AND IF THE TIMING IS AN
11	ESSENCE OF THIS AND STROKE IS SUCH AN ENORMOUS
12	PROBLEM AND SO DEVASTATING, I WONDER IF THE
13	SCIENTIFIC KNOWLEDGE THAT WE MIGHT GAIN MIGHT BE
14	VIABLE TO MORE PROJECTS THAN JUST THIS ONE ALONE.
15	CHAIRMAN THOMAS: THANK YOU. ANY FURTHER
16	DISCUSSION? MARIA, PLEASE CALL THE ROLL.
17	MR. HARRISON: AND, AGAIN, FOR THE RECORD,
18	THIS IS A MOTION TO MOVE APPLICATION 5660 TO TIER I.
19	MS. BONNEVILLE: ROBERT BIRGENEAU.
20	DR. BIRGENEAU: NO.
21	MS. BONNEVILLE: DAVID BRENNER. SUSAN
22	BRYANT.
23	DR. BRYANT: YES.
24	MS. BONNEVILLE: KEN BURTIS.
25	DR. BURTIS: NO.
	169

		BARRISTERS' REPORTING SERVICE
1		MS. BONNEVILLE: MARCY FEIT.
2		MS. FEIT: NO.
3		MS. BONNEVILLE: MICHAEL FRIEDMAN. LEEZA
4	GIBBONS.	
5		MS. GIBBONS: YES.
6		MS. BONNEVILLE: MICHAEL GOLDBERG.
7		MR. GOLDBERG: YES.
8		MS. BONNEVILLE: SAM HAWGOOD.
9		DR. HAWGOOD: NO.
10		MS. BONNEVILLE: STEVE JUELSGAARD.
11		DR. JUELSGAARD: NO.
12		MS. BONNEVILLE: SHERRY LANSING. BURT
13	LUBIN.	
14		DR. LUBIN: NO.
15		MS. BONNEVILLE: MICHAEL MARLETTA.
16		DR. MARLETTA: NO.
17		MS. BONNEVILLE: SHLOMO MELMED.
18		DR. MELMED: NO.
19		MS. BONNEVILLE: PHIL PIZZO.
20		DR. PIZZO: NO.
21		MS. BONNEVILLE: FRANCISCO PRIETO.
22		DR. PRIETO: YES.
23		MS. BONNEVILLE: ELIZABETH FINI.
24		DR. FINI: NO.
25		MS. BONNEVILLE: ROBERT QUINT.
		170
		1.0

	BARRISTERS' REPORTING SERVICE
1	DR. QUINT: NO.
2	MS. BONNEVILLE: JOAN SAMUELSON.
3	MS. SAMUELSON: YES.
4	MS. BONNEVILLE: DAVID SERRANO-SEWELL.
5	MR. SERRANO-SEWELL: YES.
6	MS. BONNEVILLE: JEFF SHEEHY.
7	MR. SHEEHY: NO.
8	MS. BONNEVILLE: JON SHESTACK. OS
9	STEWARD.
10	DR. STEWARD: NO.
11	MS. BONNEVILLE: JONATHAN THOMAS.
12	CHAIRMAN THOMAS: YES.
13	MS. BONNEVILLE: ART TORRES.
14	MR. TORRES: NO.
15	MS. BONNEVILLE: EUGENE WASHINGTON.
16	MR. HARRISON: MOTION FAILS BY A VOTE OF 8
17	YES VOTES TO 14 NO VOTES.
18	CHAIRMAN THOMAS: THANK YOU. MR.
19	HARRISON, ARE THERE OTHER DC CANDIDATES?
20	MR. HARRISON: YES. THE NEXT APPLICATION
21	THAT WAS DISCUSSED WAS 5626.
22	DR. SAMBRANO: OKAY. THAT WAS
23	EXTRACELLULAR MATRIX BY SCAFFOLD AUGMENTED WITH
24	HUMAN STEM CELLS FOR CARDIOVASCULAR REPAIR.
25	CHAIRMAN THOMAS: AND THIS WAS THE SUBJECT
	171

	BARRISTERS' REPORTING SERVICE
1	OF AN EXTRAORDINARY APPEAL.
2	DR. SAMBRANO: YES.
3	MR. SHEEHY: I WOULD LIKE TO MOVE THAT
4	INTO TIER I.
5	MS. GIBBONS: SECOND.
6	CHAIRMAN THOMAS: MOVED BY MR. SHEEHY,
7	SECONDED BY LEEZA GIBBONS. DISCUSSION FROM MEMBERS
8	OF THE BOARD. MR. SHEEHY.
9	MR. SHEEHY: SURE. SO TO BEGIN WITH, I
10	THINK THE SCORE JUSTIFIES IT. THE MEDIAN SCORE ON
11	THIS IS 75. I THINK THAT THERE WERE A COUPLE OF
12	OUTLIERS THAT BROUGHT THAT DOWN. IT HAS THE HIGHEST
13	STANDARD DEVIATION. 75 WAS APPROXIMATELY WHERE WE
14	SET THE GREEN LINE. I THINK WE ACTUALLY SET IT AT
15	76 IN THIS REVIEW. SO WITHOUT THE OUTLIERS, I THINK
16	IT WOULD HAVE BEEN FUNDABLE ANYWAY.
17	I THINK WE'RE TALKING ABOUT A PRODUCT THAT
18	COULD HAVE ENORMOUS IMPACT QUICKLY. YOU HAVE TWO
19	THINGS THAT ARE ALREADY IN THE CLINIC, WHICH IS THIS
20	MATRIX, WHICH IS ALREADY BEING PUT INTO PATIENTS,
21	AND MESENCHYMAL STEM CELLS, WHICH ARE ALSO BEING PUT
22	INTO PATIENTS, SO IT MAKES SENSE TO PUT THEM
23	TOGETHER. IT'S LIKE AN OREO. WHAT WOULD WE DO IF
24	WE HADN'T MADE THAT? SORRY. I HAVE A
25	SEVEN-YEAR-OLD.

172

1	BUT, YOU KNOW, THE OTHER THING IS I DO
2	THINK THE SAFETY IMPLIED HERE IS VERY STRONG, AND I
3	KNOW THAT WE TALKED ABOUT THE CEDARS-SINAI PRODUCT,
4	BUT THAT'S STILL AN AUTOLOGOUS PRODUCT. AND WE'RE
5	ASSUMING THAT WHEN WE DO IT ALLOGENEICALLY, WE HAVE
6	NO DATA IN HUMANS THAT IT WORKS THAT IT'S SAFE
7	ALLOGENEICALLY. SO WE'RE JUST KIND OF GUESSING THAT
8	IT'S GOING TO BE OKAY AS AN ALLOGENEIC PRODUCT. THE
9	ONLY CELLS, I THINK, THAT HAVE BEEN SHOWN TO BE SAFE
10	RIGHT NOW FOR HEART DISEASE IN HUMANS IS STILL
11	MESENCHYMAL STEM CELLS AS AN ALLOGENEIC PRODUCT, I
12	THINK.
13	THEY HAVE THE ANIMAL DATA TO SUGGEST THAT
14	THE ALLOGENEIC THING WILL WORK, BUT NOT YOU KNOW,
15	WHAT THEY WENT INTO PATIENTS WITH WAS AUTOLOGOUS,
16	AND SO I THINK THE FACT THAT WE ARE SEEING SOME SORT
17	OF IMPACT FROM PUTTING CELLS INTO PATIENTS, EVERYONE
18	SEEMS TO AGREE WE DON'T KNOW WHAT THEY ARE,
19	EVERYBODY SEEMS TO AGREE THEY DON'T STAY FOR A LONG
20	TIME, SO I THINK THIS PARTICULAR CELL TYPE, WHICH IS
21	VERY SAFE, GETTING IT TO STAY THERE FOR A LONG TIME
22	AND SEEING IF THAT MAKES A BIG DIFFERENCE IN
23	PATIENTS, I THINK, IS A PRETTY GOOD IDEA. I THINK
24	THERE'S BEEN SOME BENEFIT DEMONSTRATED FROM THE
25	PATCH. SOME STUDIES, NOT ALL THE STUDIES, HAVE
	173

1	SHOWN SOME BENEFIT FROM MESENCHYMAL STEM CELLS. SO			
2				
3	WE'RE NOT IN THIS SPACE AT ALL FOR CARDIOVASCULAR			
	DISEASE. IT SEEMS TO ME LIKE THIS IS AN EASY ONE			
4	FOR US TO TAKE A BET ON.			
5	CHAIRMAN THOMAS: LEEZA.			
6	MS. GIBBONS: I WAS REALLY JUST SAYING I			
7	THINK IT'S A VERY COMPELLING ARGUMENT, AND I			
8	APPRECIATE YOU FOR ARTICULATING IT SO BEAUTIFULLY AS			
9	YOU ALWAYS DO, JEFF.			
10	CHAIRMAN THOMAS: ANY OTHER COMMENTS ON			
11	THIS APPLICATION FROM MEMBERS OF THE BOARD? YES,			
12	DR. FRIEDMAN.			
13	DR. FRIEDMAN: I TOO FIND THIS REALLY			
14	INTERESTING AND CREATIVE. AND THE COMPETITION WITH			
15	OTHER PRODUCTS DOESN'T BOTHER ME AT ALL. I AM I			
16	DO HAVE A CONCERN, AND LET ME JUST SHARE WHAT THAT			
17	CONCERN IS, THAT WE'RE DOING TWO THINGS			
18	SIMULTANEOUSLY, EITHER ONE OF WHICH COULD BE VERY			
19	INTERESTING AND VERY POSITIVE. AND BY COMMINGLING			
20	IT, I'M GUESSING, BECAUSE I WANT TO SEE THIS BE			
21	PRACTICALLY AVAILABLE TO PEOPLE, I'M GUESSING THAT			
22	THIS IS GOING TO CAUSE SOME REGULATORY ISSUES THAT			
23	ARE GOING TO HAVE TO BE WORKED OUT LATER. THAT MAY			
24	NOT BE A REASON TO THAT MAY NOT BE A FLAW RIGHT			
25	NOW THAT STOPS IT, BUT IT IS SOMETHING THAT CAUSES			
	174			

1	ME CONCERN. AND I FIND THE WHOLE IDEA VERY				
2	INTRIGUING. I'M NOT SURE THAT IT'S READY AT THIS				
3	MOMENT.				
4	CHAIRMAN THOMAS: JOAN.				
5	MS. SAMUELSON: AS I RECALL, THE OTHER				
6	VARIABLE IN THE PARTICULAR CASE THAT THE PRIMARY				
7	THE PRINCIPAL INVESTIGATOR WAS CONCERNED WITH WAS A				
8	35-YEAR-OLD WOMAN WITH HEART FAILURE. I MAY NOT				
9	HAVE THAT EXACTLY RIGHT, BUT THAT'S MY RECOLLECTION				
10	OF THE DISCUSSION THIS MORNING, WHICH SHOULD BE				
11	BROUGHT INTO THE BALANCE WITH ANY EFFICACY QUESTIONS				
12	AS WELL AS SAFETY.				
13	CHAIRMAN THOMAS: DR. STEWARD.				
14	DR. STEWARD: I JUST WANT TO RAISE				
15	REMIND EVERYONE OF THE ISSUE OF THE LETTER, AND I				
16	DON'T MEAN THE APPEAL. I MEANT THE LETTER OF				
17	AGREEMENT THAT WAS STRUCK AND THAT WAS CERTIFIED.				
18	THAT DID COME UP AS A NEGATIVE FACTOR IN THE REVIEW,				
19	AND YOU CAN'T I THINK IT'S VERY DIFFICULT TO				
20	JUDGE HOW MUCH OF A DIFFERENCE THAT MADE IN TERMS OF				
21	THE POINTS IN THE REVIEW, BUT IT DID COME UP. AND				
22	JUST TO REMIND EVERYBODY THAT THIS WAS REALLY CLOSE				
23	TO THE BOUNDARY TO BEGIN WITH. SO EVEN THAT POINT				
24	OR TWO COULD HAVE PUSHED IT OVER THE EDGE.				
25	CHAIRMAN THOMAS: OTHER COMMENTS?				
	175				

1	COMMENTS FROM MEMBERS OF THE PUBLIC. MR. REED.			
2				
	MR. REED: I JUST REALLY LIKE THE IDEA OF			
3	REACHING OUT TO THE MEDICAL COMMUNITY, PEOPLE THAT			
4	ARE ON THE FRONT LINE TRYING TO SAVE LIVES. AND I			
5	THINK THAT WOULD BE A GOOD WAY FOR US TO GET CLOSE			
6	TO THAT QUICKLY.			
7	CHAIRMAN THOMAS: THANK YOU. ANY OTHER			
8	COMMENTS FROM MEMBERS OF THE BOARD? MARIA, PLEASE			
9	CALL THE ROLL.			
10	MR. HARRISON: AGAIN, THIS IS A MOTION TO			
11	MOVE APPLICATION 5626 TO TIER I.			
12	MS. BONNEVILLE: ROBERT BIRGENEAU.			
13	DR. BIRGENEAU: NO.			
14	MS. BONNEVILLE: DAVID BRENNER. SUSAN			
15	BRYANT.			
16	DR. BRYANT: YES.			
17	MS. BONNEVILLE: MICHAEL FRIEDMAN.			
18	DR. FRIEDMAN: NO.			
19	MS. BONNEVILLE: LEEZA GIBBONS.			
20	MS. GIBBONS: YES.			
21	MS. BONNEVILLE: MICHAEL GOLDBERG.			
22	MR. GOLDBERG: YES.			
23	MS. BONNEVILLE: SAM HAWGOOD.			
24	DR. HAWGOOD: NO.			
25	MS. BONNEVILLE: STEVE JUELSGAARD.			
	170			
	176			

	BARRISTERS' REPORTING SERVICE					
1	DR. JUELSGAARD: YES.					
2	MS. BONNEVILLE: BERT LUBIN.					
3	DR. LUBIN: NO.					
4	MS. BONNEVILLE: MICHAEL MARLETTA.					
5	DR. MARLETTA: NO.					
6	MS. BONNEVILLE: SHLOMO MELMED.					
7	DR. MELMED: NO.					
8	MS. BONNEVILLE: PHIL PIZZO.					
9	DR. PIZZO: YES.					
10	MS. BONNEVILLE: ELIZABETH FINI.					
11	DR. FINI: NO.					
12	MS. BONNEVILLE: ROBERT QUINT.					
13	DR. QUINT: NO.					
14	MS. BONNEVILLE: DUANE ROTH.					
15	MR. ROTH: YES.					
16	MS. BONNEVILLE: JOAN SAMUELSON.					
17	MS. SAMUELSON: YES.					
18	MS. BONNEVILLE: DAVID SERRANO-SEWELL.					
19	JEFF SHEEHY.					
20	MR. SHEEHY: YES.					
21	MS. BONNEVILLE: JONATHAN SHESTACK. OS					
22	STEWARD.					
23	DR. STEWARD: YES.					
24	MS. BONNEVILLE: JONATHAN THOMAS.					
25	CHAIRMAN THOMAS: YES.					
	177					

BARRISTERS' REPORTING SERVICE 1 MS. BONNEVILLE: ART TORRES. 2 MR. TORRES: AYE. 3 MS. BONNEVILLE: CHRISTINA VUORI. DR. VUORI: YES. 4 5 MS. BONNEVILLE: EUGENE WASHINGTON. 6 DAVID. 7 MR. SERRANO-SEWELL: YES. 8 MR. HARRISON: THAT MOTION CARRIES BY A 9 VOTE OF 13 TO 8. 10 CHAIRMAN THOMAS: THANK YOU. MR. HARRISON, I BELIEVE THERE'S ONE OTHER. 11 12 MR. HARRISON: YES. THERE WAS AN 13 APPLICATION RAISED IN PUBLIC COMMENT. IT'S 14 APPLICATION NO. 5730. 15 DR. SAMBRANO: SO THAT WAS MONOCLONAL 16 ANTIBODY THERAPEUTIC TARGETING A, REDACTED, 17 MONOCLONAL EXPRESSED ON HUMAN CANCER STEM CELLS. CHAIRMAN THOMAS: AND THIS WAS THE SUBJECT 18 19 OF AN EXTRAORDINARY APPEAL, CORRECT? 20 DR. SAMBRANO: YES. 21 CHAIRMAN THOMAS: DO WE HAVE A MOTION TO 22 APPROVE MOVING THIS FROM TIER III TO TIER I? 23 MS. SAMUELSON: COULD YOU REPEAT WHAT THAT 24 NUMBER WAS? 25 MR. HARRISON: 5730. 178

_	BARRISTERS' REPORTING SERVICE			
1	CHAIRMAN THOMAS: DO I HEAR A MOTION TO			
2	MOVE THIS FROM TIER III TO TIER I? HEARING NONE, I			
3	BELIEVE THAT THAT CONCLUDES OUR DISCUSSION. NO,			
4	THERE WAS ONE MORE.			
5	MR. HARRISON: YOU WILL RECALL THAT STAFF			
6	RAISED A PROPOSAL WITH RESPECT TO APPLICATION 5617,			
7	AND THAT REQUEST WAS TO MODIFY THE GRANTS WORKING			
8	GROUP'S RECOMMENDATION SO THAT THE AWARD WOULD			
9	REMAIN A DC AWARD, BUT FOCUS ON THE DRUG THAT WAS			
10	ALREADY IDENTIFIED AND ADJUST THE BUDGET			
11	ACCORDINGLY. AND I BELIEVE THE BOARD REQUESTED ALSO			
12	THAT WE BE SURE TO REQUIRE CLINICAL EXPERTISE.			
13	CHAIRMAN THOMAS: DO WE HEAR A MOTION TO			
14	THAT EFFECT?			
15	MR. SHEEHY: SO MOVED.			
16	CHAIRMAN THOMAS: MOVED BY MR. SHEEHY.			
17	MR. TORRES: SECOND.			
18	CHAIRMAN THOMAS: SECONDED BY SENATOR			
19	TORRES. IS THERE DISCUSSION? ANY PUBLIC COMMENT?			
20	OKAY. MARIA, PLEASE CALL THE ROLL.			
21	MS. BONNEVILLE: ROBERT BIRGENEAU.			
22	DR. BIRGENEAU: YES.			
23	MS. BONNEVILLE: DAVID BRENNER. SUSAN			
24	BRYANT.			
25	DR. BRYANT: YES.			
	179			
	1/3			

	BARRISTERS' REPORTING SERVICE				
1	MS	S. BONNEVILLE: KEN BURTIS.			
2	DF	R. BURTIS: YES.			
3	MS	S. BONNEVILLE: MARCY FEIT.			
4	MS	S. FEIT: YES.			
5	MS	S. BONNEVILLE: MICHAEL FRIEDMAN.			
6	DF	R. FRIEDMAN: YES.			
7	MS	S. BONNEVILLE: LEEZA GIBBONS.			
8	MS	S. GIBBONS: YES.			
9	MS	S. BONNEVILLE: MICHAEL GOLDBERG.			
10	MF	R. GOLDBERG: YES.			
11	MS	S. BONNEVILLE: SAM HAWGOOD.			
12	DF	R. HAWGOOD: YES.			
13	MS	S. BONNEVILLE: STEVE JUELSGAARD.			
14	DF	R. JUELSGAARD: YES.			
15	MS	S. BONNEVILLE: SHERRY LANSING. BERT			
16	LUBIN.				
17	DF	R. LUBIN: YES.			
18	MS	S. BONNEVILLE: SHLOMO MELMED.			
19	DF	R. MELMED: YES.			
20	MS	S. BONNEVILLE: PHIL PIZZO.			
21	DF	R. PIZZO: YES.			
22	MS	S. BONNEVILLE: FRANCISCO PRIETO.			
23	DF	R. PRIETO: YES.			
24	MS	S. BONNEVILLE: ELIZABETH FINI.			
25	Dł	R. FINI: YES.			
		180			
		100			

	BARRISTERS' REPORTING SERVICE
1	MS. BONNEVILLE: ROBERT QUINT.
2	DR. QUINT: YES.
3	MS. BONNEVILLE: DUANE ROTH.
4	MR. ROTH: YES.
5	MS. BONNEVILLE: JOAN SAMUELSON.
6	MS. SAMUELSON: YES.
7	MS. BONNEVILLE: DAVID SERRANO-SEWELL.
8	MR. SERRANO-SEWELL: YES.
9	MS. BONNEVILLE: JEFF SHEEHY.
10	MR. SHEEHY: YES.
11	MS. BONNEVILLE: JONATHAN SHESTACK. OS
12	STEWARD.
13	DR. STEWARD: YES.
14	MS. BONNEVILLE: JONATHAN THOMAS.
15	CHAIRMAN THOMAS: YES.
16	MS. BONNEVILLE: ART TORRES.
17	MR. TORRES: AYE.
18	MS. BONNEVILLE: CHRISTINA VUORI.
19	DR. VUORI: YES.
20	MS. BONNEVILLE: EUGENE WASHINGTON.
21	CHAIRMAN THOMAS: I THINK WE DON'T REALLY
22	NEED TO TABULATE THAT ONE.
23	MR. HARRISON: BUT IT CARRIES BY A VOTE OF
24	23 TO ZERO.
25	CHAIRMAN THOMAS: YES. THANK YOU. OKAY.
	181
	101

-	
1	SO NOW THAT DOES EXHAUST THE APPLICATIONS WE HAD TO
2	TAKE ON AN INDIVIDUAL BASIS. I WOULD NOW ENTERTAIN
3	A MOTION THAT WE APPROVE THE AWARDS AS AMENDED IN
4	THEIR ENTIRETY.
5	MR. TORRES: SO MOVED.
6	MS. GIBBONS: SECOND.
7	CHAIRMAN THOMAS: MOVED BY SENATOR TORRES,
8	SECOND BY LEEZA GIBBONS. ANY DISCUSSION? COMMENTS
9	BY MEMBERS OF THE PUBLIC? HEARING NONE, MARIA, WILL
10	YOU CALL THE ROLL.
11	MR. HARRISON: I'D LIKE TO REMIND MEMBERS
12	TO VOTE YES, NO, OR ABSTAIN, IF YOU CHOOSE, EXCEPT
13	WITH RESPECT TO THOSE APPLICATIONS IN WHICH YOU HAVE
14	A CONFLICT. YOU HAVE A LIST IN FRONT OF YOU THAT
15	IDENTIFIES ANY APPLICATION NUMBERS.
16	MS. BONNEVILLE: ROBERT BIRGENEAU.
17	DR. BIRGENEAU: YES, WITH THE EXCEPTION OF
18	TR3-05556 AND TR3-05565.
19	MS. BONNEVILLE: DAVID BRENNER. SUSAN
20	BRYANT.
21	DR. BRYANT: YES, WITH THE EXCEPTION OF
22	THOSE FOR WHICH I HAVE A CONFLICT.
23	MS. BONNEVILLE: KEN BURTIS.
24	DR. BURTIS: YES, WITH THE EXCEPTION OF
25	THOSE WITH WHICH I HAVE A CONFLICT.
	182
	102

BARRISTERS' REPORTING SERVICE 1 MS. BONNEVILLE: MARCY FEIT. 2 MS. FEIT: YES, EXCEPT FOR THOSE FOR WHICH 3 I HAVE A CONFLICT. 4 MS. BONNEVILLE: MICHAEL FRIEDMAN. 5 DR. FRIEDMAN: YES, EXCEPT FOR THOSE FOR WHICH I HAVE A CONFLICT. 6 7 MS. BONNEVILLE: LEEZA GIBBONS. MS. GIBBONS: I HAVE NO CONFLICTS. YES. 8 9 MS. BONNEVILLE: MICHAEL GOLDBERG. 10 MR. GOLDBERG: YES, EXCEPT FOR THOSE FOR 11 WHICH I HAVE A CONFLICT. 12 MS. BONNEVILLE: SAM HAWGOOD. 13 DR. HAWGOOD: YES, EXCEPT FOR THOSE FOR 14 WHICH I HAVE A CONFLICT. 15 MS. BONNEVILLE: STEVE JUELSGAARD. 16 DR. JUELSGAARD: YES. 17 MS. BONNEVILLE: SHERRY LANSING. BERT 18 LUBIN. 19 DR. LUBIN: YES. 20 MS. BONNEVILLE: MICHAEL MARLETTA. DR. MARLETTA: YES, EXCEPT FOR THOSE FOR 21 22 WHICH I HAVE A CONFLICT. 23 MS. BONNEVILLE: SHLOMO MELMED. 24 DR. MELMED: YES, EXCEPT FOR THOSE FOR 25 WHICH I HAVE A CONFLICT. 183

BARRISTERS' REPORTING SERVICE 1 MS. BONNEVILLE: PHIL PIZZO. 2 DR. PIZZO: YES, EXCEPT FOR THOSE FOR 3 WHICH I HAVE A CONFLICT. 4 MS. BONNEVILLE: FRANCISCO PRIETO. 5 DR. PRIETO: YES, EXCEPT FOR THOSE FOR WHICH I HAVE A CONFLICT. 6 7 MS. BONNEVILLE: ELIZABETH FINI. 8 DR. FINI: YES, EXCEPT FOR THOSE FOR WHICH 9 I HAVE A CONFLICT. 10 MS. BONNEVILLE: ROBERT QUINT. DR. QUINT: YES. AND I HAVE NO CONFLICTS. 11 12 MS. BONNEVILLE: DUANE ROTH. 13 MR. ROTH: YES, EXCEPT FOR THOSE FOR WHICH 14 I HAVE A CONFLICT. 15 MS. BONNEVILLE: JOAN SAMUELSON. 16 MS. SAMUELSON: NO CONFLICTS. YES. 17 MS. BONNEVILLE: DAVID SERRANO-SEWELL. 18 MR. SERRANO-SEWELL: YES. 19 MS. BONNEVILLE: JEFF SHEEHY. 20 MR. SHEEHY: YES, EXCEPT FOR THOSE FOR 21 WHICH I HAVE A CONFLICT. 22 MS. BONNEVILLE: JONATHAN SHESTACK. OS 23 STEWARD. 24 DR. STEWARD: YES, EXCEPT FOR THOSE FOR 25 WHICH I HAVE A CONFLICT. 184

	BARRISTERS' REPORTING SERVICE
1	MS. BONNEVILLE: JONATHAN THOMAS.
2	CHAIRMAN THOMAS: YES.
3	MS. BONNEVILLE: ART TORRES.
4	MR. TORRES: AYE.
5	MS. BONNEVILLE: CHRISTINA VUORI.
6	DR. VUORI: YES, EXCEPT FOR THOSE FOR
7	WHICH I HAVE A CONFLICT.
8	MS. BONNEVILLE: EUGENE WASHINGTON.
9	MR. HARRISON: THE MOTION CARRIES.
10	CHAIRMAN THOMAS: WELL, THANK YOU,
11	EVERYBODY, FOR A LENGTHY AND CONSIDERED DISCUSSION
12	ON VERY IMPORTANT TOPICS. I THINK WE'VE GOT SOME
13	TERRIFIC PROJECTS HERE AND CONGRATULATE ALL
14	INVOLVED.
15	LET'S NOW MOVE ON TO THE NEXT ITEM ON THE
16	AGENDA, WHICH IS CONSIDERATION OF APPOINTMENT OF NEW
17	SCIENTIFIC MEMBERS OF THE GRANTS WORKING GROUP. DR.
18	SAMBRANO.
19	DR. SAMBRANO: THANK YOU. SO TODAY WE'RE
20	BRINGING FOR YOUR CONSIDERATION THREE NOMINEES FOR
21	GRANTS WORKING GROUP MEMBERS THAT BRING KEY
22	SCIENTIFIC EXPERTISE IN THE AREAS OF NEUROBIOLOGY,
23	NEURO-ONCOLOGY, AND CARDIOLOGY. THE NOMINEES AND
24	THEIR BRIEF BIOS ARE IN YOUR BINDERS. THEY INCLUDE
25	DR. JANE JOHNSON FROM UT SOUTHWESTERN, DR. JOHN SKUO
	185

	BARRISTERS' REPORTING SERVICE
1	FROM THE UNIVERSITY OF WISCONSIN, AND DR. HESHAM
2	SADEK FROM UT SOUTHWESTERN.
3	WE REQUEST YOUR APPROVAL AND APPOINTMENT
4	OF THESE NOMINEES AS MEMBERS OF THE GRANTS WORKING
5	GROUP.
6	CHAIRMAN THOMAS: DO I HEAR A MOTION?
7	DR. FRIEDMAN: SO MOVED.
8	CHAIRMAN THOMAS: MOVED BY DR. FRIEDMAN.
9	DR. VUORI: SECOND.
10	CHAIRMAN THOMAS: SECOND BY DR. VUORI.
11	ANY DISCUSSION? COMMENTS BY MEMBERS OF THE PUBLIC?
12	MR. HARRISON, DOES THIS REQUIRE A ROLL
13	CALL VOTE OR JUST A SENSE OF THE
14	MR. HARRISON: IT REQUIRES A VOICE VOTE
15	EXCEPT FOR THOSE WHO ARE ON THE TELEPHONE, AND WE
16	NEED A ROLL CALL VOTE FOR THEM.
17	CHAIRMAN THOMAS: OKAY. SO WITH RESPECT
18	TO THOSE IN THE ROOM, ALL THOSE IN FAVOR OF THIS
19	MOTION PLEASE SAY AYE. OPPOSED? MARIA, PLEASE
20	CANVASS THOSE MEMBERS ON THE PHONE.
21	MS. BONNEVILLE: SHLOMO MELMED.
22	DR. MELMED: YES.
23	MS. BONNEVILLE: DUANE ROTH.
24	MR. ROTH: YES, EXCEPT WHICH I HAVE A
25	CONFLICT. SORRY, GUYS. I WAS LATE. I WAS TRYING
	186

BARRISTERS' REPORTING SERVICE 1 TO GET AROUND THE CORNER HERE. 2 CHAIRMAN THOMAS: SOUNDED LIKE A 3 PRERECORDED MESSAGE. 4 MR. ROTH: IT IS. I WISH I COULD PLAY IT 5 OFTEN. CHAIRMAN THOMAS: YES. NOW, THANK YOU. 6 7 THAT'S, MR. HARRISON, UNANIMOUSLY APPROVED. 8 MR. HARRISON: CORRECT. 9 MS. SAMUELSON: MR. CHAIRMAN, I NEED TO 10 ABSTAIN BECAUSE AT THIS POINT I DON'T THINK IT'S 11 ACCURATE TO CHARACTERIZE THESE PEOPLE AS SCIENTIFIC 12 MEMBERS. I THINK IT'S CONFUSING TO THE BOARD AND 13 DOESN'T REFLECT THE FACT THAT THERE ARE NOW OVER A 14 HUNDRED WHO ARE PARTICIPANTS AND IMPORTANT, BUT WE 15 DON'T AT THIS POINT HAVE A WORKING GROUP WITH 16 MEMBERS PER SE. AND I THINK THAT SHOULD BE 17 REMEMBERED. THANK YOU. 18 CHAIRMAN THOMAS: OKAY. MR. HARRISON, 19 PLEASE REFLECT THAT IN THE FINAL TALLY. 20 NEXT, ITEM NO. 10, CONSIDERATION OF RECOMMENDATIONS OF THE IP AND INDUSTRY SUBCOMMITTEE. 21 22 I'LL TURN THIS OVER TO MR. JUELSGAARD. 23 DR. JUELSGAARD: WELL, I'M GOING TO TURN 24 THIS OVER TO ELONA IN JUST A MOMENT. BUT REAL 25 QUICKLY, WE HAVE SINCE THE LAST MEETING DISCUSSED 187

1	TWO TOPICS. AND THAT'S AMENDMENTS TO THE LOAN
2	ADMINISTRATION POLICY AND THE OTHER IS THE INDUCED
3	PLURIPOTENT STEM CELL BANKING INITIATIVE THAT WAS
4	APPROVED AT A BOARD MEETING, I THINK, IN DECEMBER.
5	SO I HAVE NOTHING MORE TO SAY BECAUSE ELONA HAS IT
6	ALL.
7	MS. BAUM: I THINK MY EYESIGHT IS GOING AS
8	WELL, SO DON'T FEEL BAD. THIS IS BIG PRINT AND I
9	CAN STILL BARELY SEE IT.
10	I AM GOING TO TRY TO GO THROUGH THESE
11	ITEMS FAIRLY QUICKLY BECAUSE IT'S LATE IN THE
12	AFTERNOON AND I KNOW WE HAVE A LOT OF BUSINESS TO
13	CONDUCT. IF I AM GOING TOO FAST, PLEASE JUST
14	INTERRUPT AND ASK QUESTIONS ALONG THE WAY.
15	AND JUST FOR PRELIMINARY MATTERS, I WANTED
16	TO NOTE THAT THE AGENDA SAYS THAT THREE ITEMS WILL
17	BE DISCUSSED THAT ARISE FROM THE IP AND INDUSTRY
18	SUBCOMMITTEE. IN FACT, THERE'S TWO. WE JUST PLACED
19	THE LAST ONE, THE UPDATE ON SOME PROPOSED IP
20	REGULATIONS, AS SORT OF A PLACEHOLDER IN CASE WE
21	WERE ABLE TO ADDRESS THAT EARLIER THIS MORNING,
22	WHICH WE DID NOT, BUT KEEP YOUR EYES OUT. WE WILL
23	BE DOING THAT SOON, I HOPE.
24	SO LET ME DO THIS AS QUICKLY AS POSSIBLE,
25	BUT WITHOUT LOSING ANY OF THE CONTENT. WHAT YOU
	188

1	HAVE IN TAB 10 IS SOME DOCUMENTATION OF SOME VERY
2	MARKED-UP REGULATIONS FROM OUR LOAN ADMINISTRATION
3	POLICY. THEY ARE HIGHLY MARKED UP BECAUSE THEY
4	ACTUALLY REFLECT TWO SETS OF CHANGES. THE FIRST SET
5	WAS ALREADY APPROVED, AND THEN THERE'S A SECOND SET.
6	THE SECOND SET IS WHAT YOU ARE FOCUSING ON TODAY.
7	THEY ARE HIGHLIGHTED. AND SINCE THESE WERE POSTED,
8	I THINK, WITHIN THE TEN-DAY OR CERTAINLY THE
9	SEVEN-DAY TIME FRAME BEFORE THIS MEETING, HOPEFULLY
10	YOU'VE HAD A CHANCE TO TAKE A LOOK AT THEM.
11	SO WHAT I THOUGHT THAT I WOULD DO IS, ONE,
12	LET YOU KNOW THAT THE IP AND INDUSTRY SUBCOMMITTEE
13	LOOKED AT THESE PROPOSED REGULATIONS IN EXTREME
14	DETAIL. WE HAD A SUBCOMMITTEE MEETING THAT WAS
15	NEARLY AN HOUR AND A HALF LONG, AND WE DID A VERY
16	DETAILED PAGE-TURNING EXERCISE LOOKING AT ALL OF THE
17	LANGUAGE THAT WAS CHANGED. SO WHAT I THOUGHT THAT I
18	WOULD DO IS JUST HIGHLIGHT THE TEN OR SO SUBSTANTIVE
19	ISSUES THAT I THINK DESERVES YOUR ATTENTION TODAY.
20	I WANT TO REMIND YOU THAT ON MAY 8TH, THE
21	SUBCOMMITTEE DID BY UNANIMOUS VOTE OF ALL THOSE
22	PRESENT AGREE TO RECOMMEND THE APPROVAL OF THESE
23	REGULATIONS TODAY.
24	SO, AGAIN, I'LL GO VERY QUICKLY BECAUSE I
25	HAVE TO COVER A LOT OF GROUND. BUT THE FIRST CHANGE
	189
	103

1	I WANTED TO DRAW YOUR ATTENTION TO IS ON PAGE 1, IF
2	YOU CARE TO LOOK AND FOLLOW WITH ME. THAT JUST
3	INCLUDED A PURPOSE SECTION FOR THE LAP OR THE LOAN
4	REGULATIONS. IT WAS IMPORTANT, WE THOUGHT, TO
5	PROVIDE CONTEXT FOR THOSE WHO ARE LOOKING AT OUR
6	REGULATIONS SO THAT THEY UNDERSTOOD THAT WE'RE
7	TRYING TO STRIKE A BALANCE BETWEEN ACCEPTING
8	FINANCIAL RISK AND NOT UNDULY TRYING TO HINDER THE
9	GRANTING PROCESS WITH REGULATIONS THAT SEEK A LOT OF
10	REVENUE RETURN FROM CIRM, BUT STILL CAN PROGRESS THE
11	SCIENCE FORWARD AND ACKNOWLEDGE THAT WE UNDERSTAND
12	WE'RE NOT ONLY TAKING SCIENTIFIC RISK IN THESE
13	ENDEAVORS, BUT ALSO FINANCIAL.
14	SO MOVING ON, THE SECOND POINT OF NOTE IS
15	A CHANGE OR PROPOSED CHANGE TO THE DEFINITION OF NET
16	COMMERCIAL REVENUE. WHAT WE'RE DOING THERE IS
17	EXCLUDING PRECOMMERCIAL PAYMENTS; IN ESSENCE,
18	UP-FRONT MILESTONES OR PRECOMMERCIAL DEVELOPMENT
19	MILESTONES FROM THE DEFINITION OF REVENUE. THIS
20	WILL ALLOW THOSE WHO ARE ENGAGED IN THE RESEARCH TO
21	HAVE A BETTER ABILITY TO REINVEST THAT TYPE OF
22	FUNDING IN THE DEVELOPMENT PROCESS.
23	THIRD, WE JUST ADDED A LITTLE CHANGE TO
24	THE SECTION RELATING TO FINANCIAL SERVICES PROVIDER
25	SUCH THAT WE DIDN'T HAVE TO HAVE THAT DUE DILIGENCE
	190

1	CONDUCTED BY A THIRD PARTY. WE COULD, IF WE CHOSE,
2	HAVE A THIRD PARTY DO THE DUE DILIGENCE, OR IN THE
3	ALTERNATIVE, WE CAN USE OUR OWN INTERNAL RESOURCES.
4	WE WANTED TO PROVIDE THE FLEXIBILITY SO THAT IN THE
5	FUTURE IF WE DID DECIDE TO DO THIS IN-HOUSE, WE
6	WOULDN'T HAVE TO CHANGE REGULATIONS THEN. SO THIS
7	WAS JUST LOOKING FORWARD AND TRYING TO ADDRESS IT IN
8	THAT WAY.
9	NEXT, WE JUST ELIMINATED A LOT OF
10	TERMINOLOGY AND REGULATIONS THAT WERE EITHER
11	OVERLAPPING WITH THE IP REGULATIONS OR WERE
12	REDUNDANT WITHIN THE BODY OF THE LAP. WE AT ONE
13	POINT THOUGHT IT WAS A GOOD IDEA TO HAVE A LOT OF
14	BELT AND SUSPENDER-TYPE LANGUAGE. AND THEN WE
15	REALIZED WHEN WE WERE GETTING A LOT OF INQUIRIES,
16	THAT WE WERE CREATING A LOT OF CONFUSION BECAUSE
17	THEY WOULD READ A CLAUSE ONE PLACE AND THEN IT SEE
18	IT SOMEWHAT WORDED DIFFERENTLY SOMEWHERE ELSE WHEN,
19	IN FACT, IT ALL MEANT THE SAME THING. AND SO I JUST
20	WANTED TO BRING YOUR ATTENTION THAT ON PAGES 7, 8,
21	AND 9 WE MADE SOME CHANGES THAT WERE BASICALLY TO
22	MAKE SURE THAT ALL OF OUR REGULATIONS WERE IN LINE
23	WITH THE IP REGULATIONS IN PARTICULAR AND, OF
24	COURSE, INTERNALLY. AND I'VE OUTLINED WHAT SOME OF
25	THOSE REGULATION CHANGES ARE IN THESE SLIDES AND IN
	191

MY	MEMO
----	------

1

2 IN ADDITION, WE ALSO CHANGED ON PAGE 10, 3 AND YOU'LL SEE WHERE IT'S MARKED ON THE SLIDES, IT'S SECTION VII B., THE NOTION THAT IF YOUR LOAN WAS 4 5 FORGIVEN BECAUSE IT WAS NOT DEEMED SUCCESSFUL, THAT 6 IN THE EVENT THAT YOU HAD RECEIVED SOME INTERIM OR 7 WOULD RECEIVE SOME INTERIM REVENUE FROM LICENSING, THAT INSTEAD OF PAYING BACK CIRM A HUNDRED PERCENT, 8 9 YOU ONLY NEEDED TO PAY BACK 50 PERCENT OF 10 THIRD-PARTY COSTS OR 50 PERCENT TO EQUAL AND TO PAY FOR THE THIRD-PARTY COSTS WHICH WERE INCURRED IN 11 12 GENERATING SUCH REVENUE. THE NOTION BEING THAT 13 THERE IS THIS OBLIGATION TO MAKE ANY INVENTIONS AND DISCOVERIES AND DATA USEFUL; BUT IN DOING SO, 14 15 SOMETIMES IT COSTS ATTORNEY TIME AND IN-HOUSE TIME 16 TO INCUR THE LICENSE OR WHATNOT. SO WE'RE ALLOWING 17 THE LOAN RECIPIENT TO RECOUP ITS ATTORNEY FEE COSTS 18 OR THIRD-PARTY COSTS. 19 MOVING FORWARD, WE MADE A NUMBER OF TWEAKS 20 TO THE WARRANTS LANGUAGE THAT IS IN YOUR 21 REGULATIONS. A LOT OF THIS CAME FROM SOME QUESTIONS 22 THAT WE FIELDED. SO INSTEAD OF HAVING TO DO AN FAQ 23 THAT EXPLAINS WHAT OUR REGULATIONS MEANT, WE JUST 24 FIGURED WE'D MAKE THE CHANGES THAT, QUOTE, FIX THEM. 25 SO WE HAD A CLARIFICATION OF THE DEFINITION OF WHAT

192

1	FULLY DILUTED MEANS. IN OTHER WORDS, WE STATED THAT
2	IT INCLUDES STOCK OPTIONS. WE CLARIFIED THAT
3	WARRANTS ARE DUE NOT JUST UPON SORT OF THE SIGNING
4	OF A NOTICE OF LOAN AGREEMENT, BUT UPON EACH
5	DISBURSEMENT, AND THEY'RE CALCULATED BASED ON EACH
6	DISBURSEMENT. WE ALSO STATED THAT THE BORROWER MAY
7	ELECT TO PROVIDE THE WARRANTS IN THE FORM OF COMMON
8	OR PREFERRED STOCK. AND WE CLARIFIED, IT WASN'T
9	NECESSARY, BUT TO MAKE IT IN BLACK AND WHITE AND
10	CRYSTAL CLEAR, WE CLARIFIED THAT CIRM IS ENTITLED TO
11	RETAIN WARRANTS WHEN THEY'RE DUE AND OWING
12	REGARDLESS OF WHAT THE ULTIMATE DISPOSITION OF THE
13	LOAN IS OR THE SUCCESS OF THE PROJECT.
14	MOVING ON, I THINK I JUST HAVE A FEW MORE
15	OF THESE. WITH RESPECT TO THE MULTIPLE RISK
16	PREMIUM, YOU MIGHT RECALL THAT WAS AN ALTERNATIVE TO
17	PROVIDING WARRANTS UNDER OUR LAP. WE CHANGED THE
18	FIRST TRIGGER POINT. YOU MIGHT RECALL THAT UNDER
19	THE RISK PREMIUM, THERE WERE THREE TRIGGER POINTS AT
20	WHICH THREE TIMES THE LOAN AMOUNT WOULD BE OWED.
21	WELL, THE FIRST ONE STARTED AT 10 MILLION, AND IT
22	DOESN'T REALLY WORK WHEN YOU HAVE A \$20 MILLION LOAN
23	AND YOU'VE JUST EARNED 10 MILLION. YOU'LL BE IN
24	DEFAULT. SO WE WANTED TO FIX THAT, AND WE SAID,
25	THEREFORE, THAT THE FIRST TRIGGER PAYMENT IS 50
	102

193

MILLION. AND INSTEAD OF PAYING IT OVER 12 MONTHS,
 WHICH IS WHAT WAS INITIALLY PROVIDED FOR, SINCE IT
 IS SORT OF THE FIRST SET OF REVENUE, WE SAID PAY IT
 OVER 18 MONTHS.

5 WE ALSO DID A NUMBER OF CHANGES WITH RESPECT TO CHANGE OF CONTROL AND LOAN ACCELERATION. 6 7 AND BASICALLY WE STATED THAT CIRM MAY ACCELERATE A LOAN UPON A CHANGE OF CONTROL EXCEPT IN A CERTAIN 8 9 CIRCUMSTANCE TO MAKE IT CLEAR PEOPLE KNEW WHEN THAT 10 CIRCUMSTANCE WAS. AND AS DEFINED IN THESE PROPOSED 11 AMENDMENTS, IT IS IN THE EVENT THAT THE SURVIVING 12 ENTITY ASSUMES THE LOAN OBLIGATIONS. THAT'S AN 13 ESSENTIAL REQUIREMENT AND SHOULD ALWAYS BE. AND, OF 14 COURSE, HERE'S WHERE THERE'S A LITTLE SORT OF 15 NUANCE. THEY HAVE TO HAVE SHAREHOLDER EQUITY EQUAL 16 TO OR GREATER THAN THE LOAN RECIPIENT PRIOR TO THE 17 CHANGE OF CONTROL. 18 MOVING ON, THIS IS THE ONE TIME WITH 19 ASSIGNEES THAT WE HAD SOME BELT-AND-SUSPENDER 20 LANGUAGE. WE SAID THAT ASSIGNEES HAVE THE SAME 21 OBLIGATIONS AS THE LOAN RECIPIENT UNDER THE IP 22 REGULATIONS. I THINK THAT WOULD BE BY ORDER OF LAW 23 ANYWAY. 24 AND THIS IS MY LAST ONE BEFORE I SWITCH 25 OVER TO THE NEXT SET OF REGULATIONS. I KNOW I'M

194

1	TALKING FAST; AND IF THERE'S ANY QUESTIONS, PLEASE
2	DO INTERRUPT ME.
3	SUBORDINATION. THE OLD SET OR ACTUALLY
4	THE PENDING AND THE SET OF REGULATIONS IN EFFECT
5	PROVIDE FOR SUBORDINATION IN CERTAIN CIRCUMSTANCES
6	FOR PRODUCT-BACKED LOANS. IT'S SILENT ON
7	COMPANY-BACKED LOANS. AND WE JUST DECIDED THAT
8	BECAUSE WE ACTUALLY HAD A LOT OF QUESTIONS ON IT
9	ANYWAY, BECAUSE IT WAS SILENT ON COMPANY-BACKED
10	LOANS, THAT WE WOULD TAKE THIS ON A CASE-BY-CASE
11	BASIS. THIS WAS THE INSTRUCTION AND DIRECTION THAT
12	WE GOT FROM THE IP AND INDUSTRY SUBCOMMITTEE. AND
13	ON A CASE-BY-CASE BASIS, WE WOULD UNDERSTAND WHAT
14	THE DIFFERENT FINANCIAL STRENGTHS WERE AND A LOT
15	MORE ABOUT THE PROJECT, AND THEN INTERNALLY WE COULD
16	USE OUR EXPERTISE TO MAKE THE DECISION WHETHER OR
17	NOT TO SUBORDINATE.
18	SO THOSE ARE THE TEN MAJOR SUBSTANTIVE
19	CHANGES TO THE LAP, AND REST ASSURED THAT THE IP AND
20	INDUSTRY SUBCOMMITTEE SPENT A LONG TIME LOOKING AT
21	THIS IN DETAIL, AND WHAT YOU SEE BEFORE YOU
22	INCORPORATES THEIR SUGGESTED CHANGES. AND WITH
23	THAT, I WOULD JUST ASK YOU TO APPROVE THE PROPOSED
24	AMENDMENTS.
25	CHAIRMAN THOMAS: DO WE HAVE BEFORE WE
	195

	BARRISTERS' REPORTING SERVICE
1	ASK FOR MOTIONS HERE, MR. GOLDBERG, WOULD YOU LIKE
2	TO COMMENT AT ALL?
3	MR. GOLDBERG: I THINK THIS HAS BEEN FULLY
4	DISCUSSED AND DEBATED BY THE INTELLECTUAL PROPERTY
5	AND INDUSTRY SUBCOMMITTEE, AND I'M VERY COMFORTABLE
6	MOVING IT TO A VOTE PENDING ANY FURTHER QUESTIONS.
7	CHAIRMAN THOMAS: MR. JUELSGAARD.
8	DR. JUELSGAARD: NO, I DON'T HAVE ANYTHING
9	TO ADD OTHER THAN I MOVE THAT THIS BE APPROVED.
10	CHAIRMAN THOMAS: IS THERE A SECOND?
11	DR. FRIEDMAN: SECOND.
12	CHAIRMAN THOMAS: SECONDED BY DR.
13	FRIEDMAN. ANY FURTHER DISCUSSION? SENATOR TORRES.
14	MR. TORRES: YES. I THINK IT'S IMPORTANT
15	TO NOTE HOW THIS WILL IMPROVE POTENTIAL REVENUE TO
16	THE STATE OF CALIFORNIA.
17	MS. BAUM: WELL, THE LOAN PROGRAM IN
18	PARTICULAR IS VERY ADVANTAGEOUS BECAUSE AMONG SOME
19	POTENTIAL GRANTEES, THEY MIGHT WANT A LOAN VERSUS A
20	GRANT, BUT NOW WE ALLOW BOTH ASPECTS AND ALLOW THE
21	GRANTEES TO CHOOSE BETWEEN GRANTS AND LOANS.
22	MR. TORRES: THE WARRANT CONCEPT.
23	MS. BAUM: WELL, THE WARRANT CONCEPT, OF
24	COURSE, ALLOWS US TO PARTICIPATE IN THE SUCCESS OF A
25	COMPANY IN THAT WE END UP HOLDING RIGHTS OF VALUE
	196

	BARRISTERS' REPORTING SERVICE
1	THAT ALLOW US TO, I GUESS, SHARE IN SORT OF THE
2	INCREASED VALUE OF THE VERY COMPANIES THAT WE ARE
3	FUNDING.
4	MR. TORRES: SO THAT IN TURN INCREASES
5	REVENUE TO POTENTIAL REVENUE TO THE STATE OF
6	CALIFORNIA.
7	MS. BAUM: WELL, TO BE FRANK WITH YOU, THE
8	LOAN PROGRAM IS A PROGRAM WHERE THE PROCEEDS GO
9	DIRECTLY TO CIRM, WHICH I THINK COULD BE SAID
10	BENEFITS THE STATE AS WELL.
11	MR. TORRES: EXACTLY. THANK YOU.
12	CHAIRMAN THOMAS: DR. PRIETO.
13	DR. PRIETO: YES. QUESTION ABOUT THE
14	DEFINITION OF NET COMMERCIAL REVENUE AND THE CHANGE
15	THERE. YOU MENTIONED THAT THE REASONING BEHIND THAT
16	WAS THAT FUNDS WOULD BE REINVESTED. IF YOU COULD
17	EXPAND ON THAT A LITTLE BIT. AND DO WE HAVE ANY
18	GUARANTEE OR ASSURANCES THAT, IN FACT, THAT'S WHAT
19	WOULD HAPPEN?
20	MS. BAUM: THE THOUGHT WAS IS THAT IF WE
21	DIDN'T TRY TO CAPTURE THAT INCOME, THAT IT WOULD
22	LIKELY BE REINVESTED INTO THE PRODUCT OR PROJECT.
23	TO BE FRANK AGAIN, WE THOUGHT ABOUT PUTTING A
24	CONDITION THAT IT WOULD BE REINVESTED AS A
25	CONDITION, BUT WE FELT THAT THE ECONOMICS AND THE
	197

1	DRIVERS WOULD MOST LIKELY ALLOW THIS TO OCCUR
2	ANYWAY. AND THAT BY MAKING IT AN ABSOLUTE
3	REQUIREMENT, IT WOULD CAUSE SOME COMPANIES ACTUALLY
4	NOT TO WANT TO ENGAGE WITH CIRM AT ALL. AND THE
5	REASON BEING IS THAT SOMETIMES PEOPLE RECEIVE THESE
6	UP-FRONTS OR ESPECIALLY THESE DEVELOPMENT
7	MILESTONES, AND IT'S NOT REAL CLEAR FROM WHAT
8	PROJECT THEY ARE DERIVED FROM BECAUSE THEY'LL HAVE,
9	FOR INSTANCE, A MOLECULE OR AN ANTIBODY OR WHATNOT,
10	A THERAPEUTIC, AND WITH MANY DIFFERENT INDICATIONS,
11	AND WE FUND ON AN INDICATION-BY-INDICATION BASIS.
12	SO SOMETIMES IT'S SORT OF THE FIRST TO GET INTO A
13	CLINICAL TRIAL ENDS UP TRIGGERING A DEVELOPMENT
14	MILESTONE.
15	WELL, IF CIRM SORT OF FUNDED THAT, THE
16	INDICATION THAT CREATED THAT, THERE ARE A LOT OF
17	OTHER INDICATIONS THAT MAY HAVE BEEN IN THE WORKS
18	AND BEEN SUBJECTED TO A LOT OF R&D EXPENDITURES
19	BEFOREHAND. SO IT BECAME VERY COMPLICATED IN THE
20	WAY THAT THE COMPANIES ARE DOING BUSINESS TO REALLY
21	UNDERSTAND IN ALL CIRCUMSTANCES WHEN IT WOULD BE
22	DERIVED STRICTLY FROM CIRM TO REQUIRE THEM TO
23	REINVEST IT IN THE CIRM-FUNDED PROJECT. AND
24	SOMETIMES IT'S A PAYMENT IN ARREARS AGAIN; AND
25	BECAUSE OF THE COMPLICATED WAY THAT THESE BUSINESS
	198

1	DEALS ARE MADE, IT WAS A LITTLE TROUBLESOME TO
2	FIGURE OUT EXACTLY WHEN THAT WOULD HAVE BEEN
3	TRIGGERED STRICTLY BY CIRM. SO WE DECIDED THAT WE
4	WOULD JUST EXCLUDE THIS WITH THE MOTION THAT THAT'S
5	SORT OF THE WAY BUSINESS IS OPERATED. THEY REINVEST
6	IT. THEY'RE NOT A PUBLIC COMPANY GIVING OUT
7	DIVIDENDS.
8	DR. PRIETO: OR REIMBURSING THEIR OWN
9	OFFICERS OR I'M JUST WORRIED THAT, YOU KNOW, IS
10	THIS SOME SORT OF AN ESCAPE VALVE, AND COULD THIS BE
11	MISUSED? COULD THEY BE SUBJECT TO ABUSE?
12	DR. JUELSGAARD: WELL, IN MY EXPERIENCE
13	THESE PAYMENTS OF MILESTONES ARE, IN ESSENCE, ARREAR
14	PAYMENTS FOR INCURRING RISK. SO COMPANIES GO AT
15	RISK SPENDING THEIR OWN MONEY, TIME, AND EFFORT TO
16	DETERMINE IF YOU CAN REACH A PARTICULAR GOAL.
17	SHOULD THAT GOAL NOT BE REACHED, THOSE PAYMENTS ARE
18	NOT MADE. BUT IF THE GOAL IS REACHED, THEY ARE
19	PAID. AND, IN ESSENCE, IT'S MAKING UP FOR WHAT
20	YOU'VE SPENT IN THE INTERIM BOTH IN TERMS OF MONEY
21	AND TIME THAT WOULD HAVE BEEN SPENT DOING SOMETHING
22	ELSE HAD YOU NOT SPENT IT ON THIS.
23	SO I DON'T THINK WE WANT TO DISCOURAGE
24	COMPANIES FROM DOING THAT. AND SO TO, IN ESSENCE,
25	ADDRESS THOSE MILESTONES AS PART OF SOMETHING THAT
	199

1	WE SHOULD REACH THROUGH TO, I THINK, WILL BE
2	DISCOURAGING WITH RESPECT TO COMPANIES WANTING TO
3	OTHERWISE BE INVOLVED WITH THIS PROGRAM FROM MY
4	POINT OF VIEW.
5	CHAIRMAN THOMAS: ANY OTHER DISCUSSION?
6	COMMENTS FROM MEMBERS OF THE PUBLIC? HEARING NONE,
7	MR. HARRISON, VOICE VOTE SUFFICES HERE?
8	MR. HARRISON: CORRECT. AND AGAIN, THE
9	MOTION IS TO APPROVE THE PROPOSED AMENDMENTS TO THE
10	LOAN ADMINISTRATION POLICY.
11	CHAIRMAN THOMAS: BEFORE THE VOTE, DO YOU
12	WANT TO REITERATE ELONA AND MATT AND MANY OTHERS
13	SPENT A LOT OF TIME ON THIS. SO THIS IS THE PRODUCT
14	OF A GREAT DEAL OF THOUGHT AND ATTENTION.
15	MS. BAUM: I WANT TO ACKNOWLEDGE SCOTT TOO
16	WHO SPENT A CONSIDERABLE AMOUNT OF TIME AS WELL.
17	IT'S VERY MUCH APPRECIATED.
18	CHAIRMAN THOMAS: YES. THANK YOU VERY
19	MUCH. SO ALL THOSE IN FAVOR OF THE MOTION, PLEASE
20	SAY AYE. OPPOSED? ABSTENTIONS?
21	MR. HARRISON: NOW WE'LL DO A ROLL CALL OF
22	THOSE ON THE PHONE.
23	CHAIRMAN THOMAS: YES.
24	MS. BONNEVILLE: DUANE ROTH.
25	MR. ROTH: YES.
	200

	BARRISTERS' REPORTING SERVICE
1	MS. BONNEVILLE: SHLOMO MELMED.
2	DR. MELMED: YES.
3	CHAIRMAN THOMAS: OKAY. PASSES
4	UNANIMOUSLY.
5	BEFORE WE GET TO THE NEXT AGENDA TOPIC, WE
6	ACTUALLY HAVE A MOST IMPORTANT ANNOUNCEMENT, WHICH
7	IS TODAY, I BELIEVE, IS DR. BRYANT'S BIRTHDAY. AND
8	TO COMMEMORATE, WE HAVE CUPCAKES IN THE BACK ROOM
9	THERE WHICH, MARIA, SOMEBODY IS GOING TO PASS OUT.
10	IN THE INTEREST OF TIME, WE ARE GOING TO HAVE A
11	WORKING DESSERT.
12	DR. PIZZO: JON, WOULD YOU PLEASE LEAD US
13	IN A SONG.
14	(HAPPY BIRTHDAY WAS THEN SUNG.)
15	(APPLAUSE.)
16	CHAIRMAN THOMAS: OKAY. NOW, ELONA, DO
17	YOU HAVE ITEM NO. 2?
18	MS. BAUM: OKAY. ITEM NO. 2, THIS REGARDS
19	THE INTERIM REGULATIONS FOR THE IPS REPOSITORY. SO
20	I'LL JUST KEEP GOING. YOU ALL MIGHT RECALL THAT IN
21	DECEMBER 8TH OF 2011, THE ICOC APPROVED A CONCEPT
22	FOR THIS REPOSITORY. WHAT WILL OCCUR IS WE WILL
23	SEE, HOPEFULLY SOON, THE POSTING OF THREE RFA'S, ONE
24	FOR DISEASE MODELING, ANOTHER FOR CELL LINE
25	DERIVATION UP TO \$16 MILLION AS INITIALLY
	201

1	ENVISIONED, AND THEN THE REPOSITORY DISTRIBUTION ARM
2	OF \$10 MILLION.
3	AS WE STARTED THIS, AS I STARTED TO SORT
4	OF SINK MY TEETH INTO WHAT THIS INITIATIVE IS ALL
5	ABOUT, IT BECAME VERY SELF-EVIDENT THAT OUR IP
6	REGULATIONS WOULD ACTUALLY DETER IN MANY RESPECTS
7	THE SUCCESS OF THIS VERY INITIATIVE. AND I'LL TELL
8	YOU WHY IN A SECOND. AND EITHER THAT OR THEY JUST
9	WEREN'T APPLICABLE, BUT IT SEEMED LIKE WE NEEDED
10	OTHER MECHANISMS TO MAKE SURE THAT WE WOULD BE ABLE
11	TO ENJOY THE RESULTS OF OUR FUNDED RESEARCH.
12	SO LET ME TELL YOU A LITTLE BIT ABOUT WHY
13	THE IP REGULATIONS DON'T WORK BECAUSE YOU'LL SEE
14	WHAT I'M RECOMMENDING IS THAT THEY NOT APPLY IN THIS
15	PARTICULAR SITUATION. SO, FOR INSTANCE, THE IP
16	REGULATIONS STATE THAT THE GRANTEE OWNS ALL OF THE
17	IP, BUT HERE WE WANT TO REMAIN WE WANT TO
18	MAINTAIN ULTIMATE CONTROL OF THESE CELL LINES, IN
19	PARTICULAR BECAUSE WE WANT THE ABILITY TO ENSURE
20	THAT THEY ARE FREELY AVAILABLE TO ALL RESEARCHERS
21	WHO CAN BENEFIT FROM THEIR USE, WHICH GETS ME TO MY
22	NEXT POINT.
23	THE IP REGULATIONS REQUIRE AND ALLOW
24	EXCLUSIVE LICENSING. WELL, WE DON'T WANT THESE CELL
25	LINES TO EVER BE EXCLUSIVELY LICENSED. AND AS I
	202
	202

1	WENT THROUGH EACH OF THE DIFFERENT REQUIREMENTS THAT
2	ARE SET FORTH IN THE IP REGS, I EITHER REALIZED THAT
3	THEY PROBABLY DON'T APPLY ON POINT OR THEY SHOULD BE
4	TWEAKED IN SOME WAY. AND SO WHAT I'M ADVOCATING
5	HERE, AND, AGAIN, THIS IS WHAT THE IP AND INDUSTRY
6	SUBCOMMITTEE HAS ALREADY REVIEWED AND DISCUSSED AT
7	OUR MARCH 8TH MEETING AND HAS CONCLUDED TO RECOMMEND
8	APPROVAL, BUT I THINK APPROVAL WHICH WOULD NOT GO
9	INTO EFFECT UNTIL SOMETIME INTO DECEMBER WHEN WE
10	WILL PURSUE THROUGH THE OFFICE OF ADMINISTRATIVE LAW
11	A NEW SET OF REGULATIONS, INTERIM REGULATIONS, WHICH
12	WOULD LOOK AS FOLLOWS.
13	SO FIRST OF ALL, CIRM WOULD OWN ALL OF THE
14	CELL LINES. WE WOULD THEN THROUGH WHAT WE CALL A
15	DEPOSIT AGREEMENT HAVE THEM IN THE POSSESSION OF A
16	REPOSITORY THAT DISTRIBUTES THEM.
17	WITH RESPECT TO PUBLICATION, WE SIMPLY
18	JUST WANT THE ACKNOWLEDGEMENT OF CIRM'S FUNDING, AND
19	ALSO IT'S VERY IMPORTANT THAT THE ACTUAL NAME OF THE
20	REPOSITORY BE IDENTIFIED. SO WHEN THE RESEARCH IS
21	OUT THERE, PEOPLE KNOW WHERE TO FIND THE ACTUAL CELL
22	LINE.
23	I ALSO WANT TO HAVE A STATEMENT WITHIN
24	THESE INTERIM REGULATIONS, AND, AGAIN, THEY'RE IN
25	YOUR BINDER AND YOU CAN SEE THE ACTUAL LANGUAGE,
	203

1	THAT SAYS THE IP REGULATIONS DO NOT APPLY. BUT, OF
2	COURSE, THERE'S A PROVISION WITHIN THESE PROPOSED
3	REGULATIONS THAT STATE THE GRANTS ADMINISTRATION
4	POLICY WOULD APPLY AND SO TOO WOULD THE SCIENCE AND
5	MEDICAL ACCOUNTABILITY STANDARDS.
6	I DON'T WANT YOU TO THINK THAT THOSE ARE
7	THE ONLY WAYS THAT WE CAN CONTROL THIS RESOURCE.
8	THERE WILL BE A DEPOSIT AGREEMENT BETWEEN CIRM AND
9	THE REPOSITORY, AND THROUGH THAT WE WILL BE ABLE TO
10	NEGOTIATE THE TYPES OR THE LEVEL OF FEES THAT THEY
11	CHARGE RESEARCHERS. WE'LL BE ABLE TO ENSURE THAT
12	THERE'S FAVORABLE PRICING FOR CALIFORNIA RESEARCHERS
13	IN PARTICULAR. WE WILL BE ABLE TO INCLUDE
14	PROVISIONS BARRING THEM FROM EXCLUSIVELY LICENSING
15	THE LINES. WE MAY BE ABLE TO NEGOTIATE SOME
16	POSSIBLE REVENUE SHARING WITH THEM. I KNOW THAT
17	THERE ARE OTHER REPOSITORIES OUT THERE THAT HAVE OR
18	STARTING TO FIND THAT THEY CAN NEGOTIATE SOME
19	REVENUE SHARING AFTER A CERTAIN LEVEL IS MET. THE
20	MOST IMPORTANT THING IS THAT WE DON'T REACH TOO FAR
21	INTO THE REVENUE SUCH THAT THIS WILL NOT BE A
22	SELF-SUSTAINING OPERATION. THAT'S THE MOST
23	IMPORTANT ASPECT, SO WE DON'T WANT TO TIP THE
24	BALANCE IN THE WRONG DIRECTION.
25	AND, OF COURSE, WE WILL REQUIRE THEM TO BE
	204

	BARRISTERS' REPORTING SERVICE
1	IN COMPLIANCE WITH ALL PRIVACY LAWS, NOT JUST HIPAA.
2	SO THERE WILL BE ADEQUATE CONTROLS VIA CONTRACT AND
3	THEN, OF COURSE, BY THESE INTERIM SET OF
4	REGULATIONS.
5	WITH THAT SAID, WE ARE JUST REQUESTING
6	THAT THE BOARD APPROVE THOSE REGULATIONS. I THINK,
7	SCOTT, YOU HAD A SUGGESTION THAT THEY NOT BECOME
8	EFFECTIVE UNTIL DECEMBER OF THIS YEAR.
9	CHAIRMAN THOMAS: DO WE HEAR A MOTION TO
10	THAT EFFECT? MR. JUELSGAARD.
11	DR. JUELSGAARD: SO MOVED.
12	CHAIRMAN THOMAS: THANK YOU. DO WE HEAR A
13	SECOND?
14	MS. SAMUELSON: SECOND.
15	CHAIRMAN THOMAS: MULTIPLE SECONDS. JOAN
16	WE'LL GIVE THE SECOND TO.
17	MS. SAMUELSON: I WILL AND I HAVE A
18	CLARIFYING QUESTION.
19	CHAIRMAN THOMAS: YES.
20	MS. SAMUELSON: HOW IS THIS DIFFERENT, IF
21	AT ALL, FROM THE STATUS QUO IF THERE'S ANYTHING
22	COMPARABLE TO THIS? AND WHAT DO WE KNOW ABOUT
23	WHETHER THAT WOULD CREATE DISINCENTIVES TO THE
24	DEVELOPERS?
25	MS. BAUM: WHEN YOU REFER TO STATUS QUO,
	205

	BARRISTERS' REPORTING SERVICE
1	ARE YOU REFERRING TO THE WAY OTHER REPOSITORIES?
2	THAT'S WHAT I'M TRYING TO DO.
3	MS. SAMUELSON: THE OWNERSHIP RIGHTS.
4	MS. BAUM: WELL, THAT'S A VERY GOOD POINT,
5	AND I HAVE IT IN MY MEMO AND I FORGOT TO MENTION IT
6	HERE. WE ARE ALIGNING OURSELVES WITH THE WAY THAT
7	NIH AND IN PARTICULAR MAHENDRA RAO'S CENTER FOR
8	REGENERATIVE MEDICINE IS OPERATING. AND WE'VE
9	CONSULTED WITH THEM, AND THAT CENTER IS GOING TO OWN
10	THE LINES THAT THEY'RE PAYING TO BE DEVELOPED AS
11	WELL. SO WE'RE COMPLETELY ALIGNED OR TRYING TO BE
12	ALIGNED WITH BEST PRACTICES THAT WE KNOW OF.
13	AND HOW WILL THAT IMPACT? I DON'T THINK
14	THERE WILL BE ANY IMPACT AT ALL IN TERMS OF THE
15	RESEARCHERS' INTEREST IN ACCESSING THESE LINES
16	BECAUSE THIS IS PRETTY MUCH THE WAY IT WORKS ANYWAY.
17	THEY KNOW THAT THEY HAVE TO GO BACK IF THEY WANT A
18	COMMERCIAL RELATIONSHIP AND NEGOTIATE WITH THE OWNER
19	THAT PLACED THE SAMPLES OR THE CELL LINES IN THESE
20	REPOSITORIES ANYWAY. SO THEY'RE USED TO THAT.
21	CHAIRMAN THOMAS: FURTHER DISCUSSION?
22	COMMENTS FROM MEMBERS OF THE PUBLIC? HEARING NONE,
23	MR. HARRISON, RESTATE THE MOTION FOR A VOICE VOTE.
24	MR. HARRISON: THE MOTION IS TO APPROVE
25	THE INTERIM IPSC REGULATIONS WITH AN EFFECTIVE DATE
	206

	BARRISTERS' REPORTING SERVICE
1	OF DECEMBER 1, 2012.
2	CHAIRMAN THOMAS: ALL THOSE IN FAVOR
3	PLEASE SAY AYE. HOLD ON ONE SECOND. THAT WAS AN
4	AYE. VERY TRICKY, DR. FRIEDMAN. YOU WOULDN'T BE
5	GOOD AT AUCTIONS. ALL THOSE IN FAVOR PLEASE SAY
6	AYE. OPPOSED? ABSTENTIONS? POLLING ON THE PHONE,
7	MARIA.
8	MS. BONNEVILLE: DUANE ROTH.
9	MR. ROTH: YES.
10	MS. BONNEVILLE: SHLOMO MELMED.
11	DR. MELMED: YES.
12	CHAIRMAN THOMAS: UNANIMOUSLY APPROVED.
13	THANK YOU, ELONA. THANK YOU, SCOTT. THANK YOU,
14	MEMBERS OF THE IP AND INDUSTRY SUBCOMMITTEE ON THIS
15	ITEM. VERY EXCITING AS WE MOVE FORWARD IN BREAKING
16	NEW GROUND YET AGAIN.
17	MOVING ON TO THE NEXT ITEM, CONSIDERATION
18	OF RECOMMENDATION FROM THE FINANCE SUBCOMMITTEE
19	INCLUDING CIRM BUDGET AND THE FINANCE SUBCOMMITTEE
20	MISSION STATEMENT. WE'LL START WITH MR. GOLDBERG.
21	MR. GOLDBERG: THANK YOU, CHAIRMAN THOMAS.
22	SO WE'RE GOING TO HAVE A KUMBAYA MOMENT HERE AND
23	DISCUSS THE MISSION OF THE FINANCE SUBCOMMITTEE.
24	DR. PIZZO: MICHAEL, THIS COULD BE A
25	FIRST, THE MISSION OF THE FINANCE SUBCOMMITTEE.
	207

1	MR. GOLDBERG: SO IF YOU TURN TO ITEM NO.
2	11 IN YOUR BINDERS, THERE ARE JUST A COUPLE OF QUICK
3	MODIFICATIONS THAT HAVE BEEN PROPOSED BY OUR
4	SUBCOMMITTEE IN TERMS OF ITS MISSION STATEMENT. THE
5	FIRST IS THAT SINCE THE SUBCOMMITTEE, AS A MATTER OF
6	PRACTICE, WAS ALREADY REVIEWING THE BUDGET AND COST
7	CONTROL PROGRAMS, WE THOUGHT THAT SHOULD BE INCLUDED
8	IN THE MISSION STATEMENT.
9	SECONDLY, WE VOTED TO ENLARGE THE MISSION
10	OF THE INTELLECTUAL PROPERTY AND INDUSTRY
11	SUBCOMMITTEE TO INCORPORATE OVERSIGHT OF THE CIRM
12	LOAN PROGRAM. SO THAT HAD PREVIOUSLY BEEN WITHIN
13	THE SCOPE OF THE FINANCE SUBCOMMITTEE, AND THE
14	MISSION NEEDS TO BE MODIFIED SO IT REFLECTS THAT IT
15	NO LONGER SHOULD BE.
16	AND FINALLY, THE COMMITTEE WOULD LIKE TO
17	DESIGNATE THE VICE CHAIR OF THE SUBCOMMITTEE AS THE
18	CO-CHAIR OF THE SUBCOMMITTEE. IN THAT CONNECTION,
19	MY ABLE COLLEAGUE MARCY FEIT SHOULD RECEIVE, NOT
20	ONLY A PROMOTION, BUT A SALARY INCREASE.
21	MS. FEIT: THEY DID THAT WHEN I WASN'T IN
22	ATTENDANCE.
23	MR. GOLDBERG: SO WITH THAT, WE CAN OPEN
24	IT FOR DISCUSSION OR A MOTION.
25	DR. PIZZO: I WOULD RECOMMEND THAT WE
	208

	BARRISTERS' REPORTING SERVICE
1	INCREASE MARCY'S SALARY FROM ZERO BY 5 PERCENT OF
2	ZERO.
3	CHAIRMAN THOMAS: TAKE THAT AS A FRIENDLY
4	AMENDMENT. IS THERE A MOTION TO APPROVE THE MISSION
5	STATEMENT?
6	DR. JUELSGAARD: SO MOVED.
7	CHAIRMAN THOMAS: MR. JUELSGAARD.
8	DR. FRIEDMAN: SECOND.
9	CHAIRMAN THOMAS: SECONDED BY DR.
10	FRIEDMAN. ANY FURTHER DISCUSSION? COMMENTS FROM
11	MEMBERS OF THE PUBLIC. EXCUSE ME. HEARING NONE,
12	ANOTHER VOICE VOTE TO APPROVE THE MISSION STATEMENT.
13	ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED?
14	ABSTENTIONS? MARIA.
15	MS. BONNEVILLE: DUANE ROTH.
16	MR. ROTH: YES.
17	MS. BONNEVILLE: SHLOMO MELMED.
18	DR. MELMED: YES.
19	CHAIRMAN THOMAS: ANOTHER UNANIMOUS VOTE.
20	WE LIKE THOSE.
21	MR. GOLDBERG: CONGRATULATIONS, CO-CHAIR
22	FEIT.
23	CHAIRMAN THOMAS: SPEND THE RAISE VERY
24	WISELY.
25	OKAY. NOW WE PROCEED TO CONSIDERATION OF
	209

1	THE BUDGET FOR APPROVAL. TURN IT OVER TO MATT.
2	DR. PLUNKETT: THANK YOU. SO ON SLIDE 2,
3	FOR THOSE WHO ARE AT REMOTE SITES, WE HAVE THE GOALS
4	FOR THE COMING FISCAL YEAR FOR CIRM. AND THIS IS
5	THE FIRST TIME THAT WE'VE REALLY DIRECTLY COUPLED
6	ANNUAL GOALS FOR THE ORGANIZATION TO OUR BUDGETING
7	PROCESS. AND THE REASON FOR THIS IS WE WANT TO BE
8	ABLE FOR EVERY SINGLE LINE ITEM IN THE BUDGET TO BE
9	ABLE TO POINT BACK TO ONE OF OUR GOALS AND TALK
10	ABOUT HOW A PARTICULAR EXPENDITURE HELPS US ACHIEVE
11	ONE OF THESE VERY IMPORTANT THINGS THAT WE'RE TRYING
12	TO ACHIEVE IN THE COMING FISCAL YEAR.
13	I WON'T READ EVERY SINGLE WORD HERE, BUT
14	REALLY JUST WANT TO HIT THE HIGHLIGHTS. AND THAT'S
15	THAT WE'RE GOING TO CONTINUE TO BE GOOD STEWARDS OF
16	PUBLIC DOLLARS AS WE SEEK TO GET TWO OR MORE
17	PROGRAMS IN OUR PORTFOLIO WITH AN OPEN IND, ACHIEVE
18	\$50 MILLION IN NEW OUTSIDE FINANCIAL COMMITMENTS FOR
19	CIRM PROGRAMS, ENSURE THE FUNDING OF POTENTIALLY
20	HIGH IMPACT PROJECTS, EDUCATE AND ENGAGE THE
21	CALIFORNIA COMMUNITY, AND OPTIMIZE CIRM'S WORKFORCE,
22	STAFFING, AND PROCESSES IN LIGHT OF OUR 6-PERCENT
23	EXPENSE CAP.
24	SLIDE 3 IS A RECAP OF OUR PROCESS TO DATE.
25	AND I WOULD JUST LIKE TO REMIND EVERYBODY THAT THIS
	210

1	HAS BEEN BOTH A VERY EXTENSIVE AS WELL AS PUBLIC
2	PROCESS. WE DID PREVIEW THIS BUDGET WITH THE ICOC
3	AT OUR BOARD MEETING IN MARCH IN SACRAMENTO. WE DID
4	HAVE A VERY EXHAUSTIVE REVIEW OF THE BUDGET AT THE
5	APRIL FINANCE SUBCOMMITTEE MEETING, AND WE DID HAVE
6	SOME FURTHER INTERNAL REFINEMENT THROUGHOUT THE
7	MONTH OF APRIL, AND I WILL COMMENT ON A COUPLE OF
8	KEY CHANGES IN A COUPLE OF SLIDES DOWN THE ROAD.
9	ANOTHER THING WHICH I WOULD LIKE TO REMIND
10	THE ICOC MEMBERS OF IS THAT WE HAVE DONE A BIT OF A
11	REARRANGEMENT OF THE PRESENTATION OF THE BUDGET.
12	AND THAT'S TO REALLY HAVE SOME COST CENTERS, THE
13	COLUMNS, IN THE BUDGET REFLECT THE FUNCTIONAL AREAS
14	AND NOT REPORTING RELATIONSHIPS. AND YOU CAN SEE
15	THOSE LISTED ON THE LEFT-HAND SIDE OF THE SCREEN.
16	IN ADDITION, WE'VE TRIED TO MAKE FOR A
17	LITTLE BIT GREATER SPECIFICITY
18	MS. LANSING: HI. THIS IS SHERRY LANSING.
19	I JUST WANT YOU TO KNOW I'M NOW ONLINE. IS THAT
20	OKAY?
21	DR. PLUNKETT: WE CAN ALL HEAR YOU. THANK
22	YOU.
23	MS. LANSING: THANK YOU.
24	CHAIRMAN THOMAS: HI, SHERRY. WELCOME.
25	DR. PLUNKETT: ON THE RIGHT-HAND SIDE YOU
	211

1	CAN SEE THE ROWS WHICH WE BELIEVE GIVES GREATER
2	SPECIFICITY AND CLARITY FOR THE BUDGET.
3	ONE MORE POINT AS FAR AS THE BUDGET DETAIL
4	IS THAT THE ALLOCATIONS AGAINST OUR EXPENSE CAP,
5	GRANTS ADMINISTRATION, GENERAL AND ADMINISTRATIVE
6	AND LEGAL, ALL REMAIN UNCHANGED.
7	SO THIS IS ON SLIDE 6 IS THE ROLL-UP OF
8	THE FISCAL 12-13 BUDGET. AFTER I'M DONE WITH THIS
9	SLIDE, THIS WILL BE A GOOD POINT TO PAUSE FOR
10	DISCUSSION AND QUESTIONS. I WOULD LIKE TO REMIND
11	EACH OF THE MEMBERS OF THE ICOC THAT THERE IS
12	DETAILED LINE ITEM BACKUP THAT WAS PROVIDED TO YOU
13	IN THE BOARD PACKAGE. I CAN CERTAINLY FIELD
14	QUESTIONS ON THAT, BUT WON'T GO THROUGH THAT IN
15	SPECIFIC DETAIL UNLESS REQUESTED.
16	I WOULD LIKE TO HIGHLIGHT TWO CHANGES
17	WHICH WE DID MAKE BETWEEN THE MARCH BOARD MEETING
18	AND TODAY. IN MARCH YOU RECALL THAT WE DID HAVE A
19	PROPOSAL TO ADD AN ADDITIONAL FTE IN THE LEGAL GROUP
20	TO DO CERTAIN CONTRACTS AND INTELLECTUAL
21	PROPERTY-RELATED WORK. AFTER SOME EXTENSIVE REVIEW
22	AND DISCUSSION, WE'VE DECIDED NOT TO ADD THAT FTE TO
23	THE LEGAL GROUP AND, INSTEAD, REPLACE SOME AMOUNT OF
24	THAT WORK WITH SOME EXTERNAL SERVICES.
25	AND THE OTHER THING I WOULD LIKE TO
	212

1	COMMENT ON IS LAST WEEK CALPERS DETERMINED THAT THEY
2	NEEDED TO RAISE THE EMPLOYER CONTRIBUTION FROM 18.2
3	PERCENT OF GROSS SALARY TO 19.7 PERCENT OF GROSS
4	SALARY. THAT WAS AN \$89,000 IMPACT IN OUR EMPLOYEE
5	EXPENSES, AND THAT WAS WHAT GENERATED THE GENESIS OF
6	THE UPDATE TO THE BUDGET MATERIALS WHICH YOU GOT AT
7	THE END OF LAST WEEK.
8	SO I THINK I CAN JUST PAUSE AT THIS POINT
9	AND SEE IF THERE'S ANY QUESTIONS ABOUT ANY OF THE
10	EITHER BIG PICTURE DETAIL, HOW THINGS ARE MOVING
11	OVERALL, OR ANY OF THE SPECIFIC LINE ITEMS WHICH YOU
12	HAVE ALREADY RECEIVED.
13	SO OUR TRAVEL AND EMPLOYEE OUT-OF-POCKET
14	BUDGET FOR THE COMING FISCAL YEAR IS \$527,000. THIS
15	IS IN LINE WITH THIS YEAR'S BUDGET OF \$520,000 IN
16	AGGREGATE. I'LL NOTE THAT THIS ALSO INCLUDES AN
17	OUT-OF-STATE TRAVEL BUDGET OF 298,000. YOU WOULD
18	SEE THAT MANY OF THE LINE ITEM EXPENSES YEAR ON YEAR
19	DID GO DOWN ON A DEPARTMENTAL LEVEL. AND THE THING
20	THAT I WOULD LIKE TO EMPHASIZE HERE IS THE TRAVEL IS
21	REALLY DIRECTLY COUPLED TO THE \$50 MILLION IN
22	FINANCIAL LEVERAGE WHICH WE'RE SEEKING TO ACHIEVE
23	OVER THE COMING FISCAL YEAR.
24	SO THIS REFLECTS EVERYTHING FROM WORK
25	WHICH ELONA AND I ARE DOING WITH THE INVESTMENT AND
	213

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PHARMACEUTICAL COMMITTEE COMMUNITY, WORK WHICH ALAN
2	IS DOING WITH POTENTIAL COLLABORATIVE FUNDING
3	PARTNERS, AS WELL AS WORK WITH THE REGULATORY
4	AGENCIES AND OTHERS IN WASHINGTON, D.C., WHICH ELLEN
5	AND OTHERS ARE SEEKING TO ACHIEVE. AND, OF COURSE,
6	THERE'S ALL OF THE IN-STATE WORK THAT WE DO IN TERMS
7	OF AUDITS OF OUR GRANTEES, SITE VISITS, COMPLIANCE
8	VISITS, BOARD MEETINGS FOR STAFF MEMBERS TO TRAVEL
9	AND SO FORTH.
10	DOES THAT ANSWER THE QUESTION?
11	SO THE OTHER THING ON SLIDE 7, THEN, JUST
12	MOVING ON, IS TO TOUCH BRIEFLY UPON THE EXPENSE
13	FORECASTING. AND AS WE HAD A DISCUSSION ON THE
14	MOSS-ADAMS REPORT THIS MORNING, WE CERTAINLY ARE
15	LOOKING AT BOTH SIDES OF THE COIN HERE. AND IN
16	TERMS OF FISCAL PRUDENCE, IT'S VERY IMPORTANT FOR US
17	TO MAKE SURE THAT THROUGHOUT THE ENTIRE LIFE OF THE
18	AGENCY THAT WE STAY WITHIN OUR EXPENSE CAPS.
19	WHAT WE'VE DONE IN TERMS OF MODELING THIS
20	OUT IS PROJECTING MODEST EXPENSE GROWTH THROUGH JUNE
21	2017 AND THEN ANNUAL DECREASES THROUGH JUNE 2022.
22	AND AS WE'VE RUN THESE PROJECTIONS, WE HAVE A LIST
23	OF ABOUT 20 WHAT I WOULD CALL IRREGULAR EXPENSES.
24	AS JUST ONE EXAMPLE, WE'VE ADDED IN RENT OF A
25	MILLION DOLLARS A YEAR STARTING NOVEMBER 2015. AND
	214
	۷

1	ALL OF THOSE DIFFERENT ADJUSTMENTS WE'VE USED TO
2	CREATE A LONG-TERM EXPENSE FORECAST FOR THE
3	ORGANIZATION.
4	ON SLIDE 8, AND I APOLOGIZE THAT THE
5	COLORS HERE APPEAR A LITTLE BIT WASHED OUT, WHAT YOU
6	CAN SEE IS THE SOLID AND THE DASHED LINES ARE THE
7	SOLID LINES ARE THE CUMULATIVE EXPENSES FOR THE
8	ORGANIZATION. THE DASHED LINES ARE THE STATUTORY
9	EXPENSE CAPS CONTAINED IN PROPOSITION 71. AND THE
10	BARS WITH THE RIGHT-HAND AXIS ARE THE ANNUAL
11	EXPENSES FOR EACH OF THE TWO EXPENSE CATEGORIES
12	WHICH WE TRACK AGAINST THE EXPENSE CAPS.
13	AND THE GOOD NEWS FOR EACH OF THESE IS
14	THAT THEY'RE BOTH \$90 MILLION BASED ON THE
15	PROJECTIONS HERE. THIS IS SOMETHING THAT I WOULD
16	CHARACTERIZE AS PRECISE, BUT NOT NECESSARILY HIGHLY
17	ACCURATE. IT MAY BE A LITTLE MORE THAN THAT; IT MAY
18	BE A LITTLE LESS THAN THAT OVER TIME. AND WHAT
19	WE'LL CONTINUE TO DO EVERY YEAR IS MONITOR THESE
20	PROJECTIONS AND MAKE SURE THAT WE STAY WITHIN THESE
21	EXPENSE CAPS.
22	SO ARE THERE ANY QUESTIONS ABOUT TRACKING
23	THE LONG-TERM EXPENSES AND THE MODELING?
24	MR. GOLDBERG: I JUST WANT TO THANK YOU,
25	MATT, FOR YOUR EXTENSIVE WORK ON THIS AND THE
	215

1	COORDINATION OF YOUR TEAM AND THE COOPERATION YOU
2	GOT FROM THE ENTIRE STAFF IN BEING ABLE TO BRING A
3	BUDGET TOGETHER AS THOUGHTFULLY AND IN AS TIMELY A
4	MANNER AS YOU WERE ABLE TO DO IT. CERTAINLY SET A
5	NEW HIGH BAR FOR US IN TERMS OF WHAT WE'VE BEEN
6	ACCUSTOMED TO. AND THANK YOU, ALAN, FOR ALL YOUR
7	SUPPORT IN BEING ABLE TO ACCOMMODATE THAT FOR US.
8	CHAIRMAN THOMAS: MARCY FEIT.
9	MS. FEIT: I ALSO WANT TO ECHO MICHAEL'S
10	COMMENTS TO YOU, MATT. MATT KEEPS US UPDATED
11	ALMOST, IF NOT DAILY, WEEKLY ON ANY FINANCIAL ISSUES
12	OR CONCERNS OR UPDATES THAT ARE NECESSARY. AND IT'S
13	REALLY NICE TO HAVE THAT COMMUNICATION. HE DOES A
14	GREAT JOB. SO THANK YOU, MATT, FOR THAT.
15	DR. PLUNKETT: THANK YOU. THIS WAS TRULY
16	A COLLABORATIVE EFFORT OF HONESTLY EVERY PERSON IN
17	THE ORGANIZATION.
18	MR. SERRANO-SEWELL: SO AM I FORGIVE ME
19	IF I'M LOOKING AT THE WRONG THING. YOU CAN KIND OF
20	SEE IT FROM HERE. SO EACH AND THIS IS THE YOU
21	SEE I'M LOOKING AT THE SUMMARY PAGE. SO FOR THE
22	TRAVEL AND OUT-OF-POCKET, THAT'S EACH DIVISION
23	WITHIN CIRM?
24	DR. PLUNKETT: THAT'S RIGHT.
25	MR. SERRANO-SEWELL: OKAY. SO, FOR
	216

	BARRISTERS' REPORTING SERVICE
1	EXAMPLE, WITHIN THAT LINE ITEM, SCIENCE RESEARCH IS
2	86.
3	DR. PLUNKETT: CORRECT.
4	MR. SERRANO-SEWELL: 86,000, PROBABLY.
5	DR. PLUNKETT: CORRECT.
6	MR. SERRANO-SEWELL: OKAY. SO I SEE IN
7	LEGAL IS 80,000.
8	DR. PLUNKETT: CORRECT.
9	MR. SERRANO-SEWELL: WHAT WAS THEIR LAST
10	YEAR TRAVEL BUDGET? OR MORE TO THE POINT, I'M JUST
11	SPEAKING OUT LOUD NOW, AND IT'S MAYBE BECAUSE OUR
12	LEGAL DEPARTMENT, WE DON'T GET TO GO ON AS MANY
13	TRIPS AS WE'D LIKE, BUT WHAT IS THE JUSTIFICATION
14	FOR THAT NUMBER? IT SEEMS HIGH TO ME.
15	DR. PLUNKETT: SURE. SO FOR THE LEGAL
16	TRAVEL BUDGET NUMBER, SO I THINK, AS EVERYBODY
17	KNOWS, ELONA'S POSITION IS VICE PRESIDENT I'M
18	SORRY GENERAL COUNSEL AND VICE PRESIDENT OF THE
19	BUSINESS DEVELOPMENT. AND ELONA AND I EACH HAVE A
20	NUMBER OF TRIPS PLANNED BOTH SEPARATELY AND TOGETHER
21	OVER THE COMING YEAR TO BIOTECHNOLOGY AND
22	PHARMACEUTICAL INDUSTRY MEETINGS WHERE WE INTEND TO
23	MEET WITH BOTH LARGE AND MIDSIZE COMPANIES WHO COULD
24	POTENTIALLY OFFER CO-FUNDING FOR CIRM-FUNDED
25	RESEARCH.

217

1	IN ADDITION, ELONA HAS BEEN WORKING QUITE
2	EXTENSIVELY WITH THE ALLIANCE FOR REGENERATIVE
3	MEDICINE ON REGULATORY AND OTHER MATTERS THAT ARE
4	VERY IMPORTANT TO OUR GRANTEES IN TERMS OF
5	CLARIFYING AND STREAMLINING THE REGULATORY PATHWAY.
6	AND SO THERE ARE A NUMBER OF TRIPS TO THE
7	WASHINGTON, D.C. AREA WITH A REGULATORY FDA FOCUS.
8	CHAIRMAN THOMAS: DO WE HAVE A MOTION ON
9	THE TABLE TO APPROVE?
10	DR. FRIEDMAN: SO MOVED.
11	CHAIRMAN THOMAS: MOVED BY DR. FRIEDMAN.
12	DR. VUORI: SECOND.
13	CHAIRMAN THOMAS: SECONDED BY DR. VUORI.
14	ANY FURTHER DISCUSSION BY MEMBERS OF THE BOARD? ANY
15	PUBLIC COMMENT? MR. HARRISON, ANOTHER VOICE VOTE.
16	MR. HARRISON: CORRECT. WITH ROLL CALL
17	FOR THOSE ON THE PHONE.
18	CHAIRMAN THOMAS: THANK YOU. ALL THOSE IN
19	FAVOR OF THIS BUDGET FOR FISCAL 12-13 PLEASE SAY
20	AYE. OPPOSED? ABSTENTIONS? MARIA.
21	MS. BONNEVILLE: DUANE ROTH.
22	MR. ROTH: YES.
23	MS. BONNEVILLE: SHLOMO MELMED.
24	DR. MELMED: YES.
25	MS. BONNEVILLE: SHERRY LANSING.
	21.0
	218

	BARRISTERS' REPORTING SERVICE
1	MS. LANSING: YES.
2	MS. BONNEVILLE: THANK YOU.
3	CHAIRMAN THOMAS: OKAY. ANOTHER UNANIMOUS
4	VOTE. THANK YOU VERY MUCH, MATT, FOR CONSIDERABLE
5	EFFORT AND HARD WORK.
6	OKAY. THE NEXT ITEM WHICH WILL BE THE, I
7	BELIEVE, THE FINAL INSTALLMENT OF THE SAGA IS DR.
8	FEIGAL PRESENTING FOR YOUR CONSIDERATION THE FINAL
9	VERSION OF THE STRATEGIC PLAN.
10	DR. FEIGAL: HI. THANKS VERY MUCH. AND
11	THE FIRST THING I WANT TO THANK IS REALLY THE
12	TREMENDOUS NUMBER OF INPUTS THAT WE RECEIVED FROM
13	PATIENTS, FROM PATIENT ADVOCATES, FROM COMPANIES,
14	FROM RESEARCHERS, CLINICIANS, FROM THE CIRM STAFF,
15	FROM THE LEADERSHIP LEVEL TO PEOPLE WORKING REALLY
16	IN THE TRENCHES TO GET THE WORK DONE, AND
17	PARTICULARLY ALAN TROUNSON, PAT OLSON, ELONA BAUM,
18	MATT PLUNKETT, AND WITH PARTICULAR HELP, I THINK, IN
19	TERMS OF PUTTING TOGETHER SOME OF THESE APPENDICES
20	FROM KELLY SHEPHERD AND FROM RAUL THAKKAR. IN
21	ADDITION, I REALLY WANT TO THANK THE BOARD FOR ALL
22	THEIR INPUTS AND PARTICULARLY UNDER THE LEADERSHIP
23	OF THE CHAIRMAN, JONATHAN THOMAS.
24	SO THIS IS A LIVING DOCUMENT, AND THIS
25	WILL GUIDE ALL OF OUR WORK. AND THIS PLAN THAT
	219

1	WE'RE PUTTING TOGETHER NOW, CIRM'S ORIGINAL
2	STRATEGIC PLAN WAS PUT TOGETHER IN 2006. IT WAS
3	UPDATED IN 2009-2010 IN PREPARATION FOR A PANEL OF
4	EXPERTS THAT CAME TO REVIEW OUR AGENCY. SO THIS
5	2012 UPDATE REALLY REFLECTS THE RECOMMENDATIONS FROM
6	THAT PANEL OF EXTERNAL REVIEW EXPERTS FROM 2010. IT
7	ALSO REFLECTS OTHER SHIFTS IN THE SCIENTIFIC FIELD
8	AND REFLECTS THE INPUTS FROM ALL OF OUR
9	STAKEHOLDERS, PATIENTS, INDUSTRY, RESEARCHERS,
10	CLINICIANS, AND THIS BOARD.
11	WE'VE HAD A LOT OF DIFFERENT INPUTS WHICH
12	I'LL JUST VERY QUICKLY SUMMARIZE HERE. INTERNALLY
13	WE HAD A CIRM SENIOR STAFF RETREAT AND A SCIENCE
14	TEAM RETREAT THAT STARTED BACK IN AUGUST OF 2011. I
15	DON'T MEAN IT STARTED BACK IN 2011. WE HAD A
16	RETREAT BACK THEN TO HAVE THAT KIND OF DISCUSSION.
17	WE'VE HAD UPDATES AT EACH OF THE ICOC BOARD MEETINGS
18	SINCE AUGUST OF 2011. SO WE'VE WALKED YOU THROUGH
19	IT STEP BY STEP AT EACH BOARD MEETING. WE MET WITH
20	THE STEM CELL RESEARCH LEADERS IN SEPTEMBER OF 2011.
21	AND IN ADDITION, WE HAD A VARIETY OF PUBLIC OR
22	PRIVATE TYPE OF MEETINGS FROM SEPTEMBER THROUGH
23	DECEMBER OF 2011 WITH INDUSTRY, WITH PATIENT
24	ADVOCATES, WITH ALL OF OUR COLLABORATIVE FUNDING
25	PARTNERS, WITH THE CLINICAL DEVELOPMENT ADVISORS.
	220
	220

1	THOSE ARE THE PANEL OF ADVISORS THAT HELP GIVE US
2	INPUT ON OUR DISEASE TEAM RESEARCH AWARDS. WITH
3	PROFESSIONAL SOCIETIES AND WITH THE ALLIANCE FOR
4	REGENERATIVE MEDICINE.
5	IN ADDITION, WE PROVIDED ALL OF THE
6	STRATEGIC PLAN UPDATES WITH THE INSTITUTE OF
7	MEDICINE REVIEW COMMITTEE WHO IS REVIEWING CIRM AND
8	WILL COME UP WITH A FINAL REPORT AT THE END OF THIS
9	CALENDAR YEAR.
10	WE USED A THREE-STEP APPROACH TO REVISE
11	THIS STRATEGIC PLAN FOR 2012. AS MENTIONED, IT
12	STARTED WITH AN INTERNAL DISCUSSION OF WHERE WE'VE
13	BEEN, WHERE WE ARE, WHERE WE WANT TO GO, WHY WE WANT
14	TO GET THERE, AND HOW ARE WE GOING TO DO IT.
15	WE SOUGHT IN STEP TWO ALL THE VARIETY OF
16	INPUTS FROM THE BOARD, FROM THE PUBLIC, THE
17	INDUSTRY, AND FROM PATIENTS. AND WE'RE NOW AT THE
18	FINAL STEP, STEP 3, WHERE WE'RE FOCUSING ON THIS
19	FINAL STRATEGIC PLAN FOR YOUR CONSIDERATION.
20	IT STARTS WITH A MISSION AND A VISION. WE
21	HAVE A VERY AMBITIOUS MISSION, AND WE HAVE A VERY
22	CHALLENGING MISSION BECAUSE THERE'S A TIME URGENCY
23	AND A TIMELINE FOR IT. SO WE'RE REALLY HERE TO
24	SUPPORT AND ADVANCE STEM CELL RESEARCH AND
25	REGENERATIVE MEDICINE. WE'RE REALLY HERE TO ADVANCE
	221

THAT SCIENCE TO THE DISCOVERY AND THE DEVELOPMENT OF
 CURES, THERAPIES, THE DIAGNOSTICS, AND THE RESEARCH
 TECHNOLOGIES THAT CAN HELP PATIENTS. SO AT THE END
 OF THE DAY AND AT THE BEGINNING OF THE DAY, WE'RE
 HERE TO ACTUALLY DEVELOP THERAPIES AND POTENTIAL
 CURES FOR PATIENTS.

7 THE FIRST STAGE OF CIRM WAS REALLY SET IN EXPLORING THE FIELD. WE HAD TO CULTIVATE THE FIELD. 8 9 WE HAD TO BRING IN THE RESEARCH LEADERSHIP. WE 10 ACTUALLY HAD TO PHYSICALLY BUILD -- WE FUNDED THE 11 BUILDING OF THESE STEM CELL FACILITIES. AND IN 12 ADDITION, SEEDED THE FIELD WITH RESEARCH WITH OUR 13 FUNDING INITIATIVES. SO THIS WAS REALLY AN 14 EXPLORATION PHASE AND TO ESTABLISH THAT FOUNDATION 15 FOR LEADERSHIP IN STEM CELL RESEARCH IN THE FIELD. 16 THE NEXT FIVE YEARS, WHICH WE'RE IN NOW, 17 IS REALLY A PERIOD THAT WE BELIEVE SHOULD BE ONE OF MORE FOCUS WHERE WE REALLY HAVE A TIME OF 18 19 PRIORITIZING OUR PROJECTS AND INVESTMENT. WE'RE NOW 20 AT A STAGE OF MATURATION AND SOPHISTICATION OF THE STEM CELL FIELD WHERE WE'RE ABLE TO DRIVE AT LEAST A 21 22 COMPONENT OF THE SCIENCE INTO CLINICAL TRIALS TO 23 GENERATE SOME PRELIMINARY EVIDENCE OF THERAPEUTIC 24 BENEFIT. IT'S ALSO A TIME OF REALLY FORGING NEW AND 25 STRONGER PARTNERSHIPS WITH PATIENT ADVOCATES, WITH

222

1	INDUSTRY, WITH DIFFERENT SCIENTIFIC DISCIPLINES BOTH
2	WITHIN CALIFORNIA, ACROSS THE UNITED STATES, AND
3	INTERNATIONALLY.
4	IN ADDITION, WE HAVE A LOT OF
5	COLLABORATIONS AND COOPERATION WITH PROFESSIONAL
6	SOCIETIES, WITH DIFFERENT ALLIANCES, AND ALSO WITH
7	THE FOOD AND DRUG ADMINISTRATION BECAUSE WE REALLY
8	NEED TO HELP FORGE THAT PATHWAY FOR THIS TYPE OF
9	INNOVATIVE TECHNOLOGY SO THAT IT REALLY CAN GET INTO
10	THE CLINIC. SO WE'RE NOT JUST A FUNDING AGENCY
11	ALONE. WE ALSO DO A LOT OF WORK IN PARALLEL TO
12	ESTABLISH THESE TYPES OF INTERACTIONS AND
13	RELATIONSHIPS TO HELP THE FIELD MOVE FORWARD.
14	AND WE'RE DOING ALL OF THIS SO THAT BY
15	2017 AND BEYOND WE CAN REALLY FACILITATE THE
16	COMMERCIALIZATION OF THESE THERAPIES. WE KNOW THAT
17	WE'RE NOT GOING TO DO IT ALONE. WE'RE NOT GOING TO
18	COMMERCIALIZE THE THERAPIES. THAT'S WHY WE HAVE TO
19	SET UP THESE COLLABORATIONS AND INTERACTIONS. WE
20	WANT TO ADVANCE THESE THERAPIES TO PATIENTS FROM
21	2017 AND BEYOND AND ALSO TO ENABLE A BUSINESS MODEL
22	SO THAT THESE STEM CELL COMPANIES AND DIFFERENT
23	AGENCIES THAT ARE GOING TO BE SUPPORTING THESE
24	THERAPIES CAN EXIST AND BE VIABLE.
25	SO WE DEVELOPED OBJECTIVES AND ALSO THE
	223

1	SINGLEMOST IMPORTANT KEY OUTCOMES OVER THE NEXT FIVE
2	YEARS. AND THESE OBJECTIVES AND OUTCOMES ALIGN WITH
3	OUR MISSION. AND WE DIVIDED THESE INTO FOUR
4	CATEGORIES: SCIENTIFIC, CLINICAL, ECONOMIC, AND
5	COMMUNITY.
6	UNDER SCIENTIFIC, THE MAJOR OBJECTIVE BY
7	2017 IS REALLY TO ACCELERATE THE UNDERSTANDING OF
8	STEM CELL SCIENCE AND ITS APPLICATION SO THAT WE
9	HAVE A BETTER UNDERSTANDING OF HUMAN DISEASES AND
10	INJURY WITH THE SINGLEMOST IMPORTANT KEY OUTCOME
11	SCIENTIFICALLY IS TO ACHIEVE TRANSFORMATIVE RESEARCH
12	DISCOVERIES. SOME OF OUR WORK MAY BE INCREMENTAL,
13	BUT WE THINK WHAT WE REALLY NEED TO DO IS ACHIEVE
14	SOME TRANSFORMATIVE RESEARCH ADVANCEMENT.
15	UNDER CLINICAL, OVER THE NEXT FIVE YEARS,
16	WE'LL ADVANCE STEM CELL SCIENCE INTO CLINICAL TRIALS
17	WITH THE PURPOSE OF ACHIEVING EVIDENCE OF
18	THERAPEUTIC BENEFIT FOR PATIENTS WITH OUR KEY MOST
19	IMPORTANT OUTCOME TO ACHIEVE CLINICAL PROOF OF
20	CONCEPT FOR STEM CELL THERAPIES. DO THESE WORK IS
21	REALLY OUR BIG QUESTION. CAN WE ESTABLISH SOME OF
22	THAT PRELIMINARY EVIDENCE TO SHOW THAT?
23	ECONOMICALLY, WE ARE GOING TO BE DRIVING
24	ECONOMIC DEVELOPMENT FOR CALIFORNIA FROM THE STEM
25	CELL SCIENCE AND FROM THE THERAPIES THAT WE'RE
	224
	224

1	PUTTING OUT THERE. SOME OF THIS COULD BE REALIZED
2	WITHIN THE NEXT FIVE YEARS. PROBABLY MOST OF IT IS
3	WELL BEYOND THE NEXT FIVE YEARS. THE BIGGEST SINGLE
4	KEY OUTCOME WILL BE ONE OF LEVERAGING. CIRM HAS 3
5	BILLION WITHIN ITS DOMAIN TO WORK WITH. ALTHOUGH
6	THAT SOUNDS LIKE A VERY LARGE AMOUNT OF MONEY AND IT
7	IS, WE KNOW THAT MUCH MORE IS NEEDED TO REALLY MAKE
8	IT COME TO FRUITION. AND WHAT WE'RE REALLY TRYING
9	TO DO ECONOMICALLY IS TO LEVERAGE, TO ENTICE, TO
10	MULTIPLY THAT FUNDING FROM OTHERS OUTSIDE OF CIRM,
11	WHETHER IT BE FROM PRIVATE DONORS, VENTURE
12	CAPITALISTS, INDUSTRY, MATCHING FUNDS FROM
13	INSTITUTIONS, BUT REALLY LEVERAGE OUR INVESTMENT.
14	AND FOR THE COMMUNITY, TO MAINTAIN
15	CALIFORNIA AS THE WORLD STEM CELL LEADER SO THAT THE
16	COMMUNITY RECOGNIZES CALIFORNIA AS WELL AS IT HAVING
17	GLOBAL RECOGNITION AS THE STEM CELL STATE.
18	THESE ARE OUR STRATEGIES TO ACHIEVE OUR
19	OBJECTIVES AND GOALS. THEY'RE SET BY THE DIFFERENT
20	BINS THAT I'VE JUST OUTLINED: SCIENTIFIC, CLINICAL,
21	ECONOMIC, AND COMMUNITY, AND JUST CLEARLY TALKS
22	ABOUT WHAT OUR STRATEGIES ARE.
23	SCIENTIFICALLY WE KNOW WE'RE GOING TO NEED
24	TO CONTINUE THAT ENGINE OF DISCOVERY. WE'RE GOING
25	TO CONTINUE TO INVEST IN BASIC AND FUNDAMENTAL
	225

1	RESEARCH. WE KNOW WE NEED TO CONTINUE TO CREATE A
2	COLLABORATIVE RESEARCH COMMUNITY THAT ENHANCES
3	CALIFORNIA'S LEADERSHIP. AND WE KNOW THAT WE NEED
4	TO THINK ABOUT OUR FUNDING STRATEGY AND HOW TO
5	REALIGN OUR FUNDING PROGRAMS, OUR REVIEW, AND OUR
6	DECISION-MAKING WITH OUR STRATEGIC OBJECTIVES.
7	UNDER CLINICAL, WE'RE GOING TO HAVE TO
8	THINK ABOUT ARE THERE SOME NEAR-TERM OPPORTUNITIES
9	PERHAPS IN PARTICULAR TYPES OF DISEASES OR INJURIES
10	THAT WE MAY NEED TO BE THINKING ABOUT. IN THE
11	PREVIOUS FIVE YEARS, WE'VE BEEN VERY EXPLORATORY.
12	SHOULD WE NOW BE THINKING PERHAPS OF SOME MORE
13	SPECIFIC TYPES OF OPPORTUNITIES BASED ON EITHER THE
14	TECHNOLOGY OR THE DISEASE OR THE INJURY TO REALLY
15	EXPAND OUR COLLABORATIVE EFFORTS, TO REALLY, AS I
16	SAID, REALLY FOSTER DEVELOPING THAT REGULATORY PATH
17	FOR STEM CELL THERAPIES, AND TO HAVE PLANS IN PLACE
18	TO REALLY BOOST THE BIOTECHNOLOGY SECTOR IN
19	CALIFORNIA.
20	ONCE AGAIN, THIS IS GOING TO TAKE FOCUS,
21	PRIORITIZATION, AND EVALUATION SO THAT WE'RE MOVING
22	THE MOST PROMISING RESEARCH PROJECTS, PROGRAMS
23	FORWARD, AND THAT THIS IS GOING TO TAKE SOME VERY
24	HARD DECISION-MAKING FROM US INTERNALLY, FROM OUR
25	BOARD, FROM OUR GRANTS REVIEWERS, AND TO REALLY
	226

1	ENHANCE OUR INTERACTIONS WITH PATIENTS AND WITH
2	ADVOCATES.
3	ECONOMICALLY I THINK THE BIG KEY HERE, AS
4	I SAID, IS STRATEGIES TO IMPROVE OUR LEVERAGING OF
5	CIRM'S INVESTMENT. AND IN TERMS OF THE COMMUNITY,
6	IT'S REALLY PUTTING OUT STRATEGIES THAT WE'RE MORE
7	COMMUNICATING THE VALUE PROPOSITION OF CIRM AND OF
8	THE STEM CELL FIELD, WHY PEOPLE SHOULD CARE ABOUT
9	IT, AND REALLY CREATE AN AWARENESS AMONG
10	STAKEHOLDERS OF CIRM'S ROLE IN MAKING CALIFORNIA A
11	LEADER IN THE FIELD.
12	THESE ARE SOME OF THE TANGIBLE ONE-YEAR
13	GOALS THAT WE ARE SETTING OUT TO ACHIEVE BY JULY OF
14	2013, SO APPROXIMATELY A YEAR FROM NOW. SOME OF
15	THESE ARE QUALITATIVE, SOME OF THESE ARE
16	QUANTITATIVE. IT'S A MIX. BUT WHAT WE TRIED TO DO
17	IS HAVE A GOAL THAT ADDRESSES EACH OF THE BINS I'VE
18	JUST GONE THROUGH: SCIENTIFIC, CLINICAL, ECONOMIC,
19	AND COMMUNITY.
20	SO THE FIRST ONE HERE IS THAT WE WILL HAVE
21	WITHIN THE NEXT YEAR AT LEAST TWO PROGRAMS WITHIN
22	OUR PORTFOLIO THAT WILL HAVE AN APPROVED
23	INVESTIGATIONAL NEW DRUG FILED WITH THE U.S. FOOD
24	AND DRUG ADMINISTRATION TO ENTER HUMAN CLINICAL
25	TRIALS. WITHIN THE NEXT YEAR WE WILL HAVE ACHIEVED
	227

1	50 MILLION IN NEW OUTSIDE FINANCIAL COMMITMENT.
2	THIS COULD COME FROM COLLABORATIVE FUNDING PARTNERS,
3	FROM INDUSTRY, VENTURE CAPITALISTS, OR MATCHING
4	FUNDS FROM INSTITUTIONS. THIRDLY, THAT WE WILL HAVE
5	PRIORITIZED OUR SOLICITATIONS SO THAT WE HAVE A
6	HIGHER LIKELIHOOD OF ENSURING THAT POTENTIALLY HIGH
7	IMPACT PROJECTS THAT COULD RESULT IN TRANSFORMATIVE
8	RESEARCH ARE FUNDED. AND THAT WE WILL STRENGTHEN
9	THE EDUCATION EFFORTS AND MAKE A STRONGER EFFORT TO
10	ENGAGE THE CALIFORNIA COMMUNITY IN CIRM'S MISSION
11	AND ACHIEVEMENTS AND, IN PART, DOING THIS BY
12	INCREASING THE NUMBER OF MONTHLY ONLINE ENGAGEMENTS
13	FROM WHAT WE ARE NOW TO A LARGER NUMBER.
14	AND AS YOU HEARD EARLIER, WE'RE RAMPING UP
15	SOME THINGS, BUT THEN WE NEED TO KEEP IN MIND THE
16	EVENTUALITIES PERHAPS OF AT LEAST THE CURRENT
17	SITUATION WITH CIRM ENDING AT SOME POINT IN THE
18	FUTURE HOW TO OPTIMIZE OUR WORKFORCE, STAFFING, AND
19	PROCESSES SO THAT WE CAN MEET THE CHANGING
20	PRIORITIES, BUT STILL STAY WITHIN THE 6-PERCENT
21	CEILING.
22	THOSE ARE OUR ONE-YEAR GOALS FOR NEXT
23	YEAR. OUR FIVE-YEAR GOALS FOR JULY OF 2017, THERE'S
24	TEN OF THEM. AND ONCE AGAIN, THEY FOCUS ON THE
25	SCIENTIFIC, THE CLINICAL, THE ECONOMIC, AND THE
	228

Г

1	COMMUNITY.
2	SO THE FIRST HERE IS THINKING ABOUT THE
3	FACTORS REGULATING THE SELF-RENEWAL AND
4	TUMOR-CAUSING POTENTIAL OF STEM CELLS AND THEIR
5	DERIVATIVES AND THAT THEY WILL BE IDENTIFIED AND
6	CHARACTERIZED. IN FIVE YEARS WE'LL HAVE A MORE
7	THOROUGH DESCRIPTION OF THE STEPS OF DIFFERENTIATION
8	THAT LEAD TO THE PRODUCTION OF THE CRITICAL CELLS IN
9	THE BODY THAT ARE NEEDED FOR TRANSPLANTATION. THAT
10	WE WILL HAVE FUNDED NEW APPROACHES FOR ENSURING
11	THERE CAN BE SUCCESSFUL ALLOGENEIC CELL
12	TRANSPLANTATION IN CLINICAL DEVELOPMENT. THAT WE
13	WILL HAVE ESTABLISHED PROOF OF PRINCIPLE IN
14	PRECLINICAL ANIMAL MODELS THIS IS A CRITICAL STEP
15	IN TERMS OF MOVING FORWARD INTO HUMANS IN
16	PRECLINICAL ANIMAL MODELS FOR THE TREATMENT OF MORE
17	THAN TEN DISEASES. AND IN ADDITION TO ANIMAL
18	MODELS, WE'RE WORKING ON THE NEW TECHNOLOGY WITH
19	DISEASE IN THE DISH AND THE IPS STEM CELL-BASED
20	TECHNOLOGY WHERE WE'LL CREATE DISEASE-SPECIFIC CELL
21	LINES FOR 20 TO 30 DIFFERENT DISEASES AND USE THEM
22	TO GAIN NEW INFORMATION ABOUT THE UNDERLYING
23	PATHOGENESIS OF DISEASE, BUT, IN ADDITION, USE THIS
24	STEM CELL-BASED TECHNOLOGY HERE AS A TOOL RATHER
25	THAN AS THERAPY TO IDENTIFY NEW DRUG TARGETS FOR
	220

229

1 DISCOVERY OF NEW THERAPEUTICS. 2 IN ADDITION, IN THE NEXT FIVE YEARS WE'LL 3 HAVE DEVELOPED NEW PROCEDURES FOR THE PRODUCTION OF 4 A VARIETY OF STEM OR PROGENITOR CELLS THAT CAN MEET 5 THE REQUIREMENTS FOR GOING INTO CLINICAL 6 APPLICATION. SO HERE WE ARE TALKING ABOUT IT BEING 7 USED FOR THERAPY. 8 AND THAT WE WILL HAVE 20 CIRM-FUNDED 9 PROGRAMS WITH OUTSIDE CAPITAL COMMITMENTS FOR 10 FUNDING DEVELOPMENT WORK. THAT WE'LL HAVE TEN THERAPIES IN PHASE I OR II CLINICAL TRIALS IN AT 11 12 LEAST FIVE DIFFERENT THERAPEUTIC AREAS BASED ON STEM 13 CELL RESEARCH. AND THAT WE WILL HAVE SHOWN CLINICAL PROOF OF CONCEPT, THAT TRANSPLANTED CELLS DERIVED 14 15 FROM PLURIPOTENT OR PROGENITOR CELLS CAN BE USED TO 16 RESTORE FUNCTION IN DISEASE OR INJURY. THAT'S 17 PROBABLY OUR MOST AMBITIOUS GOAL. AND THAT WE WILL HAVE EDUCATED AND ENGAGED THE CALIFORNIA COMMUNITY 18 19 IN CIRM'S MISSION AND ACHIEVEMENTS. AND ONCE AGAIN, 20 WE'RE TRYING TO QUANTITATE IT WITH SPECIFYING THE NUMBER OF INCREASE OF MONTHLY ONLINE ENGAGEMENTS. 21 22 SO WHAT WE TRIED TO DO IS GIVE YOU SOME VERY TANGIBLE ONE- AND FIVE-YEAR GOALS AND OUTCOMES, 23 24 HOW THEY TIE TO OUR STRATEGIC OBJECTIVES, AND HOW 25 THEY ALIGN WITH OUR VISION AND MISSION. AND NONE OF 230

1	THIS IS GOING TO WORK UNLESS WE ALIGN OUR RESEARCH
2	FUNDING STRATEGY WITH OUR STRATEGIC PLAN. SO THE
3	INTENT IS THAT DOCUMENT WON'T BE SOMETHING THAT WE
4	PUT ON THE SHELF, BUT WE WILL USE IT. AND IT SHOULD
5	BE GUIDING THE DEVELOPMENT OF OUR CONCEPTS, OUR
6	SOLICITATIONS. IT SHOULD BE INFORMING THE GRANT
7	REVIEW GROUP RECOMMENDATIONS. IT SHOULD BE
8	INFORMING THE ICOC BOARD DECISIONS. AND IT SHOULD
9	INFORM HOW WE PRIORITIZE WHERE WE PUT OUR RESOURCES
10	AND HOW WE ALLOCATE THEM.
11	IN ADDITION, I SAID AT THE BEGINNING THIS
12	IS A LIVING DOCUMENT. STUFF HAPPENS. SO WE'RE
13	GOING TO HAVE RESEARCH TAKING PLACE, PROGRESS
14	UPDATES, OUTCOMES, CHANGES IN THE FIELD. THESE TOO
15	ARE GOING TO INFORM OUR ACTIONS. AND WE'LL BE
16	PROVIDING THE BOARD AS WELL AS THE PUBLIC REGULAR
17	INTERVAL UPDATES OF PROGRESS AND OF OUTCOMES AND OF
18	CHANGES IN THE FIELD. SO IT MAY BE WE NEED TO
19	REFINE THE PLAN ACCORDING TO THE REALITY AROUND US.
20	I WANT TO REMIND YOU OF SOME OF THE
21	FUNDING THAT YOU'VE HEARD IN PREVIOUS MEETINGS JUST
22	SO YOU CAN SEE HOW IT FITS AT THIS PARTICULAR
23	SNAPSHOT IN TIME AND REALIZING IT'S GOING TO CHANGE.
24	THIS WAS A SNAPSHOT AT ABOUT FEBRUARY, A FEW MONTHS
25	AGO, WITH A NUMBER OF AWARDS AND ALLOCATION OF
	231

DEDODUTNC SEDUTCE

	BARRISTERS' REPORTING SERVICE
1	DOLLARS AT THAT PARTICULAR MOMENT IN TIME. SO THIS
2	IS FLUID. THESE PIE CHARTS ARE GOING TO LOOK
3	SLIGHTLY DIFFERENT. BUT WE GAVE YOU TWO DIFFERENT
4	SCENARIOS THAT MIGHT HAPPEN IN THE FUTURE, POTENTIAL
5	SCENARIOS.
6	SO IF WE LOOK AT THE END OF THE \$3 BILLION
7	OF FUNDING, THIS IS THE WAY THE PROPORTION OF
8	FUNDING COULD LOOK BASED ON WHERE THE FUNDING GOES
9	OVER THE LIFESPAN OF CIRM. AT THE END OF THAT 3
10	BILLION OF SPENDING, IT WOULD BE APPROXIMATELY 30
11	PERCENT SPENT IN FACILITIES, CORE RESOURCES,
12	TRAINING, AND CAREER DEVELOPMENT. ABOUT 30 PERCENT
13	IN BASIC RESEARCH AND TRANSLATIONAL RESEARCH, AND A
14	LITTLE MORE THAN A THIRD DEVELOPMENT RESEARCH.
15	SCENARIO TWO, VERY SIMILAR. WE HAVE A
16	LITTLE BIT MORE IN FACILITIES, CORE RESOURCES,
17	TRAINING, AND CAREER DEVELOPMENT. BUT THE
18	PROPORTIONS ARE RELATIVELY SIMILAR.
19	WHAT WE DO KNOW IS THAT WE DO ANTICIPATE,
20	BASED ON OUR STRATEGIC PLAN, THAT THE PROPORTION OF
21	THE MONEY THAT WE EXPEND ON TRANSLATIONAL AND
22	DEVELOPMENT, IF WE'RE TO FOLLOW OUR STRATEGIC PLAN,
23	WILL INCREASE. RIGHT NOW OUR TRANSLATIONAL AND
74	

24 DEVELOPMENT PROGRAMS REPRESENT ABOUT 9 PERCENT BY

25 NUMBER AND ABOUT 31 PERCENT OF THE 1.28 BILLION

232

1	THAT'S ALLOCATED TO FUNDED PROGRAMS TODAY. WHAT
2	I'VE SHOWN HERE IS THE CHEVRON OF PRODUCT
3	DEVELOPMENT FROM BASIC RESEARCH IN PHASE II, AND
4	UNDER THIS I'VE SHOWN THE DIFFERENT TRANSLATIONAL
5	AND DEVELOPMENT INITIATIVES THAT COVER THE SPECTRUM
6	OF WHAT WE FUND RIGHT NOW.
7	SOME OF THESE HAVE ALREADY COME TO YOU.
8	SOME OF THESE WILL COME TO YOU IN JULY OR BY THE END
9	OF THE YEAR. FOR EXAMPLE, DISEASE TEAM II
10	INITIATIVE WILL COME TO YOU IN JULY, AND THE
11	STRATEGIC PARTNERSHIP FUND WILL COME TO YOU LATER
12	THIS YEAR. THE REASON I'M BRINGING THIS UP IS YOU
13	LOOK AT INITIATIVES ONE AT A TIME, BUT WE ALWAYS
14	HAVE TO KEEP IN MIND WHERE WE'RE TRYING TO GO. AND
15	THE FACT THAT IF A CERTAIN NUMBER OF MERITORIOUS
16	PROGRAMS AREN'T MET AT ONE POINT IN TIME, IT DOESN'T
17	MEAN THAT THERE COULDN'T BE SOME FUNGIBILITY IN
18	TERMS OF WHERE THOSE DOLLARS THAT MAYBE DON'T GET
19	ALLOCATED TODAY MIGHT BE ABLE TO BE USED IN THE
20	FUTURE. SO EVERYBODY KNOWS THAT. I'M JUST
21	EXPLICITLY STATING THAT.
22	WHAT I DID WITH THESE PIE CHARTS IS
23	ACTUALLY SHOW YOU THE PERCENTAGE AND ALLOCATION OF
24	FUNDING ON THE BUCKETS OF WHAT'S ALREADY BEEN
25	FUNDED, WHAT'S BEEN CONCEPT APPROVED, AND WHAT THE
	233
	٢,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

1	POTENTIAL FUTURE SCENARIOS COULD BE JUST TO SHOW YOU
2	IN A NUTSHELL HOW THE PROPORTIONS WILL BE EXPECTED
3	TO CHANGE.
4	IF WE LOOK AT THE FACILITIES, CORE
5	RESOURCES, TRAINING, AND CAREER DEVELOPMENT, IT
6	REPRESENTS WITH THE CURRENT FUNDED ABOUT 25 PERCENT
7	RIGHT NOW I'M SORRY 25 PERCENT FOR FACILITIES
8	AND CORE RESOURCES, ABOUT 25 PERCENT FOR TRAINING
9	AND CAREER DEVELOPMENT, ABOUT 33 PERCENT FOR BASIC
10	AND TRANSLATIONAL RESEARCH, AND ABOUT 18 PERCENT
11	RIGHT NOW FOR DEVELOPMENT.
12	IF WE LOOK AT CONCEPT APPROVED, WE CAN SEE
13	THAT THE DEVELOPMENT SLICE OF THE PIE IS INCREASING
14	FROM ABOUT 18 PERCENT ALMOST TO 50 PERCENT. SO
15	YOU'RE GOING TO SEE THESE PROPORTIONS CHANGE OVER
16	TIME. AND THEN IF YOU LOOK AT THE FUTURE, YOU CAN
17	SEE IT CHANGING AGAIN. I THINK FOR PURPOSES OF
18	TIME, I WON'T SPEND MUCH MORE ON THAT. BUT IT'S
19	JUST TO SHOW YOU THE PREVIOUS PIE SHOWED YOU OVERALL
20	THE 3 BILLION WHAT THE PROPORTIONS WOULD LOOK LIKE.
21	WHAT THIS IS TRYING TO SHOW YOU IS, ACCORDING TO THE
22	DIFFERENT POINTS IN TIME OF CIRM, HOW THE
23	PROPORTIONS ARE GOING TO CHANGE.
24	SO ONCE AGAIN, IF WE PUT OUR BETS RIGHT
25	AND STRATEGICALLY THINK ABOUT OUR ALLOCATION AND OUR
	234

1	PRIORITIES, WE HAVE ABOUT 1.5 BILLION LEFT OF CIRM
2	FUNDING TO ACHIEVE OUR KEY OUTCOMES. THIS IS NOT
3	TAKING INTO ACCOUNT, OF COURSE, THE LEVERAGING OF
4	CIRM INVESTMENTS FROM OTHER TYPES OF ENTITIES. BUT
5	WHAT REMAINS TO BE ACHIEVED ARE OUR KEY STRATEGIC
6	OUTCOMES WHICH INCLUDE ACHIEVING TRANSFORMATIVE
7	RESEARCH DISCOVERIES, ACHIEVING CLINICAL PROOF OF
8	CONCEPT FOR STEM CELL THERAPIES, LEVERAGING OUR
9	INVESTMENT, AND HAVING CALIFORNIA BE GLOBALLY
10	RECOGNIZED AS THE STEM CELL STATE.
11	SO THAT'S GIVING YOU, I THINK, JUST THE
12	KEY POINTS OF WHAT WE'VE BEEN TALKING ABOUT SINCE
13	AUGUST OF LAST YEAR AND JUST PUT IT ALTOGETHER IN
14	ONE PACKAGE FOR YOU.
15	AND I ALSO NEGLECTED TO ALSO THANK, I
16	MEANT TO DO THIS, DON GIBBONS WHO ACTUALLY SPENT
17	QUITE A BIT OF TIME WITH THE WRITING AND THE
18	EXECUTIVE SUMMARY, AND I ALSO WANTED TO THANK ANKA
19	URBAN WHO'S DONE A LOT OF WORK JUST PUTTING THE
20	MANUSCRIPT TOGETHER, PUTTING ALL THE APPENDICES
21	TOGETHER FOR YOU, MAKING SURE ALL THE LINKS WORK
22	WHEN YOU TRY TO GO TO THOSE DIFFERENT PAPERS.
23	SO YOU'VE GOT THE FINAL PLAN IN YOUR
24	BINDER. YOU'VE SEEN THE KEY POINTS FROM THIS
25	PRESENTATION. SO REALLY THE CONSIDERATION TODAY IS
	235

1	OF THIS FINAL VERSION. AND PERHAPS BEFORE THE VOTE,
2	IF YOU HAVE ANY QUESTIONS, I'D BE HAPPY TO ANSWER
3	THEM.
4	CHAIRMAN THOMAS: SENATOR TORRES.
5	MR. TORRES: ELLEN, I JUST WANT TO THANK
6	YOU FOR ALL THE HARD WORK THAT YOU AND THE PEOPLE
7	THAT YOU MENTIONED ALREADY, I WON'T MENTION THEM
8	AGAIN, FOR THEIR INPUT AND THEIR TRANSPARENCY TO
9	THOSE OF US THAT ARE THERE IN THE OFFICE, BUT ALSO
10	OTHER BOARD MEMBERS AS WELL TO SEEK THE INPUT. AND
11	ALSO THE FACT THAT YOU ALL TOOK THE TIME TO SEEK THE
12	INPUT OF PATIENT ADVOCATES. THAT'S EXTREMELY
13	IMPORTANT AS WE MOVE FORWARD BECAUSE WE HAVE TO MOVE
14	FORWARD TOGETHER. SO I MOVE THAT WE ADOPT THE
15	REPORT.
16	DR. LUBIN: SECOND.
17	CHAIRMAN THOMAS: SECOND BY DR. LUBIN. IS
18	THERE FURTHER DISCUSSION? MR. SHEEHY.
19	MR. SHEEHY: FIRST, I DO WANT TO
20	COMPLIMENT DR. FEIGAL AND STAFF, EVERYBODY INVOLVED
21	IN THIS. THIS IS A GREAT PRODUCT.
22	I HAD ONE AND THE PROCESS I THINK HAS
23	BEEN OUTSTANDING. I HAD ONE QUESTION. TWO
24	SCENARIOS ARE POSED. AND WHEN DOES THAT DECISION
25	POINT COME TO US? BECAUSE I WOULD BE RELUCTANT TO
	236

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	BARRISIERS REPORTING SERVICE
1	VOTE ON THIS WITH THAT BEING LEFT OUT THERE. I
2	PERSONALLY FEEL THE TRAINING ASPECT OF WHAT WE DO IS
3	VERY IMPORTANT. THE BRIDGES PIECE OF IT, TO ME, IS
4	ABSOLUTELY CRITICAL. BUT I KNOW OTHERS MAY NOT FEEL
5	THE SAME WAY, BUT AT SOME POINT WE SHOULD KIND OF
6	REACH THAT DECISION POINT.
7	CHAIRMAN THOMAS: DR. TROUNSON.
8	DR. TROUNSON: SO I THINK THAT'S A VERY
9	IMPORTANT POINT BECAUSE THERE WAS NO FINAL DECISION
10	ON IT, JEFF. AND SO I THINK WHAT WE SHOULD DO MAYBE
11	IS BRING IT FORWARD AS A SEPARATE ITEM BECAUSE THERE
12	WAS A LOT OF MATERIAL IN HERE. AND SO WITH YOUR
13	INDULGENCE, BOARD, I THINK IF WE COME FORWARD AT THE
14	NEXT BOARD MEETING AND CREATE A LITTLE SPOT ABOUT
15	DISCUSSING WHICH IS THE BEST SCENARIO, GIVE YOU A
16	LITTLE BIT MORE INFORMATION ON IT, AND THEN HAVE YOU
17	GIVE YOUR VIEWS BACK TO US. I THINK WE OUGHT TO
18	THINK THAT THAT OUGHT TO BE ABLE TO BE CHANGED IN
19	TIME BECAUSE THINGS WILL CHANGE IN TIME FOR US. BUT
20	IF YOU COULD GIVE US I THINK THE NEXT TIME, IF
21	YOU CAN GIVE US A CITE ABOUT WHETHER YOU PREFER ONE
22	OR THE OTHER, THEN WE'LL WORK TOWARDS THAT, BUT BE
23	UNDERSTANDING THAT WE COULD ALTER THAT AS WE MOVE
24	FORWARD, BUT THAT BEING THE POSITION THAT WE TAKE AT

25 THAT POINT IN TIME. IS THAT OKAY?

237

1	MR. SHEEHY: YEAH. I THINK THAT'S
2	REASONABLE. I JUST THINK WE NEED TO BECAUSE
3	THOSE PROGRAMS HAVE BEEN GOING TOO, THEY'LL NEED
4	TO IF THOSE ARE GOING TO GO AWAY, I THINK THOSE
5	PEOPLE WHO ARE DOING THAT WILL NEED TO KNOW THAT.
6	DR. FEIGAL: THE WAY I ARTICULATED IN THE
7	PLAN IS THOSE ARE JUST POTENTIAL SCENARIOS. SO I
8	DON'T THINK IT LOCKED IN.
9	CHAIRMAN THOMAS: DR. OLSON, DID YOU HAVE
10	A COMMENT?
11	DR. OLSON: I JUST WANTED TO ELABORATE ON
12	THAT POINT. I MEAN SO, FOR EXAMPLE, AS ELLEN SAID,
13	THAT WAS A SNAPSHOT IN TIME, THOSE FINANCIAL
14	SCENARIOS. BASED ON THE DECISIONS THIS BOARD MADE
15	TODAY AS FAR AS VOTING FOR AN EARLY TRANSLATION,
16	THERE'S SUDDENLY \$30 MILLION APPROXIMATELY THAT WAS
17	CONCEPT APPROVED THAT WE ASSUMED WAS ALLOCATED THAT
18	NOW COULD BE AVAILABLE FOR BEING ALLOCATED
19	DIFFERENTLY. SO I THINK THE POINT WAS THAT THE
20	BOARD NEEDS TO WHAT I THINK I WAS TRYING TO GET
21	ACROSS AT THE MEETING WAS THAT THE BOARD HAS TO
22	RECOGNIZE THAT TO ACHIEVE THE MOST COSTLY OBJECTIVE,
23	ESSENTIALLY THE DEVELOPMENT OBJECTIVE, THE CLINICAL
24	DEVELOPMENT PROOF OF CONCEPT, THAT A SUBSTANTIAL
25	AMOUNT OF MONEY WILL HAVE TO BE SPENT ON
	238

1	DEVELOPMENT-TYPE PROGRAMS, PARTICULARLY CLINICAL
2	STAGE PROGRAMS, BUT THAT THERE WILL ALWAYS BE THE
3	OPPORTUNITY FOR A DISCUSSION AT EVERY CONCEPT
4	APPROVAL AND PERHAPS A SUMMARY DISCUSSION ON AN
5	ANNUAL BASIS AT THE BOARD'S WHAT THEY WANT TO DO.
6	BUT IT WAS NOT INTENDED TO SAY THIS IS A DECISION
7	THAT HAS TO BE MADE NOW.
8	DR. FEIGAL: YEAH. THAT'S ABSOLUTELY
9	RIGHT. I MEAN THIS IS GOING TO CHANGE. THESE PIE
10	CHARTS ARE GOING TO BE DIFFERENT TOMORROW BASED ON
11	DECISIONS.
12	MR. SHEEHY: I THINK IT'S HELPFUL BECAUSE
13	I THINK, LIKE OUR DISCUSSION WE HAD EARLIER, AND
14	WE'RE GOING TO BE THINKING ABOUT HOW FAR TO STRETCH
15	OURSELVES, AND YOU KIND OF ALLUDED TO THIS WHEN WE
16	WERE HAVING THE CONVERSATION. WE'RE NOW IN THE
17	REALM OF TRADE-OFFS. SO IF WE DECIDE TO PICK UP
18	THAT EXTRA DC PROJECT AND THEN WE'RE GOING TO TURN
19	AROUND AND SAY WE ALSO WANT TO DO TRAINING AND THEN
20	WE ALSO WANT TO DO A STRATEGIC PARTNERSHIP, I MEAN
21	AT SOME POINT WE NEED TO HAVE THESE CHOICES A LITTLE
22	BIT FURTHER IN THE FOREFRONT OF OUR BRAINS AND NOT
23	NECESSARILY BACK THERE LIKE WE HAVE AN INFINITE
24	AMOUNT OF MONEY TO SPEND.
25	SO THAT'S AS MUCH AS ANYTHING WHY I WOULD
	239

1	LIKE PEOPLE TO BE THINKING SERIOUSLY ABOUT THIS AS
2	WE GO THROUGH BOTH TODAY, AND THEN NEXT MONTH WE'RE
3	GOING THROUGH A BIG ROUND WHERE WE MAY HAVE PEOPLE
4	WITH PETITIONS AND A LOT OF COMPELLING ARGUMENTS TO
5	SPEND ANOTHER \$20 MILLION HERE, ANOTHER \$20 MILLION
6	THERE. WE SHOULD BE VERY CAUTIOUS AND THINK ABOUT
7	WHAT THE COST IS DOWN THE ROAD.
8	DR. TROUNSON: WHAT I'D LIKE TO DO IS
9	MAYBE EVEN HAVE IT AS A COMPONENT PART THAT JUST
10	MOVES ALL THE TIME JUST SO THAT THE AWARENESS IS
11	THERE, SO THAT YOUR AWARENESS IS THERE. AND THEN IF
12	YOU WANT TO CHANGE SOMETHING, THEN WE CAN LOOK AT
13	THE WAY IT MIGHT CHANGE IT. BUT IF WE CAN BRING
14	THAT BACK TO YOU THE NEXT MEETING, I THINK IT WOULD
15	BE GOOD FOR US TO THINK ABOUT HOW BEST TO SORT OF
16	HAVE IT AS AN ONGOING PROCESS IF YOU WILL INDULGE US
17	IN THAT.
18	MR. SHEEHY: I THINK THAT'S A GREAT IDEA.
19	THANKS, DR. TROUNSON.
20	CHAIRMAN THOMAS: ANY OTHER COMMENTS BY
21	MEMBERS OF THE BOARD?
22	MS. SAMUELSON: I'VE GOT A COUPLE
23	QUESTIONS. I'M WONDERING ABOUT THE CHOICE OF
24	QUANTITY, THE 30 PROJECTS IN CLINICAL DEVELOPMENT OR
25	WORDS TO THAT EFFECT. IT SOUNDS TO ME LIKE IT COULD
	240

1	BE SUPPLANTING SOME SIGNIFICANT BREAKTHROUGH IN A
2	VERY, VERY GNARLY DISORDER, ONE OF THE
3	NEURODEGENERATIVE ONES, FOR EXAMPLE.
4	DR. FEIGAL: WELL, I MEAN ANY TARGET
5	IS YOU KNOW, WHAT WE DID IS LANDSCAPE WHERE WE
6	ARE, WHAT WE KNOW WE HAVE IN THE PIPELINE, AND I
7	THINK WHAT WE PUT TOGETHER ARE NOT FANTASY NUMBERS.
8	I THINK WE ACTUALLY TRIED TO BASE IT AT LEAST ON
9	PROJECTED DATA AND WHERE WE THOUGHT THE FIELD COULD
10	TAKE US. SO WE TRIED TO ARRIVE AT WHAT WE THOUGHT
11	WERE ACHIEVABLE NUMBERS.
12	MS. SAMUELSON: HOW MANY OF THOSE INCLUDED
13	THOSE?
14	DR. FEIGAL: EXCUSE ME?
15	MS. SAMUELSON: HOW MANY INCLUDED THOSE
16	VERY DIFFICULT TO ACHIEVE DISORDERS?
17	DR. FEIGAL: WELL, I MEAN WE DIDN'T
18	SPECIFY WHICH DISEASES THEY HAD TO BE. WE DIDN'T
19	PROSCRIBE WHAT WAS IN THAT LIST, BUT WE DID LOOK AT
20	A VARIETY OF THINGS. AND WE THOUGHT ON AVERAGE
21	THAT'S WHERE IT COULD BE. I CAN'T TELL YOU IF IT
22	WILL BE IN HEMOPHILIA OR IF IT WILL BE IN HIV. I
23	MEAN I DON'T KNOW WHAT THOSE 20 TO 30 DIFFERENT
24	PRECLINICAL DISEASES WILL BE.
25	ALSO, THE TEN THERAPY, THE CLINICAL
	241

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	TRIALS, PART OF IT IS GOING TO DEPEND, I THINK, ON
2	OUR PRIORITIZATION OF THE SCIENCE AND THE
3	OPPORTUNITIES WITH WORKSHOPS THAT WE'RE GOING TO BE
4	HAVING THAT WILL HELP DETERMINE WHERE THOSE WHAT
5	DISEASES WE MAY WANT TO INVEST IN. SO WE HAVEN'T
6	PROSCRIBED WHICH DISEASES THEY NEED TO BE AT THIS
7	POINT IN TIME, BUT WE MAY WORK THAT OUT OVER THE
8	NEXT FIVE YEARS.
9	MS. SAMUELSON: IT WOULD SEEM TO ME AT
10	SOME POINT YOU'D NEED TO THINK ABOUT THAT.
11	DR. FEIGAL: YES. I AGREE.
12	MS. SAMUELSON: AND WE WOULD. THIS IS
13	SUPPOSED TO BE OUR DOCUMENT, I THINK.
14	DR. FEIGAL: CORRECT. WE'RE ALL IN THIS
15	TOGETHER. I AGREE.
16	MS. SAMUELSON: YEP. YEP.
17	CHAIRMAN THOMAS: ANY OTHER COMMENTS?
18	MS. SAMUELSON: I DIDN'T SEE ANY ONE
19	MORE QUESTION. I DIDN'T SEE ANY REFERENCE TO A
20	FUTURE ROLE FOR THE GRANTS WORKING GROUP AS OPPOSED
21	TO THE EXTERNAL ADVISORY BOARD. THERE WAS ONE
22	REFERENCE ABOUT ITS ROLE AND COMPARING IT TO THE
23	GRANTS WORKING GROUP, BUT I DIDN'T SEE A FUTURE ROLE
24	FOR THE GRANTS WORKING GROUP.
25	DR. FEIGAL: WELL, ACTUALLY I HAVE
	242

	BARRISTERS' REPORTING SERVICE
1	MS. SAMUELSON: THE STATUTE, OF COURSE,
2	DOES CREATE ONE.
3	DR. FEIGAL: WELL, I MEAN GRANTS WORKING
4	GROUP WILL REMAIN A PART OF THIS. WE HAVEN'T
5	REDEFINED THEIR ROLE, BUT WE JUST WE HAVE
6	INCLUDED THEM IN THE FUTURE. I GUESS I'M NOT SURE I
7	UNDERSTAND YOUR QUESTION.
8	MS. SAMUELSON: IN ANYTHING BEYOND GRANTS
9	REVIEW, SUCH AS THE INPUT THAT WE GOT AT THE END OF
10	THE LAST
11	DR. FEIGAL: I DIDN'T GO INTO TACTICS
12	HERE. SO WE CAN DISCUSS WHAT KIND OF ADDITIONAL
13	ROLES WE THINK WOULD BE APPROPRIATE TO HAVE.
14	CHAIRMAN THOMAS: OKAY. IT'S BEEN MOVED
15	AND SECONDED. I WOULD LIKE TO ECHO THE COMMENTS.
16	ELLEN AND EVERYBODY WHO WORKED ON THIS, THIS IS A
17	THOROUGHLY PROFESSIONAL, HIGHLY CONSIDERED, REASONED
18	DOCUMENT, AND I THINK WE SHOULD ALL BE VERY PROUD OF
19	THIS, AND IT SETS THE REAL TONE FOR THE NEXT FIVE
20	YEARS. SO THANK YOU TO EVERYBODY.
21	DO WE HAVE ANY COMMENTS FROM MEMBERS OF
22	THE PUBLIC?
23	(APPLAUSE.)
24	CHAIRMAN THOMAS: HEARING NONE YES.
25	DR. TROUNSON.
	243
	215

1	DR. TROUNSON: JUST VERY BRIEFLY, WE'VE
2	ASKED KEVIN TO PREPARE A VERY LAY SHORT DESCRIPTION
3	SO THAT THAT CAN BE EASILY DIGESTED BY PEOPLE IN A
4	VERY QUICK TIME. SO WE'LL HAVE THAT AVAILABLE OVER
5	THE NEXT FEW WEEKS AND MAKE SURE YOU GET TO SEE
6	THAT, BUT IT WILL BE A SHORT LAY DESCRIPTION OF JUST
7	ONE AND A HALF PAGES. SO IF YOU'RE ASKED, YOU GET
8	THE KEY ELEMENTS IN A VERY LAY WAY FROM IT IF THAT'S
9	OKAY WITH YOU.
10	CHAIRMAN THOMAS: THAT'S GREAT. ALWAYS
11	ANYTHING IN PLAIN ENGLISH IS ALWAYS VERY HELPFUL.
12	NOT TO SAY THIS ISN'T, ELLEN. MORE SUCCINCT PLAIN
13	ENGLISH.
14	ANYWAY, ALL THOSE IN MR. HARRISON,
15	ANOTHER VOICE VOTE PRESUMABLY.
16	MR. HARRISON: YES. EXCEPT FOR THOSE ON
17	THE PHONE.
18	CHAIRMAN THOMAS: YES. ALL THOSE IN FAVOR
19	PLEASE SAY AYE. OPPOSED? ABSTENTIONS? MARIA.
20	MS. BONNEVILLE: I SEE WE'RE GETTING
21	PUNCHY. DUANE ROTH.
22	MR. ROTH: YES. ANY MORE SINGING, I'M NOT
23	GOING TO VOTE. MY CONGRATULATIONS TO THE WHOLE
24	GROUP. THEY DID A TERRIFIC JOB ON THIS.
25	MS. BONNEVILLE: SHLOMO MELMED. SHERRY
	244
	244

	BARRISTERS' REPORTING SERVICE
1	LANSING.
2	MS. LANSING: YES.
3	CHAIRMAN THOMAS: THANK YOU. AND, ELLEN,
4	CONGRATULATIONS.
5	OKAY. WE'RE NOW GOING TO MOVE TO ITEM 13,
6	WHICH IS CONSIDERATION OF THE CONTRACT OF THE REMCHO
7	FIRM. THIS IS ONE I DON'T THINK NEEDS A WHOLE LOT
8	OF INTRODUCTION. AS EVERYBODY KNOWS, THE REMCHO
9	FIRM, AND JAMES IN PARTICULAR, HAVE BEEN AN INTEGRAL
10	PART OF EVERYTHING CIRM HAS DONE STARTING BEFORE THE
11	OUTSET. AND THEY HAVE BEEN INVOLVED IN BASICALLY
12	EVERY IMPORTANT ASPECT OF WHAT CIRM HAS ACCOMPLISHED
13	SINCE THAT POINT. SPECIFICALLY MATTERS THAT THE
14	FIRM ARE INVOLVED IN INCLUDE GOVERNING BOARD AND ITS
15	SUBCOMMITTEES, IOM REVIEW, IP AND LOAN PROGRAM,
16	CONFLICTS AND STATUTORY COMPLIANCE, INTERACTING WITH
17	LEGISLATORS AND VARIOUS OTHERS IN SACRAMENTO, AND
18	MULTIPLE TIMES A DAY CONSULTATION WITH THE CHAIR AND
19	WITH MEMBERS OF THE CIRM STAFF, AND BASICALLY JUST
20	VERY, VERY CENTRAL ROLE IN EVERYTHING.
21	I KNOW THAT MY FIRST YEAR HERE I GREATLY
22	VALUED JAMES' INPUT. I KNOW HE'S TRYING TO, LIKE,
23	NOT LISTEN TO THIS AND PAY ATTENTION TO ALL THE
24	ACCOLADES, BUT IT IS A FACT. HE'S BEEN AN
25	INVALUABLE RESOURCE TO ME AND TO EVERYBODY HERE AT
	245

BARRISTERS' REPORTING SERVICE 1 CIRM. 2 THE CONTRACT CALLS FOR APPROVAL OF REMCHO'S WORK FOR FISCAL 12-13 IN THE AMOUNT OF 3 4 \$550,000. I VERY MUCH MOVE APPROVAL OF THAT IF 5 SOMEBODY WOULD LIKE TO MAKE THAT MOTION. 6 MR. TORRES: SO MOVED. 7 CHAIRMAN THOMAS: SO MOVED BY SENATOR 8 TORRES. 9 MS. SAMUELSON: SECOND. 10 CHAIRMAN THOMAS: WHERE WAS THE SECOND? 11 FROM JOAN. THANK YOU, JOAN. ANY DISCUSSION ON THE 12 TOPIC? 13 MS. SAMUELSON: QUESTION ABOUT THE AMOUNT. IS THIS A PERCENTAGE INCREASE OR BASED ON A 14 15 CALCULATION? THE NEED FOR THE SERVICES OF THIS FIRM 16 ARE GREAT, TO SAY THE LEAST. AND I WOULD WANT TO BE 17 SURE THAT IT'S FINANCED SUFFICIENTLY. CHAIRMAN THOMAS: YES. AS I UNDERSTAND, 18 19 JAMES, IT'S ROUGHLY COMPARABLE TO LAST YEAR. 20 MR. HARRISON: CORRECT. 21 MS. SAMUELSON: WAS THERE OR IS THERE ANTICIPATED TO BE ANY INFLATION, AND WAS THAT TAKEN 22 23 INTO CONSIDERATION IN THE RESPONSIBILITIES OR THE 24 ECONOMY? 25 CHAIRMAN THOMAS: RIGHT. I THINK THE 246

1	AMOUNT CAME ABOUT AFTER CONSIDERED THOUGHT BY MR.
2	HARRISON ON THIS. YES. TO THE EXTENT THERE IS A
3	NEED FOR ADDITIONAL OR EXTRAORDINARY SERVICE, WE
4	HAVE A CONTINGENCY AS WELL FACTORED INTO THE BUDGET.
5	MS. SAMUELSON: GOOD. CAN THE MOTION
6	INCLUDE REFERENCE TO THAT AND APPROVAL OF IT SO THAT
7	THERE'S NO CONFUSION ABOUT IT?
8	CHAIRMAN THOMAS: YES. SO AT THE RISK OF
9	ASKING A HIGHLY SELF-SERVING QUESTION, MR. HARRISON,
10	WOULD YOU LIKE TO STATE THE MOTION? MR. TOCHER,
11	WOULD YOU LIKE TO STATE THE MOTION?
12	MR. TOCHER: THE MOTION IS TO APPROVE THE
13	REMCHO CONTRACT FOR FISCAL YEAR 2012-2013 WITH THE
14	ADDITIONAL CONTINGENCY ALREADY INCLUDED IN THE
15	BUDGET.
16	CHAIRMAN THOMAS: OKAY. THANK YOU. WOULD
17	THE AUTHOR AND SECOND OF THE ORIGINAL MOTION TAKE
18	THAT AS A FRIENDLY AMENDMENT?
19	MR. TORRES: YES.
20	MS. SAMUELSON: YES.
21	CHAIRMAN THOMAS: OKAY. ANY FURTHER
22	DISCUSSION? ANOTHER VOICE VOTE. ALL THOSE IN FAVOR
23	OF THIS ITEM, PLEASE SAY AYE. OPPOSED?
24	ABSTENTIONS? MARIA, I'LL SAY IT WITHOUT SINGING,
25	DUANE.
	247
	247

BARRISTERS' REPORTING SERVICE 1 MS. BONNEVILLE: DUANE ROTH. 2 MR. ROTH: YES. 3 MS. BONNEVILLE: SHLOMO MELMED. SHERRY 4 LANSING. 5 MS. LANSING: YES. CHAIRMAN THOMAS: OKAY. THANK YOU VERY 6 7 MUCH. 8 JUST VERY QUICKLY, LET'S SEE, SHERRY, 9 WE'RE GOING TO COME BACK TO YOU IN ONE MINUTE HERE. 10 JUST WANTED TO GET TO ITEM 15 VERY QUICKLY, IF YOU WILL BEAR WITH US, WHICH IS CONSIDERATION OF 11 12 RECOMMENDATIONS FROM THE STANDARDS WORKING GROUP 13 REGARDING REVIEW AND OVERSIGHT OF THE CIRM-FUNDED 14 RESEARCH. MR. LOMAX. 15 DR. LOMAX: THANK YOU VERY MUCH, MR. CHAIRMAN, MEMBERS OF THE ICOC. I'D LIKE TO GIVE YOU 16 17 A REPORT BACK ON TWO ITEMS FROM THE APRIL STANDARDS WORKING GROUP MEETING FOR YOUR CONSIDERATION. THESE 18 19 ARE AMENDMENTS FOR CONSIDERATION TO THE MEDICAL AND 20 ETHICAL STANDARDS. BRIEFLY IN CONTEXT, AS I'M SURE YOU'RE 21 22 WELL AWARE BY NOW, OUR MEDICAL AND ETHICAL STANDARDS 23 MEET OR EXCEED ALL NATIONAL STANDARDS FOR OVERSIGHT 24 OF RESEARCH. IN ADDITION, WE HAVE EXTREMELY STRONG 25 LANGUAGE IN TERMS OF GUARDING AGAINST CONFLICTS, AS 248

	BARRISTERS' REPORTING SERVICE
1	WE'RE ALL VERY FAMILIAR.
2	AFTER THE BENEFIT OF SIX YEARS OF
3	EXPERIENCE AND EXTENSIVE POLICY EVALUATION, WE'VE
4	IDENTIFIED SOME AREAS WHERE WE CAN STILL MAINTAIN
5	THESE HIGH STANDARDS, BUT OFFER OUR GRANTEES SOME
6	ADDED FLEXIBILITY. I'D LIKE TO RUN THROUGH THOSE
7	TWO AREAS FOR YOU.
8	FIRST IS THE OVERSIGHT COMMITTEE
9	MEMBERSHIP. WHEN WE ORIGINALLY PUT FORTH THE
10	STANDARDS, WE ASKED THAT INSTITUTIONS AND THEIR
11	OVERSIGHT COMMITTEES INCLUDE A LAY MEMBER OF THE
12	PUBLIC, AND THAT LAYPERSON COULD RECEIVE NO MONEY
13	WHATSOEVER. SO THAT WOULD EVEN INCLUDE THINGS LIKE
14	NOT BEING ABLE TO PAY FOR PARKING OR A MODEST
15	STIPEND FOR COMING TO A MEETING AND SPENDING HOURS
16	AT AN INSTITUTION. THIS IS TYPICAL PROCEDURE.
17	INSTITUTIONS LIKE TO DO THIS FOR INDIVIDUALS WHO
18	SERVE ON INSTITUTIONAL REVIEW BOARDS, ANIMAL REVIEW
19	COMMITTEES; BUT BASED ON OUR STANDARDS, THEY HAD TO
20	HAVE A COMPLETELY SEPARATE POLICY FOR CIRM RESEARCH.
21	SO THE SUGGESTION IS THAT THE NONSCIENTIST
22	PUBLIC MEMBER, WE STRIKE THIS PROHIBITION AND JUST
23	ALLOW FLEXIBILITY, ALLOW INSTITUTIONS TO APPLY THEIR
24	POLICIES AS THEY WOULD WITH ANY OTHER COMMITTEE. SO
25	THAT'S THE FIRST PROPOSED AMENDMENT.

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THE SECOND ONE CONCERNS THE OVERSIGHT OF
2	RESEARCH, IN PARTICULAR IN VITRO RESEARCH INVOLVING
3	IDENTIFIABLE CELLS. NOW, THIS RESEARCH IS ALWAYS
4	REVIEWED BY AN INSTITUTIONAL REVIEW BOARD. AND IN
5	OUR REGULATIONS WE REQUIRED THAT THE STEM CELL
6	RESEARCH OVERSIGHT COMMITTEE FOR A PARTICULAR
7	GRANTEE INSTITUTION ALSO BE INFORMED THAT THIS
8	RESEARCH IS GOING ON. SO IT'S WHAT WE CALL A
9	NOTIFICATION REQUIREMENT. AND THE PURPOSE IS THAT
10	WE WANT THE STEM CELL RESEARCH OVERSIGHT COMMITTEE
11	TO BE AWARE OF ANY HUMAN SUBJECTS RESEARCH GOING ON
12	IN A CIRM GRANT.
13	UNFORTUNATELY A NUMBER OF OUR GRANTEES NO
14	LONGER HAVE ACCESS TO THESE COMMITTEES. THERE WAS A
15	COMMITTEE AVAILABLE THAT COULD BE USED ON CONTRACT,
16	BUT THOSE SERVICES ARE NO LONGER AVAILABLE. THIS
17	CREATES A ROADBLOCK FOR IN VITRO RESEARCH FOR SOME
18	OF OUR GRANTEE INSTITUTIONS. AND SO WHAT WE'RE
19	PROPOSING IS THAT WE APPLY A SECOND STANDARD WHICH
20	WE USE WHICH IS THAT AN INSTITUTIONAL OFFICIAL AT
21	THE GRANTEE INSTITUTION CAN PROVIDE THAT
22	INDIVIDUAL CAN BE NOTIFIED IN LIEU OF THE STEM CELL
23	RESEARCH OVERSIGHT COMMITTEE.
24	AND WHAT THIS WOULD ALLOW, AGAIN, WE'VE
25	HAD QUITE A BIT OF EXPERIENCE WITH THIS PROCESS.
	250

1	THE INSTITUTIONAL OFFICIAL HAS TO BE SOMEONE, FOR
2	EXAMPLE, IN THE OFFICE OF GENERAL COUNSEL WHO'S
3	FAMILIAR WITH APPLICABLE LAWS AND REGULATIONS, BUT
4	THAT INDIVIDUAL WOULD BE RESPONSIBLE FOR CERTIFYING
5	THAT THE RESEARCH IS DONE IN ACCORDANCE WITH CIRM
6	REQUIREMENTS OR ANY OTHER APPLICABLE REQUIREMENTS,
7	BUT, AGAIN, WOULDN'T NECESSITATE A FULL COMMITTEE
8	FOR THIS TYPE OF RESEARCH WHICH IS DEEMED IN
9	VITRO RESEARCH, WE'VE NOT ENCOUNTERED ANY ETHICAL
10	PROBLEMS, ANY TYPES OF PROBLEMS THAT WOULD REQUIRE A
11	FULL OVERSIGHT COMMITTEE.
12	SO THE RECOMMENDATION HERE, AGAIN, IS TO
13	ALLOW NOTIFICATION OF RESPONSIBLE INSTITUTIONAL
14	OFFICIAL IN LIEU OF SCRO COMMITTEE NOTIFICATION.
15	AND THE MOTION BEFORE THE BOARD WOULD BE
16	TO, MR. HARRISON.
17	MR. HARRISON: THE MOTION WOULD BE TO
18	APPROVE THE RECOMMENDATIONS FROM THE STANDARDS
19	WORKING GROUP REGARDING THE REVIEW AND OVERSIGHT OF
20	CIRM-FUNDED RESEARCH IN THE FORM OF THE PROPOSED
21	AMENDMENTS TO THE REGULATIONS.
22	MS. LANSING: I'D LIKE TO MOVE THIS.
23	CHAIRMAN THOMAS: THANK YOU. IS THERE A
24	SECOND BEFORE WE GET
25	MR. TORRES: SECOND.
	251

	BARRISTERS' REPORTING SERVICE
1	CHAIRMAN THOMAS: SECOND BY SENATOR
2	TORRES. DR. BRYANT AND THEN DR. LUBIN.
3	DR. BRYANT: SO I THINK IT WOULD BE A GOOD
4	IDEA TO SPECIFY THE INSTITUTIONAL OFFICIAL BECAUSE
5	IF IT WENT TO THE LEGAL DEPARTMENT, FOR INSTANCE, IT
6	MIGHT NOT BE APPROPRIATE. SO MOST PLACES THAT DO
7	RESEARCH HAVE AN OFFICE OF RESEARCH WITH A VICE
8	CHANCELLOR OR SOME OTHER PERSON LIKE THAT IN CHARGE.
9	AND SO I THINK THEY WOULD BE THE ONE. AND ALL THOSE
10	COMPLIANCE COMMITTEES REPORT IN THROUGH THAT OFFICE,
11	SO IT WOULD BE THE MOST APPROPRIATE ENTITY.
12	DR. LOMAX: WE DO IN THE IN OUR
13	REGULATIONS WE DO DEFINE THAT INDIVIDUAL AS SOMEONE,
14	I BELIEVE THE LEGAL TERM IS, SOMEONE WITH PLENARY
15	AUTHORITY. SO THERE IS SOME WELL
16	DR. BRYANT: IT SHOULD BE THE HEAD
17	RESEARCH AUTHORITY OF THE CAMPUS.
18	DR. LOMAX: THAT'S RIGHT. BUT IN SOME
19	CASES, PARTICULARLY WITH THE NONCAMPUS GRANTEES, IT
20	WILL BE SOMEONE THEY WON'T HAVE A VICE THEY
21	DON'T HAVE A VICE CHANCELLOR OF RESEARCH. IT HAS TO
22	BE WITH AUTHORITY FOR THE ORGANIZATION. SO WE HAVE
23	DEFINED IT THAT WAY, BUT IT WOULDN'T SAY THEY
24	DON'T SPECIFY, FOR EXAMPLE, THE VICE CHANCELLOR OF
25	RESEARCH.
	252

252

1	DR. BRYANT: BUT I THINK, BECAUSE THINGS
2	LIKE THIS CAN GET LOST IN INSTITUTIONS, I WOULD SAY
3	IT SHOULD BE THE VICE CHANCELLOR FOR RESEARCH OR
4	THEIR EQUIVALENT OR THE CHANCELLOR AND LET THEM TAKE
5	CARE OF IT OR THE HEAD OF THE INSTITUTION. I'M JUST
6	WORRIED THAT THESE THINGS, IF IT GOES TO LIKE THE
7	CAMPUS LAWYER OR SOMETHING, IT WOULD NOT GET TO THE
8	RIGHT PLACE NECESSARILY. SO I THINK IT NEEDS TO GO
9	TO THE ANYWAY, SORRY.
10	CHAIRMAN THOMAS: I THINK DR. LUBIN WAS
11	FIRST.
12	DR. LUBIN: I'M SECONDING THE MOTION.
13	CHAIRMAN THOMAS: OH, I SEE. OKAY. THANK
14	YOU. DR. STEWARD.
15	DR. STEWARD: I THINK THIS IS REALLY SORT
16	OF FOLLOWING UP ON DR. BRYANT'S COMMENT. COULD YOU
17	UNPACK A LITTLE BIT WHAT THE PROBLEMS ARE? YOU
18	MENTIONED, YOU KNOW, INSTITUTIONS THAT DON'T HAVE
19	THE SCRO COMMITTEES AND THEN DON'T HAVE SOMEBODY WHO
20	WOULD BE THE WHAT ARE WE TALKING ABOUT HERE?
21	DR. LOMAX: SO THIS PARTICULAR CASE,
22	AGAIN, IN VITRO RESEARCH INVOLVING TYPICALLY SOME
23	KIND OF PLURIPOTENT STEM CELL LINE. WE HAVE AN
24	EXTENSIVE SET OF REQUIREMENTS THAT SAY THAT STEM
25	CELL LINE HAS TO HAVE HAD PROPER INFORMED CONSENT,
	253
	233

1	KNOWN WAS PAID FOR THE USE OF THOSE CELLS. WE HAVE
2	A SERIES OF VERY SPECIFIC REQUIREMENTS.
3	AND SO THE POINT THE PURPOSE OF THE
4	NOTIFICATION REQUIREMENT WAS TO TELL THE COMMITTEE
5	THIS RESEARCHER IS INTENDING TO USE THESE MATERIALS.
6	BY OUR REGULATIONS YOU'RE ON THE HOOK, YOU'RE
7	OBLIGATED TO CONFIRM OR KNOW THAT THOSE MATERIALS
8	MEET ALL OF OUR REQUIREMENTS. AND IT'S A FAIRLY
9	STRAIGHT LIST OF REQUIREMENTS.
10	SO WHAT THIS IS INTENDED TO DO IS
11	SAY AND TYPICALLY THE WAY THE OVERSIGHT
12	COMMITTEES DO THAT IS THEY DON'T HAVE A FULL
13	COMMITTEE MEETING. THEY HAVE WHAT THEY CALL AN
14	EXPEDITED PROCESS WHERE THE CHAIRPERSON OR THEIR
15	DESIGNATED PERSON GOES AND DOES THAT CHECKING. WHAT
16	THIS AMENDMENT WOULD ALLOW IS SOMEBODY TO DO THAT
17	SAME PROCESS, BUT NOT AS A REPRESENTATIVE OF THE
18	STEM CELL RESEARCH OVERSIGHT COMMITTEE, BUT SOMEONE
19	WHO HAS EXPERIENCE, TRAINING, THE ABILITY TO MAKE
20	THAT DETERMINATION. AND, AGAIN, TYPICALLY SOMEONE
21	IN A SORT OF GENERAL COUNSEL OFFICE OR SOMEONE WHO
22	UNDERSTANDS THE REGULATORY REQUIREMENTS. SO IT'S
23	FUNCTIONALLY EQUIVALENT. IT'S JUST BEING PERFORMED
24	BY SOMEONE OTHER THAN THE ADMINISTRATIVE OR THE
25	CHAIR OF THE OVERSIGHT COMMITTEE. DOES THAT MAKE
	254

1	SENSE? DOES THAT CLARIFY?
2	DR. STEWARD: YES. EXCEPT I STILL DON'T
3	QUITE UNDERSTAND WHY WHAT SORT OF ORGANIZATION
4	WOULDN'T HAVE THE KIND OF PERSON THAT DR. BRYANT IS
5	TALKING ABOUT. SOMEONE WHOSE ROLE IT IS IN THE
6	INSTITUTION TO OVERSEE COMPLIANCE?
7	DR. LOMAX: SO OUR UNDERSTANDING IS
8	EVERYONE HAS THAT ALL OF OUR GRANTEES HAS SOMEONE
9	AT THAT LEVEL. WHAT ALL OF OUR GRANTEES DO NOT HAVE
10	IS A STEM CELL RESEARCH OVERSIGHT COMMITTEE, WHICH
11	IS A COMMITTEE FORMED IN ACCORDANCE WITH OUR
12	REGULATIONS. AND THERE'S REQUIREMENTS FOR THAT.
13	THERE'S CERTAIN TYPES OF EXPERTISE, CERTAIN TYPES OF
14	REPRESENTATION. IN ORDER TO PUT TOGETHER ONE OF
15	THOSE COMMITTEES, THAT IS A FAIRLY LABORIOUS AND
16	IT'S A MAJOR ENDEAVOR WHICH IF YOU'RE NOT OF A
17	CERTAIN SCALE, IN ORDER TO ACCOMPLISH THAT, IF YOU
18	HAVE ONE OR TWO CIRM GRANTS AND YOU'RE A SMALL
19	INSTITUTION, THAT CAN BE A VERY HIGH BAR TO GET
20	OVER.
21	SO WHAT WE'RE TRYING TO DO IN THIS CASE IS
22	GIVE THOSE INSTITUTIONS A SECOND PATH SO THEY CAN
23	MAKE THAT DETERMINATION THROUGH, LIKE I SAY, SOMEONE
24	WITH LEGAL RESPONSIBILITY, SOMEONE OF THAT NATURE.
25	DR. STEWARD: SO I GUESS, JUST TO AMPLIFY
	255

1	THEN, I THINK THAT THERE NEEDS TO BE A PRETTY CLEAR
2	DEFINITION OF WHAT THAT PERSON ACTUALLY IS AND THEIR
3	QUALIFICATIONS. YOU COULD IMAGINE THIS BEING
4	REVIEWED BY SOMEBODY WHO REALLY DIDN'T KNOW WHAT
5	THEY WERE LOOKING AT. I THINK THAT WAS DR. BRYANT'S
6	POINT. AND SO I DON'T KNOW HOW TO LAY THOSE OUT,
7	BUT IT SEEMS LIKE THERE OUGHT TO BE SOME SPECIFICITY
8	THERE.
9	DR. BRYANT: I THINK IF YOU WANT TO
10	DESIGNATE IT TO THE CHIEF COMPLIANCE OFFICER OF THE
11	INSTITUTION, THAT WOULD BE THE WAY TO DO IT. THEN
12	IT WOULD END UP IN THE RIGHT PLACE, BUT IT WOULDN'T
13	NECESSARILY BE THE HEAD LAWYER OR ANYTHING LIKE THAT
14	OR EVEN THE LEGAL DEPARTMENT.
15	CHAIRMAN THOMAS: DEAN PIZZO.
16	DR. PIZZO: I THINK WE'RE GETTING IN
17	ALL FAIRNESS, I UNDERSTAND WHERE YOU'RE GOING, BUT
18	I'D BE A LITTLE CAREFUL ABOUT SPECIFYING THE ACTUAL
19	JOB DESCRIPTION. THE REALITY IS OUR OFFICE OF
20	GENERAL COUNSEL, I CAN SPEAK TO THIS AT LEAST AT
21	STANFORD, IS CERTAINLY INVOLVED IN COMPLIANCE
22	ISSUES. THERE'S NO QUESTION ABOUT THAT. WE DO HAVE
23	A DEAN OF RESEARCH, BUT WE ALSO HAVE AUTHORITY
24	WITHIN, IN OUR CASE, THE MEDICAL SCHOOL THAT
25	OVERSEES COMPLIANCE ALMOST INDEPENDENTLY OF WHAT
	256
	230

1	TAKES PLACE. SO INSTITUTIONS VARY, WHICH IS WHY I
2	LIKED YOUR WELL, I THINK CHIEF COMPLIANCE OFFICER
3	MAY BE IT. I JUST THINK THAT PERSON COULD BE A
4	LAWYER, SO I THINK WE WANT TO BE JUDICIOUS ABOUT
5	THAT.
6	I THOUGHT YOUR OTHER RECOMMENDATION, WHICH
7	CERTAINLY WOULD ALLOW THE AUTHORITY, IS THAT IT CAN
8	GO THROUGH, IF YOU WILL, CHANCELLOR OR THE PRESIDENT
9	OR WHOMEVER IS THE INSTITUTIONAL LEADER JUST TO BE
10	SURE IT'S APPROPRIATELY DELEGATED.
11	DR. LOMAX: JUST ONE SORT OF PROCESS. IN
12	A NUMBER OF CASES, EVERY CASE I'M AWARE OF WHERE
13	INSTITUTIONS HAVE USED THIS MECHANISM, THERE'S
14	ACTUALLY BEEN I'VE ACTUALLY SAT DOWN WITH THE
15	CIRM SCIENCE OFFICER, AND IT'S BEEN THROUGH A VERBAL
16	CONVERSATION. SO I ALSO WANT TO SORT OF REMIND YOU
17	THAT WE ARE WE DON'T SORT OF TURN A BLIND EYE.
18	WE'RE VERY ACTIVE IN TERMS OF THIS PROCESS, AND
19	THERE'S BOTH THE SCIENCE OFFICER AND MYSELF ALWAYS
20	SORT OF COMMUNICATING. AND OFTEN THAT'S AN EXTERNAL
21	COMMUNICATION TO THE GRANTEE ORGANIZATION. SO IT'S
22	NOT A PIECE OF PAPER SHOWS UP AND THAT'S IT.
23	CHAIRMAN THOMAS: ANY OTHER COMMENTS BY
24	MEMBERS OF THE BOARD? I WILL SAY THAT THIS IS THE
25	FIRST STANDARDS WORKING GROUP MEETING THAT I HAVE
	257
	LJI

1	ATTENDED, FIRST ONE SINCE I'VE BEEN ON BOARD. AND
2	IT WAS, AS WITH ALL OF OUR GROUPS, A HIGHLY
3	IMPRESSIVE AGGREGATION OF PEOPLE VERY DEDICATED TO
4	DISCUSSING THESE AND OTHER TOPICS. AND I WOULD LIKE
5	TO JUST CONGRATULATE GEOFF FOR SPEARHEADING THE
6	WHOLE THING. IT'S VERY, VERY WELL DONE.
7	COMMENTS BY MEMBERS OF THE PUBLIC? MR.
8	HARRISON, RESTATE THE MOTION.
9	MR. HARRISON: THE MOTION IS TO APPROVE
10	THE RECOMMENDATIONS FROM THE STANDARDS WORKING GROUP
11	REGARDING THE REVIEW AND OVERSIGHT OF CIRM-FUNDED
12	RESEARCH AS REFLECTED IN THE PROPOSED AMENDMENTS TO
13	THE REGULATIONS.
14	CHAIRMAN THOMAS: ALL THOSE IN FAVOR
15	PLEASE SAY AYE. OPPOSED? ABSTAINING? MARIA.
16	MS. BONNEVILLE: DUANE ROTH.
17	MR. ROTH: YES.
18	MS. BONNEVILLE: SHLOMO MELMED. SHERRY
19	LANSING.
20	MS. LANSING: YES.
21	CHAIRMAN THOMAS: THANK YOU. WE WILL NOW
22	GO TO ITEM 14.
23	MS. LANSING: THAT'S ME, RIGHT?
24	CHAIRMAN THOMAS: WHICH IS SHERRY.
25	MS. LANSING: CAN YOU HEAR ME?
	258
	250

	BARRISTERS' REPORTING SERVICE
1	CHAIRMAN THOMAS: WE CAN HEAR VERY
2	CLEARLY. WHICH IS CONSIDERATION OF THE
3	RECOMMENDATIONS OF THE GOVERNANCE SUBCOMMITTEE.
4	MS. LANSING: OKAY. ON MAY 3D WE HAD A
5	MEETING OF THE GOVERNANCE SUBCOMMITTEE TO DISCUSS
6	THREE ITEMS: AMENDMENTS TO THE GOVERNING BOARD
7	BYLAWS, ADOPTION OF A CODE OF CONDUCT, AND
8	CONSIDERATION OF CHANGES TO THE CONFLICT OF INTEREST
9	CODE.
10	I'D LIKE TO ASK JAMES TO PLEASE DESCRIBE
11	EACH ITEM AND THE RECOMMENDATION FROM THE
12	SUBCOMMITTEE. AFTER EACH ITEM IS INTRODUCED, WE
13	WILL TAKE QUESTIONS FROM BOARD MEMBERS AND THE
14	PUBLIC. I WILL THEN ASK FOR A MOTION ON EACH
15	INDIVIDUAL ITEM.
16	JAMES, CAN YOU PLEASE START WITH THE
17	PROPOSED CHANGES TO THE BOARD BYLAWS.
18	MR. HARRISON: ABSOLUTELY. THANK YOU,
19	SHERRY. AND MICHAEL GOLDBERG TOUCHED ON THIS
20	EARLIER TODAY, BUT WHEN THE BOARD FIRST ADOPTED ITS
21	BYLAWS, THERE WERE ONLY TWO STANDING COMMITTEES, THE
22	GOVERNANCE AND THE LEGISLATIVE SUBCOMMITTEES. AND
23	THE GOVERNANCE SUBCOMMITTEE HAD RESPONSIBILITY FOR
24	CIRM'S BUDGET AND COST CONTROL PROGRAMS.
25	WHEN THE FINANCE SUBCOMMITTEE WAS CREATED
	259

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	IN 2007, IT UNDERTOOK RESPONSIBILITY FOR REVIEW OF
2	THE BUDGET AND THE COST CONTROL PROGRAMS, BUT WE
3	HAVE NOT UNTIL NOW CONFORMED OUR BYLAWS TO REFLECT
4	THE FACT THAT FINANCE CARRIES OUT THIS
5	RESPONSIBILITY. YOU'VE APPROVED THE CHANGE TO THE
6	FINANCE SUBCOMMITTEE MISSION STATEMENT TO MAKE ITS
7	JURISDICTION OVER THE BUDGET EXPLICIT TODAY, AND
8	WE'D ASK FOR YOUR APPROVAL TO AN AMENDMENT TO
9	ARTICLE 6, SECTION 4 OF THE BYLAWS TO CONFORM THE
10	BYLAWS TO CURRENT PRACTICE.
11	THERE IS ONE OTHER ISSUE IN THE BYLAWS
12	THAT WE ARE SEEKING YOUR APPROVAL OF. IN 2010 THE
13	BOARD ADOPTED A NEW PROVISION IN THE BYLAWS TO
14	ADDRESS AND IMPLEMENT A PROVISION IN SB 1064 WHICH
15	PROVIDED FOR THE PATIENT ADVOCATE MEMBERS OF THE
16	GRANTS WORKING GROUP AND THE PATIENT ADVOCATE
17	LEADERSHIP OF THE STANDARDS AND FACILITIES WORKING
18	GROUP TO RECEIVE COMPENSATION ON CONSULTING RATE FOR
19	THEIR SERVICE ON THE WORKING GROUPS. THE BYLAWS
20	REFLECTED THIS AND INCLUDED A CAP ON THAT
21	COMPENSATION, BUT DID NOT SPECIFY WHETHER IT WAS ON
22	A FISCAL YEAR OR CALENDAR YEAR BASIS. AND WE'RE
23	PROPOSING SIMPLY TO CLARIFY THAT THE CAP APPLIES TO
24	A FISCAL YEAR BASIS CONSISTENT WITH CIRM'S BUDGET
25	YEAR. AND WE WOULD, THEREFORE, ASK FOR YOUR
	260

260

	BARRISTERS' REPORTING SERVICE
1	APPROVAL OF THE PROPOSED AMENDMENTS TO BOTH ARTICLE
2	6, SECTION 4 AND ARTICLE 4, SECTION 7 OF THE BOARD'S
3	BYLAWS.
4	CHAIRMAN THOMAS: DO I HEAR A MOTION TO
5	THAT EFFECT?
6	MR. GOLDBERG: SO MOVED.
7	CHAIRMAN THOMAS: MOVED BY MR. GOLDBERG.
8	DR. MARLETTA: SECOND.
9	CHAIRMAN THOMAS: SECONDED BY DR.
10	MARLETTA. ANY DISCUSSION? COMMENTS FROM MEMBERS OF
11	THE PUBLIC? WE'LL PROCEED TO VOTE ON THE
12	RECOMMENDATION AS SET FORTH ON THE SCREEN UP THERE.
13	ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED?
14	ABSTENTION? MARIA.
15	MS. BONNEVILLE: DUANE ROTH.
16	MR. ROTH: YES.
17	MS. BONNEVILLE: SHLOMO MELMED. SHERRY
18	LANSING.
19	MS. LANSING: YES.
20	OKAY. SO THE MOTION PASSES. SO THE NEXT
21	ITEM CONSIDERED WAS A CODE OF CONDUCT. AND, JAMES,
22	CAN YOU PLEASE DESCRIBE THE BOARD CODE OF CONDUCT
23	AND THE RECOMMENDATION FROM THE SUBCOMMITTEE.
24	MR. HARRISON: YES. AT THE CHAIR OF THE
25	GOVERNANCE SUBCOMMITTEE'S DIRECTION, WE PREPARED A
	261

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CODE OF CONDUCT. AND WE DID SO AFTER SURVEYING THE
2	CODES OF CONDUCT OF NUMEROUS OTHER ORGANIZATIONS,
3	INCLUDING THE UNIVERSITY OF CALIFORNIA REGENTS,
4	OTHER STATE AGENCIES, AND NONPROFITS.
5	THE CODE THAT YOU WILL SEE INCLUDES A
6	STATEMENT OF EXPECTATIONS FOR BOARD MEMBERS
7	INCLUDING ATTENDANCE AT MEETINGS, THE PROTECTION OF
8	CONFIDENTIAL INFORMATION, INTERACTION WITH THE MEDIA
9	ON BEHALF OF CIRM, AS WELL AS THE PROTOCOLS FOR
10	MAKING REQUESTS OF CIRM STAFF. AS THE PERFORMANCE
11	AUDITORS MENTIONED THIS MORNING, CODES OF CONDUCT
12	ARE CONSIDERED BEST PRACTICE. SO WE WOULD ASK THE
13	BOARD FOR YOUR APPROVAL OF THE PROPOSED CODE OF
14	CONDUCT.
15	CHAIRMAN THOMAS: MOTION TO THAT EFFECT?
16	MR. TORRES: SO MOVED.
17	CHAIRMAN THOMAS: MOVED BY SENATOR TORRES.
18	SECONDED BY
19	DR. PIZZO: SECOND.
20	CHAIRMAN THOMAS: DEAN PIZZO. ANY
21	DISCUSSION? COMMENTS FROM MEMBERS OF THE PUBLIC?
22	HEARING NONE, PROCEED TO A VOICE VOTE ON THAT ITEM.
23	ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED?
24	ABSTENTIONS? MARIA.
25	MS. BONNEVILLE: DUANE ROTH.
	262
	202


BARRISTERS' REPORTING SERVICE 1 MR. ROTH: YES. 2 MS. BONNEVILLE: SHLOMO MELMED. SHERRY 3 LANSING. 4 MS. LANSING: YES. 5 SO THAT CARRIES. AND, JAMES, NOW IF YOU 6 WOULD WALK US THROUGH THE CONSIDERATION OF CHANGES 7 TO THE CONFLICT OF INTEREST CODE. 8 MR. HARRISON: THANK YOU, SHERRY. THE 9 POLITICAL REFORM ACT REQUIRES EVERY STATE AGENCY TO 10 ADOPT A CONFLICT OF INTEREST CODE AND TO CONDUCT A BIENNIAL REVIEW OF THAT CODE. CIRM'S CONFLICT OF 11 12 INTEREST CODE, LIKE THE CODES OF EVERY STATE AGENCY, 13 IDENTIFY WHO WITHIN THE AGENCY HAS TO DISCLOSE THEIR 14 FINANCIAL INTERESTS BY FILING FORM 700 AND WHAT THEY 15 HAVE TO DISCLOSE. AND RECENTLY THE FAIR POLITICAL 16 PRACTICES COMMISSION, WHICH IS RESPONSIBLE FOR 17 REVIEWING AND APPROVING CIRM'S CONFLICT OF INTEREST 18 CODE, HAS RECOMMENDED THAT CIRM AS WELL AS OTHER 19 STATE AGENCIES NARROW THE DISCLOSURE CATEGORIES SO 20 THAT THEY CLOSELY REFLECT THE NATURE OF THE WORK 21 THAT THE AGENCY PERFORMS. 22 CURRENTLY CIRM BOARD MEMBERS AND HIGH LEVEL STAFF HAS THE BROADEST DISCLOSURE CATEGORY. 23 24 WE PRESENTED THE FAIR POLITICAL PRACTICES 25 RECOMMENDATION TO THE GOVERNANCE SUBCOMMITTEE, AND 263

1	CHAIR LANSING, I THINK, SAID IT BEST WHEN SHE
2	EXPRESSED HER THANKS FOR THE FPPC'S ADVICE, BUT
3	RECOMMENDED THAT CIRM SHOULD CONTINUE TO SET AN
4	EXAMPLE BY REQUIRING THE BROADEST DISCLOSURE OF
5	MEMBERS OF THE BOARD AS WELL AS EXECUTIVE STAFF BOTH
6	BECAUSE OF CIRM'S UNIQUE MISSION, AS WELL AS THE
7	AGENCY'S LONG-STANDING COMMITMENT TO TRANSPARENCY.
8	THE GOVERNANCE SUBCOMMITTEE UNANIMOUSLY
9	AGREED WITH CHAIR LANSING AND REPRESENTED THAT THE
10	BOARD MAINTAIN DISCLOSURE CATEGORY ONE IN THE
11	CONFLICT OF INTEREST CODE FOR BOARD MEMBERS AND
12	EXECUTIVE STAFF, BUT PROCEED WITH THE TECHNICAL
13	AMENDMENTS TO THE CODE, INCLUDING CONSIDERATION OF
14	THE APPROPRIATE LEVEL OF DISCLOSURE FOR NONEXECUTIVE
15	STAFF. AND WE WOULD ASK THE BOARD TO APPROVE THAT
16	RECOMMENDATION.
17	CHAIRMAN THOMAS: DO I HEAR A MOTION TO
18	THAT EFFECT?
19	DR. STEWARD: SO MOVED.
20	CHAIRMAN THOMAS: DR. STEWARD. SECONDED
21	BY
22	DR. PIZZO: SECOND.
23	CHAIRMAN THOMAS: DEAN PIZZO. ANY
24	DISCUSSION ON THIS TOPIC? COMMENTS FROM MEMBERS OF
25	THE PUBLIC? HEARING NONE, A VOICE VOTE. ALL THOSE
	264

BARRISTERS' REPORTING SERVICE 1 IN FAVOR PLEASE SAY AYE. OPPOSED? ABSTAINING? 2 MARIA. 3 MS. BONNEVILLE: DUANE ROTH. 4 MR. ROTH: YES. 5 MS. BONNEVILLE: SHLOMO MELMED. SHERRY 6 LANSING. 7 MS. LANSING: YES. 8 AND THAT CONCLUDES THE GOVERNANCE 9 SUBCOMMITTEE AND OUR RECOMMENDATIONS. SO THANK YOU. 10 CHAIRMAN THOMAS: THANK YOU, MADAM CHAIR. 11 AND THANK YOU, MR. HARRISON. THE NEXT ITEM ON THE AGENDA WE'RE ACTUALLY 12 13 DEFERRING UNTIL JULY BECAUSE TED WAS TIED UP TODAY AND UNABLE TO MAKE IT. SO WE'LL HAVE THE OFFICIAL 14 15 PRESENTATION OF THE RESOLUTION TO HIM FOR HIS MANY 16 YEARS OF SERVICE AT THE JULY MEETING. 17 LAST, BUT NOT LEAST, ON THE VOTING AGENDA IS THE ALWAYS CONTROVERSIAL CONSIDERATION OF THE 18 19 MINUTES. 20 MS. LANSING: I MOVE THE MINUTES. 21 MS. GIBBONS: SECOND. 22 CHAIRMAN THOMAS: BEEN MOVED AND SECONDED. 23 ANY DISCUSSION ON THIS TOPIC? I DON'T THINK WE NEED 24 ANY COMMENTS FROM MEMBERS OF THE PUBLIC IF I'M NOT 25 MISTAKEN. SO ALL THOSE IN FAVOR PLEASE SAY AYE. 265

BARRISTERS' REPORTING SERVICE 1 OPPOSED? ABSTAINING? MARIA. 2 MS. BONNEVILLE: DUANE ROTH. 3 MR. ROTH: YES. 4 MS. BONNEVILLE: SHLOMO MELMED. SHERRY 5 LANSING. 6 MS. LANSING: YES. 7 CHAIRMAN THOMAS: OKAY. SO THAT CONCLUDES THE VOTING MEMBERS OF THE AGENDA. NOW, WE'RE GOING 8 9 TO TAKE A SHORT BREAK, FIVE MINUTES, AND HAVE 10 TODAY'S SPOTLIGHT, WHICH, AS ALWAYS, WILL BE SORT OF UNDER THE CATEGORY OF WHAT IT'S ALL ABOUT, AND WOULD 11 12 INVITE EVERYBODY TO COME BACK IN FIVE MINUTES TO 13 HEAR THAT. THANK YOU. 14 (A RECESS WAS TAKEN.) 15 (THE SPOTLIGHT WAS THEN PRESENTED, 16 BUT NOT REPORTED NOR HEREIN TRANSCRIBED.) 17 CHAIRMAN THOMAS: WELL, LADIES AND 18 GENTLEMEN, I BELIEVE THAT THAT CONCLUDES THE AGENDA 19 FOR THIS MEETING. THANK YOU, EVERYBODY. WE GOT 20 THROUGH AN AWFUL LOT OF HIGHLY SUBSTANTIVE STUFF, AND I THINK WE'VE DEMONSTRATED AGAIN HOW HARDWORKING 21 22 OUR STAFF IS IN PUTTING TOGETHER ALL OF THESE MANY 23 INITIATIVES THAT ARE ONGOING SIMULTANEOUSLY. SO WE 24 WILL ADJOURN THE MEETING. OUR NEXT MEETING WILL BE 25 IN JULY. AND EVERYBODY HAVE A VERY HAPPY HOLIDAY 266

BARRISTERS' REPORTING SERVICE WEEKEND, AND WE'LL SEE YOU SOON. THANK YOU. (THE MEETING WAS THEN CONCLUDED AT 4:45 P.M.)



REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

CROWNE PLAZA SFO 1177 AIRPORT BOULEVARD BURLINGAME, CALIFORNIA ON MAY 24, 2012

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUIT 270 ANAHEIM, CALIFORNIA (714) 444-4100

269